Cosmetic Bootcamp Primer
SERIES IN COSMETIC AND LASER THERAPY Series Editors David J. Goldberg, Nicholas J. Lowe, and Gary P. Lask Published in association with the Journal of Cosmetic and Laser Therapy
David J. Goldberg, Fillers in Cosmetic Dermatology, ISBN 9781841845098 Philippe Deprez, Textbook of Chemical Peels, ISBN 9781841842954 C. William Hanke, Gerhard Sattler, Boris Sommer, Textbook of Liposuction, ISBN 9781841845326 Paul J. Carniol, Neil S. Sadick, Clinical Procedures in Laser Skin Rejuvenation, ISBN 9780415414135 David J. Goldberg, Laser Hair Removal, Second Edition, ISBN 9780415414128 Benjamin Ascher, Marina Landau, Bernard Rossi, Injection Treatments in Cosmetic Surgery, ISBN 9780415386517 Avi Shai, Robert Baran, Howard I. Maibach, Handbook of Cosmetic Skin Care, Second Edition, ISBN 9780415467186 Jenny Kim, Gary Lask, Comprehensive Aesthetic Rejuvenation: A Regional Approach, ISBN 9780415458948 Neil Sadick, Paul Carniol, Deborshi Roy, Luitgard Wiest, Illustrated Manual of Injectable Fillers, ISBN 9780415476447 Paul Carniol, Gary Monheit, Aesthetic Rejuvenation Challenges and Solutions: A Global Perspective, ISBN 9780415475600 Neil Sadick, Diane Berson, Mary P. Lupo, Zoe Diana Draelos, Cosmeceutical Science in Clinical Practice, ISBN 9780415471145 Anthony Benedetto, Botulinum Toxins in Clinical Aesthetic Practice, Second Edition, ISBN 9780415476362 Robert Baran, Howard I. Maibach, Textbook of Cosmetic Dermatology, Fourth Edition, ISBN 9781841847009 David J. Goldberg, Alexander L. Berlin, Disorders of Fat and Cellulite, ISBN 9780415477000 Kenneth Beer, Mary P. Lupo, Vic A. Narurkar, Cosmetic Bootcamp Primer : Comprehensive Aesthetic Management, ISBN 9781841846989
Cosmetic Bootcamp Primer Comprehensive Aesthetic Management With DVD Edited by Kenneth Beer MD PA Founding Director Cosmetic Bootcamp West Palm Beach, Florida, USA
Mary P. Lupo MD FAAD Founding Director Lupo Center and Cosmetic Bootcamp and Clinical Professor of Dermatology Tulane Medical School New Orleans, Louisiana, USA
Vic A. Narurkar MD FAAD Founding Director Bay Area Laser Institute and Founding Director Cosmetic Bootcamp San Francisco, California, USA
Disclaimer: This eBook does not include ancillary media that was packaged with the printed version of the book. First published in 2011 by Informa Healthcare, Telephone House, 69-77 Paul Street, London EC2A 4LQ, UK. Simultaneously published in the USA by Informa Healthcare, 52 Vanderbilt Avenue, 7th Floor, New York, NY 10017, USA. Informa Healthcare is a trading division of Informa UK Ltd. Registered Office: 37–41 Mortimer Street, London W1T 3JH, UK. Registered in England and Wales number 1072954. © 2011 Informa Healthcare, except as otherwise indicated No claim to original U.S. Government works Reprinted material is quoted with permission. Although every effort has been made to ensure that all owners of copyright material have been acknowledged in this publication, we would be glad to acknowledge in subsequent reprints or editions any omissions brought to our attention. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, unless with the prior written permission of the publisher or in accordance with the provisions of the Copyright, Designs and Patents Act 1988 or under the terms of any licence permitting limited copying issued by the Copyright Licensing Agency, 90 Tottenham Court Road, London W1P 0LP, UK, or the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA (http://www.copyright.com/ or telephone 978-750-8400). Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe. This book contains information from reputable sources and although reasonable efforts have been made to publish accurate information, the publisher makes no warranties (either express or implied) as to the accuracy or fitness for a particular purpose of the information or advice contained herein. The publisher wishes to make it clear that any views or opinions expressed in this book by individual authors or contributors are their personal views and opinions and do not necessarily reflect the views/opinions of the publisher. Any information or guidance contained in this book is intended for use solely by medical professionals strictly as a supplement to the medical professional’s own judgement, knowledge of the patient’s medical history, relevant manufacturer’s instructions and the appropriate best practice guidelines. Because of the rapid advances in medical science, any information or advice on dosages, procedures, or diagnoses should be independently verified. This book does not indicate whether a particular treatment is appropriate or suitable for a particular individual. Ultimately it is the sole responsibility of the medical professional to make his or her own professional judgements, so as appropriately to advise and treat patients. Save for death or personal injury caused by the publisher’s negligence and to the fullest extent otherwise permitted by law, neither the publisher nor any person engaged or employed by the publisher shall be responsible or liable for any loss, injury or damage caused to any person or property arising in any way from the use of this book. A CIP record for this book is available from the British Library. Library of Congress Cataloging-in-Publication Data available on application ISBN-13: 9781841846989 Orders may be sent to: Informa Healthcare, Sheepen Place, Colchester, Essex CO3 3LP, UK Telephone: +44 (0)20 7017 5540 Email:
[email protected] Website: http://informahealthcarebooks.com/ For corporate sales please contact:
[email protected] For foreign rights please contact:
[email protected] For reprint permissions please contact:
[email protected]
Typeset by Exeter Premedia Services Private Ltd., Chennai, India Printed and bound in the United Kingdom
Contents
Contributors
vii
Preface
ix
Part I
Marketing and Management
1 The role of the aesthetic specialist
1
Kenneth Beer
2 The size and scope of the aesthetic marketplace
2
Neil S. Sadick
3 Aesthetic marketplace economics: Trends and performance of the top performing aesthetic medical procedures
9
Page S. Piland
4 Photography for the aesthetic patient
18
Holly P. Smith
5 Ergonomics for an aesthetic office
36
Steven K. Cordonnier
6 Interviewing the cosmetic patient
39
Susan H. Weinkle and Harriet Lin Hall
7 Red flag patients
43
Timothy Corcoran Flynn
8 Internal marketing
46
Amy Derick
9 Financial benchmarking for the aesthetic medical practice
50
Page S. Piland
10 Form, forms, forms
60
Kenneth Beer
Part II Clinical Cosmetic Patient Care 11 Skin type classification systems: Cosmetic consideration and planning for procedures
79
Wendy E. Roberts
12 When non-invasive is not enough: Limits to individual treatments
85
Roxanne J. Guy
13 Complications A to Z
98
Vince Bertucci
14 Botulinum toxins type A: Advanced techniques
106
Andreas Boker and Fredric S. Brandt
15 Botulinum toxin in the management of focal hyperhidrosis
115
Dee Anna Glaser
Fillers Advanced Techniques 16 One syringe wonder
130
Mary P. Lupo
v
vi
CONTENTS
17 Hyaluronic acid fillers
135
Mary P. Lupo
18 Calcium hydroxylapatite dermal filler for aesthetic correction of face and hands
141
Roberta D. Sengelmann
19 PLLA (Sculptra)
151
Cheryl M. Burgess
20 Permanent fillers
161
Derek Jones
21 Liposuction my way
165
Patricia Wexler
22 Chemical peeling
172
Sue Ellen Cox
Surgical Procedures 23 Aesthetic considerations in facial enhancement: A plastic surgery perspective
184
Julius Few
24 Periorbital rejuvenation utilizing blepharoplasty and adjunctive surgical techniques
189
Craig N. Czyz, Brian S. Biesman, and Jill A. Foster
25 Breast augmentation
209
Clark F. Schierle and Laurie A. Casas
26 Surgical rejuvenation of the neck
215
Anthony P. Sclafani, E. Ashlie Darr, and Ameet Kamat
Lasers and Lights 27 Intense pulsed light
225
Andreas Boker, David H. Ciocon, and David J. Goldberg
28 Fat melting devices
232
Kimberly Finder
29 Ablative fractional laser resurfacing
238
Vic A. Narurkar
30 Non-ablative devices
241
Vic A. Narurkar
31 Cosmeceuticals
245
Jeanine Downie
32 Diverse populations in aesthetics: Young patients
251
Ava Shamban
33 Diverse populations in aesthetics: Male patients
259
Toral Patel and Murad Alam
34 Diverse populations in aesthetics: Ethnic patients
265
Ava Shamban
Index
275
Contributors
Murad Alam Northwestern Medical Faculty Foundation, Chicago, Illinois, USA Kenneth Beer Cosmetic Bootcamp, West Palm Beach, Florida, USA Vince Bertucci Bertucci MedSpa, Woodbridge, Ontario, and University of Toronto, Toronto, Ontario, Canada Brian S. Biesman Vanderbilt University Medical Center, Nashville, Tennessee, USA Andreas Boker University of California San Francisco, San Francisco, California, USA Fredric S. Brandt PA and Dermatology Research Institute, Coral Gables, Florida, USA Cheryl M. Burgess Georgetown University, and Center for Dermatology and Dermatologic Surgery, Washington, DC, USA Laurie A. Casas University of Chicago Medical Center, Chicago, Illinois, USA David H. Ciocon Skin Laser and Surgery Specialists of New York and New Jersey, New York, New York, USA Steven K. Cordonnier Midmark Corporation, Versailles, Ohio, USA Sue Ellen Cox Aesthetic Solutions and University of North Carolina, Chapel Hill, and Duke University, Durham, North Carolina, USA Craig N. Czyz Ohio University College of Osteopathic Medicine, and OhioHealth Doctors Hospital, Columbus, Ohio, USA
Timothy Corcoran Flynn University of North Carolina, Chapel Hill, and Cary Skin Center, Cary, North Carolina, USA Jill A. Foster The Ohio State University, and Eye Center of Columbus, Columbus, Ohio, USA Dee Anna Glaser Saint Louis University School of Medicine, St. Louis, Missouri, USA David J. Goldberg Skin Laser and Surgery Specialists of New York and New Jersey, New York, New York; Sanctuary Medical Aesthetic Center, Boca Raton, Florida; and Mount Sinai School of Medicine, New York, New York, USA Roxanne J. Guy Brevard Plastic Surgery & Skin Treatment Center, Melbourne, Florida, USA Harriet Lin Hall Private Practice of Susan H. Weinkle, Bradenton, Florida, USA Derek Jones Skin Care and Laser Physicians of Beverly Hills, Beverly Hills, and David Geffen School of Medicine, University of California, Los Angeles, California, USA Ameet Kamat The New York Eye and Ear Infirmary, New York, New York, USA Mary P. Lupo Lupo Center, Cosmetic Bootcamp, and Tulane Medical School, New Orleans, Louisiana, USA Vic A. Narurkar California Pacific Medical Center, San Francisco; Bay Area Laser Institute, San Francisco; and University of California Davis School of Medicine, Sacramento, California, USA
E. Ashlie Darr The New York Eye and Ear Infirmary, New York, New York, USA
Toral Patel Chicago Lake Shore Medical Associates, Chicago, Illinois, USA
Amy Derick Derick Dermatology, LLC, Barrington, Illinois, USA
Page S. Piland Core Healthcare Consulting, Windermere, Florida, USA
Jeanine Downie Image Dermatology, P.C., Montclair, New Jersey, USA
Wendy E. Roberts Rancho Mirage, California, USA
Julius Few The Few Institute for Aesthetic Plastic Surgery, and Clinical Associate, University of Chicago, Division of Plastic Surgery, Chicago, Illinois, USA
Neil S. Sadick Weill Cornell Medical College, Cornell University, New York, New York, USA
Kimberly Finder The LipoSurgery Clinic, San Antonio, Texas, USA
Clark F. Schierle Northwestern Plastic Surgery Associates, Chicago, Illinois, USA
vii
viii
CONTRIBUTORS
Anthony P. Sclafani The New York Eye and Ear Infirmary, New York, New York, USA Roberta D. Sengelmann Mohs & Cosmetic Dermatologic Surgery, Santa Barbara, California, USA Ava Shamban Laser Institute for Dermatology and European Skin Care, Santa Monica; Ava MD, Beverly Hills; and UCLA School of Medicine, Los Angeles, California, USA
Holly P. Smith MedPhoto Group, Dallas, Texas, USA
Susan H. Weinkle University of South Florida, Tampa, Florida, USA
Patricia Wexler Wexler Dermatology, P.C., New York, New York, USA
Preface
The Cosmetic Bootcamp Meetings began as a way for colleagues in dermatology, plastic surgery, ophthalmology, and otorhinolaryngology to teach each other in a collegial environment. Cosmetic Bootcamp meetings are designed to provide core physicians (those in the specialties listed above) a forum to exchange ideas, explore new technologies and techniques, and discuss ways to improve patient care. In short, the focus is on advancing the science and outcomes using a multidisciplinary approach. We include each of the core aesthetic specialties at our meetings in addition to this book since we believe that one specialty does not hold all the answers. Moreover, the most interesting courses at each of our meetings are those that include physicians from different specialties to provide their perspective on a single patient issue or aesthetic technique. This book attempts to capture the flavor of these interactions Each chapter has what the editors consider essential information as well as a few “pearls”. The goal of this is to provide the framework to
understand the topic being discussed as well as the most salient, practical aspects of the chapter. While the book cannot provide the interaction that we see in our meetings, it does have an instructional DVD that helps bridge this gap. Following each meeting, the audience gathers to interact and ask questions about each lecture. Unfortunately, this is not possible with a textbook but most of the authors are participants at many meetings throughout the year and the reader is encouraged to ask him or her questions. Future versions of this text will include internet-based interactions that will foster these discussions. For those interested in a more direct interaction, please visit www. cosmeticbootcamp.com to see dates for upcoming meetings.
Kenneth Beer MD PA Mary P. Lupo MD FAAD Vic A. Narurkar MD FAAD
ix
1
The role of the aesthetic specialist Kenneth Beer
The Cosmetic Bootcamp arose from a simple concept asked at a lecture that I was delivering to a group of people attending a cosmetic meeting. An audience member responded to a statement that I made to the effect that the techniques I was discussing were best reserved for those individuals trained during a residency or fellowship to understand the anatomy and technical considerations involved. On the podium, I was asked, “If people can not learn these techniques at a meeting like this, where then should they learn them and what mechanism exists to train esthetic physicians?” Taken slightly aback, I responded that the mechanism, as I understood it, for training cosmetic physicians exists and is known as the residency or fellowship in an appropriate specialty. However, the question made me think about the role of specialists in aesthetic medicine and surgery. Ultimately it was the impetus to create a meeting where we could have an audience comprised of people that had a common level of education and skills and whom we could expose to new ideas that would enable them to advance. Specialists in medicine have traditionally been individuals who have advanced skills and/or training in a particular discipline. As medicine evolved and broader fields became more refined, some of the practitioners were “grandfathered” in as specialists. In dermatology, there are several examples of this, including those dermatologists who became certified as specialists in dermatopathology without taking the certification exam. Plastic surgery, head and neck surgery, and ophthalmology have each branched into several subspecialties whose practitioners have additional training and skills beyond the scope of the daily activities of most of the generalists in the field. In each of these areas, the specialists drive a great deal of the research and advancements in the field. There are now several physicians as well as several more nonphysicians performing cosmetic procedures far different from anything they trained in during their residency. Many of these physicians can perform basic cosmetic procedures such as injecting the glabella with botulinum toxins or spackling the nasolabial creases with soft tissue augmentation products. Some will perform enough procedures and attain the education to excel in these procedures. However, some of these physicians are also delivering babies or taking care of hypertension. While they may perform fundoscopic and otologic examinations, they typically lack the advanced skills of someone trained specifically to deal with these areas. So it is with the specialists in aesthetic medicine. What are the effects of non-specialists treating patients in this field? Usually, the consequences of the treatments are negligible and there should be no implication that specialists are all particularly gifted and free from cosmetic fiascos. One advantage that specialists have is that they typically understand advanced techniques, anatomy, and methods of combining treatments to optimize patient outcomes. Another is that they have frequently worked with other related specialties during the course of their training as well as in practice so that they are able to recognize the limitations of their own specialty and refer to a colleague when appropriate. The role of the dermatologist, ophthalmologist, otorhinolaryngologist, and plastic surgeon should be to assess the various components of aging and provide a roadmap of options for the patient and to
advance the specialties through research and educational activities. In the office, these specialists can help patients discuss the range of treatments available from lasers to intense pulsed lights, chemical peels, botulinum toxins, fillers, volumizers, cosmeceuticals, and surgery. Specialists should be able to discuss these alone and in combinations that are beyond the scope of those not trained during a formal residency or fellowship. Some of these specialists have broad areas of overlap but others do not—for instance, not all of these specialists will perform a facelift or consider themselves experts at injecting. These specialists have a responsibility to help the patient find the right person for their particular need. Specialists also have the responsibility to tell patients what they should not do. For some this means that no amount of botulinum toxins are going to make them look like they did when they were 20; for others, it is the reality that using a cream may be enough to accomplish some of their goals in a gradual, cost-efficient manner. Patients with unrealistic expectations or body dysmorphic disease should be assessed and should not be treated. There are times when they will mask their symptoms and get treated with unfortunate results for all concerned. For physicians who have participated as faculty or authors, the role of specialists in advancing the fields they are in as well as training the next generation of physicians and physician extenders is also a vital facet of their specialty. The leaders in the fields spend countless hours writing and preparing lectures to facilitate the education of their colleagues. One question that arises during any discussion of the role of aesthetic specialists is a salient one: Why bother with aesthetic specialists at all? This is asked by other physicians, medical economists, and patients concerned by the lack of “seriousness” of aesthetic medicine. My own belief is that there are three primary reasons. The first is that, since the beginning of time, man has always sought to improve his or her appearance and aesthetic medicine and surgery is a natural evolution of this process and one that will continue irrespective of what some may think. A second reason is the unintended consequences of the aesthetic technologies that evolve. Lasers once used to treat wrinkles on the face are now routinely used to treat debilitating and disfiguring burns. Fillers may be used to reconstruct areas damaged by trauma, and botulinum toxins are used to treat headaches, myofascial pain, prostate hypertrophy, spasticity associated with cerebral palsy and a host of other medical conditions. The third reason is that many patients that have an aesthetic procedure not only look better but feel better about themselves and have higher self-esteem and job performance. From botulinum toxins to lasers to fillers to breast augmentation, the properly performed procedure in the properly selected patient may significantly improve the quality of that person’s life. Specialists have the obligation to provide treatments better than poseurs. They need to contour the face instead of spackling lines. Perhaps as important is their role in education and advancing the various specialties. This includes training other specialists and students interested in the fields. The goal of any physician is to help patients and advance the field. I would hope that this book encourages readers to take the best care of their patients and educates those who need to be trained.
1
2
The size and scope of the aesthetic marketplace Neil S. Sadick
THE AESTHETIC MARKETPLACE
Aesthetics is a broad field, with physicians and trained clinical professionals of many different interests and areas of expertise. The spectrum ranges from plastic surgeons that perform reconstructive surgery and invasive procedures with lengthy recovery to dermatologists, skilled in non-invasive body contouring, laser/light rejuvenation, and injectables, to aestheticians addressing topical skin concerns and facilitating maintenance. The shared goal of aesthetics professionals is to create beauty and repair damage. However, their diverse education backgrounds and range of expertise create a vast assortment of procedures that are offered for aesthetic purposes. There is a growing demand on the part of the cosmetic consumer for holistic, aesthetic care—that is the integration of surgical and nonsurgical procedures at a medical aesthetic center. At such facilities, often termed medical spas, physicians and aestheticians can align their services into a synergistic platform to satisfy their patients’ desire for a continuum of care.
supervised by a physician, the organization and operation of an aesthetic medical center differs significantly from a typical doctor’s office. Figure 2.1 illustrates the primary difference between a traditional medical practice and an aesthetic practice—the flow and retention of patients. In a traditional model, patients flow into the office via insurance accepted by the physician. In the aesthetic model, patients are selfreferred or referred by friends and family. As such, patients/clients can come through various channels and the practice should promote itself to expand its footprint. The variety of services offered at an aesthetic medical center provides an opportunity for current patients to move up the cosmetic pyramid to more advanced procedures. The goal of any marketing program is to engage patients into the aesthetic practice at the basic level of care (facials, chemical peels, and low risk treatments) when topical and maintenance services are the patients’ primary need (due to age or financial restrictions) and migrate them into other physician administered services including surgery as they require them.
BACKGROUND
The medical spa is a term applied to aesthetic centers that offer services intended to be administered by a medical professional. The designation of “medical spa” attempts to differentiate the facility as more efficacious and therapeutic than commonplace “day spas.” There are several types of medical spas that include those that are run and owned by a physician (typically a specialist in plastic surgery or dermatology) and those that are owned by an entrepreneur with physician as medical director (either on- or off-site). Typical core services offered at most medical spas include microdermabrasion, chemical peels, medical facials, botulinum toxin, injectable fillers, hair removal, and photorejuvenation with laser and light sources. In addition, many medical spas commonly provide body contouring treatments such as cellulite reduction and skin tightening, injection lipolysis, acne treatment, tattoo removal, laser resurfacing, sclerotherapy, and leg vein removal. A few medical spas are also able to offer on-site cosmetic surgery (e.g., rhinoplasty, blephroplasty, brow, and facelifts), liposuction, and laser-assisted lipoplasty (Table 2.1). The Cosmetic Medicine Task Force (1) developed a classification system to educate the public on the outcomes and relative risks of various cosmetic procedures (Table 2.2). For example, “non-invasive” procedures do not penetrate the dermis and pose virtually no risk to health, while “minimally invasive” procedures do penetrate the skin and are associated with a slight health risk. In general, the closer the on-site involvement with a physician, the more likely “aggressive,” or “invasive” procedures are offered. The services offered by medical spas continue to evolve as novel technologies for aesthetic indications continue to be developed. The trend in demand has been toward nonsurgical procedures, and the top 10 patient-requested procedures in 2008 are shown in Table 2.3. It is interesting to note that many of the most popular procedures performed today did not exist 15 years ago or existed in a very early developmental state. For those contemplating expanding their aesthetic menu of services, it is important to stay within the top 10 most requested procedures to stay profitable as well as foresee the emergence of more powerful and efficacious approaches and invest accordingly. The aesthetic industry is projected to increase by 9% a year (2,3) and offers a lucrative and stable opportunity for expansion. Although the aesthetic services in a medical spa are often administered or closely
2
CORE SERVICES
Microdermabrasion Microdermabrasion is an exceedingly popular procedure for superficial skin resurfacing. It achieves improvement in scars, roughness, mottled pigmentation, and overall appearance, but not rhytids. The procedure involves the deposition of microcrystals, usually aluminum oxide (sodium chloride, magnesium oxide, and sodium bicarbonate are other options), on the surface of the skin with rapid strokes of the handpiece (4). Meanwhile, an aspiration tube attached to the handpiece vacuums the crystals and skin debris. The skin depth of the procedure is established by the strength of crystal flow, speed of handpiece movement, and the number of passes of the target region (4). Histology studies of microdermabrasion revealed the following changes: thickening of the epidermis and dermis, flattening of the rete pegs, vascular ectasia and perivascular inflammation, and hyalinization of the papillary dermis with newly deposited collagen and elastic fibers (5). It has been suggested that microdermabrasion produces clinical improvement by inducing molecular changes within the dermis that trigger dermal collagen remodeling and repair. Recent studies have reported that treatment activates the expression of cytokines AP-1, NF-κB, TNF-α, and IL-1β, which collectively serve to upregulate the expression of various connective tissue degrading enzymes (6). There are hundreds of different microdermabrasion machines on the market. In general, a comprehensive listing of available technology can be found in the Aesthetic Buyers Guide, a bi-monthly trade publication. The Food and Drug Administration (FDA) classifies microdermabrasion units as class 1 medical devices. As such, the machines can be sold without demonstration of clinical efficacy and operated without any medical supervision, as long as the procedure only removes the stratum corneum (7). There is a wide variation in the training of providers for this procedure and it is important to be aware that aggressive treatment can cause excesses in exfoliation, increased redness and rosacea, and dermatitis flares. Microdermabrasion is projected to remain a mainstay of “aesthetician-based” adjunctive care. The demand and increasing popularity of the procedure has resulted in the development of at-home microdermabrasion kits, although not as powerful as the technology available in professional aesthetic settings.
THE SIZE AND SCOPE OF THE AESTHETIC MARKETPLACE
Table 2.1 Procedures Offered in Medical Spas Core services
Common procedures
Microdermabrasion Chemical peels Medical facials Botulinum toxin Injectable fillers Hair removal Photorejuvenation
Cellulite reduction Tissue tightening Laser resurfacing Injection lipolysis
Less common medical procedures Sclerotherapy Laser leg vein removal Photodynamic therapy Tattoo removal Cosmetic surgery Liposuction Laser-assisted lipoplasy
Table 2.2 Classification System for Cosmetic Procedures Non-invasive
Minimally invasive
Body wraps Facials Deep-tissue massage
IPL Microdermabrasion Laser hair removal Laser leg vein removal Non-invasive fat reduction (e.g., High-intensity focused ultrasound or low level light therapy) Cellulite reduction
Moderately invasive
Invasive (surgical)
Botulinum toxin Injectable fillers Laser skin resurfacing Chemical peels
Face lifts Rhinoplasty Liposuction Abdominoplasty
Skin tightening (radiofrequency and infrared)
Breast lifts, augmentation, reduction, and reconstruction
Injection lipolysis
Arm and thigh lifts
3
A variety of mild chemical peels are available including glycolic acid, trichloroacetic (TCA) acid, salicylic acid, pyruvic acid, resorcinol, and Jessner’s solution (14% lactic acid, 14% resorcinol, and 14% salicylic acid) (8). Several proprietary peels are available including systems from Obagi and Theraplex (Melbourne, Australia). The indications for chemical peels are similar to microdermabrasion, but with considerable variation in efficacy and improvement based on depth of peel. Mild chemical peels are effective options for treating melasma in type IV-VI skin (9) and are considerably safer for this group than laser chromophore targeting. Moderate-to-deep peels are possible treatment options for patients wishing to target rhytids and achieve some degree of tightening. Medical Facials A facial is the most basic aesthetic service, typically comprising a deep cleaning, skin analysis (via a magnifying loupe), exfoliation (often with steam), extractions, massage, a mask to tighten pores, and moisturizer application. Medical facials could be defined as facials whose primary goal is to effect an improvement on the condition of the skin rather than deep cleaning and relaxation. Medical facials often focus on specific problems such as aging skin, large pores or acne, maintenance for rosacea, reduction of lines or wrinkles, reduction in hyperpigmentation, hydration, or combination of these conditions. The use of physiciandispensed products and a method of penetration that allows ingredients to penetrate more deeply in the dermis are commonly employed. Various methods to improve penetration are stratum corenum removal with chemical agents or microdermabrasion, ultrasonic devices, and heat or suction. Medical facials are mild treatments that do not claim lasting results but are appropriate adjuncts to other procedures and maintain and improve daily skin care regimens.
Sclerotherapy
Table 2.3 Top 10 Requested Procedures in 2008 1. 2. 3. 4. 5. 6. 7. 8. 9. 10.
Botulinum toxin Laser hair removal Injectable fillers Chemical peels Laser resurfacing Microdermabrasion IPL Sclerotherapy Breast augmentation Liposuction
Chemical Peels Chemical peels are typically used for treatment of acne and enlarged pores, melasma, anti-aging, and to enhance the results of other aesthetic interventions, most commonly laser treatments. Three types of peels are readily available and classified based on the depth of the peel: superficial/mild, medium, and deep. Chemical peels performed in the medical spa are usually of the superficial or “lunchtime” variety without excessive post-procedure downtime. Most medical spas use aestheticians or nurses for the administration of mild chemical peels. The more moderate-to-deep chemical peels should be administered by a physician or under the direct supervision of a physician due to higher potential for adverse events and skin sensitivity.
Botulinum Toxin Botulinum toxin type A or BTX-A (BOTOX, Allergan, Irvine, California, USA; Dysport, Medicis, Scottsdale, Arizona, USA) is a purified complex of the neurotoxin, produced from the bacterium Clostridium botulinum. Originally approved for the treatment of blepharospasm and strabismus, off-label use began to produce reports of cosmetic improvement. Injections of botulinum toxins are frequently the entry point for patients into procedural aesthetic medicine. In 1992, the first published cosmetic study reported that 16 out of 17 subjects had market improvement in glabellar wrinkles after BTX-A injections into the corrugators with results lasting for 3 to 11 months (10). Since then there have been multiple studies validating these effects and establishing optimum dosing guidelines and injection points, as well as demonstrating the prophylactic and anti-aging effects of this treatment (11–14). In April 2002, BOTOX Cosmetic received FDA approval for the treatment of moderate-to-severe frown lines of the glabella. In 2009, Dysport followed receiving the safe FDA approval. Both formulations are used off-label in other areas of the face/neck for aesthetic benefit and have become the most commonly performed cosmetic procedure. With several other formulations of BTX-A currently in development and undergoing FDA approval (e.g., Purogen, Xeotox) including a topical formulation (Reloxin), the market for BTX-A injections is only projected to grow (15). Performing BTX-A injections requires a strong knowledge of anatomy, muscle function, and toxin diffusion patterns in the treatment area. Only dynamic wrinkles that are caused or worsened by muscle movement can be expected to improve with treatment. The most common treatment area is the upper third of the face including periorbital lines, frown lines in the glabella, and transverse lines across the forehead. With experience, providers can also treat vertical lines of the upper lip, jowl contour and platysmal bands, chin dimpling caused by
4
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
Insurance
Appointment scheduled
Office visit
Billing
Retained patients
(A) Advertising
Appt. scheduled
Office visit
Consultation
Promotions No Website
Yes Word of mouth Billing PR
Retained patients
Insurance (B) Figure 2.1 Business models of traditional medicine and aesthetics. (A) Traditional model; (B) Aesthetic medical spa model—yellow diamond indicates the decision to purchase by the patient and the opportunity to convert to billing.
mentalis, muscles exacerbating marionette lines, and other areas of the lower face and neck. Unwanted local effects of BTX-A injection are generally transient. As with any injection, pain, bruising, and infection can occur. The most adverse events—aside from bruising—include asymmetry, headache, and pronounced lateral elevation of the brow. Brow and eyelid ptosis are more severe side effects, which occur in less than 1% of injections and are usually related to technique (16). Injectable Fillers Injectable dermal fillers have experienced a vast surge in popularity since the debut of injectable bovine collagen (Zyderm, Zyplast, Allergan, Irvine, California, USA) in the 1980s. Since then the demand and variety of products offered have only continued to grow with no signs of abatement. The advent of safer, longer lasting agents, as well as the increasing acceptance of and recognition of the significant enhancements that are able to be realized with these procedures strongly contribute to their popularity with both practitioners and consumers. Fillers are frequently the second procedure that cosmetic patients undergo after they have been treated with botulinum toxins and the two procedures are frequently utilized concurrently. Initially intended for the correction of localized and fine facial lines, the current arsenal of products is able to address numerous aesthetic concerns both on and off the face. FDA-approved fillers fall into several classes: hyaluronic acids, collagen-based materials, calcium hydroxylapatite (CaHA), poly-l-lactic acid (PLLA), and polymethylmethacrylate
(PMMA). All fillers are approved for nasolabial fold enhancement; however, many are widely used off-label for other procedures such as lip augmentation, brow elevation, marionette line correction, cheek and tear trough enhancement, and overall volume correction. Developed at the outset as a passive and resorbable correction, fillers have augmented their offerings to provide a biostimulatory and even in some cases permanent response. Biostimulatory fillers include Radiesse (BioForm Medical, San Mateo, California, USA) composed of CaHA microspheres in an aqueous carboxymethylcellulose gel carrier, and Sculptra (Dermik Laboratories, Berwyn, Pennsylvania, USA) composed of PLLA microparticles in a sodium carboxymethylcellulose gel. Both CaHA and PLLA particles are phagocytosed and become surrounded in a capsule of connective tissue cells, macrophages, lymphocytes, mast cells, and foreign body cells (17). As time passes, there is a fibrous-tissue response with collagen deposition providing sustained correction (18). The injection of fillers requires an artistic aesthetic sensibility, excellent eye-hand coordination, and an intimate knowledge of facial anatomy, as necrosis due to vessel occlusion is possible. The necessary skills are difficult to obtain and require much experience. Injectable fillers are recommended for use by experienced dermasurgeons or by physician assistants or nurse practitioners who are under close supervision of a derma-surgeon. Combination treatments with several fillers classes as well as lasers have brought about the nonsurgical or “liquid” facelift—a treatment algorithm focused on global volume enhancement and age-prophylaxis. This sector of aesthetics is projected to experience heavy growth as new products and indications are continuously being developed.
THE SIZE AND SCOPE OF THE AESTHETIC MARKETPLACE Hair Removal Lasers are a popular option in aesthetics for permanent hair reduction. The FDA defines this as “long-term stable reduction in the number of hairs regrowing after a treatment regime” (19). Laser hair removal first became available in the mid-1990s. As with almost all laser technologies, laser hair removal is based on the principle of selective photothermolysis (20). In the case of hair removal, the goal is to heat and destroy the follicular unit without damaging the surrounding tissue. The target chromophore is melanin in the hair follicle. The amount of melanin in hair and skin varies widely between individuals. Therefore, it is crucial to select the appropriate wavelength, spot size, and pulse duration based on the patient’s skin type and hair color for safety and efficacy. The first lasers were only effective in light-skinned and dark-haired patients. Advances in technology have allowed for safe treatments in darker-skinned patients and those with lighter colored hair. There are several different wavelengths and types of devices available, some of the most common offering are:
• •
•
•
• •
Ruby—The ruby laser (694 nm) was the first laser widely used for hair removal (21,22). Although it was effective in lighter skinned patients, it is not used frequently today. Alexandrite—The alexandrite laser (755 nm) was introduced shortly after the ruby and is still used frequently today. Its longer wavelength allowed for deeper penetration and it could cautiously treat some darker skinned patients (23). Studies have reported a reduction up to 50% after only single treatment; and up to 95% hair reduction after multiple treatments, depending upon the number of treatments and body location (24,25). Diode—Treatment of unwanted hair with the diode laser (810 nm) has been demonstrated as comparable to those of the ruby or alexandrite lasers. After a single treatment, hair reduction of about 30% have been reported; and up to 84% reduction with multiple treatments (26). The diode should also be used with caution on darker phenotypes. Nd:YAG—The Nd:YAG laser (1064 nm) is the safest type to treat unwanted hair on patients with dark skin, but the laser does not provide an optimal wavelength for hair removal. Results can be achieved, but higher energies are necessary to achieve results due to lesser affinity with melanin. Reports have shown an improvement of about 50%, depending on the number of treatments administered and body location (27). Intense pulsed light (IPL)—IPL systems have a wavelength range from 550 to 1200 nm. Filters are used to cut off certain wavelengths depending on treatment indications. Bedewi reported a mean hair reduction of 80% after five IPL treatments (28). Intense pulsed light and radiofrequency—The combination of IPL/diode laser with bipolar radiofrequency (RF) is a recently developed dual energy treatment. The hair follicle is pre-heated by light or laser and then RF causes further injury. Because RF does not require a target chromophore, this was the first technology to effectively treat light-colored hair, including white (29,30), albeit at a lower efficacy.
The number of treatments necessary and the interval between treatments are important considerations of laser hair removal and depend on the body area being treated. Only hair in the anagen or growth phase can be effectively treated. Hair in the telogen or catagen phases of rest does not have a mature enough follicle to be treated. The length of time spent in each phase depends on the location of the hair. On the scalp, hair follicles spend up to 10 years in anagen, but on the trunk, brow, and limbs, anagen lasts no longer than 6 months. This variability in hair cycling explains the need for multiple treatments, the correct timing of treatments, and the inability to remove hair 100%.
5
Recently consumer demand has contributed to emergence of at-home hair removal technologies. These technologies are in their infancy and deliver significantly lower energy levels than their professional counterparts. Nonetheless, they present an important evolution of this aesthetic concern and can provide an “entry-level” service for clients who may not be ready for a professional treatment. Photorejuvenation Photorejuvenation refers to the use of lasers and light sources to remove unwanted epidermal pigmentation and reduce upper dermal telangiectasia to improve the texture and tone of the skin. These modalities utilize the principle of photothermolysis with the target chromophores of melanin for pigmentation and hemoglobin for telangiectasia. Several devices in this category have also been reported to improve superficial wrinkles and cause some skin smoothing. IPL is the modality utilized most often for photorejuvenation and nonablative treatment of superficial damage. IPL uses non-coherent polychromatic light (500–1200 nm) to effectively target both melanin and hemoglobin. The minimal risk and virtually no downtime associated with this procedure have contributed to its success. A key IPL study by Bitter (31) showed that serial treatment with IPL visibly improved wrinkling, irregular pigmentation, skin coarseness, pore size, and telangictasias in more than 90% of patients. A newer technology that combines IPL with bipolar RF (electro-optical synergy or el s) was evaluated by Sadick et al. (32) and found to be as efficacious for pigmentation and vascularity but potentially more advantageous for pore size, superficial rhytids, and texture. This difference was caused by the addition of RF, which can penetrate more deeply into the dermis and stimulate collagen remodeling. Other modalities used for photorejuvenation are the pulsed dye laser (PDT 585 nm) and the potassium titanyl phosphate (KTP 532 nm) laser. Both wavelengths effectively target oxyhemoglobin and melanin making them effective at treating red and brown discoloraiton. In a controlled, split face study, Hsu et al. (33) investigated PDT for the treatment of rhytids and reported improvements of surface topography of 9.8% (one treatment) and 15% (two treatments) supported by histologic evidence of collagen remodeling. COMMON SERVICES
Cellulite Reduction Treatment of cellulite can be divided into four main categories: attenuation of aggravating factors, physical and mechanical methods, pharmacologic agents, and laser treatments. Many technologies employed today attempt to improve lymphatic circulation and drainage via negative pressure massage, increase connective tissue to remodel the epidermal–dermal interface, and reduce the size of adipose cells that herniate into the dermal layers. Popular approaches include the use of multi-modality devices to achieve the above aims. The use of bipolar RF, infrared light, and vacuum massage is combined by the VelaShape system (Syneron, Yokneam, Israel). Studies with device have demonstrated the improvement of surface texture, skin tightening as well reduction of circumference of thighs or abdomen (34,35). Other devices that claim to reduce the appearance of cellulite are TriActive (Cynosure, Westford, Massachusetts, USA), a combination of diode laser and massage and SmoothShapes (Eleme Medical, Merrimack, New Hampshire, USA.), a dual wavelength laser with vacuum massage. Recent studies have introduced extracorporeal pulse activation therapy (EPAT) to improve skin elasticity in cellulite. EPAT aims to induce tissue damage through the delivery of high-pressure acoustic energy; this process is followed by dermal remodeling involving recruitment of chemical mediators and neocollagenesis (36).
6
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
Overall the devices for cellulite reduction require multiple treatments (8–16) and ongoing maintenance treatments to maintain effect. The results can be modest with some improvement in contour, reduction of rippling, and slight circumferential reduction. Patients need to be properly informed about procedure timing and maintenance as well as realistic expectations to successfully incorporate this procedure into an aesthetic practice. Tissue Tightening Tissue tightening has been a major force in the aesthetic marketplace since the FDA approval of the first non-invasive treatment for rhytids in 2002. The promise to lift and firm the tissues of the face and body without surgery is an important component of nonsurgical aesthetic rejuvenation. With increasing desire on behalf of the cosmetic consumer for earlier and effective nonsurgical intervention, this sector of aesthetics will see prolific growth and development to become a core aesthetic offering in the near future. Monopolar RF devices designed to uniformly heat the dermis utilizing the tissue’s inherent resistance to current flow initiated the field of tissue tightening. This technology facilitated the creation of thermal zones within the dermis while leaving the epidermis undamaged. Results were associated with a wound-healing response by way of recruitment of heat-shock proteins and inflammatory mediators such as TNF-α, IL-β, and TGF-β (37). Histologic analysis revealed new collagen deposition at 10 weeks post-treatment characterized by increased cellularity and hyaluronic deposits (37–39). Early results with RF were promising but inconsistent and shortcomings led to the development of combination therapy using electrical and optical energies. Today the device offerings have extended to monopolar and bipolar RF, broadband infrared light, bipolar RF with broadband light, and ultrasound. Monopolar RF continues to maintain dominance in this aesthetic indication with the ThermaCool (Thermage, Inc., Hayward, California, USA) being the pacesetter. Thermage has expanded its arsenal of heating tips and products to treat the delicate thinner skin areas of the eyelids and hands, as well originate tips with deeper penetration for targeting the subcutaneous layer and treating the abdomen, flanks, thighs, buttock, and arms. Off-face applications of tissue tightening technologies are commonly employed for post-partum abdomen and laxity after sudden weight loss as well as an adjunct to liposuction. Ultrasound is an emerging modality for tissue tightening. Ultrasound delivers heat to the dermis through the absorption of acoustic energy and the cellular response is thermal damage and subsequent recruitment of specific cytokines and inflammatory mediators similar to RF (40). The Ulthera system (Ulthera, Mesa, Arizona, USA) received FDA clearance for non-invasive tissue tightening in 2009. A study by Alam et al. (41) of patients treated with a single pass at 4.5 mm focal depth and energies of 0.4 to 1.2 J demonstrated at least 0.5 cm improvement in brow elevation in 89% of evaluated subjects. Laser Resurfacing Laser technology is a rapidly growing area of skin rejuvenation and aesthetic improvement. Through different mechanisms, all laser therapies utilize thermal energy to reform and homogenize connective tissue. Initially there is a localized coagulation of collagen fibers for 14 days post-treatment, and this process is followed by new connective tissue synthesis from the thermally altered matrix (42). Histologically fibroblasts may be observed migrating to the affected regions and initiating new collagen formation (43). The entire process is mediated various inflammatory cytokines and culminates in increased elasticity and improved aesthetic appearance of the skin (44). Laser resurfacing began with the ablative devices (CO2 and erbium:YAG) that completely eliminate the epidermis and the upper
layers of the dermis, inducing the formation of a wound. This lesion subsequently reconstitutes an epithelium in approximately 7 to 14 days (45). Although ablative treatment demonstrated unparalleled effectiveness in ability treat sun-induced skin damage, it was associated with significant side effects including delayed erythema and edema, pigmentation abnormalities, significant scarring, and increased risk of infection (46,47). Furthermore, the reepithelization period constituted significant downtime. These challenges lead to the emergence of fractional lasers. Fractional photothermolysis (FP) produces distinct lesions of thermal damage surrounded by larger zones of undisturbed normal skin (48). The combination of lesions and adjacent viable tissue allows for complete reepithelization within 24 to 48 hours and creates an annular configuration of thermal coagulation which enhances tissue tightening because collagen shortening is a three-dimensional mechanism (49,50). The stratum corneum remains undamaged, which greatly reduces the risk of developing an infection and serves to function in exfoliating underlying coagulated tissue, referred to as microepidermal necrotic debris (MEND) (48). Complete regeneration and full clinical benefits of using FP takes approximately three months. The emergence of fractional resurfacing or FP has significantly advanced laser therapy. The potential therapeutic benefits of this revolutionary technology device are only beginning to unravel and many more devices and applications are expected in the near future. Injection Lipolysis Injection lipolysis, also sometimes referred to as mesotherapy, denotes the intradermal injection of multiple chemical substances and lipolytic agents for the purposes of circumferential reduction. The active ingredient appears to be deoxycholate, a detergent that saponifies fat and leads to fat’s absorption by the body. Most of the time the injection cocktail is formulated as a phosphotidylcholine/deoxycholate mixture in various proportions. The mixture is then injected—during multiple sessions—in the target area for fat reduction. While very popular, especially in Europe and South America, this technique is not standardized with most practitioners employing a proprietary mixture to which vitamins and other agents are added. A heavy criticism of this procedure has been a paucity of controlled, double-blind clinical trials supporting the results. This technique is not FDA approved and is performed by practitioners with great variability in experience and education making it a risky course of action without researching the provider. CONCLUSION
In recent years, much progress has been made in technological approaches for aesthetic indications. At the same time, the desire for holistic aesthetic care on behalf of the consumer has driven the emergence of medical spas and aesthetic medical centers offering primary services administered or closely supervised by a physician. Core services such as microdermabrasion, medical facials, photorejuvenation, laser hair removal, and injectables are fixtures at most medical spas, with cellulite reduction, tissue tightening and laser resurfacing becoming increasingly common. The growing demand for safer devices with less downtime as well as less invasive and nonsurgical approaches has led to the development of some innovative therapies. In particular novel devices able to induce thermal damage while sparring the epidermis, either for laser resurfacing or tissue tightening indications, as well as advanced injectables are posed to lead the way in nonsurgical and age-prophylactic aesthetic indications. The trend toward non-invasive approaches assures that further advances in science and technology will serve to create superior services for the aesthetic marketplace.
THE SIZE AND SCOPE OF THE AESTHETIC MARKETPLACE
REFERENCES
1. D’Amico R, Saltz R, Rohrich R, et al. Risks and opportunities for plastic surgeons in a widening cosmetic medicine market: future demand, consumer preferences, and trends in practitioners’ service. Plast Reconst Surg 2008; 121: 1787. 2. Singer N. More doctors turning to the business of beauty. New York Times, Section A, page 2. November 30, 2006. 3. Freedonia Group, Inc. Cleveland, Ohio. Cosmetic Surgery Products (Executive Summary). September 2008. 4. Grimes PE. Microdemabrasion. Dermatol Surg 2006; 31: 1160. 5. Freedman BM, Rueda-Pedraza E, Waddell SP. The epidermal and dermal changes associated with microdemabrasion. Dermatol Surg 2001; 27: 1031. 6. Karimipour DJ, Kang S, Johnson TM, et al. Microdermabrasion with and without aluminum oxide crystal abrasion: a comparative molecular analysis of dermal remodeling. J Am Acad Dematol 2006; 54: 405. 7. Food and Drug Administration. Medical device: regulation and guidance. [Available from: http://www.fda.gov/medicaldevices/ deviceregulationandguidance/default.htm] Accessed January 31, 2010. 8. Zakopoulou N, Kontochristopoulos G. Superficial chemical peels. J Cosmet Dermatol 2006; 5: 246. 9. Sarkar R, Kaur C, Bhalla M, Kanwar AJ. The combination of glycolic acid peels with a topical regimen in the treatment of melasma in dark-skinned patients: a comparative study. Dermatol Surg 2002; 28: 828–32; discussion 832. 10. Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol 1992; 18: 17. 11. Flynn TC, Carruthers J, Carruthers A. Botulinum-A toxin treatment of the lower eyelid improves infraorbital rhytides and widens the eye. Dermatol Surg 2001; 27: 703. 12. Von Lindern JJ, Niederhagen B, Appel T, et al. Type A botulinum toxin for the treatment of hypertrophy of the masseter and temporal muscle: an alternative treatment. Plast Reconst Surg 2001; 54: 197. 13. Park MY, Ahn KY, Jung DS. Application of botulinum toxin A for the treatment of facial contouring in the lower face. Dermatol Surg 2003; 29: 477. 14. Liew S, Dart A. Nonsurgical reshaping of the lower face. Aesthet Surg J 2008; 28: 251. 15. Carruthers J, Carruthers A. Botulinum toxin in facial rejuvenation: an update. Dermatol Clin 2009; 27: 417. 16. Klein AW. Complications, adverse reactions, and insights with the use of botulinum toxin. Dermtol Surg 2003; 29: 549. 17. Coleman KM, Voights R, DeVore D, et al. Neocollagenesis after injection of calcium hydroxylapatite composition in a canine model. Dermatol Surg 2008; 34: S53. 18. Lacombe V. Sculptra: a stimulatory filler. Facial Plast Surg 2009; 25: 95. 19. Food and Drug Administration. Laser dacts—hair removal. [Available from: http://www.fda.gov/Radiation-EmittingProducts/ ResourcesforYouRadiationEmittingProducts/Consumers/ ucm142607.htm] (Accessed January 31, 2010). 20. Dierickx C, Alora MB, Dover JS. A clinical overview of hair removal using lasers and light sources. Dermatol Clin 1999; 134: 837. 21. Grossman M, Dierickx C, Farinelli W, et al. Damage to hair follicles by normal-mode ruby laser. J Am Acad Dermatol 1996; 35: 889. 22. Dierickx C, Grossman M, Farinelli W, et al. Permanent hair removal by ruby laser. Arch Dermatol 1998; 134: 889.
7
23. Garcia C, Alamoudi H, Nakib M, et al. Alexandrite laser hair removal is safe for Fitzpatrick skin types IV-VI. Dermatol Surg 2000; 26: 130. 24. McDaniel DH, Lord J, Ash K, et al. Laser hair removal: a review and report on the use of the long-pulsed alexandrite laser for hair reduction of the upper lip, leg, back, and bikini region. Dermatol Surg 1999; 25: 425. 25. Bouzari N, Nouri K, Tabatabai H, et al. The role of the number of treatments in laser-assisted hair removal using a 755 nm alexandrite laser. J Drugs Dermatol 2005; 4: 573. 26. Lou WW, Quintana AT, Geronemus RG, et al. Prospective study of hair reduction by diode laser (800 nm) with long-term follow up. Dermatol Surg 2000; 26: 428. 27. Tanzi EL, Alster TS. Long-pulsed 1065 nm Nd:YAG laser-assisted hair removal in all skin types. Dermatol Surg 2004; 30: 13. 28. Bedewi AF. Hair removal with intense pulsed light. Lasers Med Sci. 2004; 19: 48. 29. Goldberg DS, Marmur ES, Hussain M. Treatment of terminal and vellus non-pigmented hairs with an optical/bipolar radiofrequency energy source with and without pre-treatment using topical aminolevulinic acid. J Cosmet Laser Ther 2005; 7: 25. 30. Sadick NS, Laughlin SA. Effective epilation of white and blond hair using combined radiofrequency and optical energy. J Cosmet Laser Ther 2004; 6: 27. 31. Bitter P. Noninvasive rejuvenation of photodamaged skin using serial, full-face intense pulsed light treatments. Dermatol Surg 2000; 2: 59. 32. Sadick NS, Alexiades-Armenakas M, Bitter P, et al. Enhanced fullface skin rejuvenation using synchronous intense pulsed optical and conducted bipolar radiofrequency energy (ELOS): introducing selective photothermolysis. J Drugs Dermatol 2005; 4: 181. 33. Hsu T, Zelickson B, Dover J, et al. Multicenter study of the safety and efficacy of a 585 nm pulsed-dye laser for the nonablative treatment of facial rhytids. Dermatol Surg 2005; 31: 1. 34. Waniphakdeedecha R, Manuskiatti W. Treatment of cellulite with bipoal radiofrequency, infrared heat, and pulsatile suction device: a pilot study. J Cosmet Dermatol 2006; 5: 284. 35. Sadick N, Magro C. A study evaluating the safety and efficacy of the velasmooth system for the treatment of cellulite. J Cosmet Laser Ther 2007; 9: 15. 36. Christ C, Brenke R, Sattler G, et al. Improvement in the skin elasticity in the treatment of cellulite and connective tissue weakness by means of extracorporeal pulse activation therapy. Aesthet Surg J 2008; 28: 538. 37. Zelickson B, Kist D, Bernstein E, et al. Histological and ultrastructural evaluation of the effects of a radiofrequency based nonablative dermal remodeling device. Arch Dermatol 2004; 140: 204. 38. Hantash B, Ubeid A, Chang H, et al. Bipolar fractional radiofrequency treatment induces neoelastogenesis and neocollagenesis. Laser Surg Med 2009; 41: 1. 39. Hodgkinson D. Clinical application of radiofrequency: nonsurgical skin tightening. Clin Plast Surg 2009; 36: 261. 40. Laubach HJ, Makin AR, Barthe PR, et al. Intense focused ultrasound: evaluation of a new treatment modality for precise microcirculation within the skin. Dermatol Surg 2008; 34: 727. 41. Alam M, White L, Martin N, et al. Ultrasound tightening of facial skin: a rater-blinded prospective cohort study. J Am Acad Dermatol 2010; 62: 262. 42. Alster TS. Cutaneous resurfacing with CO2 and erbium:YAG lasers: preoperative, intraoperative, and postoperative considerations. Plast Reconst Surg 1999; 103: 619.
8
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
43. Alster TS. Increased smooth muscle actin, factor XIIIa, and vimentin-positive cells in the papillary dermis of carbon dioxide laser-debrided porcine skin. Dermatol Surg 1998; 24: 155. 44. Sarradet M, Hussain M, Goldberg D. Electosurgical resurfacing: a clinical, histologic, and electron microscope evaluation. Laser Surg Med 2003; 32: 46. 45. Bodendorf M, Grunewald S, Wetzig T, et al. Fractional laser therapy. J Dtsch Dermatol Ges 2009; 7: 301. 46. Teikemeier G, Goldberg DJ. Skin resurfacing with the erbium: YAG laser. Dermatol Surg 1997; 23: 685.
47. Sriprachya_anunt S, Fitzpatrick RE, Goldman MP, et al. Infections complicating pulsed carbon dioxide laser resurfacing for photoaged facial skin. Dermal Surg 1997; 23: 587. 48. Hantash BM, Mahmood MB. Fractional photothermolysis: a novel aesthetic laser surgery modality. Dermatol Surg 2007; 33: 525. 49. Hantash BM, Bedi VP, Chan KF, et al. Ex vivo histological characterization of a novel ablative fractional resurfacing device. Lasers Surg Med 2007; 39: 87. 50. Goerge T, Peukert N, Bayer H, et al. Ablative fractional photothermolysis—a novel step in skin resurfacing. Med Laser Appl 2008; 23: 93.
3
Aesthetic marketplace economics: Trends and performance of the top performing aesthetic medical procedures Page S. Piland
The year 2008 marked the beginning of a challenging economic time for many aesthetic medical practices in respect of productivity and income. These economic challenges continued through 2009 and are still persistent at the time of this publication. During this challenging economic time, many practices were forced to reevaluate their strategies and make modifications to existing business plans. A major part of this process involved identifying underperforming areas and refocusing marketing activities. Frequently, this led to a shift from large surgical procedures to smaller nonsurgical procedures. This was not a welcome shift for surgeons, but many recognized the need to make a change for the short term. Many physicians initially believed that patients were deferring higher priced surgical procedures until the economy improved. Many patients opted to have nonsurgical procedures performed in the interim. These lower priced nonsurgical alternatives were viewed as a way to meet present patient demand. It also represents a way for the practice to remain engaged with its patient base and generate revenue. Cosmeceutical sales are also viewed in a similar manner and can help retain a patient’s bonds with a practice. OBJECTIVE ECONOMIC DATA: PARSING THE ASAPS COSMETIC SURGERY NATIONAL DATA BANK STATISTICS
All the data in this section have been gathered by the American Society for Aesthetic Plastic Surgery (ASAPS). ASAPS has conducted a multispecialty survey for 12 years in order to collect this information. These data are useful in analyzing the aesthetic market and measuring individual practice performance. Methodology A paper-based questionnaire was mailed to 16,000 board-certified physicians (6000 dermatologists, 6000 otolaryngologists, and 4000 plastic surgeons). A total of 894 completed and valid responses (461 plastic surgeons, 277 dermatologists, and 156 otolaryngologists) were received. Final figures have been projected to reflect nationwide statistics and are based exclusively on the board-certified plastic surgeons, otolaryngologists, and dermatologists. The findings have been aggregated and extrapolated to the known population of 23,600 physicians who are board certified in these specialties. Though the confidence intervals change by procedure, depending on the grouping’s sample size and the response variance, the overall survey portion of this research has a standard error of ±3.21% at a 95% level of confidence. The Survey on Cosmetic Procedures Performed in 2008 was compiled, tabulated, and analyzed by Industry Insights, Inc. (www.industry insights.com), an independent research firm based in Columbus, Ohio. Market Overview and Assessment There were 10,258,556 surgical and nonsurgical procedures performed in 2008. The 2008 market performance was down by 12.33% or 1,442,478 procedures compared to the number of procedures in 2007 which was 11,701,031. This reduction in the number of procedures resulted in a revenue loss of $1.37 billion. To help put this number into perspective and demonstrate the growth of the market over the last 10 years, it is important to recognize that the 2008 market loss represents half of the entire market just
10 years previously. In the 1998 market, 2,772,924 procedures were performed. In the years since that time, there have been only two other market declines. The first was in 2002 with a loss of 18.66% and the second in 2005 with a loss of 3.6% of the total market volume over the previous year. With the exceptions of 2002 and 2005, the years between1998 and 2004 were years of exceptional growth ranging from a low of 19.78% in 2003 to the peak performing year 1999 which experienced 66.14% growth. Since 1997 there has been over a 162% increase in the total number of cosmetic procedures performed. Nonsurgical procedures have led in the percentage growth category, coming in at over 233%, while surgical procedures have grown by almost 80% since 1997. In 2008, women accounted for almost 92% of the procedures. The age of patients with the highest number of cosmetic procedures in 2008 ranged between 35 and 50 years, representing 44.6% of the total market volume. Breaking Down the Economics of Surgical and Nonsurgical Proceduresa In order to organize the data for increased comprehension and ease of use, the top five surgical and the top five nonsurgical procedures will be reviewed and analyzed (Fig. 3.1A and B). The complete data set is available at the ASAPS website: http://www.surgery.org/. Surgical Procedures: The Top Five Surgical Procedures The top five surgical procedures are ranked by total expenditure or revenue generated (Fig. 3.2A and B). Figures are for physician/surgeon fees only and do not include fees for the surgical facility, anesthesia, medical tests, prescriptions, surgical garments, or other miscellaneous costs related to surgery. Figures for procedures often performed on more than one site in the same session reflect typical fees for one site. Breast Augmentationb Breast augmentation held the first position among the cosmetic surgery procedures in the years 2006, 2007, and 2008. This procedure accounted for 11.3% of the total revenue generated in 2008 within the aesthetic market (Fig. 3.3). It generated $1,327,566,071 in revenue, which was down from 2007 by 13.6% or $208,925,578. The national average physician/surgeon fee per surgery in 2008 was $3744, which was a decrease by $144 per surgery (Fig. 3.4). This procedure was performed 355,671 times in 2008, which was a decrease of 10.96% resulting in 43,769 fewer surgeries. The average number of breast augmentations in 2008 per ASAPS member was 62.6, resulting in 15.5 fewer procedures. Silicone Gel Vs. Saline Implants. Saline implants were the first choice of implant 52% of the time in 2008. The use of silicone gel implants continued to increase obtaining a 48% market share. For the last 3 years, saline implant usage has decreased significantly while silicone gel implants demonstrated a consistent growth.
a b
The American Society for Aesthetic Plastic Surgery. The American Society for Aesthetic Plastic Surgery.
9
10
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT 12,000,000 10,000,000 8,000,000 6,000,000 4,000,000 2,000,000 0 2006
2007
2008
Surgical procedures
1,922,788
2,079,032
1,766,695
Nonsurgical procedures
9,533,980
9,621,999
8,491,861
2006
2007
2008
Surgical procedures
$7,632,270,642
$8,395,851,754
$7,222,233,062
Nonsurgical procedures
$4,542,014,327
$4,752,340,323
$4,559,075,462
(A) $9,000,000,000 $8,000,000,000 $7,000,000,000 $6,000,000,000 $5,000,000,000 $4,000,000,000 $3,000,000,000 $2,000,000,000 $1,000,000,000 $0
(B) Figure 3.1 Market volume for surgical vs. nonsurgical procedures: (A) total number of procedures; (B) total expenditure. Source : The American Society for Aesthetic Plastic Surgery.
The national average physician/surgeon fee per procedure for silicone gel implants in 2008 was $3885 and $3603 for saline implants. Silicone gel implants generated $637,177,252 and saline implants generated $690,338,819 in revenue. Lipoplastyc Lipoplasty was the second among the top five cosmetic surgery procedures in 2008. This procedure accounted for 8.43% of the total revenue generated in 2008 within the aesthetic market (Fig. 3.5). It generated $984,028,900 in revenue, which was down from 2007 by 26.45% or $353,867,291. The national average physician/surgeon fee per surgery in 2008 was $2903, which was a decrease of $38 per surgery (Fig. 3.6). This procedure was performed 341,144 times in 2008, which was a decrease of 25.32%, resulting in the largest procedure decline in 2008 of 115,684 fewer surgeries. The average number of procedures in 2008 per ASAPS member was 55.1, resulting in 17 fewer procedures.
c
The American Society for Aesthetic Plastic Surgery.
Suction-assisted Vs. Ultrasound-assisted Lipoplasty. Suction-assisted lipoplasty was still the first choice 81.7% of the time in 2008. Ultrasoundassisted lipoplasty lost market share from 20.4% in 2007 to 18.3% in 2008. For the last 3 years, suction-assisted lipoplasty has been the first choice by a significant margin. The national average physician/surgeon fee per procedure for suctionassisted lipoplasty in 2008 was $2874 and $2933 for ultrasound-assisted lipoplasty. Suction-assisted lipoplasty generated $804,268,214 and ultrasound-assisted lipoplasty generated $179,760,686 in revenue. Faceliftd Facelift was the third among the top five cosmetic surgery procedures in 2008. This procedure accounted for 7.6% of the total revenue generated in 2008 within the aesthetic market. It generated $891,524,394 in revenue, which was down from 2007 by 4.99% or $46,807,663. The national average physician/surgeon fee per surgery in 2008 was the highest fee for a surgery or procedure at $6728. This was a decrease of $64 per surgery.
d
The American Society for Aesthetic Plastic Surgery.
11
AESTHETIC MARKETPLACE ECONOMICS $1,800,000,000 $1,600,000,000 $1,400,000,000 $1,200,000,000 $1,000,000,000 $800,000,000 $600,000,000 $400,000,000 $200,000,000 $0 2006
2007
2008
$907,651,429
$991,544,589
$806,185,765
$1,379,731,684
$1,536,491,649
$1,327,566,071
$791,678,946
$829,274,709
$787,844,501
$903,002,712
$938,332,057
$891,524,394
$1,162,407,264
$1,337,896,191
$984,028,900
Abdominoplasty Breast augmentation Breast reduction Facelift Lipoplasty (A) $8,000 $7,000 $6,000 $5,000 $4,000 $3,000 $2,000 $1,000 $0
2006
2007
2008
Abdominoplasty
$5,263
$5,350
$5,470
Breast augmentation
$3,678
$3,888
$3,744
Breast reduction
$5,429
$5,417
$5,630
Facelift
$6,532
$6,792
$6,728
Lipoplasty
$2,902
$2,941
$2,903
(B) Figure 3.2 (A) Total expenditure or revenue generated per procedure and (B) national average for physician/surgeon fees per procedure for the top five surgical procedures. Source : The American Society for Aesthetic Plastic Surgery.
$1,200,000,000
This procedure was performed 132,504 times in 2008, which was a decrease of 4.09%, resulting in the smallest procedure decline in 2008 of 5649 fewer surgeries. The average number of procedures in 2008 per ASAPS member was 16.1, resulting in 3.4 fewer procedures.
80.3%
58.1%
$1,000,000,000
$800,000,000
52%
$600,000,000 48% $400,000,000 41.9% $200,000,000 19.7% $0 2006
2007
Silicone gel implants
2008 Saline implants
Figure 3.3 Total expenditures with percentage of market share for breast augmentation using silicone gel implants vs. saline implants. Source : The American Society for Aesthetic Plastic Surgery.
Abdominoplastye Abdominoplasty was the fourth among the top five cosmetic surgery procedures in 2008. This procedure accounted for 6.8% of the total revenue generated in 2008 within the aesthetic market. It generated $806,185,765 in revenue, which was down from 2007 by 18.69% or $185,358,824. The national average physician/surgeon fee per surgery in 2008 was $5470, which was one of only two surgery fee increases in 2008. This was an increase of $120 per surgery. This procedure was performed 147,392 times in 2008, which was a decrease of 20.47%, resulting in the second highest surgical procedure percentage decrease in 2008. There were 37,943 fewer surgeries in 2008. The average number of procedures in 2008 per ASAPS member was 22, resulting in 8.3 fewer procedures per ASAPS member.
e
The American Society for Aesthetic Plastic Surgery.
12
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT $4,200 $4,100 $4,000 $3,900 $3,800 $3,700 $3,600 $3,500 $3,400 $3,300 $3,200 2006
2007
2008
Silicone gel implants
$3,813
$4,087
$3,885
Saline implants
$3,544
$3,690
$3,603
Figure 3.4 National average for physician/surgeon fees per procedure for breast augmentation using silicone gel implants vs. saline implants. Source : The American Society for Aesthetic Plastic Surgery.
This procedure was performed 139,926 times in 2008, which was a decrease of 8.60%. There were 13,161 fewer surgeries in 2008. The average number of procedures in 2008 per ASAPS member was 16.6, resulting in 3.8 fewer procedures per ASAPS member.
$1,200,000,000
$1,000,000,000
Nonsurgical Procedures: The Top Five Nonsurgical Procedures The top five nonsurgical procedures are ranked by total expenditure or revenue generated (Fig. 3.7A and B).
$800,000,000
$600,000,000 79.6% 82.3% 81.7%
$400,000,000
$200,000,000 17.7%
20.4% 18.3%
$0 2006 Suction-assisted
2007
2008
Ultrasound-assisted
Figure 3.5 Total expenditures for suction-assisted vs. ultrasound-assisted lipoplasty. Source : The American Society for Aesthetic Plastic Surgery.
Breast Reduction (Women) Breast reduction for women was the fifth among the top five cosmetic surgery procedures in 2008. This procedure accounted for 6.7% of the total revenue generated in 2008 within the aesthetic market. It generated $787,844,501 in revenue, which was down from 2007 by 5% or $41,430,208. The national average physician/surgeon fee per surgery in 2008 was $5630, which was the highest increase in surgery fees in 2008. This was an increase of $213 per surgery.
Botoxf Botox held the first position among nonsurgical cosmetic surgery procedures in the years 2006, 2007, and 2008. This procedure accounted for 9.3% of the total revenue generated in 2008 within the aesthetic market. It generated $1,090,374,483 in revenue, which was up from 2007 by 3.4% or $35,807,747. The national average physician/surgeon fee per procedure for Botox in 2008 was $443, which was an increase of $63 per procedure. This procedure was performed 2,464,123 times in 2008, which was a decrease of 11.21%, resulting in 311,053 fewer procedures. The average number of procedures in 2008 per ASAPS member was the highest at 222.5, accounting for 24% of the market. The procedure decrease resulted in 129.9 fewer procedures performed per ASAPS member. Laser Skin Resurfacing Laser skin resurfacing was the second among the top five nonsurgical cosmetic procedures in 2008. This procedure accounted for 6.4% of the total revenue generated in 2008 within the aesthetic market (Fig. 3.8). It generated $751,926,177 in revenue, which was up from 2007 by 70.94% and was the highest growth percentage of all surgeries and procedures on this list. Laser skin resurfacing grew by $312,039,521 over 2007. The national average physician/surgeon fee per surgery in 2008 was $1619, which was an increase of $120 per procedure (Fig. 3.9). This procedure was performed 570,880 times in 2008. This was the largest procedure percentage increase at 11.96% in 2008, resulting in 60,979 more procedures. The average number of procedures in 2008 per ASAPS member was 20.1, resulting in 2.1 more procedures.
f
The American Society for Aesthetic Plastic Surgery.
13
AESTHETIC MARKETPLACE ECONOMICS $2,980 $2,960 $2,940 $2,920 $2,900 $2,880 $2,860 $2,840 $2,820 2006
2007
2008
Suction-assisted
$2,868
$2,920
$2,874
Ultrasound-assisted
$2,936
$2,963
$2,933
Figure 3.6 National average for physician/surgeon fees per procedure for suction-assisted vs. ultrasound-assisted lipoplasty. Source : The American Society for Aesthetic Plastic Surgery.
$1,400,000,000 $1,200,000,000 $1,000,000,000 $800,000,000 $600,000,000 $400,000,000 $200,000,000 $0 2006
2007
2008
$1,326,367,287
$1,054,566,736
$1,090,374,483
Laser skin resurfacing
$546,256,262
$439,886,656
$751,926,177
Hyaluronic acid
$848,191,987
$834,460,585
$714,165,690
Laser hair removal
$550,344,982
$546,698,426
$417,299,496
Chemical peel
$485,958,315
$412,907,539
$416,573,762
2006
2007
2008
$417
$380
$443
$1,593
$1,499
$1,619
Hyaluronic acid
$532
$576
$566
Laser hair removal
$373
$387
$326
Chemical peel
$870
$718
$704
Botox
(A) $1,800 $1,600 $1,400 $1,200 $1,000 $800 $600 $400 $200 $0 Botox Laser skin resurfacing
(B) Figure 3.7 (A) Total expenditure or revenue generated per procedure and (B) national average for physician/surgeon fees per procedure for the top five nonsurgical procedures. Source : The American Society for Aesthetic Plastic Surgery.
14
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
Ablative Vs. Nonablative Resurfacing. Nonablative resurfacing was still the first choice 71.2% of the time in 2008. Ablative resurfacing lost market share from 43.1% in 2007 to 28.8% in 2008. The national average physician/surgeon fee per procedure for nonablative resurfacing in 2008 increased by $565 to $1145. Ablative resurfacing decreased by $324 to $2094 in 2008. Nonablative resurfacing generated $535,467,810 and ablative resurfacing generated $216,458,367 in revenue. Hyaluronic Acid (Injectible)g Injectible hyaluronic acid was the third among the top five nonsurgical cosmetic surgery procedures in 2008. This procedure accounted for 6.1% of the total revenue generated in 2008 within the aesthetic market. It generated $714,165,690 in revenue, which was down from 2007 by14.42% or $120,294,895. The national average physician/surgeon fee per procedure in 2008 was $566, which was a decrease of $10 per procedure. This procedure was performed 1,262,848 times in 2008, which was a decrease of 12.83%, resulting in 185,868 fewer procedures. The average $600,000,000 $500,000,000
71.2% 83.1%
$400,000,000 $300,000,000
56.9%
$200,000,000
number of procedures in 2008 per ASAPS member was 81.5, resulting in 26.5 fewer procedures performed per ASAPS member. Laser Hair Removalh Laser hair removal was the fourth among the top five nonsurgical cosmetic surgery procedures in 2008. This procedure accounted for 3.5% of the total revenue generated in 2008 within the aesthetic market. It generated $417,299,496 in revenue, which was down from 2007 by23.67% or $129,398,930. The national average physician/surgeon fee per procedure in 2008 was $326, which was a decrease of $61 per procedure. This procedure was performed 1,280,964 times in 2008, which was a decrease of 9.32%, resulting in 131,693 fewer procedures. The average number of procedures in 2008 per ASAPS member was 90.4, resulting in 38.7 fewer procedures performed per ASAPS member. Chemical Peel Chemical peels were the fifth among the top five nonsurgical cosmetic surgery procedures in 2008. This procedure accounted for 3.5% of the total revenue generated in 2008 within the aesthetic market. It generated $416,573,762 in revenue, which was up from 2007 by 0.89% or $3,666,223. The national average physician/surgeon fee per procedure in 2008 was $704, which was a decrease of $14 per procedure. This procedure was performed 591,808 times in 2008, which was an increase of 2.91%, resulting in 16,728 more procedures. The average number of procedures in 2008 per ASAPS member was 39.7, resulting in 3.5 more procedures performed per ASAPS member. CONCLUSION
$100,000,000
28.8%
43.1% 16.9%
$0 2006
2007 Ablative
2008
Nonablative
Figure 3.8 Total expenditures with percentage of market share for ablative vs. nonablative laser skin resurfacing.
The economics of the aesthetic marketplace have grown and contracted dramatically over the past few years. Some of this growth is due to the fact that the procedures have gotten so much better than the ones that preceded them. Contractions in the aesthetic marketplace have typically been due to economic downturns or from news-related blips. During contractions, practices that have coherent marketing plans can alter their strategies and try to convert to less invasive, less expensive procedures. During periods of expansion, practices that can scale with the growth have an opportunity to grow. During either, it is essential to have an understanding of economics as it pertains to an aesthetic practice.
$3,000 $2,500 $2,000 $1,500 $1,000 $500 $0
Ablative Nonablative
2006
2007
2008
$2,341
$2,418
$2,094
$845
$580
$1,145
Figure 3.9 National average for physician/surgeon fees per procedure for ablative vs. nonablative laser skin resurfacing. g h
The American Society for Aesthetic Plastic Surgery. The American Society for Aesthetic Plastic Surgery.
15
AESTHETIC MARKETPLACE ECONOMICS
APPENDIX
500,000 450,000 400,000 350,000 300,000 250,000 200,000 150,000 100,000 50,000 0 2006
2007
2008
Abdominoplasty
172,457
185,335
147,392
Breast augmentation
383,886
399,440
355,671
Breast reduction
145,822
153,087
139,926
Facelift
138,245
138,153
132,504
Lipoplasty
403,684
456,828
341,144
2006
2007
2008
Abdominoplasty
1.5%
1.6%
1.4%
Breast augmentation
3.4%
3.4%
3.5%
Breast reduction
1.3%
1.3%
1.4%
Facelift
1.2%
1.2%
1.3%
Lipoplasty
3.5%
3.9%
3.3%
(A) 4.5% 4.0% 3.5% 3.0% 2.5% 2.0% 1.5% 1.0% 0.5% 0.0%
(B) Figure 3.A1 (A) Number of procedures, (B) percentage of total procedures. (Continued)
16
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT 90 80 70 60 50 40 30 20 10 0 2006
2007
2008
Abdominoplasty
31
30.3
22
Breast augmentation
73
78.1
62.6
Breast reduction
23
20.4
16.6
Facelift
20.7
19.5
16.1
Lipoplasty
72.7
72.1
55.1
(C) Figure 3.A1 (Continued) (C) Average number of procedure per ASAPS member for the top five surgical procedures. Source : The American Society for Aesthetic Plastic Surgery.
3,500,000 3,000,000 2,500,000 2,000,000 1,500,000 1,000,000 500,000 0 2006
2007
2008
3,181,592
2,775,176
2,464,123
576,509
509,901
570,880
Hyaluronic acid
1,593,554
1,448,716
1,262,848
Laser hair removal
1,475,296
1,412,657
1,280,964
558,432
575,080
591,808
2006
2007
2008
Botox
27.8%
23.7%
24.0%
Laser skin resurfacing
5.0%
4.4%
5.6%
Hyaluronic acid
13.9%
12.4%
12.3%
Laser hair removal
12.9%
12.1%
12.5%
Chemical peel
4.9%
4.9%
5.8%
Botox Laser skin resurfacing
Chemical peel (A) 30.0% 25.0% 20.0% 15.0% 10.0% 5.0% 0.0%
(B) Figure 3.A2 (A) Number of procedures, (B) percentage of total procedures. (Continued)
17
AESTHETIC MARKETPLACE ECONOMICS 400 350 300 250 200 150 100 50 0 2006
2007
2008
183.1
352.4
222.5
Laser skin resurfacing
17.4
18
20.1
Hyaluronic acid
78.3
108
81.5
Laser hair removal
62.8
129.1
90.4
Chemical peel
25.5
36.2
39.7
Botox
(C) Figure 3.A2 (Continued) (C) Average number of procedure per ASAPS member for the top five nonsurgical procedures. Source : The American Society for Aesthetic Plastic Surgery.
4
Photography for the aesthetic patient Holly P. Smith
Photography serves a multitude of purposes in medicine; research, medical–legal reasons, comparative studies, and publication as well as for marketing purposes. All of these reasons depend on accurate photographic documentation. The majority of physicians and office staff are not properly trained in existing photographic standards for good patient photography. It is important to implement these standards into your practice because aesthetics is all about aesthetics. It is about being able to visually show an aesthetic improvement and if your photography is not good, it can often depict inaccurate results or more often, no results at all. In a cosmetic or aesthetic practice, the practice of photography can be extremely beneficial especially for communicating what your goals are to your patient. This can be performed through simulated imaging and pre-operative/treatment analysis of your patients’ photographs. Providing photography in your practice is providing a service to your patients. It is one of the most valuable tools that can assist your practice in many ways. For example, photographing your patient’s result throughout different time intervals can reinforce your patient’s perception of treatment success, which leads them to experience a greater level of satisfaction with your products and services. Another example is by providing samples of your work rather than using stock imagery. This helps gain trust with your patients by showing them that you get results. You can explain a procedure or treatment process to a patient but nothing is going to compare to showing a patient the “before and after” photographic result of an outcome you performed. Photography sets the foundation for how your work will be evaluated and presented. Setting high standards in photography and using existing protocols will ensure that your talent is properly represented. PRINCIPLES OF PHOTOGRAPHY
Staff and physicians who may not have a background in photography perform most patients’ photography. Knowing photographic basics will help improve patient photography when photographing in the operating room or clinical setting. The following are the fundamental principles of photography. Aperture Aperture refers to the size of the adjustable opening in the iris in a lens that determines the amount of light falling onto the film or sensor. The size of the opening is measured using an f-number or “f-stop” (f8, f11, etc.). Because f-numbers are fractions of the focal length, “higher” f-numbers represent smaller apertures (1). The smaller the aperture, the greater the depth of field. This means that if you use a smaller aperture, you will have the forefront, middle, and background in sharp focus. For patient photography, it is important to use a small aperture, as you want all areas to be in focus. An aperture between f11 and f22 is suitable for patient photography. Shutter Speed The shutter speed determines how long the iris of the camera is open exposing the film or sensor to light. For instance, a shutter speed of 1/125 s will expose the sensor for 1/125th of a second. Electronic shutters act in a similar way by switching on the light sensitive photodiodes of the sensor as long as requested by the shutter speed (2). For patient photography, it is important to use a shutter speed faster than 1/60.
18
Anything under a 60th of a second can produce blurring if the patient or photography moves even slightly. Depth of Field Depth of field refers to the distance between the closest and farthest in-focus area of a photograph (also called the focal range). Depth of field is affected by the aperture, subject distance, focal length, and film or sensor format. The smaller the aperture, the greater the depth of field meaning that objects within a certain range behind or in front of the main focus point will appear sharp (3). Focal Length The focal length of a lens is defined as the distance in mm from the optical center of the lens to the focal point, which is located on the sensor or film. The focal length establishes the field of view. The longer the focal length the narrower and compressed the field of view becomes. The shorter the focal length, the larger the field of view becomes (4). Camera lenses are categorized by normal, telephoto, and wide angle, according to the focal length and film size.
•
• •
Normal—When the focal length of a lens is in a range close to the diagonal measurement of the film/sensor’s format, the lens is said to be “normal.” For example, 43.27 mm is the exact distance of the diagonal of a 35 mm (35 × 24) film plane; therefore, the closest equivalent lens would be 50 mm. The 50 mm lens has a field of view of 46°. Wide—When the focal length is shorter than the film/sensor’s diagonal; it’s a “short” or wide-angle lens. For example, a 20 mm lens on a 35 mm (35 × 24) film plane would be considered a wide angle. The 20 mm lens has a field of view of 94°. Telephoto—When the focal length of a lens is longer than the film/sensor’s diagonal; it’s a “long” or telephoto lens. For example, a 105 mm lens on a 35 mm (35 × 24) film plane would be considered telephoto. The 105 mm lens has a field of view of 23°.
Single Lens Reflex (SLR) It is a camera in which a system of mirrors shows the user the image precisely as the lens renders it. This is the recommended camera type to use for patient photography. Through the Lens (TTL) Refers to a metering system in which a light sensitive mechanism within the camera body measures exposure from the image light passing through the lens. ISO How sensitive the camera’s sensor is to the amount of light falling on it. Raising the ISO of a camera makes the sensor more sensitive to light. This can be useful when photographing in low light situations where you don’t want to use a flash. The disadvantage to raising your ISO is that you increase camera noise. DIGITAL CAMERA MODES AND WHAT THEY REPRESENT
Digital cameras offer many shooting modes for photographing in various settings. Professional digital single lens reflex (DSLR) cameras primarily have the basic modes while prosumer or consumer digital cameras may
PHOTOGRAPHY FOR THE AESTHETIC PATIENT offer some of the basics but also include some predetermined settings that are represented by icons. Some of these modes may and may not be useful for patient photography. Below is a list of some of the basic modes and icons found on digital cameras and what they represent. Aperture Priority Aperture priority mode if generally represented by an AV or A depending on your camera. This is the preferred mode for photographing patients. This allows the user to choose the aperture and the camera selects the shutter speed to accommodate correct exposure. It is important to have a small aperture when photographing patients because you want all areas to be in focus-greater depth of field. Shutter Priority Mode Shutter priority mode is represented by TV or S. This mode allows users to choose the shutter speed. This mode would be important if you were trying to capture a fast moving object without blur, but it is typically not used in patient photography. Manual Mode Manual mode is represented by an M. Manual mode allows the user to choose both the shutter and aperture. This is the preferred method when photographing with studio lights in a clinical setting as it gives you complete control over the exposure of the scene. Program Mode Program mode is represented by a P. The program mode allows the user partial control over both the aperture and shutter. This mode is not necessary for patient photography. Symbol of Person Running This mode is typically used for fast moving subjects. It sets your shutter speed to a fast setting and raises your ISO. This mode is not necessary for patient photography. Symbol of Mountains Depending on your camera, this mode typically sets your aperture to the smallest setting possible given the available light, and can raise your ISO. Although it may seem unlikely, this mode can be used for capturing subjects in greater depth of field than in other modes. Symbol of a Person’s Profile This mode represents portrait mode. Although it may seem like a good mode for capturing the face of a subject, it is not recommended to use this mode as it widens the aperture putting the background out of focus. For patient photography, it is best to use a small aperture so that all features are in focus. Symbol of Flower (Macro Mode) This mode represents macro mode. It is important to know about macro mode because it can be useful to use in some situations but it does have its disadvantages. With digital photography, the term largely refers to the camera’s closest focusing distance. The macro mode generally has a flower icon. When this icon is chosen, it tells your camera that you want to focus on a subject closer to your lens (5). Typically the macro mode in patient photography is used when the camera needs to be 6 inches or less in distance to the subject being photographed. The disadvantage when photographing in macro mode for patient photography is that it typically tells your camera to use a large aperture, which decreases your depth of field. WHAT TO LOOK FOR IN A DIGITAL CAMERA
There are many objectives to look for when shopping for a digital camera.
19
One of them is the capability of the camera’s zoom. There are typically two types: digital and optical zoom. The digital zoom takes a part of the scene and interpolates data to fit on the CCD sensor plane. It mimics a greater zoom without actually gaining any additional image detail. It often results in a blurry and pixilated image. The optical zoom changes the amount of the scene falling on to the CCD sensor. It is preferable to have an optical zoom because the information is not interpolated and can be enlarged and cropped with higher quality results (6). A 3× optical zoom will give you a focal length of 35 to 105 mm, which is the minimum necessary for photographing the face and body. There are different types of viewfinders available on digital cameras. The viewfinder is the window you look through to compose the scene (7). The following are examples of the different types of viewfinders. Optical Viewfinder on a Digital Compact Camera The optical viewfinder on the digital compact camera is positioned above the camera lens so what you see through the optical viewfinder is different from what the lens projects onto the sensor. This type of sensor has parallax error, which can make framing inaccurate when photographing close-up. Optical Viewfinder on a Digital SLR Camera (TTL) The optical viewfinder of a digital SLR shows what the lens will project on the sensor via a mirror and a prism. It does not have parallax errors and shows information at the bottom of the LCD viewfinder that has a camera and exposure settings. LCD on a Digital Compact Camera (TTL) The LCD on a digital compact camera shows in real time what is projected onto the sensor by the lens. This is also called “through-the-lens” (TTL) viewing. The LCD does not have parallax errors but does shorten battery life and can be difficult to see LCD screen in bright sunlight conditions. Electronic Viewfinder (EVF) on a Digital Compact Camera (TTL) The electronic viewfinder shows in real time what is projected onto the sensor by the lens. It simulates in an electronic way the effect of the (superior) optical TTL viewfinders found on digital SLRs and doesn’t suffer from parallax errors. EVF allows more accurate framing but can shorten the battery life. Video Capability Another important feature to look for when purchasing a digital camera is whether or not it has video capability. Many consumer cameras come with digital video capability but some do not. Having the capability to shoot digital video on your camera is useful for relaying important information between physicians, patients, and for media presentations. Flash Options There are many options for flash capability on digital cameras. If you are using studio lights with your digital camera, it is important that you purchase a digital SLR that has either a hot shoe or an external flash input connection on the camera. These types of connections allow the user more flash and remote flash synchronization options. CONSIDER THE PATIENT
Your patient photography should be performed in a private location, even if it only consists of photographs of the face. Public areas such as open rooms or hallways should be avoided when photographing your patient. Many patients may feel intimidated and embarrassed about being photographed so ensuring privacy will make the experience
20
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
Figure 4.1 Watermark of doctor’s name shown on top of an image.
more comfortable. Being aware of how your patient feels about the experience and discussing the reasons for taking the photographs with your patient will help make them more at ease, especially when documenting more sensitive areas of the body. Allow them to express any concerns they may have and discuss them with your patient prior to photographing them. The person responsible for photographing should always inform the subject what areas are being recorded in the camera’s field of view. To provide anonymity, the head should never be recorded in the same field of view with the breasts or body. Although a chaperone is not typically used when photographing, patients should be offered the opportunity for a chaperone if they would like one. If the patient is under 18, a parent or legal guardian must be present during the photography session. PATIENT PREPARATION
Photographic Consent The practice of photography should be included in the Health Insurance Portability and Accountability Act (HIPAA) mandated notice of information signed on admission (8). This should cover photographing and ownership of photographs for treatment purposes only. Below is an example of what is typically incorporated into the informed consent. Sample Paragraph for HIPAA Mandated Notice of Information Signed on Admission that Covers Photography for Treatment Purposes I understand that photographs, videotapes, digital, or other images may be recorded to document my care, and I consent to this. I understand that [organization name] will retain the ownership rights to these photographs, videotapes, digital, or other images, but that I will be allowed access to view them or obtain copies. I understand that these images will be stored in a secure manner that will protect my privacy and that they will be kept for the time period required by law or outlined in [organization name]’s policy. Images that identify me will be released and/or used outside the institution only upon written authorization from my legal representative or me. If you want to use your patient’s photographs for non-treatment purposes; education, publication, marketing, Internet, discuss this with your patient and request that they sign a consent for non-treatment purposes, which lists the possible uses of the images. This should be a separate consent form and should be made as a request only.
Sample Photography for Non-treatment Purposes Consent I hereby authorize ______________ to make audio recordings or to take photographs, videotape, or digital images of me (“Images”). I understand that ______________ may use and release my images to the general public for the following purposes: (1) educational lectures and presentations for health care professionals; (2) scientific publications such as journals or books; (3) patient education materials; (4) broadcast, print or Internet media for educational or public interest purposes. I understand that after release of my images to the general public, they may be subject to redisclosure. I understand this authorization is voluntary and I may refuse to sign. There are different state laws that govern the use of photographs so always review your consent form with an attorney prior to using. If the patient is under 18, a parent or legal guardian should be requested to sign the photographic consent form for non-treatment purposes and use. Make a point to discuss the release for the Internet. Because of the nature of the web, any image can be downloaded and repurposed so make sure your patient understands this possibility. To deter others from taking your work, embed a watermark with your name/practice name on top of the image (Fig. 4.1). In the past, masking the eyes was used to de-identify a subject. Today the stance that the International Committee for Medical Journal Editors takes is that “Identifying details should be omitted if they are not essential, but patient data should never be altered or falsified in an attempt to attain anonymity. Complete anonymity is difficult to achieve, and informed consent should be obtained if there is any doubt. For example, masking of the eye region in photographs of patients is inadequate protection of anonymity” (Fig. 4.2) (8). Attention to Detail After the proper consents have been obtained, the patient can be photographed. Attention to detail is an important aspect of medical photography. You want your photographs to be generic and neutral to best depict the anatomy. This can be achieved by having the subject remove any jewelry (including navel rings) from the camera’s field of view as this can often distract the viewer from seeing what is intended. Personal undergarments can be another distraction and disposable undergarments should be supplied for patients to wear to achieve consistency throughout a series of photographs taken at different time intervals and to keep the patients generic looking.
PHOTOGRAPHY FOR THE AESTHETIC PATIENT
(A)
21
(B) Figure 4.2 (A, B) Techniques used in the past to de-identify a subject.
Make-up should be removed prior to photographing as it can camouflage the skin’s condition and texture. Having cleaners readily available for your patients to use can speed up the process of make-up removal. After your subject has washed their face, wait until the skin has returned to its normal moisture level before photographing. This will ensure that it is in its most natural state. Requesting the patient to come in without make-up prior to their consultation is the best way to ensure accurate documentation. Hair should be pulled back with hair-colored headbands. If the bangs are too short to be pulled back, have hair-colored bobby pins available for use. Long hair should be pushed off the shoulders. People have been trained to smile when being photographed but this should be avoided for patient photography as it can distort facial features. Unless a particular series calls for animation, careful attention should be paid to not animating the face. Having someone completely relax his or her face is not typically a natural feeling. Request your patient to relax their brow, eyes, and jaw rather than requesting them to just relax their face. This approach can be more successful as often patients don’t realize these areas are animated until they are specifically pointed out. If a series calls for repose and animated views, ensure that the repose views are photographed prior to the animated ones as it is often difficult for the subject to completely relax the facial muscles after animation. These small nuances can often make extreme differences in comparative photographs, especially in non- and minimally invasive procedures such as botulinum toxin injections. If a patient is having difficulty with keeping their eyes open during the flash, have the subject close their eyes and then take the photograph right as they open them. The goal of clinical cosmetic photography is to provide accurate photographic representations from clinical results. This documentation relies on standardizing photographic variables. These variables can be categorized in five components: Standardized views, positioning and alignment, lighting, focal length and camera-to-subject distance, and simplifying the background. Standardized Views Different staff members often perform photography in a clinical practice so it is helpful to use a standardized series. A standardized series is a
predetermined set of photographs per procedure that ensures that the patient will have the same views photographed each time they come in. The series is built for each specific treatment and the patient is generally photographed either 180° or 360° in 45° increments, depending on the procedure and treatment. It is recommended to have the series readily available for whoever is performing the photography. The following are standardized series for some of the cosmetic and aesthetic procedures (Figs. 4.3–4.11). These series not only ensure that the same views are photographed, but they also help define reference points for accurate positioning. There are variables that exist in each face series depending on the surgical procedure or treatment being performed. These variables are noted in each section.a POSITIONING AND ALIGNMENT
Proper anatomical positioning and alignment are important. Identifying reference points and using positioning devices can be helpful in achieving this. For example, placing a target on the wall for the patient to view in the lateral position can help with standardizing the head alignment. Head Positioning: The Frankfort Plane vs. the Natural Horizontal Facial Line The Frankfort plane is used as a reference line for correct head positioning in an X-ray film and has also been used by physicians as a standard for head alignment when photographing the face. Some physicians choose to use the natural horizontal facial plane for alignment (9,10).
a
Author’s note : The focal length information supplied is assuming a 35 mm format of film and/or equivalent CCD/CMOS size of 24 × 36 mm. On some digital cameras, an equivalent lens will have a much smaller focal length because image sensors are much smaller than 35 mm film. For example, while 35 mm has an area of 36 × 24 mm, a 2/3-inch image sensor is only 8.8 by 6.6 mm (11 mm diagonal). For cameras with smaller sensors, a focal length modifier is necessary for achieving the same focal length as with the 35 mm lens.
22
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
(A)
(D)
(B)
(E)
Figure 4.3 (A–F) Standardized face/neck series. Camera orientation: Focal length lens/distance: Landmarks: Reference points:
Key points:
(C)
(F) Optional views showing subject with teeth gritting on the left and head down on the right. These views help to depict platysmal banding and submental fat.
Vertical 80 mm at 1 m full face 80 mm at 0.6 close up views Hairline to clavicle Anterior—Align naturally as if subject were looking into a mirror Obliques—Medial part of the eye to the dorsum Laterals—Align brow to chin Make sure that the head is in the standard anatomical position and that the patient is sitting straight and not slumping. Any degree of neck flexion or head retraction can greatly enhance the effect of submental fat/jowl line or conversely neck extension can improve the jowl line.
The Frankfort Plane (Fig. 4.12A) Horizontal plane that transverses the top of the tragus (external auditory canal) across the infraorbital rim (11). Can cause noticeable changes in jaw definition and submental soft tissue (12).
• •
The Natural Horizontal Facial Plane (Fig. 4.12B) Achieved when the patient looks straight ahead as if looking into a mirror at eye level (10). Preferred for use in plastic surgery photography. Used in patients that have low-set ears (10).
• • •
Lateral Face Alignment Having the subject open their mouth and checking commissure alignment can perform proper alignment of the lateral side of the face. This
helps to prevent over or under side-to-side rotation of the head. To help correct the up and down orientation of the head, vertically align the brow with the chin. Consistency in head alignment from photographs taken during different time intervals is important. Placing a sticker on each wall at eye level height and asking the subject to point their nose at it can achieve this (Fig. 4.13). LIGHTING
Lighting is one of the most important variables to standardize in cosmetic photography because it can dramatically change the appearance of the patient with even slight changes. All light has color depending on its wavelength. Our eyes have the ability to correct for color differences in light; the camera however, does not. This can be easily demonstrated by taking a photograph in ambient light without the use of a flash. Your photograph will have an orange colorcast.
PHOTOGRAPHY FOR THE AESTHETIC PATIENT
(A)
(B)
(C)
(D)
23
(E) Figure 4.4 (A–E) Standardized eye/brow series. (Photographs below are to be taken in addition to the face series.) Focal length lens/distance: 80 mm at 1 m full face 80 mm at 0.6 close up views Camera orientation: Horizontal Landmarks: Eyes—Slightly above eyebrows to slightly below lower orbital rim. Brow—Just above hairline to just below eyebrows Eyes looking into camera with pupils aligned horizontally Eyes looking up (shows submental lower eyelid fat and any upper eyelid hooding) Eyes looking down (shows submental lower eyelid fat and excess upper eyelid skin) Brow (shows detail of horizontal lines and close up of glabellar muscle) Key points: Make sure that the brow is not raised in the photograph with the eyes looking up. Have the subject relax their brow while simultaneously looking up with their eyes.
Using a daylight balanced flash in your photography will help prevent this so you can depict more accurate color for your patient’s skin (Fig. 4.14). Not only do you want to use a flash, you want to use multiple flashes. Using a single on camera flash can produce harsh contrasting of the shadows and highlights.
There is not one lighting technique that can produce the proper lighting for all procedures, so decisions need to be made before setting up your lights. The size of the area, the clinic workflow, and the staff experience are all factors that should be addressed prior to choosing lighting techniques for your photography.
24
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
Generalized Lighting The typical studio lighting setup has two flashes (strobes) positioned at 45° angles and 3 to 6 feet away from the subject (Fig. 4.15). This studio lighting produces an overall even distribution of light, is easily reproducible, and works well for most face and body procedures.
(A)
It also provides an efficient clinic workflow. This lighting setup is best used in a clinical setting where multiple staff members are assigned to photograph. This ensures that lighting variables are controlled because the lights are stationary not repositioned per different procedures.
(B)
(C)
(D)
(F)
(E)
(G) Figure 4.5 (A–I) Standardized laser/skin series. (Photographs below are to be taken in addition to the face series.) (Continued ).
25
PHOTOGRAPHY FOR THE AESTHETIC PATIENT
(H) Figure 4.5 (Continued) Camera orientation: Focal length lens/distance: Landmarks:
Key points:
(A)
(I) Vertical and horizontal 80 mm at 1 m full face 80 mm at 0.6 close up views Main thirds of the face Top—Just above hairline to just below eyebrows Middle—Just above the eyebrows to just below the nose Bottom—Just above nostrils to just below chin Cheeks—Just above the eyebrow to just below the jawline Lateral to neck—Ensure consistent rotation by aligning corners of subject’s mouth when mouth is opened. This view is intended to show tonal changes of the skin, if any, from the cheek to the jaw to the neck. Position slightly above eyebrow to collarbone. Make sure that all make-up has been removed prior to photographing.
(B)
(E)
(C)
(F) Figure 4.6 (A–K) Standardized botulinum toxin series. (Continued ).
(D)
26
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
(G)
(H)
(I)
(J)
(K) Figure 4.6 (Continued) Camera orientation: Focal length lens/distance: Landmarks:
Key points:
Vertical and horizontal 80 mm at 1 m full face 80 mm at 0.6 close up views Glabellar (top third of face)—Just above hairline to just below eyebrows. Horizontal brow lines (top third of face)—Just above hairline to just below eyebrows Crow’s feet (middle third of face)—Just above the eyebrows to just below the nose Vermillion border (bottom third of face)—Just above nostrils to just below chin. Ensure that repose views are photographed prior to animated views. It can be difficult to fully relax facial muscles after having animated them. Photograph a full face view animated and repose in addition to the close up views. The close-up view alone can sometimes be difficult to determine if post injection if the patient is animated or not.
Facial Lighting The preferred lighting technique especially for rhinoplasty, facial fillers, and other cosmetic procedures, produces more three-dimentional effect of the facial structure (Fig. 4.16). This lighting technique is performed similar to the generalized lighting technique except the lights
are positioned above and closer to the subject. This causes shadows to be created by the dorsum, nasolabial folds, and jawline. The disadvantage of this technique is that it is more prone to produce inconsistencies between comparative photographs because the slightest change in flash positioning can produce a dramatically different result rendered
27
PHOTOGRAPHY FOR THE AESTHETIC PATIENT
(G)
(A)
(B)
(C)
(D)
(E)
(F)
(H)
(I)
(J)
Figure 4.7 (A–J) Standardized filler series. Camera orientation: Vertical Focal length lens/distance: 80 mm at 1 m full face 80 mm at 0.6 close up views Landmarks: Just above the hairline to just below the chin. Align like face series. Key points: Make sure that repose views are photographed prior to animated views. It can be difficult to fully relax the face after having animated it.
28
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
(A)
(B)
(C)
(D)
(E)
(F)
(G)
(H)
Figure 4.8 (A–H) Standardized lip augmentation series. Camera orientation: Landmarks: Key points:
Vertical and horizontal Just above the hairline to just below the chin. Make sure that repose views are photographed prior to animated views. It can be difficult to fully relax the face after having animated it. Photograph lips slightly parted so the full volume of the lips can be shown in the photographs. Remove lip liners and lipstick prior to photographing.
PHOTOGRAPHY FOR THE AESTHETIC PATIENT
(A)
(B)
(C)
(D)
29
(E) Figure 4.9 (A–D) Standardized rhinoplasty series. (Photographs below are to be taken in addition to the face series.) Camera orientation: Horizontal Focal length lens/distance: 80 mm at 1 m full face 80 mm at 0.6 close up views Landmarks: Basal view (Worm’s eye) Head tilted all the way back with top of nose between eyebrows. Shows contour and asymmetries of the nostrils and alar, tip defining points, width of alar and any deviation. (May require adjustment if subject has extremely low tip projection or large lips that block the alar area) Half basal view—Head tilted back with tip of nose just below eyes. Shows dorsal hump and/or deviation of nose. Cephalic view (Bird’s eye)—Head tilted down and photographed from front of subject. Shows cephalic shape, tip defining points, subtle depressions in the dorsum and deviation and/or existing facial fractures. Oblique variables—The oblique can be photographed different ways depending on personal choice. The first way aligns the tip of the nose to the cheek and the second way aligns the dorsum to the inner eye. Key points: The subject should look straight ahead in all views. Place a dot on both sidewalls and ask the patient to point their nose at the dot. This often helps with being consistent with alignment. Supplemental views: (E) If a depressor-septi release s to be performed, additional views of the patient smiling are often taken to show the muscle pulling the nose downward.
30
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
Figure 4.10 Standardized breast augmentation series. Camera orientation: Horizontal Focal length lens/distance: 50 mm at 3 m Breast alignment: The breasts are photographed with the head and feet in alignment. Again, a positioning mat and tripod will help to keep the height consistent and lens parallel with the subject. Care should be taken to ensure that a proper lateral is taken. This can be identified by two ways. First, if the subject has their shoulders relaxed and arms positioned to the side, a reference point can be established by seeing how much of the back is shown. If no back is seen then the patient is turned too far towards the camera. If both sides of the back are seen then subject is over rotated. Using the back rather than the breasts to identify correct lateral views is more dependable. If the breasts were used instead, for example, both breasts were shown in the lateral view, can be often undependable because of the natural asymmetry of the breasts. Landmarks: Just above the inframammary fold to just below the naval. This shows the proportion of the breasts to the rest of the body. Key points: A foot placement mat is helpful for correct alignment. Have subject relax shoulders prior to photographing. For the obliques, when arms are relaxed to the sides of the body, the upper arm should touch the top of the breast.
PHOTOGRAPHY FOR THE AESTHETIC PATIENT by the shadows. This technique would be recommended for clinics that have a person trained in medical photographic techniques, a clinic that provides more space for different photographic setups, and one that is limited to photographing just a few different types of procedures. Cellulite Lighting However, there are some procedures that are better depicted with different studio lighting set-ups. These setups can become more time
31
consuming and more apt to inconsistency and reproducibility because the lights are being repositioned for specific procedures. The advantage is more definition of the skin, contour, and facial features. One lighting technique is for cellulite. This lighting emphasizes the skin’s tone and texture and is accomplished by placing the flash above and about 1 to 2 feet in front of the subject. This produces harsher shadows but gives the skin more definition. An additional light placed behind the subject and pointed at the backdrop can reduce the background shadows (Fig. 4.17).
(A) Figure 4.11 (A–D) Standardized body contouring series. (Continued ).
32
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
(B) Photograph on the left shows the patient with the legs too close together. Middle figure shows correct stance for a patient. Knees should not extend passed the hips. Photograph on the right shows patient with legs to far extended.
(C) Figure depicts distorted view of patient when camera is not kept parallel to subject. These photographs were taken seconds apart and are of the same subject. The left figure shows camera at a downward angle, the right an upward angle. Distortion can greatly affect comparative photographs as shown by the comparison of the waist in these two photographs.
(D) Figure shows optional body contouring view called the divers view and is used to depict skin laxity. Figure 4.11 (Continued) Camera orientation: Focal length lens/distance: Body alignment:
Landmarks: Key points: Supplemental view:
Vertical 50 mm at 3 m The body should be aligned from head to toe. The legs should be separated at hip width as shown in the middle photograph in (B). Feet should remain parallel to each other. Twists of the torso should be avoided as they can greatly distort the body and make consistency between photographs taken during different times difficult to compare. To achieve consistent results, a foot-positioning mat should be used to ensure that correct positioning is maintained. Using a tripod is necessary to ensure the camera lens is parallel to the subject and positioned at the midpoint of the body. Distortion can occur if the lens is tilted up or down towards the subject as shown in (C). Just above the inframammary fold to just below the knees. A foot placement mat is helpful for correct alignment. Arms should be bent and held out of the field of view at breast height only. Weight should be distributed evenly and feet should be parallel to each other. The distance between the feet should not extend the knees past the hips. (D) A “diver’s” view is often taken for patients to demonstrate skin laxity and fat.
PHOTOGRAPHY FOR THE AESTHETIC PATIENT
(A)
(B) Figure 4.12 (A) Frankfort plane vs. (B) natural horizontal facial plane.
Figure 4.13 Lateral face alignment. Left depicts over rotation, middle photograph is correct lateral rotation and the photograph on the right is under rotated.
Figure 4.14 Example of with and without flash.
33
34
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
FOCAL LENGTH AND CAMERA TO SUBJECT DISTANCE
Figure 4.15 Studio example of two 45° flashes.
Figure 4.16 Preferred lighting technique.
Photography has changed dramatically in the past 10 years and the use of digital over 35 mm is commonplace in healthcare. These changes have called for changes in standardizing photography for patient photography. This is most evident in the control of focal length and distance. Proper focal length and subject to camera distance need to be controlled for patient photography to avoid unwanted distortion. Before digital cameras, using a fixed focal length lens in manual focus mode performed proper focal length. The photographer would move back and forth to the patient in order to achieve focus rather than using auto focus. This technique ensured that the correct distance and focal length were used for the area being photographed (9). With the advent of digital cameras, this technique can be reproduced but often consumer zoom lenses are used making it more difficult. The photographer should be aware of the focal length being used and place identifying markers on the floor so that he or she stands the same distance from the subject each time. It is important to control the focal length and distance to prevent unwanted distortion as shown in Figure 4.18. The Cardiff/Westminster scales of reproduction, that was the magnification of the 35 mm film plane for patient photography, decided the focal length. For example, the breasts were photographed with a normal 50 mm lens at a distance of 1/10 while the face was photographed using a long 100 mm at a distance of 1 m (13). All depended on the film plane to be a set size 24 × 36. Then came digital cameras with variable sized sensors making the focal length more difficult to determine per camera. The focal lengths and distances of lenses built for the 35 mm would need to take into account the smaller sensor sizes. For example, the 50 mm lens would now be the equivalent to a 30 mm lens on a digital camera with a 2/3 sensor size. This was determined by using the following formula now known as the FLM—focal length modifier. By taking the diagonal of the sensor and multiplying it by 1.5. Simplify Background with Backdrop Using a backdrop will help simplify your photographs, eliminates distracting objects, helps to produce a contour of the patient and maintains consistency between photographs taken during different timed intervals. The choice of a background color is important. Medium blue is often used and was carried over for the same reasons that laps and
Figure 4.17 Studio example showing difference in lighting techniques used to photograph cellulite.
PHOTOGRAPHY FOR THE AESTHETIC PATIENT
35
Figure 4.18 Proper focal length of the face is shown on the left and distorted facial features from improper focal length on the right.
drapes are blue and green in the operating room, to counter the amount of red seen to prevent eyestrain as well as offering contrast to the red seen in medical subjects (9). Naturally it carried over into the clinical setting to make the backdrop colors in operative and clinical photographs consistent. Medium blue also contrasts well with a variety of skin tones. A white background should be avoided because it reflects light and can make subjects appear washed out. It is also not as aesthetically pleasing and does not work well to provide enough contrast to provide contour definition. Black is often used but can absorb a lot of light. It may not work well with dark-skinned people but has been used successfully with additional background or rim lights to highlight the subject’s contour from behind (11). If a room has been dedicated for photography, the wall can be painted blue. A flat-based paint should be used instead of a gloss to prevent reflections from the flashes. If material is used, make sure it is a wrinkle-free material that does not have a lot of sheen to it. Polyester works well for most cases. Rolled paper backdrops can be used with stands and are available at professional photography stores. CONCLUSION
The value of photography in a clinical practice is often underestimated. Staff members are regularly used to perform the practice of patient photography and are often not properly trained in photographic standards. Using these guidelines you can improve the quality of your photography, which in turn improves the documentation of your talent and can create better communication and trust with your clients and patients. REFERENCES
1. Bockaert V. Aperture. [Available from: www.dpreview.com/learn/?/ Glossary/Exposure/Aperture_01.htm] (accessed May 6, 2010).
2. Bockaert V. Shutterspeed. [Available from: www.dpreview.com/ learn/?/Glossary/Exposure/Shutterspeed_01.htm] (accessed May 6, 2010). 3. Bockaert V. Depth of field. [Available from: www.dpreview.com/ learn/?/key=depth+of+field] (accessed May 6, 2010). 4. Bockaert V. Focal length. [Available from: www.dpreview.com/ learn/?/Glossary/Optical/Focal_Length_01.htm] (accessed May 6, 2010). 5. Rowse D. Macro photography tips for point and shoot cameras. [Available from: www. digital-photography-school.com/macrophotography-tips-for-compact-digital-camera-users] (accessed May 6, 2010). 6. Bockaert V. Digital zoom. [Available from: www.dpreview.com/ learn/?/Glossary/Digital_Imaging/Digital_zoom_01.htm] (accessed May 6, 2010). 7. Bockaert V. Viewfinder. [Available from: www.dpreview.com/ learn/?/Glossary/Camera_System/viewfinder_01.htm] (accessed May 6, 2010). 8. International Committee of Medical Journal Editors. Protection of patients’ rights to privacy. Br Med J 1995; 311: 1272. 9. Williams AR, Nieuwenhuis G. Clinical and operating room photography. In: Vetter JP, ed. Biomedical Photography. Boston: Focal Press, 1992:: 251–301. 10. Galdino GM, DaSilva D, Gunter JP. Digital photography for rhinoplasty. Plast Reconstr Surg 2002; 109: 1421–34. 11. Williams AR. Positioning and lighting for patient photography. J Biol Phot 1985; 53: 131–43. 12. Sommer D. Pitfalls of nonstandardized photography in facial plastic surgery patients. Plast Reconstr Surg 2004; 114: 10–14. 13. Young S. Maintaining standard scales of reproduction in patient photography using digital cameras. J Audiov Media Med 2001; 24(4): 162–5.
5
Ergonomics for an aesthetic office Steven K. Cordonnier
INTRODUCTION
Ergonomics plays an extremely vital role in an aesthetic office. It can often mean the difference between a very successful and growing practice and one that is barely surviving. This is why it should be an important component during the design and layout of any examination or procedure room and aesthetic office. It should also be a consideration during any equipment purchases and staff training. Unfortunately, ergonomics is often an overlooked area that many times is not given serious attention. When it comes to healthcare facilities, ergonomic principles are just as important for patients as it is for physicians and staff. For patients, the issue is also one of accessibility, which can often be tied to ergonomic principles. When implemented correctly, ergonomic principles can help the healthcare facility owner achieve the highest levels of comfort and safety for patients, physicians, and staff. The foundation for any efficient and successful practice is the level of comfort and safety provided by the facility, especially its exam and procedure rooms. BENEFITS OF ERGONOMIC PRINCIPLES
The benefits of implementing good ergonomic principles in the aesthetic office are many. And these benefits are felt by patients, physicians, and staff. As we mentioned earlier, the two most significant benefits of ergonomic principles are that the office and exam rooms will be more comfortable and safe for everyone. These two factors alone can directly influence the quality level of the physician/patient relationship during a visit. Following are the benefits, including comfort and safety, that can be realized when ergonomic principles are implemented in an aesthetic office. Comfort Comfort is one of those basic human needs, that when met, can help put someone at ease, foster efficient performance, and help facilitate a pleasant experience. These results are especially important in a healthcare environment. For patients, the level of comfort can directly influence their level of anxiety and help ease “white-coat syndrome.” Meanwhile, physicians need to be comfortable in their environment in order to provide efficient and effective patient care. For instance, the inability to easily maneuver in the examination or procedure room can often cause physicians to alter their work style over time, which can result in repetitive motion injuries. Simple comfort considerations in design and equipment can play a significant role in helping physicians conduct a more thorough and accurate exam or procedure and increase the overall satisfaction level of the patient.
procedure table. In many facilities, the burden falls on staff to lift or assist the patient. This sort of patient/staff interaction has a high potential for serious injury to one or both of the parties involved. At the very least, it could result in back injuries for staff, which is a serious issue in the healthcare industry. The National Institute for Occupational Safety and Health (NIOSH) estimates that direct and indirect costs associated with back injuries in the healthcare industry are about $20 billion annually. Accessibility As the healthcare industry evolves, equal access healthcare is an increasingly important issue affecting our healthcare system across the country. It basically pertains to a practice’s ability and willingness to ensure that healthcare is accessible and inviting for elderly patients, as well as those with other mobility concerns, such as patients with disabilities or obesity issues. Quality of Care/Efficiency of Procedures Implementing ergonomic and accessibility principles in a healthcare facility, and in particular the exam/procedure room, will raise the level of the quality of care being provided and increase the efficiency of the procedures being conducted. The basic fact is that the less physicians and staff are forced to strain to move patients or endure uncomfortable positions, the more they will be able to focus on the patient and provide the best quality care possible. Reputation and Perception From a business standpoint, the perception of the patient and the reputation of the healthcare practice are very important. The more pleasant the patient experience, the more likely it is that they will not only return for other procedures; they may even recommend these services to a friend or family member. In any medical practice, especially a cosmetic one, the appearance of your exam tables, lighting, etc. immediately tells a patient whether you are using the best and staying current or whether you are a poseur. GROWING IMPORTANCE OF ACCESSIBILITY
Too many facilities and clinics still lack total architectural and programmatic accessibility. By providing an accessible healthcare environment that works for everyone, providers improve the quality of patient care as well as the quality of their patients’ lives. Full accessibility is closely tied to many ergonomic principles. As a result, it can greatly improve patient safety and patient outcomes, as well as productivity and profitability for the practice. CONSIDERATIONS FOR THE AESTHETIC OFFICE
Safety It is important that patients and staff feel safe when they are in the office and exam/procedure room. A safe environment is conducive to a pleasant experience for everyone. If a patient does not feel safe, they may become agitated and decide not to visit this office in the future. Staff who do not feel safe may become dissatisfied and decide to look for different employment. And if an accident does occur, a safety concern can quickly lead to a liability issue. For example, with the average age of patients on the rise, it is more likely that patients may need assistance in accessing an exam or
36
To fully understand the significant role ergonomic and accessibility principles can play in an aesthetic office, it is important to look individually at specific areas and equipment found inside the facility. Entrance and Lobby For patients, ergonomic and accessibility principles can have an effect on them before they ever step foot inside the exam or procedure room. Simple considerations such as accessible parking, wheelchair accessibility, and power door operators can make the office more inviting and create a more safe and comfortable environment. Additionally, it
ERGONOMICS FOR AN AESTHETIC OFFICE is important to have adequate and comfortable seating for patients and any staff. Another ergonomic issue often found in entrance and lobby areas is the potential for trips and falls caused from environmental hazards such as slippery or wet floors, uneven surfaces, cluttered or obstructed passageways, inadequate lighting, or poorly maintained walkways. Exam and Procedure Rooms Since physicians spend most of their time with patients in exam and procedure rooms, it makes sense that these areas are where ergonomic and accessibility principles can have the greatest impact on the quality level of the healthcare environment and care provided. The design and layout of the exam/procedure room can have a significant effect on the quality of patient care and comfort and safety of the facility. The size of the room is very important. It needs to be large enough to comfortably accommodate the patient, physician, and staff and allow procedures to be properly performed. The industry standard for an exam room is approximately 8 ft × 8 ft; however, increasing the room to 10 ft × 10 ft—or larger, if possible—provides a 60-inch diameter area to accommodate wheelchair turnaround for disabled patients, as recommended in guidelines of the Americans with Disabilities Act (ADA). Procedure rooms can be 12 ft × 12 ft, depending on procedure equipment, and patient positioning required. The slightly larger room allows the door to be reverse-hinged to increase patient privacy. If a staff member enters the room to assist the physician, the patient is not exposed to other patients in the corridor. Larger rooms will also accommodate newer equipment, such as lasers, and will allow for versatility down the road if one needs to add new in-office procedures. For most aesthetic procedures, the work of the physician and staff is concentrated around the head section of the table. However, there are other procedures that occur at the foot and midsection of the table, so access around the entire table is critical. To facilitate this access, the procedure table should be positioned either in the middle of the room or at an angle, allowing the physician and staff to work at the head end of the table, and as much as possible in a neutral position, without too much overreaching or bending and twisting of the back and head. And adequate room space will mean that the physician can easily move about while seated on a stool, minimizing any aches that might be caused by continually sitting and standing during an exam or procedure. Procedure tables must be able to afford the physician an opportunity to inject, laser or otherwise treat without having too much neck flexion. It is also a good idea to include side chairs in the room. These chairs can have multiple uses. Two chairs are commonly used for the patient and potentially an accompanying family member to sit together during any sort of consultation. Typically, the patient would sit on the procedure table and a family member would be seated across the room. This is less desirable because the physician must consult the patient and answer questions from all people, wherever they are located. The two chairs, positioned side by side, allow the physician to consult with both individuals simultaneously and maintain eye contact without constantly moving the head or torso, thereby decreasing the stress on the neck and back. As with the lobby and entrance, the exam and procedure room is another area where trips, slips, and falls often occur. Along with slippery and uneven surfaces, other hazards include cords from all the equipment in the room that stretch across the floor. By using floor outlets, the power cord of the procedures table can be shortened and kept from stretching across the floor. Additionally, outlets located on the procedures table enable the physician to plug equipment into the table and keep the associated cords from stretching
37
across the floor. Lastly, using wireless controls can completely eliminate the control cords going to the equipment and allow staff to position the controls where they make the best ergonomic sense. An emerging trend that certainly helps the ergonomics of the office is to incorporate a consultation area in the procedure room. This has the benefit of reducing room changes for both the physician and the patient. The doctor can then stay seated and simply turn around when they want to go from the consultation to the procedure. This setup certainly requires a very aesthetically pleasing and friendly, warm environment. The placement of surfaces, instruments, equipment, and access to equipment all require a well thought out plan to make this setup a success but when it is done correctly it can be a very ergonomic solution Lighting It is important to have medical lighting in the exam/procedure room that provides a large pattern size with an even distribution of light throughout that eliminates shadows. It should also remain safe and cool to the touch. The lighting should be counterbalanced to provide precise positioning without drifting and without any undue spring or frictional force that would cause the user to overly push or pull in order to position the light. Thus, it should be easy to maneuver, eliminating any strain on physicians. Physician Stool For a physician, the ergonomic properties of the stool are very important. The ideal stool should feature a contoured seat that molds to the shape of the body and provides maximum comfort and support for the buttocks, feet, and torso. It should also feature a strong base structure that offers stability and minimizes the chances of tipping. Padding is essential in order to avoid compression during consultations. The stool should be easily adjustable and maneuverable, to allow physicians to find the most comfortable working height and effortlessly interface with the patient. The adjustable height will allow physicians to maintain neutral postures and keep shoulders relaxed and the head balanced and looking essentially straight ahead, while minimizing overreaching and sustained bending, and twisting. Stools with armrests should be avoided, as these often limit access to the patient and interfere with other items in the room. Procedure Table or Chair The procedure table or chair is the one piece of equipment in a practice that touches nearly every patient. It can be the most valuable asset of a successful practice. The right procedure table can increase the level of efficiency, comfort, and safety, and enhance the delivery of care. For example, being able to easily get onto a procedure table can increase a patient’s comfort during the visit. In addition to patient and physician comfort, the right procedure table can mitigate risk by preventing injuries and falls. The most important feature of the table is that it should be barrierfree and be able to lower to a height of 19 inches or less so patients are able to get on it with little or no assistance. Being able to easily get onto a procedure table can increase a patient’s comfort, help the physician conduct a more thorough and accurate exam or procedure, decrease potential for staff ’s back injuries and increase the satisfaction level of the overall patient experience. Barrier-free tables also reduce the likelihood of distress and injury to patients who are elderly, disabled, obese, or even pregnant who may have difficulty in accessing a standard procedure table. The tables and chairs should be fully adjustable and feature power height, back, foot, and tilt. This will enable the patient to remain relatively still during the entire procedure. This will also enable easy access and flexibility during examinations and procedures, saving the
38
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
physician from overreaching, twisting or bending the back or torso too much resulting in awkward postures. According to Occupational Safety and Healthy Administration (OSHA), “‘awkward postures’ means working with various parts of the body in bent, extended or flexed positions rather than in a straight or neutral position. Working in awkward postures increases the exertion and muscle force that employees must apply to complete a task and compresses tendons, nerves and blood vessels.” In addition, the federal agency points out that “twisting the torso creates an asymmetry which stretches some sets of muscles while compressing others forcing smaller, isolated groups of muscles to provide the needed force for the task. Twisting the spine creates nonsymmetrical forces on the fibers of the disc which weakens the structure making it more susceptible to bulging and rupture … .” It is clear from OSHA that to minimize the risk of injury, the physician and staff should minimize awkward postures as much as possible. Of special importance to the aesthetic medicine physician is the ability to have close access to the patient. Having close access enables the physician and staff to stand upright without unnecessary bending or twisting while still performing the procedure. Since much of the aesthetic medicine work is performed on the face, neck, and upper body, having a procedure table with a small headrest and a very narrow back section is vital in providing this close access. And because many physicians or staff work from a seated position, it is important to have a thin headrest and back section without obstructions. This gives physician the ability to roll in close to the procedure table’s back section or headrest without bumping their legs or knees on the table components. All of this facilitates proper posture and will reduce strains and injury to the physician. Powered height, from 19 inches up to 40 inches, is crucial to keep the physician and staff from bending over the patient. This large height range adjustment allows both shorter and taller physicians and staff to work at the most appropriate height and limits the amount of neck and back flexion. OSHA studies have found that the work site should be such that the forearm and upper arm should be at 90° angles because it helps keep the strain off of the shoulder muscles. Rotation of the table should also be considered because it allows the physician to move the patient to the other equipment in the room instead of requiring the physician to move around or require movement of the equipment. In addition, by rotating the patient, the physician can position the work site close to a counter or supply storage area so that twisting movements and overreaching can be minimized. A final consideration for the procedure table or chair should be its controls. The controls for moving the table or chair should ideally either be wireless or in the form of accessible, easy-to-use foot controls. And the size of the controls should not be overly large and obtrusive that they cause a trip hazard or force the doctor or staff away from the work site. The latter would result in the user leaning over the patient and put undue strain on the lower back and neck. Casework/Cabinetry Casework designed specifically for medical environments is often more durable and will not break down under medical use, unlike common wood casework. While casework does have an aesthetic effect on the image of the practice to patients and staff, it also can be tied closely to ergonomic principles.
For example, a pull-out writing surface at an approximate height of 30 inches would allow any paperwork needed during an examination to be readily and conveniently accessed. And locating the sink in the corner maintains a countertop surface closer to the working environment and isolates any splashing to eliminate potential slippery spots on the floor. Another important area on the cabinetry is the kick area of the base cabinet. This should be high enough to allow the legs of the stool to slide under the edge of the base cabinet while the user’s foot is positioned on the base in a very common use scenario. This allows the user to get in closer to the cabinets and countertop and eliminates frequent and unnecessary bending or stretching. And consideration should be given to how items are placed in the cabinetry. For example, keeping the most frequently accessed supplies on the lowest shelves keeps physicians and staff from constantly overreaching. Monitors Monitors have become a critical part of the exam/procedure room. Physicians need to be able to easily view the monitor during any procedure. For this reason, it is important to have a fully adjustable monitor on a monitor arm that allows it to be easily positioned for both sitting and standing postures and for a variety of procedures. Making sure that the monitor is of high resolution and free of smudges will eliminate any eye strain, blurred vision, dry eyes, or headaches that may result from prolonged concentration to view images that are unclear or washed out. An emerging trend is to use mobile carts that can be brought to the side of the procedure table so the physician can maintain the provider/ patient eye connection while still entering data into a practice management system or electronic health records (EHR) system. This arrangement eliminates staff twisting to access any electronic systems or eliminates any awkward balancing that happens with portable tablet computers. Ideally these mobile carts should be height adjustable so a physician can work either sitting or standing. Staff Awareness and Training OSHA recommends that practices establish a training program designed and implemented by qualified persons to provide continual ergonomics education and training. It should also be a part of any new employee orientation. The training should cover not only ergonomic hazards and principles, but appropriate procedures, such as patient lifting guidelines, as well as the proper use of the equipment. The training should also provide an overview of the potential risks, causes and symptoms of back injuries, and work-related musculoskeletal disorders. CONCLUSIONS
The well-designed esthetic office needs to not only look good but also function well. It does the physician little good if he or she is able to build a practice only to become disabled due to a herniated disk in the neck or back. By following guidelines and using well-designed equipment, the physician can enjoy a long and comfortable career. In addition, his or her patients will have the knowledge that the office has invested the time and money to make each visit comfortable and safe as possible.
6
Interviewing the cosmetic patient Susan H. Weinkle and Harriet Lin Hall
INTRODUCTION
The initial visit of a dermatology cosmetic patient has specific nuances that the medical dermatology patient visit does not have. Many of the treatments given and issues addressed are for conditions that are not pathologic, but rather for normal physiologic phenomena (1). Some patients may come to the office not necessarily knowing what they need but are unhappy with their present appearance. Other patients may come to the office with a specific concern but may not be a good candidate for cosmetic rejuvenation because of an underlying systemic disease. In order to fully meet the cosmetic dermatology patient’s expectations, a complete pre-operative assessment including a thorough medical and psychosocial history and focused physician examination is imperative. Key information is obtained through the medical interview. Mastering the skills of interviewing the cosmetic patient will assist in building trust and contribute to the successful treatment of the dermatology patient desiring cosmetic enhancement. THE MEDICAL INTERVIEW
Engel (2) stated “the interview is the most powerful, encompassing, and versatile instrument available to the physician.” The medical interview is highly personal and confidential, so much so that access to the content and records of the physician–patient conversation is protected by law (3). The Accreditation Council for Graduate Medical Education (ACGME), the American Association of Medical Colleges (AAMC), and the American Board of Medical Specialties all have adopted requirements that specify core clinical competencies and performancebased evaluations addressing clinician–patient interaction (4). Importance is placed on domains involving medical professionalism and communication with emphasis on interviewing skills. Talking with patients is not a skill reserved for such specialists as psychiatrists, psychologists, and social workers (4). Cosmetic dermatologists need to develop strong skills in medical interviewing to separate a good cosmetic candidate from a poor cosmetic candidate that may have an underlying personality disorder, such as body image dissatisfaction. In addition to solid interviewing skills, dermatologist/psychologist Richard Fried has written extensively on when patients may not be a good candidate for cosmetic rejuvenation. Dr. Fried developed a screening profile called the CPS-D (Cosmetic Procedure Screen-Derm) (5), which will be discussed in more detail later in this chapter. Sarwer has also written extensively on the psychological assessment of patients who present for cosmetic surgery plastic (6). Other organizations that help clinicians enhance their communication skills include the American Academy of Physician and Patient (AAPP) and the Bayer Institute for Health Care Communication (BIHCC) (7). CONSULTATION SUCCESS STARTS WITH EDUCATION
Historically, patient education occurs throughout the entire encounter with the medical dermatology patient with emphasis that functions toward the end of an interaction or subsequent visits. The cosmetic patient should be educated throughout the complete cosmetic consult. Educating patients means giving them information and, if necessary, motivating them to act on it (8). According to Werschler, education starts from the time before the cosmetic patient even comes to the office (9). Education can start via your website or from the receptionist who answers the phone (Fig. 6.1). Your website should in fact be an
educational tool, describing your services, credentialing you for your expertise and your experience, in addition to everything else, such as directions to the office (9). Many dermatologists who have incorporated cosmetics into their practice have spent time educating their staff and have specially trained practice coordinators. Because of the sensitive nature of the initial interaction, it is critical to have practice coordinators who are receptive, understanding, and aware that patients may display a limited understanding of cosmetic dermatology (10). The majority of cosmetic patients’ knowledge base comes from the media and fashion magazines. They may lack the knowledge and understanding of the procedures themselves, however, are often quite clear on how they want to look after the procedure (10). If the cosmetic patient elects to utilize your practice, the patient will like to have questions concerning costs and payment plans. Consultation charges are frequently questioned by cosmetic patients. The practice coordinator can address this with the patient prior to arriving at the office. Whether there is a charge or not needs to be clearly communicated. Many cosmetic dermatologists elect to waive the consultation fee if the patient decides to have a procedure performed the same day or soon after the consult. INTERVIEWING AS PART OF THE COSMETIC CONSULT
The initial cosmetic consult between the dermatologist, the staff, and patient should include some major themes of medical interviewing. During the interviewing process, the dermatologist should be objective, precise, sensitive, specific, and reliable when making observations about the patients’ cosmetic desires (8). Active listening skills connect the dermatologist with the patient. Below is a partial list of listening skills that help build a therapeutic relationship with the cosmetic patient (8). 1. Choose a mutually comfortable setting. 2. Remain attentive. 3. Observe the patient respectfully as a whole person, not just as a person needing facial rejuvenation. 4. Allow the patient to tell a story with as few interruptions as possible. 5. Note discrepancies in meaning between what the patients say and how they say it. Additionally, the need to demonstrate respect for the cosmetic patient is important in order to connect with the patient and provide optimal treatment. MEDICAL HISTORY AS PART OF THE COSMETIC CONSULT
Once a sound medical history is completed, the cosmetic component of the consult can commence. The consult should take place in a comfortable setting where the patient and physician can exchange valuable information. During this time, the patient may be assessing the environment, asking about credentials, and voicing concerns about their expectations. It is also a good practice standard to inform the patient who will be performing the procedures whether it is the dermatologist, the advanced practice nurse, the physician’s assistant, or aesthetician. Patients are increasingly knowledgeable and sophisticated about cosmetic procedures and expect the most up-to-date treatments. According to Schlessinger (10), it is advantageous to give a tour of your practice to help put your patients at ease. Someone who is knowledgeable about your practice and a firm advocate
39
40
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
Figure 6.2 Having patient identify their specific concerns. Figure 6.1 Education starts with the receptionist during the first phone call.
Table 6.1 Patient Framework should give this tour. If your practice has several facets such as general dermatology, surgical dermatology, i.e., Mohs micrographic surgery, or clinical cosmetic research, these options should be highlighted. All staff encountered should be introduced, and the staff should be urged to respond pleasantly to the patient and tour guide (10). If the appropriate measures discussed have been taken, the consultation process in the exam room should progress smoothly. The patient should be much more likely to follow your lead as a physician, allowing you to take the time to explain the procedure chosen, review pictures of previous patients, interact openly and honestly with the patient and establish priorities that would offer optimal treatment (10). THE FIRST TIME COSMETIC PATIENTS VS. THE EXPERIENCED COSMETIC PATIENT CONSULT
Many first time cosmetic patients will not only have one specific concern but many. A good starting point with these patients is to provide a mirror and have them point out their specific concerns (Fig. 6.2). Patients often identify multiple areas of concern, but also tend to prioritize what bothers them the most (1). What may seem like a cosmetic flaw to the physician may not be a concern to the patient and if the physician suggests an area for treatment that the patient has not mentioned, the patient may feel offended. Werschler (9) developed a framework that divides the cosmetic patient into one of three distinct buying groups: (i) enhancement patients, (ii) rejuvenation patients, and (iii) restoration patients ( Table 6.1). According to Werschler (9), the restoration patient has traditionally been the bread and butter of dermatologists because they frequently deal with skin cancer, agerelated concerns of the skin such as rosacea, lentigos, and pre skin cancers. These patients typically have had interaction and good experience with dermatology. The enhancement patients have been patients of plastic surgery because the majority of dermatologists usually do not offer extensive facial reconstructive services for that group of patients. The rejuvenation group may opt to visit both dermatologists and plastic surgeons, depending on demographics and availability of cosmetic dermatologists. When consulting with the cosmetic patient, keep in mind their psychodynamic drivers. Give careful consideration to why they are in your office. For example, if you offer to make enhancement patients’ lips look like a famous celebrity’s lips they will probably indicate “That’s exactly what I want.” If you were to offer the same service to a rejuvenation patient, they might respond “ No, that’s a little too much,
Enhancement patient
Rejuvenation patient
Restoration patient
Very young; range 18–29 years of age; may have acne; desires better skin care, bigger lips, correct “bump” in nose; wants to look better than genetically made
Usually 30–50 years of age; complaints of looking older than they feel; want to look younger not change entire appearance; usually take good care of themselves
Generally 55+; desires to be the best looking for age group; interested in repairing sun damage, prevention of skin cancer; slowing aging process
I just want a little bit of filling and just have a bit more of a pouty look.” The notion of interacting with patients to identify their concerns and decide upon the best course of therapy should always define how cosmetic dermatologists structure their practices and evaluate the various cosmetic procedures available (10). Once the patient’s concerns are identified, the physician can proceed with a pretreatment assessment. Physician concerns should include and address the type and extent of wrinkles, folds, furrows, and other signs of aging including any disease state such as skin cancer or actinic keratosis. It is at this point that photographic documentation is crucial. The physician should set goals with the patient about cost, timeline of treatments, follow-up visits, and agreeing to the extent of correction possible. PATIENTS WHO SHOULD NOT HAVE COSMETIC FACIAL REJUVENATION
Patients that do not make good candidates for cosmetic procedures include patients displaying, underlying personality disorders including depression. Also, any patient with active systemic disease should not have cosmetic treatment. For example, a female patient in her late 60s with unstable angina is probably not a good candidate for laser surgery. According to Fried and Werschler (5), the late Eugene Farber wrote in the 1990s about the other dimension in the management of psoriasis; that intrapsychic factors and stress can affect treatment outcomes. Dermatologists frequently have patients present to their office with complaints of feeling stressed and unhappiness with their appearance. Many patients have been misinformed about cosmetic procedures and products via the internet and media. This sensory overload makes it difficult for patients to make well-chosen cosmetic interventions that maximize the likelihood of achieving their desired result (5). Fried and Werschler developed a screening tool for dermatologists to identify patients that will be most likely dissatisfied with a cosmetic
41
INTERVIEWING THE COSMETIC PATIENT
CPS-D (COSMETIC PROCEDURE SCREEN-DERM) Please specify the cosmetic/skin problem(s) that bother you.
Please specify the cosmetic/skin problem(s) you would like improved or corrected.
How do you envision your life will change after your cosmetic procedure?
Will having a cosmetic procedure “fix” any of your problems?
Yes
No
Have you seen any other physicians for cosmetic concerns?
Yes :
No
If yes, how many?
What were your concerns? Were you satisfied with the results? Have you had any previous cosmetic procedures? If yes, which ones? Were you happy/satisfied with the results? Do you drink alcohol? : Yes
No
How often? How much?
Are you taking prescription medications for pain? Do you feel overwhelmed or confused?
Yes
Yes
No
If yes, which ones?/How often?
No
Are you being strongly encouraged or discouraged from having a cosmetic procedure? Yes : Are you generally satisfied with your life?
Yes
No
Are you worried about the way you look and wish you could think about it less? How many minutes or hours in an average day do you think about how you look? Do you cut or otherwise purposely harm your skin?
No
Yes
Yes
No Minutes
Hours
No
Are so distressed by your cosmetic concern to the point where it interferes with you ability to be happy or carry out your necessary daily chores? Yes No Have your cosmetic concerns gotten in the way of doing things with your friends and family?
Yes
No
Figure 6.3 Fried & Werchler Screening Tool.
intervention (Fig. 6.3). Dissatisfied cosmetic patients can drain the physician and staff and potentially damage the reputation of your practice (11). Choosing the appropriate patients is the key to selecting cosmetic treatments that will satisfy and exceed patient expectations (Fig. 6.3). Besides the self-administered CPS-D questionnaire, Fried developed the STEP (Society of Trust and Estate Practitioners) program for helping the dermatologists identify patients you should avoid treating. The STEP program encompasses medical, surgical, and psychodermatology. A PLETHORA OF OPTIONS
The availability and novel applications of dermal fillers has made the reversal of the aging face accessible to a wide range of patients. The trend is likely to continue as the public becomes more familiar with existing nonsurgical treatment options and the Food and Drug Administration (FDA) continues to approve newer treatments. The challenge for physicians is to screen cosmetic candidates to identify high risk patients that would not be appropriate for cosmetic procedures. In the moments prior to and at the initial cosmetic consultation, there are many facets of the consultation that bear scrutiny and reinforcement with staff (10). Cosmetic consultations can be a rewarding experience for both physicians and patients when appropriate key interaction is
displayed for selecting cosmetic procedure that satisfies and exceeds patient expectations. REFERENCES
1. Beynet D, Greco J, Soriano T. Approach to the cosmetic patient. In: Murad A, Gladstone H, Tung R, eds. Cosmetic Dermatology. London: Saunders Elsevier, 2009: 3–6. 2. Frankel R. Forward. In: Smith, R, ed. Patient Centered Interviewing, 2nd edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2002: ix. 3. Frankel, R. The interview in history. In: Smith R, ed. Patient Centered Interviewing. 2nd edn. Philadelphia, PA: Lippincott, Williams & Wilkins, 2003: xi. 4. Coulehan JL, Block MR. Introduction. In: The Medical Interview. Mastering Skills for the Clinical Practice. 5th edn. Philadelphia, PA: F.A. Davis Company, 2006: xvii–xviii. 5. Fried R , Werschler W. The key to mastering cosmetic dermatology patient selection. Skin & Aging 2006; 14(10): 42–5. 6. Sarwer DB, Grossbart TA, Baker AW. Understanding the cosmetic surgery patient. In: Kaminer MS, Arndt KA, Dover JS, Rohrer TE, Zachary CB, eds. Atlas of Cosmetic Surgery, 2nd edn. Philadelphia, PA: Saunders Elsevier, 2009: 3–9. 7. Coulehan JL, Block MR. Interviewing as a clinical skill. In: The Medical Interview. Mastering Skills for the Clinical
42
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
Practice. 5th edn. Philadelphia, PA: F.A. Davis Company, 2006: xvii–xviii. 8. Smith RC. Patient centered interviewing, 2 edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2003: 235–52. 9. Werschler WP. Integrating dermatology and cosmetic dermatology practice: an expert interview with William Phillip Werschler, MD.
Medscape Dermatology, Nov 7, 2008. [Available from http:// cmemedscape.com/viewarticle/582738] 10. Schlessinger J. First contact: improving consultation techniques and procedure selection. Practical Dermatology, August 2009: 43–6. 11. Fried R. Visions of beauty. Skin & Aging 2007; 15(10): 45.
7
Red flag patients Timothy Corcoran Flynn
One of the joys of practicing cosmetic dermatology is the relationship that exists between physician and patient. Cosmetic patients are by and large intelligent, interesting, active individuals who seek to improve their appearance as an augmentation to their robust lives. Many of these patients are dynamic people who comment that their outward appearance does not match how they feel inside. They are frequently seeking to restore their face or body to a more youthful appearance. They usually wish to appear a bit younger and fresher than many in their peer group. Cosmetic patients can be delightful to work with. They are upbeat and positive individuals who enjoy coming to the dermatologist. Most cosmetic dermatologists with busy practices enjoy the interaction. Inevitably, however, one encounters individuals that are unpleasant or difficult. These patients are termed “red flag patients.” They can trigger a mental warning signal when initially encountered. These “red flag patients” should be approached with caution and if the warning signal turns into an alarm, they should be avoided. Studies have shown that up to 47% of patients seeking consultation for a cosmetic procedure meet criteria for a mental disorder (1). Ritvo et al. (2) have noted that common conditions seen in the cosmetic population include body dysmorphic disorder, narcissistic personality disorder, and histrionic personality disorder. A thorough medical and social history can be used to gain a complete understanding of the cosmetic patient and discover these traits. Usually people with personality disorders produce strong feelings in the physician. Body dysmorphic disorder patients can demonstrate a preoccupation with an imagined problem with their body or excessive concern over one body area. This concern causes them significant distress and can occupy great amounts of time and energy on their part. Listening carefully will help identify these patients with more serious psychiatric conditions. Judgment on which patients to treat and which to reject takes time to acquire. Eugene Tardy Jr.’s excellent chapter in the book Facial Aesthetic Surgery (3) wrote “surgical residents in training quickly and accurately learn the physical characteristics favorable for aesthetic surgical correction, but the experience in judgment to assess emotional motivations are less readily acquired.” He further goes on to state “every effort must be made to develop a sixth sense about patient expectations and motivation.” While some red flag patients are easy to recognize by their brashness and atypical behavior, other difficult patients require a bit more care to recognize. Oftentimes your office staff gets the first clue that a person is a drapeau rouge. They may have an unusual interaction on the telephone or during the consultation with your cosmetic coordinator. Some red flag patients, particularly those who are arrogant or feel that they are a “VIP,” may seem extremely pleasant to you, the treating physician. However, they have treated your nursing staff with contempt and disgust. It is wise for the cosmetic dermatologist to pay attention to the opinions of your office staff from the front to the back office. Staff are often correct in their assessment. Identifying difficult patients can be helped by carefully listening to the wishes and desires of the patients, fine-tuning one’s listening skills (with the emphasis on listening) will help ferret out the red flag patients. Oftentimes they give clues within their comments or expression, which helps the experienced cosmetic dermatologist know what patients to avoid. For example, there can be a warning sign if differing inflections are used in the sentence “the other doctor used a filler.” If
you detect sarcasm when the patient states “the other physician,” it is an important clue that this may be a patient who is very difficult to be pleased. The paragraphs below describe the types of “red flag patients” which one can encounter in the office.
“WHERE CAN I GET IT DONE THE CHEAPEST?”—THE BARGAIN HUNTER
Bargain hunters are people who are continually moving from doctor to doctor or calling practices trying to find the absolute best price. They are incorrectly paying attention to the cost of the procedure and not focusing on the outcome. These patients can be like a ping pong ball, going from place to place or spending hours on the phone or internet. They are frequently unhappy because they are seeking treatment from non-experts in the field, oftentimes encountering physicians outside of the non-core specialties. These physicians, in turn, are trying to lure patients to their practice using price as a motivator. They frequently do so by, for example, using less botulinum toxin units than that may be required, thus reducing their cost. Obviously the patient is not going to get as desirable a result when they are undertreated. Bargain hunters can be avoided by establishing a reasonable price for the correct therapeutic regimen. Many times they are treated by non-physicians.
“I WANT TO LOOK EXACTLY LIKE …”—THE PATIENT WITH UNREALISTIC EXPECTATIONS
The patient with unrealistic expectations come to see the cosmetic dermatologist wishing to have a wrinkle “completely removed” or to have the doctor produce “perfection.” Sometimes patients will bring in a photograph from a magazine, stating that they wish to have their complexion exactly match the one in the picture. Alternatively, they may desire something that is physically impossible to achieve, such as a person with very thin lips wishing to have 12 mm of red show on the upper lip only. These patients with unrealistic expectations fail to understand the anatomic limitations. Several of these patients may have seen other physicians or undergone scalpel surgery to try and achieve their idealized appearance. One warning sign for these patients is the feeling that they are inflexible in their goals and the cosmetic dermatologist may have a sense that the patient is not listening to or understanding the cosmetic dermatologist.
“HOW ABOUT 10% OFF DOCTOR?”—THE CHEAP PATIENT Many patients are concerned about expense, particularly in the times of a down economy. However, there are some red flag patients who continuously attempt, at each visit, to get a discount on their services. These patients can be annoying, but more so their focus is often not on the outcome, but rather on the cost. They take extra time during the treatment session, arguing over a few bucks. A statement such as “We do not discount for our services” will usually stop this constant price haggling. Some of these types of patients may be made happy by giving them a little something extra. However, you must be careful in providing a value-added service, because they usually will want it at every visit.
“DOCTOR, CAN’T WE GET MY INSURANCE TO PAY FOR IT?”—THE MANIPULATOR
While there are certain dermatological treatments that can be billed to insurance (e.g., the use of a vascular laser to treat a port wine stain),
43
44
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
there are very few procedures in cosmetic dermatology which are appropriate to charge to an insurance company. It is important to clearly state to the patient that you can only do this when appropriate and in their case it is not. You can comment to them that you practice medicine with the highest ethical standard and that the patient’s medical records must reflect that. Sometimes a simple joke such as, “I don’t think the insurance company or the government would appreciate it,” can simply sum up the situation quickly and diffuse their wish for you to be dishonest.
“IT HAS TO BE PERFECT!”—THE PERFECTIONIST Perfectionistic people are frequently be encountered by the cosmetic dermatologist. These patients are often immaculately dressed and their grooming is exquisite. They may literally have “not a hair out of place.” Perfectionistic patients may come in with long, detailed lists of their problems or may write detailed letters discussing their problems. Other warning signs that you may be working with a perfectionistic patient may be that they refuse to take off their makeup when asked to do so by your staff. While they seem to understand that a dermatologist must examine the skin unencumbered with cosmetics, they cannot bring themselves to remove their camouflage. Many perfectionists will not be satisfied until every detail is corrected and their appearance becomes “flawless.” A simple phrase which the author has used not to treat perfectionists is “I don’t think I will be able to provide you what you want.” Giving perfectionists the name of other reputable cosmetic dermatologists who may be interested in treating the patient is a courteous service to the patient, but a burden for your colleagues. Perfectionistic patients can also include people with an untreated obsessive–compulsive disorder and are obsessed with their appearance. Some of these people can fall into the category of body dysmorphic disorder. These patients can seem to be greatly disturbed by their perceived cosmetic deformity when, in fact, on examination there is no disorder to be seen. These patients with normal outward appearance who focus in detail on their perceived deficiency are among the most dangerous to treat, because they are usually not satisfied and, in fact, can turn angry about the money and time that they have spent.
“DOCTOR, I CAN’T MAKE UP MY MIND”—THE INDECISIVE Indecisive patients are people who have come in for multiple inquiries, but never can quite decide to receive a treatment. They may have seen several other doctors only for consultation, never having a treatment. These patients may have trouble with decision making. This behavior can be a sign of abnormal passivity, in which their lives are full of other people making their decisions. These patients may state “it’s up to you” or “do whatever you want.” This is not a good idea because the patient should always have a clear understanding as to what will be done and have appropriate “buy in” to the situation. Their informed consent must reflect complete knowledge of what is done and then their desire to have the procedure.
“DOCTOR, YOU ARE SO GREAT!”—THE SEDUCTIVE PATIENT Occasionally, when encountering people, one gets an uncomfortable feeling of inappropriateness. It seems that the patient does not seem to understand normal social boundaries and the doctor is getting the feeling that they are being seduced. These patients range from being overly familiar to being sexually inappropriate. These patients may have a pattern in their life of getting attention and manipulating situations. They may have learned that these skills can, at times, afford them certain advantage. However, any flirtation is not appropriate between a doctor and a patient. These people are often trying to gain the favor of the physician for preferential treatment and can be difficult.
“YOU ARE THE ABSOLUTE BEST IN YOUR FIELD”—THE EXCESSIVELY COMPLIMENTARY PATIENT
We would all like to feel that we are the best in our specialty, but a good cosmetic dermatologist can usually recognize another physician whose skills in certain areas are superior to their own. Thus, the cosmetic dermatologist will understand that the patient who comes in and states repeatedly “I know you are the best” is a patient to be worried about. These people can be over-flattering and frequently commenting on the reputation and an almost magical power that the treating physician may possess. At times you may hear demeaning comments about other dermatologists or other cosmetic practitioners. One has to be careful of these patients because if the result is not what they expect, then their excessive compliments may turn into overt criticism. They may be angry and outraged following their treatment.
“DO I HAVE TO SHOWER BEFORE THE PROCEDURE?”—THE PATIENT WITH POOR HYGIENE
All patients are entitled to an occasional bad hair day, but these difficult patients are unkempt, dirty and show a lack of care for themselves. They may be at risk for skin infections due to their slovenly existence, and may not practice simple wound care. These people can be at risk to treat because they may not always follow the cosmetic dermatologist’s advice. They do not seem to care much for themselves. If they will not follow the simple rules of hygiene, brushing ones teeth or bathing, how can you know that they will follow your instructions following the procedure?
“I CAN ONLY COME IN AT NOON FOR JUST 20 MINUTES, TOPS!”— THE VIP PATIENT
People, who are involved in the media, appear before the public, or hold positions of importance frequently seeking improvement by the cosmetic dermatologist. However, some of these people can be extraordinarily demanding. Clues for this include only a limited range of times that they can be seen by the dermatologist and inflexibility surrounding their schedule. They frequently seek “special appointments,” exceptions from standardized treatments, and other forms of special care that can be of disaster to a busy practice. We have had patients who have asked us to open the office on Sunday morning and who have requested that the doctor “cancel his vacation because I need to be treated.” These people are oftentimes not worth treating, as they are unable or unwilling to follow the usual care guidelines, as they spend their life cutting corners or doing only what they want. In their minds, they are such important persons that the usual rules do not apply to them.
“LET ME TELL YOU ABOUT ME”—THE LOQUACIOUS PATIENT Many cosmetic dermatology patients are fascinating and have many stories to tell. Many of them seem to be packing more fun or activities into their lives than many folks. It is often fun to listen to them and to learn. However, there are some patients who are excessively talkative. They often interrupt the doctor, refuse to listen, and verbally dominate every encounter with the dermatologist. When obtaining an informed consent many of these individuals will not let the doctor or the nurse finish the consenting process. Occasionally this can be seen in manicdepressive individual (perhaps in a manic phase) but more often than not it simply reflects a self-obsessed individual who fails to ever listen to others.
“I KNOW I AM GOOD LOOKING”—THE NARCISSIST Caution must be exercised in people with narcissistic personality disorders. Outwardly these people seem to be extremely conceited and vain. They have an inflated sense of self-importance and are preoccupied with one’s self. They exaggerate talents and achievements and react to criticism with rage. This requires constant attention and admiration.
RED FLAG PATIENTS Inwardly they are often unhappy, frequently dissatisfied, believe they are fundamentally unacceptable to others and will often be displeased with their cosmetic outcomes. One clue for narcissism is the negative comments that they often make about others while describing how wonderful they are. They frequently take advantage of others to achieve their own ends. Narcissists are rarely satisfied and have been known to return to the office, demanding their money back due to the “terrible results,” which they may proclaim loudly at your front desk.
“YOU’RE THE EIGHTH DOCTOR I HAVE SEEN”—THE DOCTOR SHOPPER
The clue for a dissatisfied and unappeasable patient is a patient who has seen multiple physicians, often for the same cosmetic treatments. This is a clue that, as they were not satisfied with their initial treatment, they are unlikely to be satisfied even with your good outcome. It is best to decline them get treated unless you feel that you have something specifically different to offer, and that your treatment will truly improve them.
“I THINK I NEED ANOTHER PROCEDURE”—THE SURGIHOLIC Often one glimpse of this individual is enough to identify that they are a person who has had repeated cosmetic procedures, sometimes to a degree of either inappropriateness or disfigurement. Their medical history may reveal that they have had several breast augmentations, each time seeking additional improvement. These patients will continue their unending quest, moving beyond treatment to disfigurement and excess. They no longer fit into the normal range of human appearance.
“I AM GOING TO SUE THAT QUACK”—THE LITIGIOUS PATIENT There is not a doctor who enjoys hearing that their patient is involved with or considering litigation. A pause in the interaction will often cause the patient to describe their unhappiness with their previous physician and their decision to sue. It is extremely essential that the cosmetic dermatologist not make disparaging remarks about the previous physician. If one detects excessive focus on the negative
45
results, or perceived negative results, avoid treating the patient. They are already angry. It is worth noting that currently in the practice of medicine, it is common to see patients who may be on psychoactive medications. We commonly see patients on an antidepressant medication such as an SSRI (selective serotonin reuptake inhibitor) or perhaps an anxiolytic. Many of these patients are fine to treat. Many of these patients have been put on the medication for minor issues or the drugs may be used off-label for treatment of other symptom collections such as menopause. Spending a few minutes discussing those medications and trying to get a sense of the patient’s psychiatric stability usually reveals that the patient is not significantly impaired. One also encounters patients with a more serious psychiatric diagnosis, which is being treated with additional or higher doses of medications. We always openly discuss the psychiatric drugs with these patients and if under regular care of a psychiatrist, usually ask to place a phone call to their treating doctor. It is important to remember that in the current practice milieu you must ask the patient’s permission to contact their psychiatrist. When the patient gives permission you should state that you have obtained permission from the patient when you call their psychiatrist. The practice of cosmetic dermatology can be rewarding and fun. Most cosmetic dermatologists state that they really enjoy their cosmetic patients and have a great deal of joy making people look and feel better. Learning to avoid red flag patients can make your practice delightful and satisfying. REFERENCES
1. Ishigooka J., Iwas M., Suzuki M, et al. Demographic features of patients seeking cosmetic surgery. Psychiatry Clin Neurosci 1998; 52: 283–7. 2. Ritvo EC, Melnick I., Marcus GR., Glick JD. Psychiatric condition in cosmetic surgery patients. Facial Plast Surg 2006; 22: 194–7. 3. Tardy ME, Thomas JR, Brown RJ. Initial encounter: a personal approach (Chapter 3). In: Facial Aesthetic Surgery. St. Louis, MO: Mosby, 1995: 66–83.
8
Internal marketing Amy Derick
OVERVIEW
Definition In this chapter, internal marketing is defined as the process of persuading existing patients of a dermatological practice to purchase cosmetic services or products. Advantages of Internal Marketing Internal marketing is a highly effective way to increase cosmetic revenue. Whether you are serving a medical patient considering cosmetic services or products for the first time, or an experienced cosmetic patient contemplating an additional purchase of cosmetic services or products, internal marketing has the following advantages over external marketing: 1. An ongoing medical practice already has a stream of potential cosmetic patients walking through its doors without having to spend additional advertising dollars to reach them. 2. Existing patients are a captive audience during their visits to the practice. 3. Existing patients are typically receptive to the advice of their trusted provider. Leveraging these inherent advantages in a professional manner will help a practice grow its cosmetic revenue—probably to the elevated satisfaction of both patient and provider. Methods Discussed The methods of internal marketing can be assembled into the following major categories: 1. 2. 3. 4.
Building a cosmetic brand Capturing patients who are predisposed to cosmetic treatments Stimulating new cosmetic interest in existing patients Maintaining strong overall relationships with patients
Each of these categories will be discussed in this chapter. At the conclusion, the reader should feel confident about implementing these methods in his or her practice. BUILDING A COSMETIC BRAND
Defining the Cosmetic Brand A brand, in the context of this chapter, is the collection of images or ideas a patient perceives when considering to patronize a given medical practice. A good cosmetic brand will clearly convey that the medical practice in question is a “provider of choice” for cosmetic services and products. Delivering a Cosmetic Brand to Patients There are two main processes through which a cosmetic brand can be clearly conveyed to patients: explicit internal marketing and implicit internal marketing. Explicit Brand Building In explicit brand building a practice overtly states the message it wants to deliver. One advantage of explicit brand building is that the practice has complete control of the message. For example, a practice might adopt the slogan “ABC Dermatology: A Leader in Cosmetic Skin Care.”
46
This message directly presents a cosmetic brand to patients. Explicit brand building can be used through vehicles such as print advertisements, radio or television advertisements, practice materials such as brochures or business cards, and the website of the practice. The first step toward developing an explicit brand building campaign is defining the value proposition of the practice. The value proposition is the unique combination of service, quality, and price that each practice offers its patients. Each organization must focus on no more than two of these elements. For example, a practice that offers the highest quality care and service will not probably be able to offer the lowest possible price. Each practice must analyze its position within its chosen marketplace and demographics to determine the best competitive approach. Once the value proposition has been determined, it needs to be communicated clearly to targeted patients. As an example, XYZ Dermatology is a practice in a small market. In the area in which it practices, the doctors have built a reputation for providing excellent medical care, but they have little cosmetic business. The primary cosmetic competition in the area is a medispa that operates without on-site physicians. XYZ Dermatology believes its practice provides higher quality care than the competition but feels it cannot compete on price with the medispa. The practice determines that it will focus on high service and quality as its value proposition. Accordingly, the practice adopts the slogan, “XYZ Dermatology: Medical and Cosmetic Skin Care Advice from the Doctors You Trust.” This slogan highlights the chosen value proposition, and it gives patients a clear reason to consider the practice for their cosmetic needs. Implicit Brand Building The second channel for communicating a cosmetic brand to patients is implicit brand building. Implicit brand building does not directly state a brand message. Instead, it conveys a brand impression indirectly through the patient experience. Some examples of implicit internal brand building covered in this chapter include the physical office environment and customer service. The physical office environment is a critical influencer of overall patient experience. The environment can either enhance or detract from the internal marketing campaign. A practice that wants its patients to feel comfortable spending money on discretionary cosmetic procedures must pay attention to details. Cosmetic services are luxuries for most patients, and the goal of the environment is to put the patient in a state of mind that is receptive to luxury spending. The office should, above all, be clean and free of clutter. Flat surfaces should be clear of papers or debris. The décor should be updated and coordinated. Furniture should be comfortable and in good condition. Ideally, the patient should “experience” the ambiance of the practice. Patients should “feel” the brand. The interaction between staff and patients presents additional opportunities for implicit brand building. Each employee of the practice, from providers to reception staff, should be cognizant of his or her individual contribution to patient experience. The common saying is that patients might not remember what a doctor said or did, but they will always remember how the practice made them feel. In the context of internal marketing, the goal should be to make each patient feel important all the time. It is common, in a busy medical practice, for staff and providers to lose focus on the patient as the constant and highest priority. Reception
INTERNAL MARKETING staff may be distracted with phone calls or chart-work. Clinical staff may be focused on documentation or assisting. Providers may be caught up in the stress of running behind schedule. All members of a practice have many important jobs and worries, and no one person can solely be responsible for providing customer service. It takes a team focus on service to make a positive impression on patients for each and every step of the patient process, and it is entirely worth the extra effort. A patient who feels truly appreciated is much more likely to trust a practice with his or her cosmetic business—and may become a source of valuable referrals as well. CAPTURING PATIENTS WHO ARE PREDISPOSED TO COSMETIC TREATMENTS
Identify Patients Who Want Cosmetic Services The simplest and most effective way to increase cosmetic business from existing medical patients is to identify patients who are predisposed to cosmetic services. After predisposed patients have been identified, the staff and providers can address these patients’ cosmetic needs. One straightforward way to determine which medical patients have an interest in cosmetic services is simply to ask them. Use a Cosmetic Interest Form at Check-in Each time a patient arrives for a medical appointment, the practice has an opportunity to gather valuable information. A cosmetic interest form is one way that a practice can easily (and with no guessing) determine what cosmetic products or services might be of interest to a particular patient. This form typically looks like a menu of services and products offered by the practice. The form allows the patient to indicate topics for which the patient might welcome additional discussion from the clinical or aesthetic staff. The key is to use the form effectively. Discuss the Cosmetic Form with Patients At the conclusion of the patient’s medical visit, a member of the staff or a provider, depending on the preferred flow of the practice in question, can discuss the patient’s cosmetic form. Here is a typical discussion:
• • • • •
Provider: “Mrs. Johnson, we have now concluded your medical visit. Do you have any further questions about your diagnosis or treatment?” Patient: “No, I think I understand everything. Thanks for your help.” Provider: “You’re welcome Mrs. Johnson. I notice on your intake forms you mentioned that you have an interest in learning more about laser hair removal. This is a service our practice provides. Would you like to hear more about laser hair removal?” Patient: “Sure. I’ve always been bothered by the hair on my upper lip, but I didn’t know your office could help with that.” Provider: “We certainly can. If you are interested, I can go over the basics with you. Then our aesthetician can come in for a few minutes and explain your options in detail. Would you like that?”
In this example, the patient had a predisposed interest in laser hair removal. Without the use of the cosmetic interest form, the provider would not have been aware of this interest. In addition, because the patient had indicated on her form that she wanted more information about this particular procedure, the provider should not feel awkward bringing it up at the conclusion of the medical visit. The form can act as an effective ice breaker between patients who may be nervous about discussing cosmetic procedures and providers who do not want to appear pushy about cosmetics.
47
Reputation Is Everything The reputation of a practice is its most valuable asset. All care must be taken to protect and build a practice’s good name. Without daily vigilance, a practice can develop a negative reputation for being pushy with cosmetics. Aggressive sales behavior in the practice will almost certainly be reported by word of mouth to the detriment of the practice, that is, as referrals evaporate. No one wants the following comments to be floating around in the community: “I went to XYZ Dermatology for a wart, and the doctor spent the whole time trying to sell me Botox.” The simplest way to avoid a pushy reputation is to use the cosmetic interest form. A provider or cosmetic coordinator should discuss only the issues for which a patient has explicitly expressed interest. This policy will ensure that no patient is offended by the suggestion that he or she consider a cosmetic procedure. If the provider feels it is important to bring up cosmetics with a patient who has not expressed interest on the cosmetic interest form, this must be handled delicately. One viable approach is to ask simply, “How are you taking care of your skin?” This question usually leads to a discussion of products, routines, and cosmetic concerns. If diplomatically handled, this conversation may result in either a cosmetic service or a scheduled consultation. Focus on the Relationship To achieve long-term success as a cosmetic practice, each provider must focus on the patient relationship. Whenever a patient is considering a cosmetic purchase, there are two factors in play: the transaction and the relationship. The transaction is the short-term consummation of a purchase. The relationship is the long-term association between provider and patient that is based on trust and mutual benefit. Whenever a provider is considering a cosmetic procedure for a given patient, he or she must ensure that the transaction does not interfere with the relationship. This can be accomplished by doing only what is best for the patient. Often this means a provider will have to discourage a patient from choosing a procedure that is not a good fit for him or her. Although giving such counsel means forgoing a profitable transaction, it will build trust and benefit the patient relationship in the long run. STIMULATING NEW COSMETIC INTEREST IN EXISTING PATIENTS
Educate Patients About the Offerings of the Practice Medical patients may come to a practice having never previously considered cosmetic procedures. This does not mean that these patients would not be interested in cosmetic procedures or products if they were educated about their options. It is a primary goal of internal marketing to ensure that no potential cosmetic patient leaves a practice without at least being aware of what services the practice offers. To educate existing medical patients effectively, a practice should do the following:
• • • •
Take polite advantage of a captive audience Show off good results Offer cosmetic consultations Host group seminars
Take Polite Advantage of a Captive Audience When patients are sitting in the waiting room, or waiting in an exam room for a provider, they are effectively a captive audience. They typically have few distractions other than what the practice provides. To leverage this opportunity, a practice can offer educational materials that inform patients about cosmetic services and products provided. Brochures describing specific procedures or products allow patients to read about areas of interest in a low-pressure environment. Educational videos, such as those sponsored by the American Society for Dermatologic Surgery, can provide ambient information for patients’
48
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
education. Each practice will have a different comfort level with the amount of promotional material it wants to make available in the waiting room, and it is important to find a balance. Show Off Good Results Good photography is critical for any practice offering cosmetic services. One of the most effective internal marketing tools is a wellconstructed before-and-after portfolio of patient photographs. Copies of this portfolio can be displayed in the waiting room and in exam rooms. Patients will browse through the portfolio out of curiosity, and this will often stimulate interest in the displayed procedures. For many medical patients, words such as Botox, Restylane, laser, or IPL are terms they have previously heard but do not fully understand. This is what makes a before-and-after portfolio such a terrific entry point for marketing cosmetics to medical patients. A picture requires no preexisting knowledge to interpret. A patient can identify with the appearance of the person in the before picture, and admire the cosmetic improvements in the after picture. Such enlightenment will often lead to this typical discussion:
• • • •
•
Patient: “Doctor, I was looking at the before-and-after book while I was waiting today, and I noticed a picture of a lady with red veins on her nose like mine.” Provider: “Yes, those are called telangiectasias, and they are a common cosmetic complaint in fair-skinned patients your age.” Patient: “In the after picture, the veins looked much better. In the binder, I read that she had three treatments with a laser, but I don’t remember the name of the laser.” Provider: “She had three treatments with our pulsed-dye laser. If you are interested in the procedure, I can evaluate you formally to determine if you are a good candidate for this laser. If, after the evaluation, you have additional questions, or would like to discuss the price of treatment, I can have our cosmetic coordinator go over the details with you.” Patient: “That would be great. I didn’t even know those veins could be fixed.”
In this example, the patient did not know that a laser remedy is available for her telangiectasia. She did, however, know that she did not like the look of the red veins on her nose, and when she saw the before-andafter pictures, she asked questions that were important to her. This common scenario highlights the importance of showing off your good cosmetic results. Offer Cosmetic Consultations Perhaps the best way to educate existing medical patients about cosmetic services and products is to conduct a cosmetic consultation. First, though, a patient needs to be aware that cosmetic consultations are available in the practice. For example, a sign in the waiting room can alert patients that the practice offers cosmetic consultations. Cosmetic consultations can also be mentioned on the cosmetic interest form completed at check-in. During the cosmetic consultation, the patient learns (from a provider or from a cosmetic coordinator) about all available options for treating his or her cosmetic concerns. If handled properly, cosmetic consultations can expand existing medical patients into cosmetic patients. The individual practice should determine whether or not to charge for cosmetic consultations. If such consultations are complimentary, expect many more patients to schedule appointments. However, to minimize numbers of the curious only, some practices charge a fee that can be applied toward any procedure purchased. The best price structure may ultimately depend on who within the practice is actually conducting the consultation, that is, an aesthetician may not command a premium price for a consultation, but a physician may.
Host Group Seminars Another way to reach existing medical patients who are predisposed to cosmetics is to hold educational seminars. Some patients are more comfortable in a group setting, and they may prefer to attend seminars over scheduling individual consultations. Each seminar can be as general or specific as the practice chooses. Often patients are offered an incentive to attend, such as a discount on procedures scheduled at the event. These seminars can conveniently be hosted at the practice, if physical space allows. To solicit reservations for these seminars, the practice can send flyers or emails to targeted patient groups, as well as display announcements in public areas of the office. In addition, a practice can seek out patients who are social connectors and have many friends or ties to the community. These patients can be given an incentive to help organize the events. An example of an incentive could be a discount on cosmetic procedures for each attendee the patient recruits. MAINTAINING STRONG OVERALL RELATIONSHIPS WITH PATIENTS
A practice that maintains strong overall relationships with its existing medical patients will have a much easier time converting patients into cosmetic customers. Patients like to feel that they are more than a medical record number. Above all, patients want to feel important. There are many effective ways to maintain lasting and positive relationships:
• • •
Newsletters Digital marketing Patient appreciation
Newsletters A newsletter can keep patients routinely engaged with the practice. The content of a newsletter can be a mix of educational and promotional material. For example, depending on the frequency of publication it might make sense to offer seasonal skin care tips. A summer newsletter might offer sun-safety advice—thus leading to a promotional announcement about a new line of sunscreen products available at the practice, as well as a discussion of laser options for treating sun damage. Newsletters also offer the opportunity to discuss changes and developments at the practice that will be of interest to patients. For example, if the practice purchases a new laser or adds a new provider, a newsletter is a perfect vehicle to reach patients with this important information. Digital Marketing As communication has become increasingly electronic, the options available to practices wishing to stay in touch with existing patients have expanded. A website for the practice can be a valuable way to stay connected with patients. If elements such as posted lab results or online consultations are incorporated into a website, medical patients will have a reason to log in regularly. This web traffic will provide a platform that is useful for delivering marketing information. A practice might incorporate a blog to supplement the promotional information in a newsletter. Blogs have an advantage over print media in that they can be updated quickly with current information. A blog also has a low cost of publication, and its audience is more easily traceable. It is easy for a practice to know how many newsletters it mails, but it is impossible to know how many are read by patients. Web-based marketing can give accurate and up-to-date metrics on the number of people who view a practice’s marketing materials, as well as the time spent viewing. The one caveat about blogs is that a practice must be cautious about communicating content (into the public domain) that has not been approved by appropriate authorities or for which the providers are not entirely confident. If in doubt, leave it out. In addition to website-based communications, email is an important component of a complete internal marketing campaign. Email has
INTERNAL MARKETING many of the same advantages that a blog enjoys over print media with a particular added benefit. Because each email is targeted to a specific patient, the tracking data can be more specific. Email-based marketing firms can give patient-specific information on response rates to various promotions. The more information a practice can learn about what truly works, the more effective its marketing will become. Patient Appreciation A sure way to build relationships with patients is to let them know they are appreciated. A simple gesture, such as a birthday or holiday card, can keep a practice at the top of its patients’ minds. A practice can also extend special privileges to the patients it wants to recognize as VIPs. VIPs can be designated based on cosmetic dollars spent in a given year or on any metric the practice feels will adequately describe the demographic it is aiming to recognize. VIP patients can be offered perks such as increased access to providers after hours or during special time slots. VIP patients could also qualify to participate in special promotions the practice occasionally offers. These benefits can create an additional incentive for medical patients to seek and accept cosmetic services and products at the practice.
49
CONCLUSION
Key Lessons from This Chapter All practices that want to maximize cosmetic volume should first direct their attention toward internal marketing. The cost of delivering a message to existing patients is relatively low compared with the cost of creating new patients. In addition, the likelihood that a marketing message will be well received is much higher in a base of patients who already know and trust a given practice. Apply These Lessons in Practice There are many channels through which a practice can pursue internal marketing. Ultimately it will be up to the individual practice to determine which methods will work best with its specific patient population. Ideally, all four major categories discussed in this chapter can play a role in a coordinated internal marketing campaign. A practice that successfully builds a cosmetic brand, captures patients who are predisposed to cosmetic treatments, stimulates new cosmetic interest in existing patients, and maintains strong overall relationships with patients will dramatically improve patient satisfaction and the sale of cosmetic services and products.
9
Financial benchmarking for the aesthetic medical practice Page S. Piland
FINANCIAL HEALTH OF THE PRACTICE
The financial performance of a cosmetic practice is, next to patient care, the most important component of your practice. Yet, in most instances, it receives little attention until a problem arises that calls attention to it. Frequently, this problem is of a magnitude that it affects the viability of the practice and its ability to meet its financial obligations. Many physicians have become complacent with respect to the financial health of their practices. They rely heavily upon the skills of others, some of whom have little more than a high school degree and a paucity of experience. In many practices, the financials are left to the office manager and the physician defers to his staff. In my experience, this is a mistake because no one has more of a vested interest in the financial health of the practice than the physician. In order to make good decisions, it is imperative to have the right information and to act upon it in a timely manner. Over the past decade, I have had the opportunity to work with many of the leading cosmetic practices and in this chapter, I would like to share some of what I have gleaned. Knowing the necessity of measuring the financial health of your practice is the first critical step. Carving out the time to actually do this is the second. Many of the practices that I work with have a mandatory meeting with me and their financial team (which can include an accountant, bookkeeper, office manager, etc.) on a quarterly basis. The demand for this type of meeting has dramatically increased during 2009 when many such practices were impacted by the global economic downturn. One cautionary note to remember while analyzing your financial data is to avoid the pitfall of analysis paralysis. This occurs when the data cause the physician to freeze like a deer in the headlights—this is bad and should be avoided. The goal of any analysis is to gather pertinent information and use it to take action. Physicians that spend too much time diving deep into the data without confronting their problems will become victims of data overload. This chapter will help one to identify significant numbers and understand the metrics that will define the success or failure of your practice. INSPECT
There are several ways to inspect the financial health of a medical practice. I highly recommend comparing your practice’s performance to both internal and external metrics. Internal metrics include a profit and loss statement prepared by an accountant, productivity reports, payroll summary reports, and an accounts receivable aging analysis. Areas that deserve special attention include collections, new and existing patient encounters, fixed and variable overhead ratios, net collected revenue by provider, and revenue per patient encounter. Comparing this with prior year’s data will help one to identify trends that define the success or failure of your practice. INTERNAL ASSESSMENT
Evaluate Once you have completed the internal assessment, it is essential to understand how it compares with other practices. External practice data are available from many sources. Among the ones that I use are the AAD, ASAPS, and ASPS, The Health Care Group, Kline and Company, the Healthcare Group and the BSM Consulting Group/Allergan Practice Consulting.
50
Most physicians have a familiarity with a profit and loss statement. Unfortunately, the amount of time spent reviewing this statement is usually minimal and is focused only upon the top and bottom line numbers. The numbers in between frequently tell the real story of the practice and physicians need to spend more time looking at them and understanding these. Spending hours evaluating and re-calculating the numbers is not productive. Your accountant and bookkeeper should already have a mastery of these and be able to distill them for you. I recommend increasing your understanding of the larger, individual line-item expenses. Typical large areas include payroll, rent, medical supplies, and marketing. These line items are all areas that represent an opportunity to increase efficiency and eliminate wastage. Once the larger items have been scrutinized, attention can be turned to the items lower on the list. Table 9.1 provides a quick reference that can be used to compare your practice’s financial performance to the key benchmarks of the Allergan/ BSM Consulting Financial Database. The table includes the mean and median values for the key benchmarks from the years 2006, 2007, and 2008. Each category will be discussed in detail throughout this chapter. COSMETIC MEDICAL PRACTICE BENCHMARKS: INCOME
One of the biggest challenges faced by practices when trying to measure the practice financial performance is obtaining reliable data. There are many sources for data but most physicians do not know where to access it or how reliable the data are. Most practices rely on the data from the Allergan/BSM Consulting Group Financial Benchmarking database. These data have been collected from the actual financial documents, tax returns, payroll summary reports, and practice summary reports. The data come from dermatology, plastic surgery, facial plastics, and oculoplastic practices. These data are verified, published every year, and shared freely with the industry. I will reference many of the Allergan/BSM Consulting 2008 benchmarks in this chapter. There are many terms and formulas used when discussing the financial performance of the medical practice that can very often be confusing to non-accountants. I will attempt to simplify the terminology and focus upon the areas that provide the most pertinent data for measuring your practice performance. Let’s start with the top line number also known as net collected revenue. The net collected revenue is classified as all monies received by the practice during the fiscal year by way of professional services, facility fees income, and spa services. Basically it is the money the practice has brought in before expenses. The usefulness of the top line number is not as pertinent when making comparisons because of the large variety and types of practices. The different practices include solo, group, and multi-specialty. Many practices also have mid-level providers and aestheticians that contribute to the practice revenue. Therefore, a direct practice comparison is not the most accurate method to measure your practice performance. For this reason, we will look at all of the key contributors on an individual basis in order to compare “apples to apples.” NET COLLECTED REVENUE PER FULL TIME EQUIVALENT PHYSICIAN
The net collected revenue per full time equivalent (FTE) physician is the first category we will examine (Fig. 9.1). An FTE physician is classified as a physician who works 1600 hours per year or 4 days per week. The total net collected revenue of the practice is divided by the
51
FINANCIAL BENCHMARKING FOR THE AESTHETIC MEDICAL PRACTICE
Table 9.1 Key Benchmarks 2006 Benchmark Net collected revenue per FTE physiciana ($) Revenue rate per hour per FTE physicianb ($) Net Collected revenue per FTE non-physician providerc ($) Collected revenue by cosmetic providersd ($) Net collected revenue per FTE aestheticiane ($) Revenue rate per hour per FTE aestheticianf ($) Net collected revenue per FTE support staffg ($) Operating expense ratioh (%) Non-provider payroll ratioi (%) Rent expense ratioj (%) Marketing and advertising ratiok (%) Number of FTE support staff per FTE providerl
2007
2008
Mean
Median
Mean
Median
Mean
Median
1,395,469
1,244,391
1,467,812
1,306,776
1,478,829
1,385,389
872
778
917
817
924
866
399,385
349,450
453,016
391,667
485,360
426,768
283,482
209,281
308,870
199,840
300,421
207,636
145,675
122,026
141,701
125,799
152,412
132,281
70
59
68
61
73
64
345,545
313,716
365,020
322,991
337,748
304,497
62.8 15.3 5.1 4.4
62.8 14.9 4.5 3.2
63.0 15.0 5.2 4.5
62.2 14.3 4.7 3.4
65.3 15.7 5.7 4.7
66.0 15.6 5.0 3.7
4.82
4.33
4.95
4.46
5.40
4.99
a
Net collected revenue per FTE physician—The total physician-collected revenue divided by total full-time equivalent physicians. A full-time physician is assumed to work 1600 hours or more per year. b Revenue rate per hour per FTE physician—The total physician collected revenue divided by the total hours worked by the physician. This measure provides an evaluation of physician productivity in relation to hours worked during the measured period. c Net collected revenue per FTE non-physician provider—The total non-physician provider collected revenue divided by total full-time equivalent non-physician providers. Non-physician providers include physician assistants and nurse practitioners and full time is calculated at 2080 hours per year. d Net collected revenue by cosmetic providers—The total revenue collected for services performed by cosmetic providers. A cosmetic provider includes registered nurses, licensed practical nurses, medical assistants, and others who are performing injections, laser procedures, and other cosmetic services. This excludes licensed aestheticians, physician assistants, nurse practitioners, and other service providers performing non-medical procedures, i.e., massage therapists. e Net collected revenue per aesthetician—Total aesthetician-collected revenue divided by total full-time equivalent aestheticians (FTEs calculated at 2080 hours per year). f Revenue rate per hour per FTE aesthetician—The total aesthetician-collected revenue divided by the total hours worked by the aestheticians employed by the practice. g Net collections per FTE support staff—The practice’s total collected revenue divided by the sum of full-time equivalent support staff employees. A support staff employee includes cosmetic providers, licensed aestheticians, and non-physician providers working in a support capacity, i.e. those not producing revenues independently. A full-time support staff employee is assumed to work 2,080 hours per annum. h Operating expense ratio—Total expenses (cost of goods sold and operating expenses) divided by the total net collected revenue as reported on the practice’s financial statements or tax return. Operating expenses exclude provider compensation, bonuses, retirement contributions, automobile expenses, as well as depreciation. i Non-provider payroll ratio—Gross non-provider payroll divided by the total net collected revenue as reported on the practice’s financial statements or tax return. j Rent expense ratio—Total rent expense or occupancy costs divided by the total net collected revenue as reported on the practice’s financial statements or tax return. k Marketing and advertising ratio—Total marketing and advertising costs divided by the total net collected revenue as reported on the practice’s financial statements or tax return. l Support staff per FTE provider—Total full-time equivalent support staff divided by the sum of full-time equivalent physicians and non-physician providers.
$1,400,000 $1,350,000 $1,300,000 $1,250,000 $1,200,000 $1,150,000
2006
2007
Figure 9.1 Net collected revenue per full time equivalent physician.
2008
52
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
actual number of FTE physicians working in the practice. The 2008 median range was $1,100,000 to $1,600,000. The median is $1,385,389.a The percentage growth rate over 2007 ($1,306,776) was 6.02%. The percentage growth rate of 2007 versus 2006 ($1,244,391) was 5.01%. Many economic factors contributed to the slower growth rate in 2008. There aren’t any data available for 2009 yet, but it should prove to be an interesting year. Some early anecdotal information suggests that the 2009 growth will be flat. It appears that practices that were primarily focused upon high dollar surgical procedures saw a decline in revenue in 2009. Practices that had a balanced portfolio of cosmetic services were able to weather the storm a little better and in some cases actually grew their revenue over 2008. REVENUE RATE PER HOUR PER FTE PHYSICIAN
The revenue rate per hour per FTE physician is another important number to monitor (Fig. 9.2). The pertinence of this metric is that helps physicians understand the value of their time. This measurement also helps achieve perspective pertaining to the physician’s daily activities. Example I have worked with many physicians who insist upon performing non-patient’s care-related projects in order to avoid the expense of paying someone else to do these projects. Some physicians undertake projects such as creating marketing materials or working on their website because it is a “hobby.” When this information was discovered, most of these physicians found a new hobby, hired additional personnel, or outsourced specific projects. By comparing the value of their time versus the much lower cost of finding the right person for the right job, most physicians opted to bring in additional personnel. The revenue rate per hour per FTE physician is calculated by dividing the actual net collected revenue of all of the physicians in the practice by the total number of physician hours worked. The hours worked assumes 1600 hours for an FTE physician and is adjusted for part-time physicians working less than 1600 hours. The median revenue rate per hour per FTE physician for 2008 was $866 per hour and the healthy benchmark range was from $625 to $1000 per hour.b The percentage
growth over previous years is similar to the growth seen in the net collected revenue per FTE provider. The percentage growth over 2007 ($817 per hour) was 6% and the percentage growth of 2007 over 2006 ($778 per hour) was 5.01%. NET COLLECTED REVENUE PER FTE NON-PHYSICIAN PROVIDER (MID-LEVEL PROVIDER)
Physician assistants and nurse practitioners continue to make a significant contribution to the profitability and quality of patient care in the aesthetic medical practice. The median net collected revenue value for 2008 was $426,468, which was an 8.89% growth over 2007. The 2008 growth percentage was lower than the 2007 versus 2006 growth percentage of 12.08%. The median value for 2007 was $391,667 and for 2006 it was $349,450.c The number of Physician Assistants and Nurse Practitioners continues to increase as more physicians understand the positive impact achieved by incorporating them into the practice. This is reflected by the positive growth seen in the number of practices that have a nonphysician provider (Fig. 9.3). In 2006, 22.5% of the practices in the Allergan database had an MLP/NPP. In 2007, the number was 24.5% and that grew to 28% in 2008.d The increase in the popularity of mid-level providers has been caused by several factors. The fact that the demand for specialized care has outpaced the supply of physicians for several years is one primary reason. Physician assistants and nurse practitioners have done a more than adequate job in helping practices meet this demand. Another reason contributing to their success is that they have been accepted by the patients. This acceptance continues to grow as the patients are educated and gain understanding of the qualifications and capabilities of physician assistants and nurse practitioners. This is supported by the consistently high scores they have earned on patient quality of care surveys conducted over the last few years (Fig. 9.4). NET COLLECTED REVENUE PER FTE AESTHETICIAN
The median value for aesthetician’s net collected revenue for 2008 was $132,281e (Fig. 9.5). This number reflects aesthetician services only. The median net collected revenue value for 2008 was $132,281, which was a 5.15% growth over 2007. The 2008 growth percentage
$880 $860 $840 $820 $800 $780 $760 $740 $720
2006
2007
2008
Figure 9.2 Revenue rate per hour per full time equivalent physician.
c a b
Source: Allergan/BSM Consulting Financial Database. Source: Allergan/BSM Consulting Financial Database.
d e
Source: Allergan/BSM Consulting Financial Database. Source: Allergan/BSM Consulting Financial Database. Source: Allergan/BSM Consulting Financial Database.
FINANCIAL BENCHMARKING FOR THE AESTHETIC MEDICAL PRACTICE 30.00% 25.00% 20.00% 15.00% 10.00% 5.00% 0.00%
2006
2007
2008
Figure 9.3 Practices with non-physician providers.
$500,000
$400,000
$300,000
$200,000
$100,000
$0
2006
2007
2008
Figure 9.4 Net collected revenue per FTE non-physician provider.
$64 $63 $62 $61 $60 $59 $58 $57 $56
2006
2007 Figure 9.5 Revenue rate per hour per FTE aesthetician.
2008
53
54
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
outperformed the 2007 versus 2006 growth percentage of 3.09%. The median value for 2007 was $125,799 and for 2006 it was $122,026. Product sales are not included in this number and will be reviewed separately. The aesthetician median revenue rate per hour for 2008 was $64 per hour, which was an increase of 4.92% over 2007 at $61 per hour. The aesthetician net collected revenue rate per hour for 2006 was $59 per hour. I have often debated with physicians regarding the value of offering aesthetician services in the cosmetic medical practice. The argument I hear from physicians and managers is that the aestheticians are barely breaking even when they look at the profit and loss statement. The first point I like to emphasize is that it is important to include the aesthetician’s revenue generated from product sales (Fig. 9.6). This is often approximately equal to the revenue generated from aesthetician services. The second point I like to make is that there is a value that is difficult to measure because of intangible factors. Aestheticians often offer gateway procedures that bring in new patients. If the practice has a conversion strategy in place, these new patients often convert to the higher valued services provided by the practice. Depending upon the job description and office infrastructure, many aestheticians contribute to the front and back office serving as back-up or patient educators.
RETAIL PRODUCT SALES
Retail product sales continue to be one of the biggest areas of opportunity for the cosmetic medical practice in regard to revenue earning opportunities. According to the 2009 market overview published by Kline & Company, the total cosmeceutical market volume for 2008 was $1,055,700,000. The market grew by 7.54% in 2008 over 2007. Medical care providers generated 26.4% or $279,200,000 of this volume, which represents an 11.5% growth change from 2007. Spas and salons continue to hold the lead position in the market share at 50.7% or $535,700,000 but experienced the slowest growth over 2007 at 5.4%. Retail stores have the lowest volume at $240,800,000 and were in second place with a growth of 8% over 2007f (Fig. 9.7). The fact that medical care providers hold only ¼ of the market share should be enough information to motivate most practices to take action. This is the low hanging fruit in my opinion because nobody knows more about skin health and maintenance than a qualified medical practice. To further emphasize this point, consider the following facts. The median retail sales volume per office in 2008 was $118,300 according to the 2008 Allergan Practice Consulting Financial Benchmarking database. This was one of the largest growth areas in the database at 28.3% over 2007, which was $92,204. The 2007 growth over 2006
$134,000 $132,000 $130,000 $128,000 $126,000 $124,000 $122,000 $120,000 $118,000 $116,000
2006
2007
2008
Figure 9.6 Net collected revenue per FTE aesthetician.
$120,000 $100,000 $80,000 $60,000 $40,000 $20,000 $0
2006
2007 Figure 9.7 Retail sales.
f
Source: 2009 Kline & Company.
2008
FINANCIAL BENCHMARKING FOR THE AESTHETIC MEDICAL PRACTICE of $86,597 was 11.47%.g This growth trend leads me to the conclusion that medical practices are beginning to recognize the opportunity this represents and are formulating strategies to better provide their patients with the highest quality of skincare products available. COSMETIC MEDICAL PRACTICE BENCHMARKS: EXPENSES
This section pertains to the less glamorous, but equally important area of cosmetic medical practice expenses. We will examine several areas which are traditionally the largest line item expense categories but are easily controlled with proper attention and focus. Similar to income categories, it is easier to measure your internal performance because you already have the data on hand and can compare it to data from previous years. Measuring against external data is more difficult because it is often harder to find. Inspecting the financial health of the medical practice requires vigilance on the part of the physician and management team. The physician needs to have a working knowledge of the components of a profit and loss statement, but as stated before, the physician should avoid being consumed with data analysis. There are several ratios and line items that can be evaluated to provide a snapshot of the financial health of the practice. When the financial numbers are running in the appropriate ranges, then scrutiny is sometimes relaxed because of a false sense of security. When they began to go outside of the desired ranges, then some practices increase their attention level to investigate more deeply into what is causing the fluctuations. Sometimes this can be too late to make quick course corrections. The goal should be to create a habit of reviewing the data on a monthly basis, which will enable the practice to make small course corrections as needed rather than trying to turn the ship away from the iceberg one minute before impact. OPERATING EXPENSE RATIO
The operating expense or overhead is the ongoing cost for running a business or all of the money you spend to run your practice. Fixed and variable expenses are the two main components of a practice’s total overhead expense. Fixed costs are those that do not fluctuate with changes in productivity or sales volume. Examples of fixed costs include rent, insurance, society dues, journal subscriptions, equipment leases, payments on loans, management salaries, and advertising. Variable costs are those that respond directly and proportionately to
changes in activity level or volume, such as surgical supplies, hourly wages and commissions, utilities, cosmeceutical inventory, office supplies, mailing, and shipping costs. The operating expense ratio is calculated by dividing the operating expenses by total practice net collected revenue. Operating expenses used in this ratio exclude physician and non-physician provider compensation, bonuses, retirement contributions, depreciation, and automobile expense. The cost of goods sold is included in the operating expenses. The benchmark healthy range of the operating expense ratio for the cosmetic medical practice in 2008 was 55% to 70%. The median was 66%, which is an increase of 3.8 percentage points. The median in 2007 was 62.2%, which was down from 62.8% in 2006h (Fig. 9.8). NON-PROVIDER PAYROLL RATIO
The non-provider payroll or the support staff payroll is traditionally the largest line item expense that a cosmetic medical practice has. This ratio is calculated by dividing the total non-provider gross payroll by the total net collected revenue. Payroll includes the gross wages but does not include employee benefits or payroll taxes. The median non-provider payroll ratio for 2008 was 15.6% with a benchmark healthy range of 12% to 18%. This was 1.3 percentage points higher than the 2007 median of 14.3%. The median for 2007 was slightly lower than 2006, which was 14.9%i (Fig. 9.9). Example If your net collected revenue is equal to the mean of the database at $1,385,389 and your non-provider payroll ratio is also at the mean value of 15.6%, then your yearly payroll should be around $216,121 to be considered within the healthy range. There are a couple of ways to verify whether your payroll ratio is right for your practice. The first is to calculate your number of FTE support staff per provider. FTE support staff includes all non-provider personnel working 2080 hours. The FTE number can be calculated by adding all support staff hours from your payroll summary report and dividing by 2080. In 2008, the FTE support staff ratio was 4.99 support staff to one provider. This is up from 2007, which was 4.46 and 2006, which was 4.33j (Fig. 9.10). The second method of verifying your payroll expenses is to compare your individual support staff positions to published data. The Health
66.00% 65.00% 64.00% 63.00% 62.00% 61.00% 60.00%
2006
2007
2008
Figure 9.8 Operating expense ratio.
g h
Source: Allergan/BSM Consulting Financial Database. Source: Allergan/BSM Consulting Financial Database.
55
i j
Source: Allergan/BSM Consulting Financial Database. Source: Allergan/BSM Consulting Financial Database.
56
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
Care Group conducts an annual Staff Salary Survey which provides nationwide salary statistics for 38 key office positions. It is organized by position, years of service, and locale and also provides data on benefits and turnover rates. One example of these data is for the position of medical assistant (MA). The data collected for this position came from 1248 surveys collected from multiple types of practices across the United States. An MA with less than 2 years of experience earned $12.41 per hour. An MA with 2 to 5 years of experience earned $13.52 per hour and one with more than 5 years of experience earned $15.32 per hour.k While these data are not specific to cosmetic medical practices, it is still very useful in gauging the range of salaries you will be competing with when recruiting. It is also a valuable measurement tool you can use to ensure that you are offering your current employees a competitive wage. It is also a useful management tool that can be used to improve employee performance by holding them to a higher standard if you are currently paying them at the top of the range. RENT EXPENSE RATIO
Many physicians I work with throw up their hands in surrender when the discussion turns to the rent. They basically say “it is what it is and it is something that I have no control over.” Whether you are paying a landlord or if you own the property and pay yourself, this ratio will at the least give you an idea of where you stand. You may not be in a
position to negotiate your rent now, but when the time comes you will know that there is a benchmark available regarding healthy ranges. The rent expense ratio is calculated by dividing the total practice rent by the total practice net collected revenue. Rent expense does not include additional occupancy expenses such as utilities and maintenance. The 2008 median rent expense ratio for cosmetic medical practices was 5% (Fig. 9.11). The rent expense ratio has increased slightly over the two previous years in which it was 4.7% in 2007 and 4.5% in 2006.l Example If your net collected revenue is equal to the mean of the database at $1,385,389 and your rent expense ratio is also at the mean value of 5% then your yearly rent should be around $69,269 to be considered within the healthy range. MARKETING EXPENSE
The discussion pertaining to marketing expense is usually very interesting. Some practices are lackadaisical in regard to advertising/ marketing their practice and consider the printing of business cards sufficient in meeting their needs. Other practices feel compelled to be on every billboard in town, on the back of the phone book, and on broadcast media once every hour. I will defer judgment on what is beneficial and what is not because each practice is different and what works for one may not work for another.
16.00%
15.50%
15.00%
14.50%
14.00%
13.50%
2006
2007
2008
Figure 9.9 Non-provider payroll ratio.
5.00 4.80 4.60 4.40 4.20 4.00
2006
2007
2008
Figure 9.10 Number of FTE support staff per FTE provider.
k
Source: The Healthcare Group – Year 2008.
l
Source: Allergan/BSM Consulting Financial Database.
FINANCIAL BENCHMARKING FOR THE AESTHETIC MEDICAL PRACTICE Two activities regarding marketing that have proven to be effective are as follows. The first is to maximize your internal marketing efforts before considering external marketing. It is more cost effective, easier to manage, and typically has a much higher return on investment. The other tip is to track your advertising. Whether it is internal or external marketing, it is very difficult to know what is working and what is most cost effective if you do not track and measure it. This can be easily accomplished by assigning each marketing program a unique identification code and adding a “How did you hear about us?” type of question to your intake form or on patient surveys. The mean value ratio of marketing expense for 2008 was 3.7% of the total net collected revenue. This ratio has continued to increase as demonstrated in 2007 when it was 3.4% and 2006 at 3.2%m (Fig . 9.12). Example If your net collected revenue is equal to the mean of the database at $1,385,389 and your marketing expense ratio is also at the mean value of 3.7% then your yearly marketing should be around $51,594 to be considered within the healthy range. TACTICAL OPPORTUNITIES
The financial benchmarks provide the healthy parameters for practice operations. If you are outside of the healthy range or if you want to
ensure that you stay there then the next question is usually “now what do I do?” If you have gone through the inspection and evaluation of your practice and you have identified areas of opportunity, the next step is to modify or take action. The financial health of your practice can be impacted by reviewing your internal controls and processes. A good place to begin is to review your cash-handling procedures. Ensure that you appropriately segregate duties. Investigate all areas in which cash and checks are handled. One good idea is to have different personnel receive the monies and another to post the payments. The goal is to minimize the risk of embezzlement by removing the temptation. A good offense is to create an oversight process that is known by all. It is important to educate the staff and to demonstrate that all cash handled is accounted for and scrutinized during all phases from landing in the mailbox to being deposited at the bank. This will effectively reduce the opportunity and temptation to embezzle by the fact that if the books do not add up at the end of the day then a full audit will be conducted and the loss will be identified. Example I worked with a practice many years ago that had just begun offering cosmetic services. Before then the practice was all medical and did not receive cash from the patients. The majority of the transactions were through third party payers. The checks came in the mail and went
5.00% 4.90% 4.80% 4.70% 4.60% 4.50% 4.40% 4.30% 4.20%
2006
2007
2008
Figure 9.11 Rent expense ratio.
3.70% 3.60% 3.50% 3.40% 3.30% 3.20% 3.10% 3.00% 2.90%
2006
2007 Figure 9.12 Marketing and advertising expense ratio.
m
Source: Allergan/BSM Consulting Financial Database.
57
2008
58
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
straight to the bookkeeper. They did not have a process in place to receive cash payments directly from the patient. This all became evident during a financial benchmarking analysis. The chief concern from the physician was that they were performing more and more cosmetic procedures but the growth percentage was not in line with revenue. This was verified by comparing the productivity analysis report with income statement. The revenue growth was a flat and slightly smaller percentage than the aesthetic versus medical procedure growth. This was the first red flag. It was fairly simple to identify the problem and create a solution in this scenario. We simply discussed the cash flow process, identified the problem, and created a solution. The problem was that all cash received from patients was put into an unlocked drawer at the front desk. There was no cash tray, no lock box, no cash register, and no organization. Sometimes a handwritten receipt was given to the patient, but usually only if the patient asked for it. The cash was not regularly deposited, and sometimes weeks would pass between deposits. No one ever really knew how much cash was on hand or much less how much cash was supposed to be on hand. The cash was completely accessible to staff and patients. It was often treated as petty cash for staff lunches, office supplies, etc. It was also unattended which provided disgruntled employees and/or employees who thought they were underpaid or overworked the opportunity to supplement their income. The solution was to take away the opportunity by creating new cash-handling procedures with multiple waypoints for inspecting and auditing. A cash register was purchased and incorporated into the daily operations. The cash register provided organization and security. Each person performing check-out duties had an individual batch. These batches provided the link to the superbill and were reconciled at the end of each day. These minor changes effectively removed temptation and created the necessary oversight to ensure accurate accounting. EXTERNAL PROFESSIONALS
This is the right time to re-assess the relationships you have with external professionals. It amazes me that some businesses have not figured out that a down economy is one that you can’t take their business for granted in. The competition for the customer has increased dramatically, and these businesses don’t provide exemplary customer service and a high quality product, then the chances of being replaced increase exponentially.
finally established communications it took another week to receive the management report. To add insult to injury, the payroll company charged her a ridiculous fee for a document that they should have provided many months before. The result of this experience was that the medical practice now has a new payroll company that understands customer service and provides timely management reports as part of the service. The demand for better service applies to all professionals who support your practice. These are some questions that you need to ask yourself. Are you getting what you need from your current attorney, accountant, and consultants? Are they serving your practice to the best of their abilities, or have they taken your business for granted? Are they delivering timely, accurate, and useful information at a fair market price? Make sure you are getting your money’s worth and that you utilize them to the fullest. This is also a good time to review all of your insurance policies and evaluate the necessity. Are any of them redundant? You may want to consider having several brokers bid for your policies. EXPENSE CONTROL: NEW OPPORTUNITY
A new opportunity for aesthetic medical practices in the area of decreasing medical and surgical supply costs has recently emerged in the form of a group purchasing organization (GPO) offered by the Aesyntix Physician Network. This GPO can help practices achieve cost savings from 5% to 20% on their medical, surgical, and business supply purchases. It is endorsed by ADA/M and is a free service to ADA/M members. Additional information is available by following this link: http://www.corehc.com/articles.html. TACTIC: CREATE A BUDGET
The single biggest area of opportunity I have observed regarding fiscal responsibility in the medical practice lies in the area of budgeting. The days of falling backwards into the flowery fields of success have come to an end for most medical practices. Having a plan and a budget with operational and expenditure parameters is essential to successful daily operations. A budget is simply a financial planning tool that lists all planned expenses and revenues. It is a forecasting tool which enables the management team to apply appropriate intervention in a timely manner. A simple six-step process for creating a budget is outlined below. 1. Gather all historical income and expense financial data. 2. Separate into fixed and variable expenses. 3. Perform assessment of future trends and changes based upon past performance. 4. Establish expenditure limits. 5. Monitor and compare the actual results on a monthly basis (at a minimum) and compare it to the plan. 6. Make necessary changes and modifications.
Example I was recently conducting a financial analysis for one of my clients. They were having difficulty obtaining one document that we needed in order to complete the analysis. The document was a year-end payroll summary report. The practice administrator couldn’t get her payroll company representative to call her back for several weeks. When she
Table 9.2 Specialty Breakdown of Cosmetic Practices 2006 Specialty type Plastic surgery Facial plastics Oculoplastics Cosmetic dermatologya Total a
2007
2008
No. of practices
Percentage (%)
No. of practices
Percentage (%)
No. of practices
Percentage (%)
162 38 7 82 289
56.1 13.1 2.4 28.4 100.0
160 36 7 73 276
58.1 13.0 2.5 26.4 100.0
113 23 5 53 194
58.2 11.9 2.6 27.3 100.0
Dermatology practices where 50% or more of collections are attributable to cosmetic procedures.
FINANCIAL BENCHMARKING FOR THE AESTHETIC MEDICAL PRACTICE Make sure that you diligently work within the parameters of your budget. Celebrate success with your management team when this is accomplished. When you exceed the budget, strive to understand what happened. Have your management team provide the cause and then offer coaching and counseling to avoid going over budget in the future. Holding yourself and the management team accountable is essential to the success of budgetary compliance. The budget planning process will provide you with the information needed to implement changes. Appropriate oversight, accountability, and flexibility will help you achieve the goal of improved financial growth and stability for the practice. The first step to improve the financial strength of your practice is to take action. Find the time to work with your management team and
59
communicate what you are looking for and why it is important. Schedule monthly meetings to review the top line data and hold yourself and your team responsible for sustaining your financial diligence. SUPPLEMENTAL INFORMATION
Allergan/BSM Consulting Financial Database Parameters As of December 2009, the database includes information from 289 practices for 2006, 276 practices for 2007, and 194 practices for 2008. A breakdown of participating practices by specialty is illustrated on Table 9.2. Since participating offices typically provide data for the most recent complete year plus two previous years, the number of practices in the database for each year will continue to grow as additional practices submit their information.
10
Forms, forms, forms Kenneth Beer
Our lives as cosmetic specialists depend not only on our skills and education but on the various forms that define our daily practice. Whether these forms are on paper or in an electronic format, they are the means by which we document what we have done, define the risks and benefits to the patients and instruct them on what we expect them to do before and after each treatment. In broad terms, forms may be divided into pre-operative instructions, financial agreements, examination/ progress notes, procedure/ operative notes, consent forms, and postoperative care sheets. PRE-OPERATIVE
Pre-operative checklists for the operating room staff need to have all of the required lab and examination data checked off to ensure patient safety (Fig. 10.1). Equipment and instrumentation required for the procedure is also spelled out and this avoids the risk of delay that occurs when a procedure occurs without the correct equipment (Fig. 10.1). Good patient pre-operative forms articulate the dos and don’ts that will have an impact on the outcome of the procedure. The length and depth of this form depend on the level of invasion and impact of the procedure as well as the style of the physician and prevailing norms for the medical community in the area. For instance, some highly litigious areas will have several pages of pre-procedure instructions for a routine soft tissue augmentation procedure and this is the norm. In these locations, the form will be delivered to the patient and a signed, carbonless copy will be retained to document the transaction. For geographic areas that have more reasonable attitudes, the norm will be to either verbally discuss what is required or to provide a written form advising the patient on what they should and should not do. The length of the form should be long enough that it encompasses the various factors that will optimize outcomes but short enough that patients can read the form and integrate the information. For injectables such as soft tissue augmentation and botulinum toxins, many physicians do not routinely provide pre-operative forms but rather will advise the patient on ways to minimize bruising such as avoiding aspirin and other platelet inhibitors. Fractional lasers, intense pulsed lights, laser hair reduction, and vascular lasers require more pre-procedure instructions (such as sun avoidance and herpes prophylaxis) and thus the forms need to encompass the entire scope of pre-procedure requirements. Lack of proper information in the form for these procedures will result in postponement of procedures or increased rates of complications. As the level of invasiveness increases, the pre-operative form must also be more comprehensive. Thus, for breast augmentation, liposuction, blepharoplasty, and other procedures in this category the pre-operative forms need to be more encompassing and patients need to articulate and agree with the regimen prior to the procedure. Elements of a good pre-operative form include all elements of pre-operative preparedness. This may include preoperative antibiotics and antivirals (which need to be spelled out), avoidance of certain foods, supplements, and medications. In addition, if general anesthesia is involved, when the patient should refrain from eating needs to be carefully communicated. Laser and light procedures need to have sun avoidance discussed and treatments involving dark skin types should mention pre-treatment bleaching creams when appropriate.
60
FINANCIAL AGREEMENTS
When and what type of financial agreements to use depend on the relationship with the patient (is it a first time consultation leading to a procedure or a patient you have known for decades?) and the amount of money involved. Bringing financial agreements into a consultation for botulinum toxins used in one area probably is not appropriate but not having one in place for a face lift is similarly inappropriate (Fig. 10.2). A good financial agreement needs to be clear about what is provided and how much it will cost. If a surgical procedure will involve a facility fee, anesthesia, and pathology charges, these need to be spelled out so that the patient has a complete understanding of the costs involved. In addition to these costs, what is not covered is also important to discuss. Some physicians routinely use antibiotics and pain medications and it makes sense to tell patients that the fee for this is or is not included (depending on whether the physician dispenses these drugs). When multiple procedures are contemplated (whether these are spaced out over time as in a fractional laser procedure or they are performed at the same time) each of these should be defined with a clear cost attached to it. If discounts are applied to these combinations, they should also be spelled out so that patients know that such discounts are only applicable when the entire program is performed. Despite the degree of preparation associated with each of these agreements, some patients will fail to honor them. Whether they believe that the results obtained were not “worth” the fee charged or they intentionally defraud the practice, there will be costs associated with recovering the fee if the physician chooses to pursue this route. If the physician intends to attempt to recover fees when this occurs, the costs associated with this need to be part of the financial forms. Financial forms are a necessary part of esthetic medicine and surgery but the degree of detail depends on the philosophy of the individual practitioner. EXAMINATION/PROGRESS NOTES
In order to capture the information about what was done to a patient, the data must be documented in a form devoted to this activity. In broad categories, injectables, lasers, intense pulsed lights, chemical peels, and sclerotherapy each require a separate progress note. Surgical procedures also require an operative note specific to each. No matter what the procedure, each form needs to have documentation of patient allergies, materials, devices and settings used, and areas treated. The fact that post-operative care is discussed and that a post-operative care sheet is given (if one does this routinely) is also documented. It is highly recommended that each form documents the fact that photographs were taken and by whom they were obtained. Notation of any adverse events should also be recorded. There are many different forms to choose from and in this section, I will detail some of the components that I find helpful but by no means find definitive (Figs. 10.3–10.8). Injectable forms typically have several sections (Fig. 10.3). The first ascertains whether or not the patient has any allergies. In addition, a section documenting the type of anesthetic and quantity used is included. A diagram of the face with the underlying muscle groups and folds typically targeted forms the middle of the form. This is used to sketch out what products have been used in each area so that a botulinum toxin dose can be documented in each of the muscles injected, fillers are diagrammed where injected and other notes are also made to
61
FORMS, FORMS, FORMS
PREOPERATIVE CHECK LIST OPERATING SURGEON ________________________________ Patient Name_____________________________ Chart# _________________________________________ Date of Surgery: ______________________________________ Date of Pre-op: ____________________________
8:00 arrival
On-call for arrival time
Pre-op Nurse:_______________________________
PROCEDURE(S):_________________________________________________________________________ _______________________________________________________________________________________ _______________________________________________________________________________________ _______________________________________________________________________________________ TO BE COMPLETED PRIOR TO SURGERY: ()
Date pre-surgical packet sent___________________
()
Pre-op consent forms completed
()
Mentor gel consent *dated 7 days prior to sx
()
Labs:
( ) CBC, ( ) CMP, ( ) PT, PTT, ( ) EKG ( ) CXR ( ) STRESS TEST
Received
( ) CBC, ( ) CMP, ( ) PT,PTT, ( ) EKG ( ) CXR ( ) STRESS TEST
mail
email
Required
in person
N/A
Additional Orders:______________________________________________________________ Labs at S.P.S. ________________________________ ()
Medical Physician:______________________________
Medical Clearance Required Phone:______________________
Medical clearance received:__________
Faxed Request: _______________________ ()
Mammogram_________________________________
()
Prescriptions:___________________________________
()
Pre-op Pictures: Day of surgery
()
Implant (s): ___________________________________________________________________ Breast Implants:
Saline
Gel
Profile:
Required Called in
moderate
mod +
N/A
Under age 40
written script given
high
()
Implant (s) ordered: _____________________________________________________________
()
Operative garmet:
()
Weight:______________ Measurements:______________ Waist _________________Hips
Surgibra
Girdle _____________________________________________
copy of checklist to O.R.___/_____/____ _
Completed chart to O.R.____/_____/____
Account Balance Paid in Full________________________________ Reviewed by: ________________________________ Chart ready for Sx ( ) Yes ( ) No R.N. _________________________________ Chart ready for Sx ( ) Yes ( ) No Anesthesiologist _________________________________ Chart ready for Sx ( ) Yes ( ) No Surgeon Revised 05/22/08
Figure 10.1 A sample pre-operative checklist.
62
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
MEDICAL HISTORY and PHYSICAL Patient Name: Patient No:
4241
Today’s Date:
11/6/2009
Surgery Date:
11/10/2009
Surgeon Name: Jason N.Pozner, M.D., F.A.C.S. AUGMENATION MAMMAPLASTY (Silicone): BILATERAL
Procedures: Chief Complaint:
Past History:
Family History:
Allergies: Medications: Operations – Minor: – Major:
Physical Findings:
BP: WNL
Temp:
Pulse:
Resp.
Abnormal Findings
Head Neck Chest Cardio–Vascular Abdominal Genito–Urinary Skin Bones and Joints Glandular Neuromuscular Working Diagnosis Physician’s Signature: Date: Figure 10.2 Pre-operative form for breast augmentation. (Continued)
Wt.
63
FORMS, FORMS, FORMS
FINA NCIA L
P OLICIES As patients approach surgery, they frequently need information about the various payment options and have questions about their potential insurance benefits. We hope the following information will be helpful. Our financial coordinators are readily available to meet with you personally to provide the specific information you desire. They specialize in this area and will use their expertise to help you obtain the maximum benefits from your policy.
PAYMENT OPTIONS
Payment for cosmetic plastic surgery is due in full at the time of your preoperative visit. We provide a number of payment options which may be used individually or combined according to your wishes. CASH OR CHECK:–Personal check, cashier’s check, or cash. CREDIT CARDS:–Visa, Master Card, Discover or American Express.
OPTIONAL FINANCING PLANS: We will be happy to assist you with applying for financing should you so desire. INSURANCE COVERAGE
INSURANCE: Our practice does not accept insurance. If you are having a procedure that may be covered by insurance, we will be happy to provide you with insurance forms however payment is expected in full for all procedures. PATHOLOGY: On certain occations it will be necessary to send tissue samples to the pathologist for examination. The fee for this service will be billed directly to you the patient by the pathologist. We will inform you if this service is necessary and you can contact them regarding insurance coverage. Please discuss all arrangements regarding payment of your account with us.
CANCELLATION POLICY
We understand that a situation may arise that could force you to postpone your surgery. Please understand that such changes affect not only your surgeon but other patients as well. Dr. Pozner’s time, as well as that of the operating room staff, is a precious commodity, and we request your courtesy and concern. A non-retbndable deposit of 10% of your surgical fees are due at the time you book your surgery. The balance of your surgical fees are due 2 weeks before surgery. If you cancel your surgery within 48 hours, your fees will not be refunded. Surgery can only be rescheduled due to medical reasons. If you have any questions or need assistance with financial matters, please ask Valerie Pasqualini, R.N. to help you.
SIGNATURE
SIGNATURE: I understand and agree to the afore stated financial policies.
Signature of Patient Jason N. Pozne, MD., F.A.C.S. (561) 367-9101
Figure 10.2 (Continued).
Date
64
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
BOTULINUM TOXIN TYPE A AND SOFT TISSUE AUGMENTATION/VOLUME REPLACEMENT OPERATIVE NOTE Patient Name Date of Birth
ALLERGIES
Date of Service
_________________ HX COLD SORES _________________ ANESTHESIA 1% lidocaine/septocaine/ citanest with 1:100k epi ml injected locally infraorbital mental <30 ml topical _____________ FILLER Evolence Juvederm Perlane Prevelle Silk Restylane Radiesse Sculptra ___ml/bottle
Reason for Cosmetic Evaluation:
AREAS TREATED with Soft Tissue Augmentation nasal labial cease upper lip lower lip glabella marionette zygoma
Prior Cosmetic Treatment Include: Date of last Cosmetic Procedure: Adverse Effects to Prior Cosmetic Procedure Y / N ? If Yes,
Examination/Assessment/Plan: AREAS TREATED with Botox/Dysport glabella mentalis periorbital frontalis neck other _____________
Procedure:
TOTAL UNITS OF BOTOX/DYSPORT INJECTED ________ PHOTOS TAKEN
Risks, benefits, alternatives including no treatment, duration spectrum of treatment proposed havealso been discussed: (initial/date)
/
/
Figure 10.3 Operative note for botulinum toxin type A and soft tissue augmentation/volume replacement.
Revised: 09.22.09
65
FORMS, FORMS, FORMS
Kenneth Beer MD PA Esthetic, Surgical & General Dermatology Center Kenneth Beer, M.D.
Hillary Oakley, PA-C
LASER CENTER: IPL/PDT OPERATIVE REPORT Patient Name_____________________ Consult
Date_______________________ Follow-up treatment
Initial Treatment
Consent reviewed
Treatment #________________
# of Levulan Stick: _____________________
Protective eyewear
Allergies___________________
Time Levulan Applied: __________________
Photos
Pre
Post
Laser Time: ________________________
Current Meds:_________________ Date of last sun exposure:_______________________________ Diagnosis: ____________________________Location _____________________________ Examination/Assessment/Plan_____________________________________________________________ ______________________________________________________________________________________ LASER TYPE StarLux IPL Palomar
Ellipse IPL
Blue Light : Yes
No
Minutes: _____
Other____________
The patient was fully informed of the planned procedure, the alternative methods of treatment, the limitations, the expected results, the risks and complications, both short and long term. Written consent was obtained. < 30ml topical/local/no anesthesia was obtained with____________no occlusion. Laser procedure was performed using all standard safety precautions. Starlux IPL Parameters Treatment Site
Energy Density J/cm2
Pulse Width (ms) 1st pass
Hand Piece
Energy Denisity J/cm2
Pulse Width (ms) 2nd pass
Energy Density J/cm2
Pulse Width (ms) 3rd pass
Ellipse IPL Parameters Treatment site
Laser
Laser setting
Skin Type
Pigment
Energy
# Pulses
IPL
Comments____________________________________________________________________________________ ____________________________________________________________________________________________ ___________________________________________________________________________________________ __ Post-op instruction given & reviewed _________initial/date Ice applied
Answered all questions
SPF 30 Applied SBR Lipocream/Aquaphor/Clinique Recovery/Revale Intensive Repair/Other______________________________ Follow-up was recommended in _________weeks/months. Complications:_________________________________________________________________________________ ___________________________ Provider Signature/Date
____________________________________ Staff Signature/Date
Figure 10.4 A sample operative report for an intense pulsed light/photodynamic therapy (IPL/PDT) procedure.
66
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
Kenneth Beer MD PA Esthetic, Surgical & General Dermatology Center Kenneth Beer, M.D.
Hillary Oakley, PA-C
PIGMENTED LESION LASER TREATMENT CONSENT FORM I, ___________________________ have a benign pigmented lesion called a café-au-lait/ solar lentigo / nevus of Ota / benign nevus/ hair removal /Other__________ for which I have requested treatment. Dr. Beer or Hillary Oakley, PA-C has explained to me that although laser surgery is effective in most cases, no guarantees can be made that I will benefit from the treatment. I understand that several treatment sessions may be needed to obtain the desired level of improvement and that there is a separate charge for each subsequent treatment. Sometimes a lesion will not completely clear, but should appear paler in color. Rarely, a pigmented lesion may not respond to laser treatment at all. The most common side effects and complications of the pigmented 755 Alexandrite specific laser area: PAIN. The snapping and heating sensation of each laser pulse may produce minimal to moderate
discomfort. An
anesthetic cream or injection may be used to reduce pain.
Initial ___________
BRUISING. Immediately after the laser treatment, the skin may appear red or bruised. The discoloration over the next several hours, but bruising can last as long as two weeks.
will fade Initial ___________
SWELLING. Areas most likely to swell are under the eyes, lips or neck. The swelling subsides within 3-5 days with ice or cool compress application.
Initial ___________
BLISTERS or SCABS. These rarely develop and can take 1 to 2 weeks to resolve.
Initial ___________
INFECTION. Swelling, crusting, pain and fever could indicate an infection, requiring the use of topical or oral antibiotics. This is rarely seen. Rarely may also have reaction to anesthetic.
Initial ___________
SKIN DARKENING. (Hyperpigmentation) “Tanning” of the skin can occur in treated areas and usually fades within 2 to 6 months. This reaction is more common in patients with olive or dark skin tones or after laser treatment on legs and can worsen if laser treated area is exposed to the sun.
Initial ___________
SKIN LIGHTENING. (Hypopigmentation). Light spots can occur, particularly in skin areas that have received prior treatments. The pale areas usually darken or re-pigment in 3-6 months, but could be permanent in rare cases. Initial ___________ ULCERATIONS/SCARRING. This is extremely rare after pigment-specific laser therapy, but scarring can occur upon any disruption of the skin’s surface. Following all advised post-operative instructions will reduce the possibility of this occurrence.
Initial ___________
LESION PERSISTENCE. Some lesions may not disappear completely despite the best efforts made by the doctor. Initial ___________ OCULAR (EYE) DAMAGE. Risks to the retina, uvea, choroids and iris exist when using near infrared and IPL devices. Metal eyeshields will be used if treatment is inside the bony orbit. Contact lenses MUST be removed prior to the use of metal eyeshields. Cryogen, Zimmer cooler and topical anesthesia may damage the cornea
Initial ___________
I further understand that, if left untreated, my Pigmented lesion would not be expected to go away on its own. It also may become darker, larger or more raised with time. By providing my signature below, I acknowledge that I have read and understood all the information above and have had all my questions answered to my satisfaction. I feel that I have been adequately informed of my alternative treatment options, the risks of the proposed laser surgery and the risks of not treating my condition as well as the treatment benefits. Any questions or concerns I have, have been discussed and fully answered to my satisfaction. I have no history of cold sores, fever blisters or shingles.
Initial ___________
I do or donot have a history of cold sores, fever blisters or shingles. (Circle as appropriate) Most recent outbreak (area/date): _______________
Initial ___________
Treated with Zovirax/Acyclovir, Famvir, Valtrex, Other ______________________________ (Circle as appropriate) I understand that multiple laser treatments may be needed.
Initial ___________
Initial ___________ I understand that there is a separate charge for each treatment. I hereby freely consent to the laser surgery to be performed by Dr. Beer or Hillary Oakley, PA-C and give authorization for clinical photographs, which will be used for education, clinical and/or publicity use. __________________________________ Patient or Guardian Signature Date
_____________________________ Witness Signature Date Updated 09.14.09
Figure 10.5 Consent form for pigmented lesion laser treatment.
FORMS, FORMS, FORMS
67
Operative Note:TCA Chemical Peel Kenneth Beer,MD, PA Patient name: Date of Chemical Peel: Type of Chemical Peel: 20%TCA Jessners& %TCA Informed consent signed and in chart: Y / N Preoperative photographs taken Y / N Post Care Instructions Given To Patient and explained to patient: Y/ N Patient with history of cold sores: Y / N (if yes, preoperative antiviral and rx for antiviral has been given to the patient: Y / N Areas treated: Face and Ears/ Neck / Hands / Arms / Legs / Neck / Chest After informed consent is obtained and post peel care is discussed, the patient’s skin is cleansed with alcohol/ acetone. Using eye protection the peeling agent is applied in an even manner to the entire area being treated. The patient tolerated the procedure well. Following frosting of the TCA, ice chilled compresses are applied to the patient’s skin. The skin is then cleansed with a mild cleanser such as Cetaphil. An intramuscular injection of 40 mg Kenalog was / was not given to the patient after discussion of the relative risks and benefits as well as ascertaining that the patient is not diabetic nor had a history of tuberculosis The patient is instructed in postoperative care(including sun avoidance) and is to call with any questions and to return for follow up care. Figure 10.6 Operative note for trichloroacetic acid (TCA) chemical peel.
ensure that whatever was done in that particular procedure is captured. Intense pulsed lights and laser forms need to have areas to document the type of issue being addressed, anesthetic used (if any), the devices used, areas treated and energy settings, and spot sizes utilized (Figs. 10.4 and 10.5). Whether or not the patient has a history of herpes and what treatment for this is prescribed is also noted. Documentation of the anticipated number of treatments may also be noted in this form. Chemical peel forms are among the easiest to formulate (Fig. 10.6). These need to capture the area treated and indication for treatment. The type of peel used as well as the concentration and duration of peel (when applicable) need to be noted. Post-treatment care should be charted. Sclerotherapy forms require notation of the area treated and the type of veins found in these areas (Figs. 10.7 and 10.8). Use of ultrasound to identify the vessels is noted when appropriate. The type of sclerosant and amount injected must be recorded. Extravasation, when it occurs, should also be documented. Operative procedures are the most complicated forms as they require multiple data points. The type, time, and amount of anesthetic and the person administering it are requirements for any procedure using anesthesia. Start time and end time of the procedure are also integral to the form. The narrative of what actually transpired is the heart of the form and this must be captured in enough detail to enable another physician to re-create what happened when read. Any unusual events or complications should be noted. For procedures requiring sponges, the counts should be noted. It is beyond the scope of this chapter to detail the entirety of a good operative note but examples are available at most university hospitals during training.
Liposuction operative notes should include the areas treated, amount of tumescent fluid infused, time of infusion, use of any additional medications, vital signs at regular intervals, and the instrumentation used during the procedure. In addition, the amount of material removed should be noted by area. Infratant and supranatant should be documented so that the amount of fat removed can be calculated. For breast augmentation, facelifts, rhinoplasty, blepharoplasty, and other similar procedures, the induction of anesthesia and mode of anesthetic should be noted. The time of incision, type of incision, implant used, blood loss, and other relevant information need to be captured. Most of these procedures have standardized operative forms and it is beyond the scope of this chapter to provide them in great detail. CONSENT FORMS
Consent forms are the legal documentation that detail the patient’s permission to perform the procedure as well as some disclosure of the risks. A good consent form should detail the likely adverse events as well as the rare events that can be catastrophic such as anaphylaxis. For botulinum toxins, it is important to have mention of the newer medical guidance required by the Food and Drug Administration (FDA) (Figs. 10.9–10.11). Filler consent forms should have the most common adverse events listed as well as some of the most severe ones so that the patients have a broad perspective on the treatments they are undergoing (Fig. 10.12). The best consent forms may not always be practical as they would be intrusive and time consuming beyond the scope of what would be practical. For instance, some surgical procedures are so fraught with liability that surgeons have taken to videotaping the patient during the consent form and they have the patient verbalize
68
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
Kenneth Beer, M.D., P.A. 1500 N. Dixie Hwy., Suite 303 West Palm Beach, Florida OPERATIVE REPORT Patient Name: Date: PreOperative Diagnosis: Post Operative Diagnosis: Procedure:
Surgeon: Anesthesia:
Localized Lipodystrophy Same Suction Assisted Lipectomy of: Face/Neck/Upper abdomen/Lower Abdomen/Breasts/Hips/Flanks(lovehandles)/ Arms/Inner Thighs/Outer Thighs/Buttocks/ Knees/Ankles/Other Areas:_______________________________________________ ________________ Kenneth Beer, M.D. Local Tumescent Anesthesia With Oral Sedation(standard Klein solution of 50cc 2% lidocaine/ 1cc Epinephrine 1:1000/12.5cc NaBicarb 10mEq/0.25 cc 40mg/cc kenalog)
Oral Sedation: _________________ Total Amount Of Tumescent Fluid Infused: _____Liters Total Amount Of Lidocaine: ______mg Amount of Lidocaine in mg/kg: ______mg/kg Complications: NONE Blood Loss: _____cc Preparation: Surgical antimicrobial scrub Indications:
Procedure:
This patient has lipodystrophy and desires improvement in his or her appearance. The risks of surgery including adverse reaction to anesthesia, bleeding, scarring, rippling, irregularity, asymmetry etc were discussed. The patient accepts the risks and agrees to proceed. After preoperative evaluation and oral sedation, the patient was marked in the upright position and then placed in the supine position on the operating table. The patient was prepped and attached to monitoring equipment. Using several 3-5 mm incisions made with an 11 blade, the areas to be treated were infiltrated with tumescent solution. Using a combination of cannulas including Mercedes and Cobras ranging from 3-4mm, suction assisted lipectomy was performed on the following areas : Face/Neck/Upper abdomen/Lower abdomen/Breasts/Hips/Flanks (lovehandles)/Arms/Inner Thighs/Outer Thighs/Buttocks/Knees/Ankles OtherAreas:_________________________________________ until satisfactory change in pinch and contour was obtained. A total of _________cc of fatwas resected. Sutures were placed in several incisions while others are left to drain. Dressings are placed over the incisions and a garment is placed on the patient. The patient tolerated the procedure well and is monitored during the recovery phase Kenneth Beer, M.D. Figure 10.7 Operative report for a suction assisted lipectomy procedure.
FORMS, FORMS, FORMS
Kenneth Beer, M.D., P.A. LIPOSUCTION PRE-OPERATIVE/POST-OPERATIVE STANDING ORDERS LIPOSUCTION STANDING (PRE/POST-OP) ORDERS 1.
Patient Name:
2.
Date of Surgery:
3.
Diagnosis (Lipodystrophy/Localized Adiposity - 278.1)
4.
Signed surgical, anesthesia and photo consents for liposuction surgery.
5.
Pre-op laboratory tests to include; SMA 21, CBC with Diff., PT, PTT, HIV 1 and 2, UA, Hepatitis C Antibody, Hepatitis B Antigen, Pregnancy Test (qualitative βHCG). Patient understands the cost of testing is separate from the procedure.
6.
Diet: No solid food after midnight for morning cases; no solid food 5 hour prior to surgery for later cases. Patient may take clear liquids in small amounts before surgery.
7.
Insert heplock for IV access(optional)
8.
Anesthesia: Local anesthesia standard Tumescent Technique.
9.
Concentration of local anesthetic as per verbal order of Dr. Beer (no to exceed 45mg/kg Lidocaine). See Anesthetic Record Flow Sheet for specific concentrations.
10.
Patient may have small frequent sips of apple juice during surgery.
11.
Keflex 500 mg. PO TID, begin day before surgery.
LIPOSUCTION POST-OP ORDERS: 1.
After orthostatic blood pressure and pulse is taken, may disc. Heplock.
2.
Post op dressings: Apply standard sterile absorbent dressings and compression garment.
3.
Written after care instructions given to patient and companion.
4.
May discharge 30 minutes post op.
5.
Tylenol 500mg. 2 tabs PO PRN. pain.
6.
Return appointment to be made for 1 weeks post op.
Signature:_____________________________________Date:____________________ Kenneth Beer, M.D. Figure 10.8 Standing pre-operative/post-operative orders for a liposuction procedure.
69
70
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
KENNETH BEER MD PA Surgical, Esthetic & General Dermatology Center Kenneth Beer, M.D.
Hillary Oakley, PA-C
Dear Patient, Attached to this letter is a medication guide for botulinim toxins such as Botox and Dysport. This medication guide is given out per FDA guidelines to all patients receiving Dysport and/or Botox treatments. This guide outlines all ofthe risks associated with the medical use of Dysport, not necessarily for cosmetic use. The FDA has acknowledged that none of these serious life-threatening side effects for Dysport and Botox have been seen in patients receiving cosmetic treatments and have only been seen in patients receiving large amounts of Botoxfor conditions such as cerebral palsy. We strongly believe that the use of Dysport or Botox is both safe and effective. There are risks to any medication however, and those risks will be discussed and are outlined in the consent. If you have any questions, please ask your physician or our physician assistants.
Sincerely,
Kenneth Beer MD Figure 10.9 Letter accompanying the medical guide for botulinum toxins.
each of the salient risks as well as any questions about the procedure. Other forms that are used have spaces for the patient to write the risks in a blank area so that all of the relevant adverse events are documented by the patient in his or her own hand. Following either of these, it is difficult for a patient to argue that he or she was not properly informed. Patients frequently complain that they are presented with so much information as to render it useless. One potential to this is to break the consent form into smaller pieces and have each component piece initialed and dated. Perhaps the most important aspect of the consent process is the one most overlooked—the rapport with the patient. Each of us will have adverse events provided we do enough procedures. Patients, in general, will be forgiving of a great deal if the physician has explained the risks and benefits in a thorough and compassionate manner. When a physician does not have a good fit with the patient, it is best to let him or her find someone else to perform the cosmetic procedure. For instance, during the consent process for skin cancer reconstruction I will sometimes have patients ask whether they will have a scar. These are usually the patients that do not understand the nature of the proposed procedure and I will try to get them to understand it by explaining it again. If the same question persists, it means that they need to find someone that can do a better job of explaining or guarantee that they will not
have a scar, but at that point I recognize that I can do neither. For those patients, the consent process serves as a triage for patients that have unrealistic expectations. POST-OPERATIVE CARE SHEETS
These forms are among the least recognized in practice but they can be the most important. Patients have the ability to undermine their own progress by actions that they take following a procedure. In the absence of a documented post-operative care sheet that has been reviewed and explained, the physician will be blamed for any adverse events resulting from these actions. After a surgical procedure, it may be mandatory to ambulate in order to avoid the risk of developing deep vein thrombosis but just as important to avoid lifting so that sutures don’t dehisce. Patients undergoing procedures are frequently anxious about the procedure and are presented with a great deal of information during the perioperative period. These factors mean that they may not integrate any of the information essential for optimal healing. For botulinum toxins and fillers, one needs to determine what guidance to provide following each procedure (Figs. 10.13 and 10.14). Some physicians recommend avoiding lying down, exercise, and sun exposure while others think that none of these have any relevance. Whatever one’s
FORMS, FORMS, FORMS
MEDICATION GUIDE BOTOX™ (Bo-tox) DYSPORT™ (DIS-port) (abobotulinumtoxinA) Injection Read the Medication Guide that comes with BOTOX™/DYSPORT™ before you start using it and each time BOTOX™/DYSPORT™ is given to you. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment. You should share this information with your family members and caregivers. What is the most important information I should know about BOTOX™/DYSPORT™? BOTOX™/DYSPORT™ may cause serious side effects that can be life threatening. Call you doctor or get medical help right away if you have any of these problems after treatment with BOTOX™/DYSPORT™:
•
Problems swallowing, speaking, or breathing. These problems can happen hours to weeks after an injection of BOTOX™/DYSPORT™ usually because the muscles that you use to breathe and swallow can become weak after the injection. Death can happen as a complication if you have severe problems with swallowing or breathing after treatment with BOTOX™/DYSPORT™.
•
People with certain breathing problems may need to use muscles in their neck to help them breathe. These patients may be at greater risk for serious breathing problems with BOTOX™/DYSPORT™.
•
Swallowing problems may last for several weeks. People who can not swallow well may need a feeding tube to receive food and water. If swallowing problems are severe, food or liquids may go into your lungs. People who already have swallowing or breathing problems before receiving BOTOX™/DYSPORT™ have the highest risk of getting these problems.
•
Spread of toxin effects. In some cases, the effect of botulinum toxin may affect areas of the body away from the injection site and cause symptoms of a serious condition called botulism. The symptoms of botulism include:
• • • • • • •
loss of strength and muscle weakness all over the body double vision hoarseness or change or loss of voice (dysphonia) trouble saying words clearly (dysarthria) loss of bladder control trouble breathing trouble swallowing
These symptoms can happen hours to weeks after you receive an injection of BOTOX™/ DYSPORT™. These problems could make it unsafe for you to drive a car or do other dangerous activities. See “What should I avoid while receiving BOTOX™/DYSPORT™. What is BOTOX™/DYSPORT™? BOTOX™/DYSPORT™ is a prescription medicine that is injected into muscles and used: • to treat the abnormal head position and neck pain that happens with cervical dystonia (CD) in adults • to improve to the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults younger than 65 yearsof age for a short period of time (temporary) Figure 10.10 Medication guide for botulinim toxins. (Continued )
71
72
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
CD is caused by muscle spasms in the neck. These spasms cause abnormal position of the head and often neck pain. After BOTOX™/DYSPORT™ is injected into muscles, those muscles are weakened for up to 12 to 16 weeks or longer. This may help lessen your symptoms. Frown lines (wrinkles) happen because the muscles that control the facial expression are used often (muscle tightening over and over). After BOTOX™/DYSPORT™ is injected into the muscle that control facial expression, the medicine stops the tightening of these muscles for up to 4 months. It is not known whether BOTOX™/DYSPORT™ is safe or effective in children under 18 years of age. It is not know whether BOTOX™/DYSPORT™ is safe or effective for the treatment of other types of muscle spasms. It is not known whether BOTOX™/DYSPORT™ is safe or effective for the treatment of other wrinkles. Who should not take BOTOX™/DYSPORT™? Do not take BOTOX™/DYSPORT™ if you:
• are allergic to BOTOX™/DYSPORT™ or any of the ingredients in BOTOX™/DYSPORT™. See the end of this Medication Guide for a list of ingredients in BOTOX™/DYSPORT™
• are allergic to cow’s milk protein • had an allergic reaction to any other botulinum toxin product such as Myobloc®* or Botox®* • have a skin infection at the planned injection site What should I tell my doctor before taking BOTOX™/DYSPORT™? Tell your doctor about all your medical conditions, including if you have: • a disease that affects your muscles and nerves (such as amyotrophic lateral sclerosis [ALS or Lou Gehrig’s disease], myasthenia gravis or Lambert-Eaton syndrome). See “What is the most important information I should know about DYSPORT™? • allergies to any botulinum toxin product • had any side effect from any botulinum toxin product in the past • a breathing problem, such as asthma or emphysema • swallowing problems • bleeding problems • diabetes • a slow heart beat or other problem with your heart rate or rhythm • plans to have surgery • had surgery on your face • weakness of your forehead muscles (such as trouble raising your eyebrows) • drooping eyelids • any other change in the way your face normally looks Tell your doctor if you:
• are pregnant or plan to become pregnant. It is not known if BOTOX™/DYSPORT™ can harm your unborn baby
• are breast-feeding or planning to breast-feed. It is not known if BOTOX™/DYSPORT™ passes into breast milk. Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins and herbal and other natural products. Using BOTOX™/DYSPORT™ with certain other medicines may cause serious side effects. Do not start any new medicines while taking BOTOX™/DYSPORT™ without talking to your doctor first. Figure 10.10 (Continued ).
FORMS, FORMS, FORMS
Especially tell your doctor if you: • have received any other botulinum toxin product in the last four months • have received injections of botulinum toxin, such as Myobloc® (Botulinum Toxin Type B) or Botox® (Botulinum Toxin Type A)* in the past; be sure your doctor knows exactly which product you received • have recently received an antibiotic by injection • take muscle relaxants • take an allergy or cold medicine • take a sleep medicine Ask you doctor if you are not sure if your medicine is one that is listed above. Know the medicines you take. Keep a list of your medicines with you to show your doctor and pharmacist each time you get a new medicine. How should I take BOTOX™/DYSPORT™? • BOTOX™/DYSPORT™ is an injection that your doctor will give you • BOTOX™/DYSPORT™ is injected into the affected muscles • Your doctor may give you another does of BOTOX™/DYSPORT™ after 12 weeks or longer, if it is needed • If you are being treated for CD, your doctor may change your dose of BOTOX™/DYSPORT™ until you and your doctor find the best dose for you • The dose of BOTOX™/DYSPORT™ is not the same as the dose of any other botulinum toxin product What should I avoid while taking BOTOX™/DYSPORT™? DYSPORT™ may cause loss of strength or general muscle weakness, blurred vision, or drooping eyelids within hours to weeks of taking BOTOX™/DYSPORT™. If this happens, do not drive a car, operate machinery, or do other dangerous activities. See “What is the most important information I should know about BOTOX™/DYSPORT™? What are the possible side effects of BOTOX™/DYSPORT™? BOTOX™/DYSPORT™ can cause serious side effects. See “What is the most important information I should know about BOTOX™/DYSPORT™? Other side effects of BOTOX™/DYSPORT™ include: • dry mouth • injection site discomfort or pain • tiredness • headache • neck pain • muscle pain • eye problems: double vision, blurred vision, decreased eyesight, problems with focusing the eyes (accommodation), drooping eyelids, swelling of the eyelids • allergic reactions. Symptoms of an allergic reaction to BOTOX™/DYSPORT™ may include: itching, rash, red itchy welts, wheezing, asthma symptoms, or dizziness of feeling faint. Tell your doctor or get medical help right away if you get wheezing or asthma symptoms, or if you get dizzy or faint Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of BOTOX™/DYSPORT™. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. Figure 10.10 (Continued ).
73
74
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
General information about BOTOX™/DYSPORT™: Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. This Medication Guide summarizes the most important information about BOTOX™/DYSPORT™. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about BOTOX™/DYSPORT that is written for healthcare professionals. For more information about BOTOX call 800-433-8871 or go to www.botoxcosmetic.com for DYSPORT™ call 877-397-7671 or go to www.dysport.com or www.DysportUSA.com. What are the ingredients in BOTOX™/DYSPORT™? Active ingredient: (botulinum toxin Type A) Inactive ingredients: human albumin, and lactose. DYSPORT™ may contain cow’s milk protein. *All trademarks are the property of their respective owners Figure 10.10 (Continued ).
CONSENT FOR BOTULINUM TOXIN (BOTOX/DYSPORT) TREATMENT Purified Botulinum Toxin (Botox/Dysport) is FDA approved for cosmetic use to minimize frown lines in the glabella area. Botulinum Toxin (Botox/Dysport) works by causing temporary weakness or paralysis of the muscles in this area. Often purified Botulinum Toxin (Botox/Dysport) is used “off-label” for non-FDA approved indications, specifically for areas of the face and neck other than the glabella. Dr. Beer will discuss with you the suggested areas of treatment, some of which will be non-FDA approved or off-label uses. What you can expect: The effects of purified Botulinum Toxin (Botox/Dysport) begin to appear in as early as 24 hours, but often may take up to 7 days or more to be fully effective. You can expect some slight swelling and occasionally bruising in areas where the injections are given. Botulinum Toxin (Botox/Dysport) generally lasts between 3 and 4 months, but may have a shorter or longer effective life depending upon your individual physiology. Your doctor will discuss the choice of the two different FDA approved toxins, Botox or Dysport. While these toxins work in a similar way, they are not interchangeable. There are differences in the effects of the toxins and individuals who have received Botox in the past may not have exactly the same effects with Dysport. The treatment may not be effective in individuals. You may have temporary asymmetry of your face. Contraindications to receiving Botulinum Toxin (Botox/Dysport): You should not take Dysport or Botox if you are: 1. Allergic to Dysport or Botox or any of the ingredients in Dysport or Botox. 2. If you are allergic to cow’s milk protein. 3. If you had an allergic reaction in the past to any Botulinum Toxin (Botox/Dysport) including Myobloc or Botox. 4. If you have a skin infection in the injection site. 5. You should also not take Botulinum Toxin (Botox/Dysport) if you are pregnant, or if you possibly think you could be pregnant. Figure 10.11 Consent form for botulinum toxin treatment. (Continued )
FORMS, FORMS, FORMS
6. You should not take Dysport or Botox if you are breast-feeding. 7. Additionally, you should tell your doctor about all your medical conditions, specifically if you have a disease that affects your muscles or nerves such as ALS or Lou Gehrig’s disease, myasthenia gravis or Lambert-Eaton syndrome. INITIAL: DATE :
Risks and complications: Significant complications from cosmetic use of Botulinum Toxin (Botox/Dysport) are very rare, but risks and complications from the procedure can include the following: 1. 2. 3. 4.
5. 6.
7.
8.
Patients can have swelling or bruising at injection sites. Patients may occasionally have numbness lasting 2 to 3 weeks or longer. Transient headaches can occur. Toxin has a rare potential to spread from the specific site of injection and in clinical trials approximately 2 percent of individuals can have a temporary droop of an eyebrow or an eyelid. You may also experience temporary asymmetry. Rarely patient’s may experience temporary blurring or double vision. Additionally, many side effects including death have been reported with the use of Botulinum Toxin (Botox/Dysport) for conditions other than cosmetic use. Primarily these have occurred in patients including children with cerebral palsy who were injected with much larger doses of Botulinum Toxin (Botox/Dysport) in areas such as the neck, arms, legs and back. You will be given a patient guide, which outlines all of the known risks for Botulinum Toxin (Botox/Dysport). The FDA has clearly indicated that none of the severe complications that have been seen in the clinical use of Botox and Dysport such as in patients with cerebral palsy and other medical conditions. None of the severe complicationshas been seen in patient’s receiving cosmetic Botulinum Toxin (Botox/Dysport). I understand that several sessions may be needed to complete the injection series and the multiple sessions are planned understand that there is a separate charge for any subsequent treatments. I understand that I need to remain upright for four hours after my procedure and not exercise for 24 hours following my treatment. Also, that I am to exercise the muscles treated by frowning and smiling for one day.
Photographs: I authorize to taking new clinical photographs in the use for scientific purposes, both in publication/presentations and publicity. Payment: I understand this procedure is cosmetic and the payment is my responsibility.
I have read the above and understand it. My questions have been answered satisfactorily by the doctor and the doctor’s associates. I accept the risks and complications of the procedure. In signing this, I also acknowledge that I have reviewed the patient bulletin regarding Botulinum Toxin (Botox/Dysport).
Signature of Patient____________________________________________________________ When patient is under age 18 or unable to affix signature; signature of person authorized to consent for Patient:________________________________Date:_______________________ Witness:_______________________________Date:_______________________ Figure 10.11 (Continued ).
75
76
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
Kenneth Beer MD PA Esthetic, Surgical, & General Dermatology Center Kenneth Beer, M.D.
Hillary Oakley, PA-C
Consent to Treatment: Injectable Tissue Augmentation with Juvederm, Radiesse, (Radiance), Restylane, Perlane, Evolence andPrevelle Silk This is to certify that I consent to a tissue augmentation treatment given by XXXX; at this time. I am not known to be allergic to hyaluronic acid products or lactic acid. I understand that complications may occur with any injectable substance.
Initial_______ I also understand waviness of the skin, bumps, depressions, movement of product and cysts can result from Juvederm, Radiesse, (Radiance), Restylane, Perlane, Evolence, Prevelle Silk and Elevesse injections. I understand that each of these injections may NOT be FDA approved for cosmetic indications and its use constitutes an “off label” indication. Results will NOT Initial_______ be a perfect resolution of wrinkles but will be a best effort by the physician to improve my appearance. In addition, rare but possible complications may include: infection, damage to nerve resulting in numbness or paralysis, anaphylaxis (allergic reactions) which could result in death and injection of material into a blood vessel resulting in blindness. other rare complications include necrosis (death) of the skin resulting in large scars requiring skin grafting. Initial_______ I understand that any of these problems may occur at any time, even after having uneventful treatments in the past. I UNDERSTAND THAT THERE IS NO GUARANTEE REGARDING LONGEVITY OR DEGREE OF CORRECTION WITH THE USE OF JUVEDERM, RADIESSE (Radiance), RESTYLANE, PERLANE, EVOLENCE, PREVELLE SILK, AND ELEVESSE INJECTIONS.
I understand there is a subsequent charge for each syringe used on this or subsequent visits (including “touch-ups”).
Initial_______ Initial_______
I understand that if XXXX; judges at any time that my surgery should be postponed or canceled for any reason he/she may do so. I understand that if in the event of an emergency, I will be transferred to the nearest hospital. Subcutaneous nodules and papules may occur with any soft tissue filling agent and the most frequent adverse events noted with Radiesse (Radiance). No assurance regarding the extent or duration of the correction is given or implied.
Initial_______
I hereby state that the information furnished to XXXX; during my evaluation is correct and that I have disclosed all known medical conditions, allergies or adverse reactions to medical preparations.
Initial_______ I agree to follow the instructions given to me by XXXXXX; to the best of my ability before, during and after the procedure, and that I will, as soon as possible, notify them of any questionable conditions that may arise.
Initial_______ I understand this is an elective cosmetic procedure and I assume full financial responsibility for my procedure today as well as
Initial_______
any revisions or corrective treatments that may be needed.
I hereby waive and hold harmless XXXXX; from any and all financial costs, including but not limited to facility fees and anesthesia charges, laboratory and other costs associated with such revisionary procedures.
Initial______ I give permission to XXXXXXX; to use photographs of me for education and/or publicity. I understand that a caresheet is available and if I do not receive one I can ask for one.
Initial______ Initial______
_________________________________________________________________________________________________ Patient
Date
_________________________________________________________________________________________________ Witness
Date
Updated 09/14/09
Figure 10.12 Consent form for treatment by injectable tissue augmentation procedure.
FORMS, FORMS, FORMS
Botulinum Toxin Post-Operative Instructions 1. Do not lie down for 4 hours. 2. Work the treated areas by wrinkling the forehead or frowning for 1 – 2 hours. 3. Do not exercise (running, aerobics, weight lifting, etc…) for 24 hours. 4. Try to avoid aspirin or ibuprofen for 24 hours. 5. It will take 3 – 7 days for the full effect to be achieved. If you have any questions or concerns, we are here for you, please call 561-655-9055. The Medical Assistant who cared for you was _____________________ Figure 10.13 Post-operative instructions for botulinum toxin.
Care Sheet for Fillers Some bruising is normal and may last for 5-7 days. Aspirin, Vitamin E and non-steroidal anti-inflammatory drugs may make the bruising worse. We normally do not recommend discontinuing these drugs and we expect some bruising following these procedures. There will be minimal discomfort for a day or two. You may apply antibiotic cream to the site following treatment for 1 – 2 days (twice a day). You may apply makeup immediately following the treatment. Some lumpiness and swelling is normal and lasts up to 7 days. Swelling typically is the worst two days after treatment. Some patients need more treatment for optimal results. If you have any questions or concerns, we are here for you, please call 561-655-9055. The Medical Assistant who cared for you was _____________________ Figure 10.14 Care sheet for fillers.
77
78
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
philosophy, it is important to document it and make certain that the patient understands so that any adverse events are not blamed on a lack of instruction. Fractional laser patients need to be instructed what products to apply to the skin and at what intervals. Intense pulsed light and chemical peel patients need to be told what sun protection to use and what products to apply. Each procedure performed by a cosmetic physician will have its own post-procedure requirements that can help to optimize the outcome attained. Laser hair reduction care sheets need to mention the fact that hairs may look more prominent as they emerge and that multiple treatments will help to minimize the residual hairs present. CONCLUSION
Forms are a necessary evil and it will save time and effort to find and use the best forms possible. My own goal is to convert all of my
forms into electronic versions that are on wireless clipboards in each room. The forms provided here are just starting points for discussion. Perhaps future versions of this text will have online forms for collaborative form postings. I have added several of my forms to this chapter and those of you who wish to use them are welcome to do so. For those of you with better forms, please consider this chapter an invitation to send them to me so that they might be included in future versions or perhaps posted in an online accompaniment for this book. These forms are provided for educational purposes only and are in no way to be construed as legal documents for use without review by an attorney or appropriate advisor in compliance with State and Federal regulations to determine the appropriateness of them (in sum or in part) to the practice of medicine such as it is.
11
Skin type classification systems: Cosmetic consideration and planning for procedures Wendy E. Roberts
Evaluation of skin type is part of the standard physical examination of the skin prior to procedure. This chapter will elucidate why skin type determination is essential before any cosmetic procedure is planned or performed The three objectives of this chapter are firstly, to provide you with the tools to identify your patient’s skin type; secondly, understand how to plan for the two most common untoward effects in procedure’s dyspigmentation and scarring; and lastly provide tips on intervention to prevent these adverse outcomes, There are skin components which clinically react more than others to surgery, light, laser, and many modalities discussed in this book. As the cosmetic surgeon, we must be able to predict the responses of the skin to these procedures prepare the skin for optimal outcomes and protect the skin from adverse side effects. This chapter focuses on considerations and recommendations for intervention and prevention. Chemical peels, ablative and non-ablative laser resurfacing, intense pulsed light (IPL), and hair removal laser are some of the more commonly performed cosmetic procedures that have a higher risk of complications. The most common overriding assumption based on past experience is that skin types I–II rarely develop postinflammatory hyperpigmentation and scarring whereas skin types IV–VI have a greater chance of developing these complications. In fact the skin of greatest risk for complication is the skin that has not been skin typed or classified. Beware of the blue-eyed blonde from Oklahoma. … she is half Cherokee Indian (native American) and you do not want to find that out after you administer a deep resurfacing procedure and face severe hyperpigmentation. It is well known that post-procedural hyperpigmentation and hypopigmentation is increased in skin types IV–VI. But does this account for the phenotypical type II patient who has skin that behaves like type IV. This is an area of unknowns, trial, and conjecture. CHANGING GLOBAL DEMOGRAPHICS
In a world population of 6.7 billion, 80% of the world’s population consists of individuals with pigmented skin (1). Mixed racial marriage and progeny has resulted in an increase of interracial genotypes and an emerging phenotype that may be hard to classify unless you specifically ask the question. Where are your birth grandparents from? It is not enough to simply elicit the race of an individual because skin type is much more complex. The 2000 U.S. Census Department records the U.S. population at 281.4 million people (2). There are six races which are catagorized as (i) White, (ii) Black or African American, (iii) American Indian and Alaska native, (iv) Asian, (v) native Hawaiian and other Pacific Islander, and (iv) some other race. The term “White” refers to people having origins in any of the original peoples of Europe, the Middle East, or North Africa. It includes Irish, German, Italian, Lebanese, near Easterner, and Arab. In addition 35.3 million Hispanic people (12.5%) of the population, which includes Mexico, Cuba, Central America, South America, Spain, and Caribbean, are considered White. Clearly these diverse groups under the umbrella of “White” have a rainbow of skin color and skin types. The term “Black” refers to 36.4 million people (12.9%) who indicate Black, African American, Nigerian or Haitian decent. It also includes Blacks who indicate Hispanic origin American Indian. The term “American Indian” is often used in this chapter to refer to the American Indian and Alaska native population totaling 4.1 million (1.5%). “Asian” refer to the 11.9 million people (4.2%) having origins in any of
the original peoples of the far East, Southeast Asia, or the Indian subcontinent (e.g., Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam). “Native Hawaiian and other Pacific Islander” total 874,000 (.3%) and are people with origins from Hawaii, Samoa, Guam, Fiji and of Polynesian, Micronesian, Melanesian ancestry (1). With the introduction of the “mixedrace” category, the 2000 census showed interracial marriage to be somewhat further widespread, accounting for 2,669,558 such marriages, or 4.9% of the total statistics; however, they do not take into account the mixing of ancestries within the same “race;” e.g., a marriage involving Indian and Japanese ancestries would not be classified as interracial due to the census regarding both as Asian. Likewise, since Hispanic is considered White, Hispanic marriages with non-Hispanic Whites are not registered as interracial because both are considered White (3). Interracial marriage results in new potential skin types (Table 11.1). This mixing of ethnicities leads to a significant evolution in the world demographics as we continue to diversify at unprecedented levels. We are developing new skin types at a rapid rate. The U.S. Census Bureau statistics in 2000 lists six race categories with 57 possible combinations (2). To classify a person by skin color is obsolete. Skin color is a complex subject. There are many factors which determine the appearance of skin color. Nordlund et al. state that a number of chemicals contribute to skin color. A major determinant of skin color is melanin, its quantity, type, distribution, and location of melanin within the epidermis and dermis. Other significant determinants are capillary blood flow, chromophores such as carotene or lycopene, and collagen within the dermis (4). To that end, we understand that we are dealing with biologically separate structures i.e., keratinocyte, melanocytes, collagen, ground substance, blood vessels and these all may have an individual or cumulative effect on skin color and also “the aesthetic” of the post-procedure skin appearance. Historically we have identified patient at risk for untoward procedures by their Fitzpatrick skin phototype. The Fitzpatrick skin type classification system has been the gold standard in communicating skin type (5). It is by definition, however, a “phototype” limited to describing the predilection for burning and tanning only. It does not address the predilection for hyperpigmentation and scarring. Hyperpigmentation and scarring are the two most common complications from skin injury and insult in cosmetic procedures in diverse skin types. They are followed by prolonged erythema, hypopigmentation, and keloid formation. While many skin type classifications have been proposed, the Roberts skin type classification system is unique in its focus on four elements, which include hyperpigmentation and scarring. Though not as user friendly as the Fitzpatrick scale because it encompasses more parameters, it is a tool to communicate important data needed for safe outcomes (6). ROBERTS SKIN TYPE CLASSIFICATION SYSTEM
To determine a patient’s profile using the Roberts skin type classification system the clinician should first refer to Tables 11.2 and 11.3. There are four elements and each element is assigned a numeric value called a feature. Clinical Patient Example 1 A 25-year-old blonde hazel eyed woman of Caucasion and Cuban decent would like to know if she is a good candidate for a skin resurfacing procedure. She, per history, burns minimally and tans well (FZ3).
79
80
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
Table 11.1 Married Couples in the United States in 2006 (3) White wife
Black wife
Asian wife
White husband
50,224,000
117,000
530,000
Other wife 489,000
Black husband
286,000
3,965,000
34,000
45,000
Asian husband
174,000
6,000
2,493,000
13,000
Other husband
535,000
23,000
41,000
558,000
Table 11.2 Roberts Skin Type Classification System Four elements with the corresponding feature aka number 1. *Fitzpatrick (FZ) scale (measures skin phototypes) Fitzpatrick features (numbers) Type FZ I white skin, always burns, never tans Type FZ II white skin, always burns, minimal tan Type FZ III white skin, burns minimally, tans moderately and gradually Type FZ IV light brown skin, burns minimally, tans well Type FZ V brown skin, rarely burns, tans deeply Type FZ VI dark brown/black skin, never burns, tans deeply 2. Roberts hyperpigmentation (H) scale (measures propensity for pigmentation) Roberts features (numbers) Type H0 hypopigmentation Type H I minimal and transient (<1 year) Type H II minimal and permanent (>1 year) hyperpigmentation Type H III moderate and transient (<1 year) hyperpigmentation Type H IV moderate and permanent (>1 year) hyperpigmentation Type H V severe and transient (<1 year) Type H VI severe and permanent (>1 year) hyperpigmentation 3. Glogau (G) scale (describes photoaging) Glogau features (numbers) Type G I no wrinkles, early photoaging Type G II wrinkles in motion, early to moderate photoaging Type G III wrinkles at rest, advanced photoaging Type G IV only wrinkles, severe photoaging 4. Roberts scarring (S) scale (pre-existing scar morphology) Roberts scarring features (numbers) Type S 0 atrophy Type S I none Type S II macule Type S III plaque within scar boundaries Type S IV keloid Type S V keloidal nodule
She has, per medical history, moderate and transient hyperpigmentation. Post-inflammatory hyperpigmentation (PIH) is noted on skin examination of old acne sites (H3). She has no wrinkling, or early photo-aging (G1). She has two hypertrophic knee scars (S3) also seen on skin examination. Her Roberts skin type profile is FZ3, H3, G1, and S3. The clinical response included the following: Given her Roberts skin type profile, this individual is not a candidate for a deep resurfacing procedure. There is a risk for hyperpigmentation with her H3 score and also a risk for scarring with her scarring score of S3. Alternatively, you could proceed with IPL but at a very low fluence. She would also benefit from some superficial peeling with low percentage glycolic acid or even salicylic acid for her acne. She would need more treatments than a patient with a lower score so it would also be necessary to inform the patient about the pros and cons of staged treatments (Fig. 11.1).
Table 11.3 Using the Robert’s Skin Type Classification System To define patients’ individualized skin type profile using the Roberts skin type classification system, the clinician does the following three steps 1. Conducts a physical examination, performing a complete visual review of the skin 2. Gathers historical information, such as ancestry, history of pigmentation, and scarring. May need to perform and evaluate test site reactions 3. Assign a feature (number) to the four elements according to the guidelines for each following the serial format FZ number/H number/G number/S number Once a clinician establishes the skin type profile using the four-part Roberts system, the data can be used to outline a safe, efficacious treatment plan based on the patient’s likely response to the procedure. Patients may carry this designation from clinician to clinician, similar to a blood type, and use it as a means of communication, when necessary, to identify procedural or environmental risks.
Figure 11.1 Patient 1. Roberts type profile: FZ3, H3, G1, S3.
Clinical Patient Example 2 A 50-year-old Caucasian woman is referred for excision of a presternal nevus and on physical examination has an abdominal hypertrophic scar. She is given her Roberts skin type profile of FZ2, H1, G3, and S3. Given the patient’s Roberts skintype profile and the location of the nevus, she is at possible risk for a scar in a highly visible location. Despite her white complexion she has a propensity to scar, which is determined by history and skin examination. When this is discussed with the patient, she decides to keep the benign nevus versus risk an unsightly scar on her décolleté (Fig. 11.2). Clinical Patient Example 3 A 60-year-old Hispanic male has solar lentigines and is scheduled for chemical peeling. His Roberts profile is FIV, H2, G4, and SO. His Roberts skin type profile indicates a risk for hyperpigmentation but not scarring. He can be pre- and post-treated with topical hydroquinone and retinoids to prevent this possible occurrence (Fig. 11.3). PREVENTION OF DYSPIGMENTATION AND SCARRING IN AT RISK PATIENTS
The field of color blind devices, chemical peeling agents, and lasers continue to grow but it is still important to be completely knowledgeable
SKIN TYPE CLASSIFICATION SYSTEMS: COSMETIC CONSIDERATION AND PLANNING FOR PROCEDURES
Figure 11.2 Patient 2. Roberts type FZ2, H1, G3, S3.
Figure 11.3 Patient 3. Roberts type FIV, H2, G4, SO.
about the best device and technique to use for your at risk patient. A simple removal of a DPN may result in scarring and hyperpigmentation if not performed well (7). The entry into cosmetic surgery is wrought with possible complications if you are not knowledgeable about your patient’s skin type, your tool’s characteristics, and the best practices of the specific procedure. This is most important with laser and light-based modalities (8–11). DYSPIGMENTATION
We know that the melanocyte is more reactive to injury, UV, and heat in certain skin types (12). Interestingly, there is also evidence that melanin as well as being a photoprotectant may also act as a photosensitizer in certain skin types (13). Pigmentary changes in the skin are among the most common side effects of chemical, laser and light therapies. In laser therapies they are caused by the absorption of light
81
by epidermal melanin. The darkening of the skin in or around the treatment site is the result of increased melanin production by epidermal and follicular melanocytes in response to thermal changes. The higher the epidermal melanin content, the more at risk the patient may be. Patients with darker skin types tend to be particularly at risk of unwanted pigmentary changes especially if the treatment area is on a part of the body that is likely to be exposed to sunlight, such as the face (14). Inflammatory dermatosis may result in dyspigmentation. In vitro studies have shown that cytokines and inflammatory mediators have effects on melanocytes (13). The following inflammatory mediators have been reported to increase melanogenesis: leukotriene B4, prostaglandins D2 and E2, endothelins, interleukins 1 and 6, and tumor necrosis factor-α. A decrease in melanogenesis has been reported to be caused by leukotriene C4. Particular cytokines and leukotrienes, such as leukotriene C4 and transforming growth factor-α, cause movement of melanocytes (15). In each individual, certain inflammatory mediators are released. Those specific mediators that are released will be responsible for either increasing melanogenic function of the melanocyte or decreasing melanogenic function of the melanocyte, thus leading to the postinflammatory hyperpigmentation or hypopigmentation. Primary cytokines may be acutely induced after wounding of the skin (16). Is the production of cytokines a common pathway for both inflammatory and injury-induced dyspigmentation? Does this cytokine cascade impact on the intensity of erythema? The role of erythema during a cosmetic procedure in darker skin types cannot be overemphasized. Transient erythema, a precursor to PIH is an adverse effect with most of the ablative and non-ablative laser procedures and can affect up to 100% of patients (17). It is caused by heat resulting from absorption of laser light by epidermal melanin (18). It is this author’s opinion based on the body of evidence that darker skin with high melanin content will have increased laser absorption more than lighter skin. This may result in intense and prolonged erythema, possibly coupled with increased cytokine production, which may increase the risk of dyspigmentation. The development of PIH may be inextricably linked with erythema. Unfortunately erythema in darker skin types may be hard to diagnose for the novice. Ratner et al. report that PIH occurs in 5% to 83% of patients who have undergone cutaneous laser resurfacing. Although seen in all skin types, the majority are skin types III-VI (19). The unwanted darkening or lightening of the skin in or around treated areas is normally a transient effect. PIH occurs between 2 weeks and 2 months after the procedure, it is preceded by erythema and resolution times may vary widely between 6 and 12 months without intervention. Often pigmentary changes may not become evident until months after treatment and can endure for several months and, in the case of hypopigmentation, may sometimes be permanent (20). Goh et al. in 2002 looked at PIH in a small series of Asian patients with skin types IV–VI post-laser resurfacing, moderate pigmentation developed in 15% at 6 weeks. At 3 months 33% had varying degree of pigmentation. At 6 months one (12%) patient had residual pigmentation. One patient developed mild minimal hypopigmentation at 6 months, which cleared at 12 months (21). PERIPROCEDURAL INTERVENTION TO AVOID ERYTHEMA AND DYSPIGMENTATION
Because of the difficulty to diagnose erythema in darker skin a deliberate strategy is warranted. A strategy to enhance laser safety in ethnic skin is listed in Table 11.4. The five S’s of laser safety in ethnic skin are as follows. 1. Skin type is identified by physical examination and medical/ family history. 2. Safe laser choices are made for the skin type, the procedure, and desired outcome.
82
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
Table 11.4 Five S’s of Laser Safety in Ethnic Skin 1. Skin type identification by examination and history 2. Safe laser choices for the outcome based on selective photothermolysis 3. Skin cooling throughout the procedure with cool gel, chilled air, or ice (trim hairs that may further conduct heat) 4. Stage/spread out the visits for safe outcomes 5. Set low fluences and long pulse durations on first laser session which can be increased slowly on subsequent visits as tolerated. Avoid stacking of pulses which can lead to hypopigmentation
3. Skin cooling throughout the entire procedure beginning before the laser makes contact with the skin. Apply cool gliding gels when possible, with chilled air on the skin and periprocedural ice packs throughout the entire procedure. For high risk patients a 5 to 10 minute ice break halfway through the procedure is advisable. Note that cryogen sprays may create dyspigmentation specifically where the spray contacts the skin similar to liquid nitrogen. Check with your manufacturer and you can always perform a test site. 4. Staged procedures or spreading out the laser procedure over two or more sessions. 5. Set low fluences and long pulse durations on your first session and increase slowly as tolerated. Pre-treatment application of depigmenting agents and retinoids to prevent primarily hyperpigmentation has been well demonstrated in the chemical peeling literature (22). The skin is pre-conditioned with hydroquinone, kojic acid, Azelaic acid or depigmenting agent of choice for 2 to 4 weeks prior to the procedure. Often retinoids are mixed together with the depigmenting agent. Care must be taken to have the patient discontinue the pre-conditioning mixture 3 days prior to the procedure. The reason for pretreatment with hydroquinone is for suppressing melanocyte activity and the tretinoin adds for enhanced penetration of the peeling agent and a more predictable outcome. There have been some who disagree feeling that preconditioning the skin with tretinoin added time for erythema (23). The literature is even less supportive for preconditioning or treating the skin of darker skin types with hydroquinone and tretinoin before laser resurfacing. Alster et al. concluded that there was no significant difference in the incidence of post-CO2 laser resurfacing hyperpigmentation between subjects who received pretreatment with either topical glycolic acid cream or combination of tretinoin/hydroquinone creams and those who received no pretreatment regimen (24). Though there was a great study design the 100 patients, were all Fitzpatrick skin types I–III and may not be indicative of the same outcome as skin types IV– VI. Regarding the use of retinoids in the preconditioning treatment to speed wound healing Orringer et al. concluded there was no evidence of enhanced collagen formation, accelerated re-epithelialization, or quicker resolution of postoperative erythema with tretinoin pretreatment before laser resurfacing (17). A depigmenting agent should be used for 2 to 6 weeks postoperatively or as soon as re-epithelialization is complete (19). There is a high incidence of periprocedural dyspigmentation with cutaneous laser resurfacing in darker skin types and phenotypically light skinned individuals with darker skinned family members. These high risk patients need to be identified prior to the procedure. Outcomes and periprocedural management should be discussed. Broad spectrum sunscreen should be used generously but knowledgeably to avoid possible photocontact dermatitis especially with products containing octyl methoxycinnamate and para-amino benzoic acid (PABA) (25). Sun avoidance and sun protection by limiting sun exposure and using sun protective clothing especially wide brimmed hats is most effective for decreasing the UV stimulus of melanin synthesis.
Figure 11.4 White skin with a keloid.
SCARRING
The evaluation of scars has been very subjective with sparse clinical organization. Roberts introduced an easily communicated scarring scale which encompassed the spectrum of atrophic scarring to the furthest end of the scarring spectrum, keloid formation (6). As we center on the prevention and management of periprocedural scar formation, we must be alert to those who are predisposed to scarring. Both keloids and hypertrophic scars have an incidence 5 to 18 times higher in African Americans and 3 to 5 times higher in Asians compared with Caucasians. It is estimated that they affect both the African American and Hispanic populations between 4.5% and 16% (26). While we all are comfortable with the increased incidence of scarring in the Black population, there is an unfamiliarity with scarring in other global populations. In a large subject study that looked at keloidal scarring in Malaysian, Indian, and Chinese patients the incidence of keloidal scars was highest in the Chinese at 56%, followed by Indian at 22.9% and 17.15% in the Malaysian (27). Lim et al. reported keloids as the sixth most common self-reported diagnosis in the Arab American community (28). In my own practice, I have seen severe hypertrophic scars and keloids on patients with eastern European/Baltic ancestry (Fig. 11.4). It is clear with increasing globalization of skin types the safest way to determine the propensity of a patient to scar is through visual examination of the skin. When encountering scars on complete body skin examination inquire about the type of injury, the duration of the scar and any treatments that were used. These all provide insights on how to create a treatment plan. Remember, keloidal scar formation may run in families so take a quick family history of scarring. Scarring results from dermal trauma from surgery, tattoos, burns, piercings, or aggressive lasering, and some times they may arise spontaneously. PERIPROCEDURAL INTERVENTION OF SCARRING
Once you have determined that your patient is at high risk for scar development by virtue of the patient’s skin type, early recognition of the emerging scar is critical in its management. One of the simplest choices for initial medical therapy for impending scars is the use of corticosteroids. These are substances that are based on four fused carbon rings that derive from the cholesterol molecule. The glucocorticoids (e.g., triamcinolone, hydrocortisone, methylprednisone, and dexamethasone), in the corticosteroid family, have immunomodulatory, and anti-inflammatory properties. Inflammatory mediators such as cytokines, cellular adhesion molecules, and other enzymes are
SKIN TYPE CLASSIFICATION SYSTEMS: COSMETIC CONSIDERATION AND PLANNING FOR PROCEDURES decreased (29). The exact mechanism is unknown but it is thought to be related directly to the anti-inflammatory properties, reduction of collagen, glycosaminoglycans, and fibroblasts, along with overall lesion growth retardation. Used as a topical, both with and without occlusion, there is a wide range of clinical response. Be warned that prolonged topical corticosteroid use (greater than 3–5 days) has also been shown to retard wound healing (30,31). It is this diminished fibroblast effect that I find particularly useful in the initial woundcare for a patient who is at risk for scarring. For patients at risk of scarring I will often apply a low potency corticosteroid preparation to the wound immediately after the procedure for a one time application that will be removed during subsequent wound care on the following day. For emerging scars, I may select a higher potency corticosteroid with occlusion for 1 week. After 1 week we will evaluate for ongoing treatment with retinoids, imiquimod, or silicone gel. The body of the literature is vast for the treatment of hypertrohic scars and keloids with occluded topical and intralesional corticosteroids and devices. The reader is referred to other sources for the treatment of existing lesions (32,33). RETINOIDS
Pretreatment with retinoids before epidermal injury is thought to speed wound healing (34). One study found that 0.1% tretinoin pretreatment for 2 weeks before a 35% trichloroacetic acid peel significantly accelerated wound healing with 75% of the tretinoin-pretreated hemifaces completely healed as opposed to only 31% of the placebotreated hemiface (35). One study however showed that continued and daily tretinoin therapy was associated with delayed re-epithelialization and persistent dermal inflammation (36). To date the overall body of information would suggest that that anti-inflammatory immunoregulation properties of topical retinoids would be favorable to prevent post-procedure scarring, Topical retinoids should be applied in the evening only; avoid using if the patient cannot wear daily sun protection factor (SPF) due to lack of epithelium or contact sensitivity. SILICONE GEL/SHEETING
Two studies examined the prevention of hypertrophic scars after surgery. The first study by Ahn et al. (37) prospectively followed 19 scars resulting from elective surgery. They treated half of the scars with silicone gel. Nine scars became hypertrophic; the untreated parts of the scar were 25% to 75% larger than the treated parts, suggesting that silicone gel may be useful in preventing scars from developing. No statistical analysis of the treatment results was provided. In the second study Nissen et al. (38) evaluated 129 patients who had undergone breast-reduction surgery. Silicone products were used postoperatively to prevent hypertrophy of scars. No keloidal scars formed with use of the silicone. Neither of these studies had controls of the studies on silicone treatment had controls. At present, this treatment appears to be most useful for treating hypertrophic scars. Its role in prophylaxis is uncertain. There were no adverse effects from the silicone products. Silicone sheeting also helps minimize new hypertrophic scarring when applied about 2 weeks after wounding Gold et al. (39) showed that in patients at high risk—those who had a significant history of hypertrophic scar or keloid formation after a surgical procedure—29% developed hypertrophic scars after silicone gel sheeting whereas 44% developed hypertrophic scars after routine postoperative care. Most notably, in those patients identified as high risk who underwent scar revision there was a significant statistical difference (P = 0.035), suggesting that topical silicone sheets are effective in reducing the development of abnormal scars after surgical excision. Katz (40) supported these findings in an examination of 14 patients with 14 hypertrophic scars less than 3 months old. Nine patients had long-standing hypertrophic scars that were completely excised and treated with silicone sheeting
83
soon after re-epithelialization. Five patients had a history of hypertrophic scar formation and were given silicone sheeting within 2 months of operation to prevent recurrence. In 11 of these cases (79%), hypertrophic scars did not recur after at least 6 months of follow-up. IMIQUIMOD
A randomized, double-blinded study of 15 patients investigated the use of 5% Imiquimod cream in the prevention of hypertrophic scarring after breast operation (41). Imiquimod or Petrolatum was gently rubbed over the scar for 5 minutes once every 3 to 4 days for a period of 8 weeks. At 24 weeks postsurgery, imiquimod treatment improved scar quality, especially color and elevation, when compared with the control groups. This treatment may be beneficial for surgical scars in at risk patients. VITAMIN E
Despite anecdotal reports there is little scientific evidence exists to support the beneficial claims of vitamin on any aspect of wound healing. Jenkins et al. in an attempt to reduce scarring after reconstructive surgery in patients with burn, used topical vitamin E in the postoperative period. No significant differences were found in range of motion, scar thickness, change in graft size, and overall cosmetic appearance between the vitamin E treatment group and base cream control group 1 year after surgery. In addition, 20% of patients reported local reactions to the vitamin E cream (42). ONION EXTRACT
There is no evidence that it is beneficial in improving or preventing hypertrophic scars. In the few studies conducted to date, more patients in the petrolatum control group reported greater improvements in wound healing when compared with those who used onion extract (43,44). SUMMARY
The body of knowledge regarding skin type awareness and classification systems continues to grow. Since a patient may not have the expected phenotype and actually look nothing like their skin type, It is most important to be alert to the changing demographic in your cosmetic practice, and be able to recognize the patient with the “at risk” skin type. The Roberts classification system is a tool for classifying your cosmetic and medical patients. This classification system is designed to stay relevant as new skin types continue to emerge with world diversity and population expansion. The five S’s of laser safety in Ethnic skin are a simple way to insure safe outcomes for your laser patient with global or ethnic skin. Most importantly the objectives of this chapter are to provide you with the tools to identify your patient’s skin type, understand how to plan for the patient at risk for dyspigmentation and scarring, and lastly provide tips on intervention to prevent these adverse outcomes, A cosmetic treatment plan based on skin type classification that includes pretreatment evaluation, preoperative preparation, fastidious procedural technique, and targeted post-procedural care will lead to optimal outcomes. REFERENCES
1. Halder RM, Noothi PK. Ethnic skin disorders overview J Am Acad of Dermatol 2003; 48(Suppl 6): S143–S148. 2. US Census Bureau. [Available from: http://www.census.gov/ population/www/cen2000/briefs/]. 3. Jones NA, Smith AS. [Available from: http://www.census.gov/ prod/2001pubs/c2kbr01-6.pdf]. 4. Nordlund JJ, Ortonne JP, Cestari T, Grimes P, Chan H. Confusions about color: Formulating a more precise lexicon for pigmentation, pigmentary disorders, and abnormalities of “chromatics”. J Am Acad of Dermatol 2006; 54(5 Suppl 2): S291–7.
84
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
5. Fitzpatrick TB. The validity and practicality of sun-reactive skin types I-VI. Arch Dermatol 1988; 124: 869–71. 6. Roberts WE. The Roberts skin type classification system. J Drugs Dermatol 2008; 7(5): 452–6. 7. Lupo MP. Dermatosis pupulosa nigra; treatment options. J Drugs Dermatol 2007; 6: 29–39. 8. Jacskson BA. Lasers in ethnic skin: a review. J Am Acad Dermatol 2003; 48(Suppl 6): S134–8. 9. Battle EF, Hobbs LM. Laser therapy on darker ethnic skin. Dermatol Clin 2003; 21(4): 713–23. 10. Drosnor M, Adatto M. Photo-epilation guidelines for care of the European Society for laser dermatology. J Cosmet Laser Ther 2005; 7: 33–8. 11. Lanigan SW. Incidence of side effects after laser hair removal. J Am Acad Dermatol 2003; 49: 882–6. 12. Taylor SC. Skin of color: biology, structure, function, and implications for dermatologic disease. J Amer Acad Dermatol 2002; 46(2) C: S41–62. 13. Hill HZ, Li W, Xin P, Mitchell DL. Melanin: a two-edged sword? Pigment Cell Res. 1997; 10: 158–61. 14. Alster TS, BryanH, Williams CM. Long pulsed Nd:YAG laserassisted hair removal in pigmented skin: a clinical and histological evaluation. Arch Dermatol 2001; 137: 885–9. 15. Morelli JG, Norris DA. Influence of inflammatory mediators and cytokines in human melanocyte function. J Invest Dermatol 1993; 100: 191S–195S. 16. Morelli JG, Kincannon J, Yohn JJ, Zekman T, Weston WL, Norris DA. Leukotriene C4 and TGF-alpha are stimulators of human melanocyte migration in vitro. J Invest Dermatol 1992; 98: 290–5. 17. Orringer JS, Voorhees JJ, Hamilton T, Hammerberg C, Kang S, Johnson TM, Karimipour DJ, Fisher G. Dermal matrix remodeling after nonablative laser therapy. J Am Acad Dermatol 2005; 53(5): 775–82. 18. Handley JM. Adverse events associated with nonablative cutaneous visible and infrared laser treatment. J Am Acad Dermatol 2006; 55(3): 482–9. 19. Ratner D, Tse Y, Marchell N, Goldman M, Fitzpatrick RE, Fader DJ. Cutaneous laser resurfacing. J Amer Acad Dermatol 1999; 41(3): 365–92. 20. Chan HH, Lleung RS, Ying SY, Lai CF, et al. A retrospective analysis of complications in the treatment of nevus of ota with other Q switched alexandrite and Q switched Nd;YAG lasers. Dermatol Surg 2000; 26; 100–6. 21. Goh Cl, Khoo L. Laser skin resurfacing treatment outcome of facial scars and wrinkles in Asians with skin types III/IV with the Unipulse CO2 laser system. Singapore Med J 2002; 43: 28–32. 22. Rubin MG. Basic Concepts in Skin peeling: Manual of Chemical Peels. Philadelphia, PA: Lippincott, 1995: 44–59. 23. Alt TH. The value of effective therapeutic and cosmetic dermabrasion. In: Epstein E, Epstein EJ, eds. Controversies in Dermatology. Philadelphia, PA: WB Saunders, 1984: 439–46. 24. West TB, Alster TS. Effect of pretreatment on the incidence of hyperpigmentation following cutaneous CO2 laser resurfacing. Dermatol Surg 1999; 25: 17–7. 25. Victor FC, Cohen DE, Soter NA. A 20 year analysis of previous and emerging allergens that elicit photoallergic contact dermatitis. J Am Acad Dermatol 2010; 62(4): 603–10.
26. Shaffer JJ, Taylor SC, Cook-Bolden F. Keloidal scars: a review with a critical look at therapeutic options. J Am Acad Dermatol 2002; 46(2(Suppl 2): S63–S97. 27. Alhady SM, Sivanantharajah K. Keloids in various races: a review of 175 cases. Plast Reconstr Surg 1969; 44: 564. 28. El-Essawi D, Musial JL, Hammad A, Lim HW 2. A survey of skin disease and skin related issues in Arab Americans. J Am Acad Dermatol 2007; 56(6); 933–8. 29. Norris DA. Mechanisms of action of topical therapies and the rationale for combination therapy. J Am Acad Dermatol 2005; 53(Suppl 1): S17–25. 30. Hengge UR, Ruzicka T, Scwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006; 54(1): 1–15. 31. Jalali M, Bayat A. Current use of steroids in management of abnormal raised skin scars. Surgeon 2007; 5: 175–80. 32. Urioste SS, Arndt KA, Dover JS. Keloidal scars and hypertrophic scars: review and treatment strategies. Semin Cutan Med Surg 1999; 18: 159–71. 33. Zurada JM, Kriegal D, Davis IC. Topical treatments for hypertrophic scars. J Am Acad Dermatol 2006; 55(6): 1024–31. 34. Mandy S. Tretinoin in the preoperative and postoperative management of dermabrasion. J Am Acad Dermatol 1986; 15: 848. 35. Hevia O, Nemeth AJ, Taylor JR. Tretinoin accelerates healing after trichloracetic acid chemical peel. Arch Dermatol 1991; 127: 678. 36. Ruiz-Esparza J, Gomez JMB, DeLaTorre OLG, David L. Erythema after laser skin resurfacing. Dermatol Surg 1998; 24: 31–4. 37. Ahn S, Monafo WW, Mustoe TA. Topical silicone gel for the prevention and treatment of hypertrophic scar. Arch Surg 1991; 126: 499–504. 38. Nissen FB, Spauwen PHM, Robinson PH, Fidler V, Kon M. The use of silicone occlusive sheeting (Sil-k) and silicone occlusive gel (epiderm) in the prevention of hypertrophic scar formation. Plast Reconstr Surg 1998; 102: 1962–1972. 39. Gold M, Foster TD, Adair MA, Burlison K, Lewis T. Prevention of hypertrophic scars and keloids by the prophylactic use of topical silicone gel sheets following a surgical procedure in an office setting. Dermatol Surg 2001; 27: 641–4. 40. Katz B. Silicone gel sheeting in scar therapy. Cutis 1995; 56: 65–7. 41. Prado A, Andrades P, Benitez S, Umana M. Scar management after breast surgery: preliminary results of a prospective, randomized, and double-blind clinical study with aldara cream 5% (imiquimod). Plast Reconstr Surg 2005; 115: 966–72. 42. Jenkins M, Alexander JW, MacMillan BG, Waymack JP, Kopcha R. Failure of topical steroids and vitamin E to reduce postoperative scar formation following reconstructive surgery. J Burn Care Rehabil 1986; 7: 309–12. 43. Clarke L, Baker B, Trahan C, Myers L, Metzinger SE. A prospective double-blinded study of Mederma skin care vs placebo for post-traumatic scar reduction. Cosm Dermatol 1999; 12: 19–26. 44. Chung V, Kelley L, Marra D, Jiang SB. Onion extract gel versus petrolatum emollient on new surgical scars: prospective doubleblinded study. Dermatol Surg 2006; 32: 193–8.
12
When non-invasive is not enough: Limits to individual treatments Roxanne J. Guy
INTRODUCTION
We have all heard the old adage “if all you have is a hammer, everything looks like a nail.” So is it also in medicine, and particularly, in surgery. For that reason, plastic surgeons tend to evaluate patients with an eye toward a surgical correction, while nonsurgeons will likely look for a nonsurgical approach. Presently, the new age of non-invasive and minimally invasive aesthetic medicine has allowed a paradigm shift in the thinking of the plastic surgeons and an empowerment of nonsurgeons in the realm of aesthetic medicine. In plastic surgery residency, we were taught to “climb the reconstructive ladder” on each case needing reconstructive surgery. That is, perform the most effective surgery, using the least invasive and complicated approach, which would provide a stable and long-lasting solution for the defect, as well as one which the patient could tolerate and would ultimately accept. Once one eliminates the lower rungs of the so-called “ladder” as not adequate, then one can climb up the steps, one-by-one, to the more sophisticated and complicated approaches and procedures. The sea change for plastic surgeons is to do the same thing for aesthetic deformities. Non-invasive and minimally invasive modalities have allowed us to fill-in the lower rungs of the “aesthetic ladder.” It is, however, also important to address the filling of the upper rungs of the ladder for the nonsurgeons. When does one refer to a plastic surgeon? When does one embark on a surgical approach, albeit minimally invasive? When and how does one know his or her own limits and, more importantly, ascertain the kind of correction expected by the patients for full satisfaction? What are the limits of the fillers, toxins, and non-ablative lasers? I have (gratefully) learned from my dermatology colleagues that some patients will never desire a surgical remedy for an aesthetic problem. Others may never be satisfied with anything but the full surgical endeavor along with every adjunctive treatment available. The devil is, as always, in the details. The details of the deformity, the patient’s history and health status, and that often nebulous entity we refer to as “patient expectations” (which can, of course, be moving targets). In addition, it is the physician’s duty to explain the relative risks, benefits, alternatives and limitations of the different treatments, as well as cost comparisons. If some patients spend several thousand dollars on fillers, neurotoxins and collagen tightening treatments over several months and still have significant skin laxity that continues to vex them a year later, we may not have made any friends nor done any favors for our practice. Likewise, patients who have not been adequately apprised of the process of surgical post-operative healing and wound maturation may be upset about “down” time, swelling, bruising, and scarring. So, the all-important selection of the right procedure for the right patient at the right time is the true “art” of being a physician, regardless on which side of the surgical fence one may reside. MECHANISMS AND CLASSIFICATIONS OF AGING
Skin clarity and beauty generally decrease with the natural aging process. This change is exacerbated by sun damage, smoking, and disease. Dyschromias, telangiectasias, actinic keratoses, dryness, dullness, sallowness, enlarged and clogged pores and comedones are signs of aging skin. Thanks to the advances in skin research, we have various topical agents to counter and postpone many of these issues, keeping skin looking fresh, healthy, and reflective longer. Tretinoin, topical acid products, and bleaching agents, along with
effective sunscreens can truly maintain skin beauty for much longer than previously. Along with the textural and surface changes of the skin with age, come wrinkles. A natural loss of collagen and hyaluronic acid occurs, as well as a decrease in elastin resilience. The dermis thins, collagen decreases, and the skin folds upon itself, resulting in wrinkles. There are many different wrinkle scales used in medicine to categorize the severity of wrinkles. One example is the Glogau classification (1) wherein type I describes no wrinkles, type II describes wrinkles in motion, type III describes wrinkles at rest, and type IV describes only wrinkles (Fig. 12.1). In addition to the skin changes, loss of soft tissue volume in the face contributes greatly to the aging process, as described by Lambros (2). Volume loss, along with the skin changes, causes the skin to appear lax and ptotic. In fact, not just skin aging, but changes in the integrity of all tissues affect the enveloping connective tissue, as well. Recent studies by Rohrich and Pessa of individual, distinct fat pads of the face reveal descent of these fat pads with age. Certain of the fat pads descend earlier than others (3). The loss of overall collagen and elastin resilience, along with a decrease in soft tissue volume and the descent of the individual fat pads of the face, cause drooping of the facial tissues and a conversion of the normally aesthetic oval shape of the face to one which is square and less aesthetic (Fig. 12.2). Many skin laxity scales also exist, such as the Dedo classification of neck aging (4), for example. In his classification, a class I neck is youthful and normal, class II and III show early abnormalities of skin and fat, class IV shows platysmal abnormalities, such as platysmal banding, and class V shows loss of the cervicomental angle with an obtuse neckline (Fig. 12.3). Aesthetic endeavors should attempt to rejuvenate the surface color and texture of the skin, and fill-in and/or relax lines. Various skin care regimens, fillers, and neurotoxins do these jobs quite well. Skin laxity and fat pad descent can be filled or camouflaged by volumizing fillers, such as poly-l-lactic acid, placed strategically. However, these modalities do have their limits. It is not difficult to agree, for example, that a Glogau class IV or a Dedo class V will not do very well with noninvasive modalities unless the patients’ expectations are relatively low. Using examples of these scales to advise patients of probable results or to query them of the results they expect, can be quite helpful in ascertaining which type of aesthetic modality should be used. LASER SKIN RESURFACING OR DEEP PEELING
Brighter, clearer skin will improve anyone’s appearance and enhance any aesthetic or cosmetic intervention. In fact, a soon-to-be-published series of over 100 poly-l-lactic acid facial injections showed a more dramatic and long-lasting effect of the volumizing filler if the patient used tretinoin routinely (5). Sometimes skin care alone may be enough improvement for the time being, and sets up the patient for a lifetime of good skin health habits. Thus, skin care is often the first intervention for a patient seeking rejuvenation and a relatively non-intimidating foray into the realm of aesthetic medicine. Once the surface texture, color, and clarity of the skin have been optimized and superficial rhytids improved, one may move to neurotoxins and fillers to relax and fill lines. The success of these modalities depends upon the patient expectations and the severity and location of
85
86
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
1
2
3
4
Essentially no wrinkles Mild skin changes
Wrinkles on animation Moderate skin changes
Wrinkles at rest (static) Very visible skin changes
Only wrinkles Severe skin damage
Figure 12.1 Examples of the Glogau wrinkle scale.
Figure 12.2 Facial shape changes from square to oval after facelift surgery.
the deformities. Deeper lines and dyschromias not reversed with topical skin care can require a referral for more aggressive treatments. I find the skin rhytids that require more aggressive techniques than skin care products, toxins or fillers are the Glogau IV classification type of patients who have lines virtually all over the face. Facelifting alone is also not adequate (Fig. 12.4). In these instances, the referral for a deep ablative resurfacing laser procedure, such as a CO2 or erbium skin
resurfacing, or some variation of a deep facial peel, such as the Hetter modification of the phenol peel (6), would be more efficacious. It is quite common for patients to present with significantly deep vertical perioral rhytids that are not adequately improved with fillers, toxins, or light peels. These lines are also not amenable to “lifting” as are some forehead or cheek wrinkles and do not improve with facelifting alone. I find that early, aggressive ablative laser treatment of these
87
WHEN NON-INVASIVE IS NOT ENOUGH: LIMITS TO INDIVIDUAL TREATMENTS
1
2
3
4
5
Normal, youthful neck
Mild laxity
Moderate laxity and submental fat
Laxity, fat and platysmal bands
Obtuse neck: loss of angle
Figure 12.3 Examples of the Dedo neck aging classification scale.
Figure 12.4 Patient with Glogau IV skin rhytids pre- and post-facelifting procedure. Treating the surface rhytids with deep resurfacing would have greatly augmented the surgical result.
lines is the best approach, before the lines become quite deep. Once the lines become very deep, adequate ablation with lasers or peels are more likely to cause irreversible complications, such as hypopigmentation or scarring of the perioral skin. It is advisable to treat before the patient gets to the severely deep stage (Fig. 12.5). BLEPHAROPLASTY
A blepharoplasty for excess, hanging upper eyelid skin, with or without medial upper eyelid fat pad protrusion is often one of the first
surgical procedures patients seek from a plastic surgeon for a younger looking appearance. Most complain that they are asked by friends or co-workers if they are tired when, in fact, they are not. They may be bothered that they can no longer apply eye shadow without it collecting in the lines of the redundant skin, or mascara without it smearing on the redundant skin sitting on the base of the lashes. A referral for an upper lid blepharoplasty can take years off of a persons’ appearance and, if needed later, can allow neurotoxins and fillers
88
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
Figure 12.5 Patient pre- and post-treatment with deep (600 µm depth) erbium laser ablative perioral and chin resurfacing.
Figure 12.6 Patient pre- and post -treatment with upper eyelid blepharoplasty.
for brow and crow’s feet amelioration to become much more effective (Fig. 12.6). Lower eyelid complaints include excess hanging skin, which may be associated with lower eyelid fat pad descent (lower eyelid “bags”). Because of the fat protrusion, the light reflection on the face from overhead lighting throws the tear trough areas into shadows, adding to the “dark circled” look under the lower eyelids. Excess lower eyelid skin, combined with animation can produce rows of lower eyelid lines which curve down over the lateral cheek. Removal of some of the redundant skin and removal or repositioning of the fat pads can rejuvenate the lower eyelids immensely. For very lax and patulous lower eyelids, a lateral canthopexy and/or an orbicularis muscle sling may be needed. A few animation lines are likely to persist, which are then much more effectively treated with fillers or neurotoxin. The patient in this example opted for fillers to her tear troughs. She clearly has herniated orbital fat in all three lower lid fat compartments. While the filler did help to some extent, she was not satisfied with the result and her expectations were not met. A lower eyelid blepharoplasty would have been a better choice for her (Fig. 12.7).
The next patient example had long-lasting (1 year indication) filler material used throughout her cheeks, nasolabial folds, and jowl/chin area. She has very visible herniated lower eyelid fat bags on the pretreatment view, which are much improved on the middle view at 17 days post filler treatment. The third view is 1 year post filler treatment and the patient is about back to midline. A lower eyelid blephroplasty would have been a more permanent solution and would have cost about the same amount as the multiple vials of filler which she received 1 year previously (Fig. 12.8). BROW LIFTING
Neurotoxins have revolutionized the treatment of glabellar frown lines, transverse forehead lines, and mild lateral brow ptosis (the so-called “chemical brow lift”). Fillers in the lateral supra-brow area and as an adjunct with neurotoxins for filling toxin relaxed glabellar and transverse forehead lines can be amazingly effective. Many patients who use the products early and often enough can virtually prevent the static, deeply etched lines of the glabella. But aging of the brow often takes on many other forms than mild rhytids or brow ptosis.
WHEN NON-INVASIVE IS NOT ENOUGH: LIMITS TO INDIVIDUAL TREATMENTS
89
Figure 12.7 Patient treated with tear trough fillers. Lower lid blepharoplasty may have been a better choice.
Figure 12.8 Patient treated with calcium hydroxyapatite fillers, five vials, at pre-treatment, 17 days post treatment and at 1 year.
Referral for a brow lift is appropriate when one or more of the following exist. 1. Severe glabellar static rhytids even after neurotoxin and filler. 2. Heavy, hypertrophied corrugator muscles with medial brow ptosis, which ptosis is made worse with neurotoxin. 3. Transverse forehead rhytids which are essential and compensatory for raising very ptotic brows or heavy or hooded eyelids. 4. Severe lateral eyelid hooding with laxity and numerous “crow’s feet” lines. 5. Severe brow ptosis with brow position at or below the supraorbital rim in a woman (the aesthetic of male brows can tolerate this). Fillers above the brow and/or neurotoxin in the subbrow cannot correct the deformities adequately. Several methods of brow lifting can be performed. Endoscopic brow lifting is minimally invasive and effective. For severe ptosis with heavy
corrugators and etched transverse forehead lines, I prefer one of the open approaches with excision of the redundant skin and excision of the corrugator and procerus muscles from between the nerve branches under direct vision. The patient in the example (Fig. 12.9) presented with the complaint that people told her she always looked angry, though she did not often feel that way. The photos show severe brow ptosis, eyelid hooding, transverse forehead wrinkles, and static glabellar lines at rest. She was treated with a four-lid blepharoplasty and an open, coronal brow lift with resection of the corrugator and procerus muscles, and skin excision. FACE AND NECK LIFTING
Early signs of facial aging usually consist of deepening of the nasolabial folds, loss of facial volume, diminution of the ogee curve (7) of the cheek on oblique view, lateral oral commissure lines, marionette lines, fat pad descent with mild jowling, and the beginning of submental neck skin laxity.
90
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
Further aging intensifies these deformities and adds concentric cheek rhytids, vertical perioral rhytids, lip thinning, more volume loss in the cheeks and areas around the chin, and platysmal banding of the neck. As stated previously, the face, on frontal view, takes on a square appearance, with loss of the ideal oval shape (Fig. 12.2). Early changes can be improved with volumizing fillers to the malar and submalar areas, the pre-jowls, nasolabial folds, tear troughs, and other areas. Neurotoxins can help efface the lips and soften the platysmal bands. Facelifting should be considered when the fillers no longer convert the face to an adequate oval or when the neck skin is simply too lax to be camouflaged. In addition, if the amount of filler needed to produce the desired result and the required re-injection schedule is
more expensive relative to the amount of correction and longevity of the facelifting procedure, one should certainly consider the latter (Fig. 12.8). Modern face and neck lifting generally includes lifting and repositioning of the ptotic deeper structures, plication of the neck platysmal bands with lower neck platysmal band interruption, attention to the vectors of pull which will enhance the shape of the face (and may be different on each side of the face), and often soft tissue volume augmentation at the time of surgery. The patient in Figures 12.10 and 12.11 is the same as in Figure 12.2, showing the oblique view and the lateral view, to illustrate the improvement in the jowls and neck, as well as the nasolabial folds, marionette lines, crow’s feet, eyelids, and lateral brows (Figs. 12.10 and 12.11).
Figure 12.9 Patient pre- and post-op from coronal brow lift and four-lid blepharoplasty.
Figure 12.10 Oblique views. Patient pre- and post-op from facelift, browlift, and four-lid blepharoplasty.
WHEN NON-INVASIVE IS NOT ENOUGH: LIMITS TO INDIVIDUAL TREATMENTS
COMBINATION PROCEDURES
The most gratifying results I have experienced have been from patients who do their best to address all the areas which are in need of intervention: skin care, dyschromias, rhytids, skin ptosis, and volume loss. The following is a patient who first had 6 weeks of intensive skin care. She later had a full face ablative laser resurfacing and a brow lift (Fig. 12.12).
91
The next patient had a full facelift, a four-eyelid blepharoplasty and chemical peeling to her facial dyschromias, as well as a new hair color and style (Fig. 12.13). The patient in the next figure (Fig. 12.14) had a facelift, a browlift, and fat injections to her cheeks. The next examples are of a patient who underwent facelifting, rhinoplasty, chin implantation, and browlifting. She also began a regimen of
Figure 12.11 Lateral views. Patient pre- and post-op from facelift, browlift, and four-lid blepharoplasty.
Figure 12.12 Patient pre-treatment on left. Middle view—patient treated first with intensive skin care for 6 weeks. Right photo is of a patient treated with a brow lift and full face ablative laser resurfacing, using the Erbium laser.
92
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
facial care, make-up, and a new wardrobe, for a full make-over. All the elements combine together to make the whole. My assessment is that she went from a rather matronly, middle-aged woman to a rather glamorous, mature woman (Figs. 12.15–12.17). INJECTABLES, TOXINS, LASER, AND SKIN CARE POST SURGERY
Relinquishing a patient to the plastic surgeon does not mean, however, that their toxin, filler and skin care days are over. Surgery does
not get rid of every line, nor should it. The best surgery is that which provides for a natural and non-operated look. I often use fillers post surgery to fill the cheeks, as the aging process continues to deplete the face of volume, sometimes more so after the surgery (Fig. 12.18). In addition, the glabellar musculature is quite resilient even to surgical intervention, and toxins are often still needed in the glabella, forehead or crow’s feet. This is particularly true after an endoscopic forehead lift or transconjunctival lower blepharoplasty.
Figure 12.13 Patient pre- and post-op from facelift, browlift, chemical peeling of facial dyschromias, and new hair coloring and styling.
Figure 12.14 Patient pre- and post-op from facelift, browlift, and fat injections to cheeks.
WHEN NON-INVASIVE IS NOT ENOUGH: LIMITS TO INDIVIDUAL TREATMENTS Good skin care should be an ongoing process, regardless of intervention. LONG-TERM RESULTS
Modern aesthetic medicine has been a boon to patients and physicians because it satisfies the desire for correction which is fast,
93
without time off of life activities and with subtle, natural results. Never-the-less, the return on investment over time must be taken into account. As stated previously, some patients will never wish to entertain a surgical solution because of fear, risks, the possibility of not looking “natural”, and worry over what others may think and because of finances. The collective modern consciousness, however,
Figure 12.15 Frontal views. Patient pre- and post-facelift, browlift, rhinoplasty, chin implant, skin care regimen, make-up, hair, and wardrobe change.
Figure 12.16 Oblique views. Patient pre- and post-facelift, browlift, rhinoplasty, chin implant, skin care regimen, make-up, hair and wardrobe change.
94
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
Figure 12.17 Lateral views. Patient pre- and post-facelift, browlift, rhinoplasty, chin implant, skin care regimen, make-up, hair and wardrobe change.
Figure 12.18 Previous facelift patient pre- and post-treatment with malar and submalar poly-l-lactic acid volumizing fillers; without and with make-up.
has adopted an attitude that early intervention with non-invasives will prevent the need for later surgical intervention. To some extent, that may be true, but aging never rests. Time is, indeed, the “subtle thief of youth.” To continue to espouse that the non-invasives will
prevent such eventualities is disingenuous. There will be patients who want a more dramatic and longer-lasting solution. Those are the patients who should be counseled and, perhaps, referred. The last few examples are of surgical patients who enjoyed correction
WHEN NON-INVASIVE IS NOT ENOUGH: LIMITS TO INDIVIDUAL TREATMENTS
95
Figure 12.19 Frontal views. Left photo shows a patient at age 51 years prior to surgery of facelift and perioral dermabrasion. Middle photo shows the same patient 12 years after the surgery. Right photo shows the same patient at age 63 years, 6 months after a secondary facelift, browlift, and lower lid blepharoplasty.
Figure 12.20 Oblique views. Left photo shows a patient at age 51 years prior to surgery of facelift and perioral dermabrasion. Middle photo shows the same patient 12 years after the surgery. Right photo shows the same patient at age 63 years, 6 months after a secondary facelift, browlift, and lower lid blepharoplasty.
for many years and returned for a repeat surgical correction many years later. I submit that both of these examples look in many ways better after each of their two procedures than they did before their first.
In both cases, however, skin care and adjunctive procedures were also continued. All this denotes the motivation of the individuals to do the best they can to look good throughout their different life stages (Figs. 12.19–24).
96
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
Figure 12.21 Lateral views. Left photo shows a patient at age 51 years prior to surgery of facelift and perioral dermabrasion. Middle photo shows the same patient 12 years after the surgery. Right photo shows the same patient at age 63 years, 6 months after a secondary facelift, browlift, and lower lid blepharoplasty.
Figure 12.22 Frontal views. Left photo shows a patient at age 53 years prior to surgery of facelift, four-lid blepharoplasty, and perioral dermabrasion with removal of skin lesion above right brow. Middle photo shows the same patient 6 months post-op from the surgery. The right photo shows the same patient at age 63 years, 6 months following secondary facelift with full face laser resurfacing.
CONCLUSION
Cosmetic or aesthetic medicine has been a boon for modern, busy people wishing to look their best. Skin care, toxins, fillers, and nonablative laser treatments are excellent as first-line therapies, as well as
adjunctive therapies. The use of plastic surgery with non- or minimally invasive aesthetic medicine is certainly not mutually exclusive, but can work in synergy to produce beautiful results.
WHEN NON-INVASIVE IS NOT ENOUGH: LIMITS TO INDIVIDUAL TREATMENTS
97
Figure 12.23 Oblique views. Left photo shows a patient at age 53 years prior to surgery of facelift, four-lid blepharoplasty, and perioral dermabrasion with removal of skin lesion above right brow. Middle photo shows the same patient 6 months post-op from the surgery. The right photo shows the same patient at age 63 years, 6 months following secondary facelift with full face laser resurfacing.
Figure 12.24 Lateral views. Left photo shows a patient at age 53 years prior to surgery of facelift, four-lid blepharoplasty, and perioral dermabrasion with removal of skin lesion above right brow. Middle photo shows the same patient 6 months post-op from the surgery. The right photo shows the same patient at age 63 years, 6 months following secondary facelift with full face laser resurfacing. REFERENCES
1. Glogau RG. Aesthetic and anatomic analysis of the aging skin. Semin Cutan Med Surg 1996; 15: 134–8. 2. Lambros V. Observations on periorbital and midface aging. Plast Reconstr Surg 2007; 120:1367–76. 3. Rohrich RJ, Pessa JE. The fat compartments of the face: anatomy and clinical implications for cosmetic surgery. Plast Reconstr Surg 2007; 119: 2219–27. 4. Dedo DD. “How I do it” – plastic surgery. Practical suggestions on facial plastic surgery. A preoperative classification of the
neck for cervicofacial rhytidectomy. Laryngoscope 1980; 90: 1894–6. 5. Casas LA, MD, FACS, personal communication. 6. Hetter GP. An examination of the phenol-croton oil peel: part IV. Face peel results with different concentrations of phenol and croton oil. Plast Reconstr Surg 2000; 105: 1061–83. 7. Little JW. Volumetric perceptions in midfacial aging with altered priorities for rejuvenation. Plast Reconstr Surg 2000; 105: 252–66.
13
Complications A to Z Vince Bertucci
INTRODUCTION
The promise of aesthetic enhancement with minimal down time and highly favorable safety profile has fuelled tremendous public interest in minimally invasive procedures over the last decade. Whereas surgery was the treatment of choice in the very recent past, today we have a rapidly growing number of options available to us in our quest for facial rejuvenation. Nothing less than a paradigm shift is occurring in the way we assess and treat the aging face. The aging face is the result of more than the effect of simple gravitational forces—it is a combination of cellular senescence, photodamage, environmental factors, loss and redistribution of soft tissue volume, and remodeling of the craniofacial skeleton, amongst other things. With new and evolving procedures and techniques, one inevitably sees adverse effects and complications, some predictable and others not. Many definitions for the term complication have been put forth over the years. For the purposes of this chapter, the term complication shall refer to any undesirable outcome. In this chapter, I will discuss complications associated with some common cosmetic procedures including botulinum toxin, injectable fillers, and lasers. By understanding mechanisms for these complications and by incorporating preventive measures into his or her practice, it is hoped that the practising physician will minimize or altogether avoid adverse outcomes. Finally, where available, management options for complications will be presented so as to help the physician minimize or avoid long-lasting adverse effects. BOTULINUM TOXIN COMPLICATIONS
Many physicians, industry observers, and the public credit botulinum toxin with starting the tremendous boom in minimally invasive aesthetic enhancement procedures. For many, Botox® (OnabotulinumtoxinA, Allergan Inc., Irvine, California, USA) is synonymous with minimally invasive cosmetic enhancement procedures. So pervasive is the awareness of botulinum toxin, sold under various brand names around the world, that many members of the public erroneously use the term to denote all cosmetic procedures and believe it to be the solution for all facial aging issues. The ability to precisely tailor muscular activity so as to create desirable facial expressions, shapes, and features has provided aesthetically minded physicians with an irreplaceable tool in their armamentarium as they seek to enhance and precisely sculpt facial features. However, botulinum toxin must be used precisely with a deep understanding of fluid facial anatomy and careful patient assessment so as to provide outstanding results and minimize adverse outcomes. Non-Specific Complications Complications associated with use of botulinum toxin are quite predictable. Some adverse effects are strictly related to injection with a needle. These include local discomfort, bleeding, ecchymosis, and edema. Use of ultra-fine, 31-gauge short needles helps to reduce discomfort and shearing that sometimes occurs with dull needles or needles that have burrs (1). Some individuals report development of headache after botulinum toxin treatment, although many actually report improvement of headaches, probably related to resultant muscular relaxation in headaches of muscular origin. Most headaches are mild and self-limited but, rarely, severe headache may occur requiring stronger analgesics or corticosteroids (2).
98
Forehead Over-treatment with botulinum toxin results in reduced ability to contract the affected muscle, leading to varying effects, depending on the site of treatment. When the forehead is treated excessively, frontalis muscle activity is diminished, leading to reduced elevator activity, possibly leading to brow ptosis. Thus, although transverse forehead rhytides will be diminished, the overall effect may be to give an appearance of fatigue as the brows rest lower on the face, possibly giving rise to upper eyelid “hooding.” This complication may be avoided by reducing forehead dosing and/or injecting higher up on the forehead with advancing age and in those individuals who have evidence of preexisting brow ptosis. In some cases of prominent pre-existing brow ptosis, it may be best to avoid frontalis treatment altogether. Concomitant treatment of the brow depressors (i.e., the procerus, corrugators, depressor supercilii, and orbicularis oculi lateral to the temporal fusion line) helps to minimize this complication by diminishing the downward pull of the depressors, thus permitting further upward mobility of the brow (3). Another consideration when assessing and treating the forehead is the vertical distance between the brows and the frontal hairline. With shorter distances or “small” foreheads, one may wish to consider treating higher up on the forehead to reduce the risk of brow ptosis. Additionally, if the glabella is to be treated as well, one may wish to either reduce the dose or altogether avoid frontalis treatment in these individuals. Botulinum toxin diffusion from glabellar injections in individuals with a small forehead may be adequate to soften transverse forehead rhytides. It is certainly easier to add more botulinum toxin at a follow-up visit than to have to deal with brow ptosis because of over-treatment. Most individuals would agree that a few residual forehead wrinkles are preferable to brow ptosis, the impression of fatigue, and lack of expressivity that results from the lowered brow position. Glabella In treating the glabella, as with other areas, careful physical examination prior to botulinum toxin treatment is mandatory. Brow position, muscle bulk, redundant upper eyelid skin, facial symmetry, and the presence of static rhytides are some of the features that should be carefully assessed and documented. Gaining an understanding of the patient’s needs and wishes is particularly important for the glabella, perhaps especially so in individuals whose occupation may require glabellar movement to convey certain feelings or emotions. While some individuals wish to retain some ability to furrow the glabellar region, others do not wish to have any movement in this area. Eyelid ptosis, a complication that can be seen with botulinum toxin treatment of the glabellar region, is thought to be related to local toxin spread to the levator palpebrae muscle (4). By injecting 1 cm above the superior orbital rim, one may reduce the risk of ptosis while still adequately treating glabellar furrows. Eyelid ptosis is typically transient and mild but may occasionally last over one month. In addition to reassuring the patient that it spontaneously resolves, ptosis may be ameliorated with an alpha adrenergic agent such as apraclonidine hydrochloride ophthalmic solution 0.5% (Iopidine®, Alcon Laboratories Inc., Fort Worth, Texas, USA). Application of one to two drops three times per day as needed may achieve 1 to 2 mm elevation of the eyelid, secondary to contraction of Müller’s muscle. Rapid access to such an
COMPLICATIONS A TO Z alpha adrenergic agent is important for physicians using botulinum toxin in the glabellar region. Upward migration of botulinum toxin will diminish brow elevator activity, possibly leading to brow ptosis or mid-brow droop. Avoidance of inadvertent injection into the frontalis helps to avert this undesirable outcome. Another potential complication of botulinum toxin treatment of the glabella is the so-called quizzical brow or diabolical brow. This appearance consists of prominent lateral brow elevation without medial brow elevation, leading to the unusual appearance. This effect is easily prevented by using a small amount of botulinum toxin over the lateral forehead in those individuals that show prominent lateral brow elevation prior to treatment. Correction of the quizzical brow may be achieved by injecting a very small amount of botulinum toxin into the frontalis muscle that shows exaggerated elevation. Treatment of the glabellar complex may lead to splaying of the eyebrows. I advise my patients of this ahead of time as it may alter the way they care for their eyebrows. Lower dosing minimizes but may not completely prevent this effect. Crow’s Feet Treatment of the crow’s feet rhytides presents its own unique challenges. Once again, careful pre-treatment assessment and knowledge of anatomy will help to prevent unwanted outcomes. The zygomaticus major and minor muscles, which elevate the corners of the mouth, may be inadvertently weakened if one injects too low in the area of the zygomatic arch. This leads to an asymmetric smile because of the inability to raise the ipsilateral side of the mouth when smiling. The risk of this complication may be minimized by injecting superior to the zygomatic arch. When injecting the crow’s feet it is important to stay at least 1 cm lateral to the orbital rim so as to avoid diplopia (5). The latter may occur when botulinum toxin is injected too close to the orbital rim, allowing it to diffuse to the extraocular muscles, leading to reduced contractility of one or more of these muscles. The clinical outcome is reduced movement of the globe in certain directions and resultant diplopia. Static and dynamic assessment of the cheeks is critical when treating the crow’s feet. In those individuals who have large cheeks that prominently move upward with a smile, it is advisable to use lower dosing toward the inferior portion of the crow’s feet so as to avoid the appearance of a cheek “shelf ” when smiling. This undesirable appearance occurs when the cheek moves upward with a smile but movement is stopped at the lower end of the crow’s feet, giving the appearance of a bulge inferiorly with flattening superiorly. Infraorbital Region Treatment of the infraorbital region has many benefits in the appropriate patient, including reduced infraorbital rhytides and a more alert appearance with widened palpebral aperture, and more rounded lower eyelid shape. Complications related to botulinum toxin injection that may arise in this region include excessive scleral show, festooning, and excessive tearing. Excessive scleral show typically occurs in individuals who have a significant pre-existing portion of the ocular globe visible, or, what some may describe as “large eyes.” It may be best to avoid treating the infraorbital area in these individuals. Individuals with skin laxity in the infraorbital area, or who have poor elastic recoil as demonstrated by the snap test, tend to develop festoons after botulinum toxin treatment. Festoons refer to soft tissue bulging that develops in the infraorbital region after injection. It is thought to be secondary to inhibition of the lymphatic muscle pump after botulinum toxin treatment. It tends to be most prominent in the morning and often improves with gravitational effects as the day progresses. Gentle massage may ameliorate this complication which may last for days to weeks.
99
Excessive lacrimation is a rare complication seen when too much botulinum toxin is injected in the infraorbital area, leading to poor apposition of the lower eyelid against the ocular globe, thus leading to impaired ability of the lacrimal duct to collect tears. The end result is that tears drain onto the cheek. The best treatment for this is prevention. Lower Face Lower face treatment with botulinum toxin is considered by many to be an advanced technique that is best reserved for experienced injectors. Some of the areas that may be treated include the perioral region, depressor anguli oris (DAO), mentalis, and masseter. Treatment of each of these areas can lead to predictable benefits, and, in some cases, predictable complications. When treating the perioral area, the orbicularis oris muscle is weakened, leading to reduced perioral rhytides. Excessive treatment may reduce one’s ability to purse the lips firmly, resulting in an inability to properly enunciate the letters “B” and “P”. The resultant weakness may also impair one’s ability to whistle, drink out of a straw, or play a musical instrument, amongst other things. When the DAO is injected too medially and superiorly or when the mentalis muscle is injected too high, the depressor labii muscle may be inadvertently weakened, leading to an inability to depress the lower lip and an asymmetric elevation of the ipsilateral lower lip. The latter may be especially evident with smiling (Fig. 13.1). The risk of this complication may be minimized by injecting the DAO at the intersection of the jawline and a line formed by the caudal continuation of the nasolabial fold. Low injection into the mentalis, staying away from the mental crease, will similarly reduce risks associated with treatment of this muscle. If the masseter muscles are unevenly injected in individuals with hypertrophy, one may see fascicles of muscle contraction, giving the appearance of a focal bulge. Careful distribution of botulinum toxin at the time of treatment will minimize this risk. If this occurs, a small amount of botulinum toxin injected into the area of fasciculation will correct the problem. When the masseters are injected too far medially, inadvertent weakening of the risorius muscle may occur, with resultant reduced smile
Figure 13.1 Following injection of 5 units of Botox® (OnabotulinumtoxinA) into each depressor anguli oris (DAO) muscle, lower lip asymmetry develops. This complication occurs when product migrates superiorly to the right depressor labii muscle, leading to inability to move the ipsilateral lower lip inferiorly.
100
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
excursion on the ipsilateral side. Avoiding medial injections reduces this risk. Neck Treatment of the neck with botulinum toxin is helpful in reducing platysmal bands and horizontal neck lines. Additionally, the jawline contour may be improved with the ‘Nefertiti lift’ technique (6). The dose-related risks associated with treatment of the neck region include dysphagia and neck weakness. The former is secondary to over-treatment and diffusion of botulinum toxin into the muscles of deglutition. Dysphagia may rarely be so severe as to require nasogastric tube feeding. Neck weakness is also dose dependent and is best demonstrated by asking the patient to lift the head while in the supine position. For platysmal bands, precise injection into the bands themselves so as to avoid inadvertent injection of deeper muscles, and avoidance of aggressive dosing will help to prevent these complications. Transverse neck lines are best injected superficially, avoiding the subcutaneous plane so as to prevent weakening of the muscles of deglutition (7). Although there is no definitive agreement on maximal dosing for the neck, precise injection of up to approximately 60 units OnabotulinumtoxinA may be safe. Other Safety Considerations Distant spread of botulinum toxin beyond the site of injection has been raised as a concern and prompted the U.S. Food and Drug Administration to modify the labeling of botulinum toxins. It is important to note that “… no definitive serious adverse event reports of distant spread of toxin effect associated with dermatologic use of Botox at the labeled dose of 20 Units (for glabellar lines) or 100 Units (for severe primary axillary hyperhidrosis) have been identified” (8). The majority of reported problems occurred in children with cerebral palsy being treated for muscular spasticity. The majority of adult cases occurred when treating spasticity or cervical dystonia. In light of the above, cosmetic use of botulinum toxin in adults does not appear to be a concern. However, patients and caregivers should be aware of potential adverse events that may occur due to distant spread of botulinum toxin. These effects include unexpected loss of strength or muscle weakness, dysphonia, dysarthria, bladder incontinence, difficulty breathing, dysphagia, diplopia, and eyelid ptosis. These adverse events have been reported as early as several hours and as late as several weeks after treatment. Patients should be advised to seek immediate medical attention if they develop any of these symptoms. In order to avoid accidentally over-treating with botulinum toxin, it is important for physicians to recognize that botulinum toxin doses are not interchangeable from one botulinum toxin formulation to another. Thus, for example, the dosing and injection technique for OnabotulinumtoxinA is unique and distinct from that for AbobotulinumtoxinA. INJECTABLE FILLER COMPLICATIONS
The injectable filler market has exploded in recent years in concert with the dramatic expansion in the number of good treatment options. An evolving appreciation of the importance that facial shape and volume play in facial aging has allowed the experienced injector to use fillers to restore aesthetically pleasing facial contours. An exhaustive discussion of all fillers is beyond the scope of this chapter. I will limit my discussion to complications associated with hyaluronic acid (HA) fillers (e.g., Restylane®, Medicis Pharmaceutical Corp., Scottsdale, Arizona, USA; Juvéderm®, Allergan Inc., Irvine, California, USA), collagen-based fillers (e.g., Zyderm®/Zyplast®, Allergan Inc., Irvine, California, USA; CosmoDerm®/CosmoPlast®, Allergan Inc., Irvine, California, USA; Evolence®/Evolence Breeze®, Johnson & Johnson, Morris Plains, New Jesrsey, USA), silicone, calcium
hydroxylapatite (CaHA) (Radiesse®, Merz Aesthetics Inc., San Mateo, California, USA), poly-L-lactic acid (PLLA) (Sculptra®, Sanofi–Aventis, Bridgewater, New Jersey, USA), and polymethylmethacrylate (ArteFill®, Suneva Medical Inc., San Diego, California, USA). A pre-requisite for physicians using fillers is what might be termed an “aesthetic eye.” While this intangible is difficult to quantify, an appreciation of the features that together make for an aesthetically pleasing face is key to successful outcomes. Although there is no universally accepted definition of beauty, it seems that certain features of beauty cross racial lines include, amongst other things, prominent zygomatic arches with high, full, convex cheeks as well as convexities of the temples, lips and jawline. Over the years, a number of attempts have been made to analyze and quantify facial attractiveness (9). By recognizing these and other features of facial attractiveness, physicians will be better able to achieve aesthetically desirable results while minimizing the likelihood of creating an unsightly appearance. Physicians, especially novices, may wish to consider using reversible, short-lasting HA-based fillers prior to proceeding with long-lasting fillers in challenging areas such as the lips and infraorbital region and in first-time patients who are unsure of their desired outcome. This will allow the patient to become comfortable with the appearance prior to committing to a longer term solution. HA fillers are perhaps the most widely used fillers in the world and offer numerous advantages: Wide availability, ease of use, low risk of inflammatory reaction, and reversibility. Although some believe HA fillers to be the gold standard and safest of all fillers, adverse events may occur even with this group of products. Non-Specific Complications As with botulinum toxin, some of the complications seen with injectable fillers are related to the act of injection itself, rather than to the specific filler being used. These non-specific complications include pain, tenderness, redness, bleeding, and ecchymosis. Knowledge of anatomy and careful attention to detail will help to minimize the risk of bleeding and ecchymosis. Sometimes, gentle stretching of the skin allows better visualization of vessels, reducing the risk of vessel perforation and ecchymosis. A history of recent use of acetylsalicylic acid, non-steroidal anti-inflammatory drugs and some vitamin supplements may increase the risk of bleeding (10). Of course, it is not possible to completely predict bleeding and ecchymosis no matter how careful the technique is. Injection scheduling should thus take these risks into consideration. Pain may be minimized with local anaesthetic, either topically, as a nerve block or injected locally. Recently, some injectable fillers premixed with lidocaine have become available. In the absence of premixed formulations containing lidocaine, some physicians manually add a small amount of local anaesthetic such as lidocaine into their filler of choice. Edema and swelling may occur with all injectable fillers but may vary in timing and severity with the particular agent used. For example, collagen-based fillers tend to cause less edema than HA fillers. With the latter, edema may be delayed as the hygroscopic nature of HA results in binding of more water with time. Patient factors such as dermographism may also influence the amount of swelling. Asking about a tendency to swell may be help to identify some individuals who are prone to more pronounced swelling. Glogau and Kane found that local adverse events in patients treated with non-animal stabilized hyaluronic acid were associated with rapid flow rates, higher volumes, rapid injection, and fanlike injection technique, while injection depth, single injection correction, and intrinsic properties of the non-animal stabilized hyaluronic acid did not have a significant effect on adverse events (11).
COMPLICATIONS A TO Z
101
Appropriate choice of the injection technique for a given filler can improve outcomes and reduce the risk of complications. Examples of accepted techniques include the microdroplet technique for silicone, linear threading for polymethylmethacrylate, and depot for Perlane® (Medicis Pharmaceutical Corp., Scottsdale, Arizona, USA) and Juvéderm Ultra Plus® (Allergan Inc., Irvine, California, USA).
common bacteria, mycobacteria, or other organisms. Wound culture may help to guide therapy. The discussion of biofilms below adds an interesting dimension to our understanding of infections. A previous history of Herpes simplex virus infection warrants the use of antiviral prophylaxis. Where an abscess is suspected, it must be drained. Sterile abscesses may also rarely occur and require drainage.
Injector-Dependent Adverse Outcomes Some injector-dependent adverse outcomes include asymmetry, overcorrection, undercorrection, and unsightly facial shape, amongst others. Each of these complications may be avoided by careful assessment before and after treatment. Local edema may make it difficult to accurately assess the degree of correction once the first few injections are carried out. Thus, it is important to note pre-existing asymmetry and to pay close attention to the amount of product injected into each area. A follow-up visit and touch-up injection may be necessary where undercorrection is noted. Overcorrection may lead to unattractive facial contours. This can often be improved by gentle manual moulding and/or massaging of the treated area. Care must be exercised so as to avoid creation of a concavity with massage. Where there is a very focal area of overcorrection in a delicate area such as the tear trough, it may be treated with gentle manipulation using a cotton-tipped applicator. A gentle rolling movement of the cotton tip often suffices. When overcorrection doesn’t respond to gentle manipulation, use of hyaluronidase is a suitable treatment alternative (12). This technique is more completely described below in the discussion of ischemia and necrosis with HA fillers.
Inflammatory Reactions Inflammatory reactions are uncommon and range from transient erythematous papules lasting a few days to prolonged granulomatous reactions lasting from months to years. Allergic and hypersensitivity reactions are rare. Findings may include focal erythema, edema, pruritus, induration and rarely dyspnea, and generalized angioedema. Some collagen-containing fillers such as Zyderm® and Zyplast® require skin prick testing prior to treatment to detect allergy. Treatment of hypersensitivity reactions includes oral antihistamines and systemic steroids. True granulomatous reactions are uncommon, especially with shorter lasting temporary fillers such as HAs. However, with the proliferation of longer lasting fillers, such reactions are more commonly seen. Granulomatous reactions typically occur months to years after injection, and are characterized by tenderness, swelling, and possibly suppuration (16). Granulomas with permanent agents may be more resistant to treatment. The concept of biofilms as a cause of chronic granulomas has gained increasing attention in recent years (17). A biofilm can be defined as a structured community of bacterial cells enclosed in a self-produced polymeric matrix and adherent to an inert or living surface (18). The biofilm protects organisms from the host’s immune response, promoting antibiotic resistance, and prolonged survival. Given the role of bacteria in the development of biofilms and possibly in granulomatous reactions, prevention is of utmost importance. Use of a simple alcohol swab may not be sufficient to prevent biofilms. As more information becomes available, we may find that a more stringent antiseptic preparation is in order, especially when using permanent or long-lasting fillers. Once a granuloma forms, management consists of oral antibiotics such as minocycline or clarithromycin, often for weeks or longer
Nodules Nodules may occur with any injectable filler product. Unlike true granulomas, which represent an inflammatory response to the foreign substance, nodules typically represent focal product accumulation or focal excessive fibrosis as a result of stimulation by the product. Focal product accumulation may sometimes be related to too much product injection into a focal area, injection into areas of dynamic muscle movement, inadequate volume when reconstituting the filler (such as with PLLA), and failure to massage after treatment. Massage is especially important with PLLA (13) and Evolence. Where nodules represent focal product “clumping,” they may sometimes be dispersed with sterile saline in the case of PLLA and manually massaged or extracted with a needle or #11 blade in the case of HA fillers. Sometimes, intralesional steroids may be effective, and in rare cases, surgical excision may be necessary, especially in the case of permanent products (Fig. 13.2). Tyndall Effect The Tyndall effect refers to a bluish discoloration that occurs when fillers are injected too superficially. This complication may be avoided by not injecting into the epidermis or superficial dermis. When this effect is seen with HA fillers, resolution may be achieved by using either a #11 blade (14) or a needle (25 or 27 gauge) to manually drain the product, or by injection of hyaluronidase into the affected area. Hirsch and colleagues also described cases where the Q-switched 1064 nm ND-YAG laser was effective in treating HA-induced Tyndall effect (15). For non-HA products, treatment is difficult and there is no simple solution, other than to wait for spontaneous resolution with temporary fillers or, in the case of a long-lasting product, excise the problem area. Infection Infection is only rarely seen with injectable fillers. Early infections are often secondary to Staphylococcus aureus and sometimes Streptococcus species. Treatment of these organisms is discussed in the section on laser complications. Delayed onset infections may be due to less
Figure 13.2 Polymethylmethacrylate (Artecoll) nodules are visible 3 years after superficial injection.
102
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
depending on the response to therapy (19). Incision and drainage with culture should be considered for fluctuant lesions. For late onset inflammatory lesions, biopsy, and culture should be done. Corticosteroids (typically intralesional, but possibly systemic depending on the severity of the case) may be considered but are best used in conjunction with antibiotics to prevent biofilm activation. Surgical excision may be considered if other measures are ineffective, especially with permanent fillers. Product Migration Product migration refers to filler movement beyond the site of original placement. This may occur as a result of poor injection technique or placement along a plane where muscle movement allows the product to shift (e.g., perioral and infraorbital areas). Use of the serial microdroplet technique with silicone will minimize the risk of migration. Temporary products such as HA fillers may be manually repositioned in some cases or drained manually as described above. Correction of migration with permanent implants such as silicone may require disfiguring surgical resection with complicated reconstructions (20). Vascular Compromise One of the most worrisome, but luckily very rare, complications associated with fillers is vascular compromise, leading to ischemia and necrosis or blindness. With its limited vascular supply, the glabella is the most commonly reported site of necrosis but this complication may occur in other regions such as the nasolabial fold, nose, lips, and along the
(A)
labio-mental line (Fig. 13.3 A–E). Possible etiologic factors include intravascular injection, external vascular compression, and vasospasm. Blindness is thought to occur secondarily to intravascular injection into the supratrochlear artery which connects to the ophthalmic artery (21). Clinically, ischemia manifests as a sometimes painful, violaceousblue–gray discoloration with slow refill, typically in the distribution of the affected vessel. A reticulate pattern may also be seen. This must be distinguished from ecchymosis, which appears as non-blanchable discoloration. Persistent ischemic changes may be followed by erosion and ulceration. Although ischemia may manifest shortly after injection, a delayed onset of one to two days may sometimes occur. The risk of vascular compromise may be reduced by drawing back the plunger prior to injecting so as to insure that the needle is not intravascular. Because of the viscosity of many filler products, this is not always helpful. Injecting slowly, carefully avoiding known vessels and not overfilling will help to minimize the risk of necrosis. Many physicians prefer to use a HA with smaller particle size in the glabellar region to minimize the risk of ischemia. Examples include Restylane® and Juvéderm Ultra®. The author finds it helpful to pull the skin up and away from the underlying structures when injecting the glabellar and marionette regions. By doing so, one creates a potential space where product may be slowly injected, away from underlying vessels. Prompt diagnosis and treatment of ischemia is mandatory so as to maximize the chances of reperfusion and reduce the risks of permanent sequelae such as scarring or deformity. Management algorithms have been detailed elsewhere (22–24) and consist of application of
(B)
(D)
(C)
(E)
Figure 13.3 Ischemia after hyaluronic acid filler injections into lips. (A) Pre-treatment. (B) Immediately after lip injection, a reticulate violaceous-gray discoloration is noted over the left upper lip region, associated with pain. Treatment with topical nitroglycerin paste, warm compresses, hyaluronidase injections, and massage was instituted immediately. (C) At 9 hours, the ischemic pattern appears slightly worse. (D) At 4 days, the skin color has significantly improved. (E) At 6 weeks, the ischemic changes have completely resolved without any visible sequelae.
COMPLICATIONS A TO Z nitroglycerin paste, warm compresses (to promote vasodilation), gentle local massage to dissipate the filler and, for HA fillers, injection of hyaluronidase. The latter, which is available both commercially and as a compounded product, is used to dissolve HA. Hypersensitivity reactions to hyaluronidase have been rarely reported, prompting some physicians to do skin prick testing prior to use so as to prevent this serious adverse effect. Should ulceration develop, local wound care is critical so as to minimize scarring. Finally, once healing is complete, one may consider various modalities for residual scarring, including, but not limited to, ablative and non-ablative laser resurfacing, pulseddye laser, and dermabrasion. Neovascularization Neovascularization refers to the development of telangiectasia at the site of filler injections. Amongst other sites, potential areas of involvement include the superior nasolabial fold. This rare event may be treated with intense pulsed light, pulsed dye laser and 532 or 1064 nm lasers (25). LASER COMPLICATIONS
The array of lasers and light sources available has rapidly multiplied over the last 15 to 20 years. Today we have numerous technologies to treat a plethora of concerns including vascular lesions, scars, tattoos, pigmented lesions, rhytides, skin laxity, and more. A discussion of laser complications is a topic, which could easily fill a chapter of its own, but, because of space constraints, I shall limit my discussion to an overview of laser and light complications using examples of how these complications may occur, rather than describing complications associated with specific laser and light devices. In many cases, an understanding of laser principles and mechanism of action can help to predict potential complications. Lasers generally work by delivering very high energy within a very short period of time to the targeted tissue while sparing surrounding structures. Anderson and Parrish’s theory of selective photothermolysis (26) has prompted the development of laser systems that target a specific chromophore, such as melanin, while sparing surrounding tissue. Lasers that adhere to this principal are generally safe and effective because of their ability to minimize the amount of thermal damage to adjacent tissue. Nonetheless, complications may occur despite attempts to improve laser and light safety. As with all cosmetic procedures, it is imperative that the physician acquire a thorough understanding of laser physics, laser-tissue interactions, and laser safety issues prior to practicing laser surgery. Because each laser system has unique features and parameters, hands-on training is highly valuable. Laser and light complications often arise due to a combination of device issues and operator inexperience or error. Careful management of complications can often prevent permanent adverse effects. Safe operation of laser and light devices is the cornerstone of patient and operator safety. Protective equipment such as goggles specific to the laser device must be worn by the laser operator. Eye shields are mandatory for the patient to reduce the risk of ocular damage and blindness. Because laser plume is known to transmit infectious particles such as the human papilloma virus, appropriate masks, and a smoke evacuator should be used where appropriate. If tissue splatter is a concern, gloves and protective gowns should be worn. Reflective surfaces such as mirrors should be eliminated or covered during laser procedures. Windows should be covered so as to prevent laser light from inadvertently injuring someone outside the room. Appropriate signage outside the laser room must warn individuals to refrain from entering the room. Edema and erythema are common with most laser and light systems. The duration and intensity varies with the device used, being
103
longest for ablative resurfacing lasers (up to 12 months), less for nonablative fractional lasers and even less for most hair removal devices. In a study of 20 patients, Alster and Wanitphakdeedecha reported that post-fractional laser erythema may be reduced with light-emitting diode photomodulation immediately after fractional laser skin resurfacing (27). Blistering and crusting may occur with most laser and light systems but may be prevented in many cases with appropriate choice of settings, epidermal cooling and post-operative care. Pigmentary changes secondary to laser and light treatment include both hyper- and hypopigmentation (Fig. 13.4). Although typically temporary, these complications may occasionally be permanent. Hyperpigmentation tends to occur more commonly in individuals with Fitzpatrick skin types III–VI. Prophylactic use of skin lightening agents such as those containing hydroquinone or tretinoin should be considered 1 to 2 weeks preoperatively in these individuals. Avoiding a tan before and after treatment will reduce the risk of hyperpigmentation. Additionally, fluence settings should generally be adjusted downward in darker-skinned individuals. Use of cryogen spray may help to prevent hyperpigmentation but, used aggressively, may also cause hyperpigmentation. If significant inflammation is noted after laser or light treatment, immediate use of a potent topical corticosteroid may help to reduce the likelihood of hyperpigmentation. Broad spectrum sunscreens and reduced sun exposure will also help to minimize post-inflammatory hyperpigmentation. Topical bleaching agents are the mainstay of therapy for hyperpigmentation. Hypopigmentation may be true hypopigmentation, which is generally due to over-aggressive therapy with ablative resurfacing lasers, devices that target pigment (e.g., Nd: YAG, Q-switched ruby, and alexandrite lasers) and intense pulsed light devices. Alternatively, one may see relative or pseudohypopigmentation when the treated skin reverts to its whiter, pre-photodamaged state compared to the surrounding untreated skin which retains its blotchy hyperpigmentation. Individuals with a tan or darker skin color are more susceptible to this preventable complication. Certain anatomic locations with less adipose tissue such as the shins and chest tend to be more prone to hypopigmentation, possibly related to the fact that the skin is thinner with less surrounding tissue available to dissipate the thermal energy. Adjustment of settings to minimize this risk is critical.
Figure 13.4 IPL-induced hyper- and hypopigmentation 6 months after a single back treatment.
104
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
In the days when ablative CO2 laser resurfacing was common, delayed and often permanent hypopigmentation occurred not infrequently, eventually leading to a fall from favor for this technology. This prompted development of some of today’s lasers, which minimize this risk by utilizing longer pulse durations to spread the energy delivery over a longer time (e.g., long-pulsed Nd:YAG lasers), thus reducing melanocyte damage. Alternatively, fractional technology may be employed to spare tissue (e.g., fractional CO2 lasers), thus providing a repository of intact melanocytes that may be used to populate adjacent areas of damaged melanocytes. Hypopigmentation is difficult to treat. Luckily, in many cases it spontaneously resolves within a few months. If it persists, one may consider “feathering” the pigmentation with the surrounding skin, thus minimizing the contrast between treated and untreated skin. This can be done by gently treating the adjacent skin that is not hypopigmented. Purpura or bruising is an expected effect of some devices such as pulsed dye lasers when they are used aggressively to treat vascular lesions such as port wine stains. A discussion prior to treatment will allow the patient to select an appropriate time for treatment. Purpura duration varies from a few days to approximately two weeks. Newer lasers with longer pulse durations allow the operator to minimize the risk of purpura by spreading out the energy over a longer period of time. Although it occurs less commonly, other devices such as those utilizing intense pulsed light may also cause bruising, especially in individuals with prominent erythema, flushing or vasculature in the area of treatment. Paradoxical hypertrichosis has been reported in individuals undergoing laser hair removal. Although the mechanism is not fully understood, it may be may be that suboptimal fluences stimulate dormant hair follicles (28). While respecting skin type, use of optimal fluence settings may help to prevent and treat this problem. Infection may occur with any treatment that affects skin barrier integrity, but is more common with ablative laser resurfacing because of the significant interruption of the skin barrier, providing a portal of entry for organisms. Signs of infection include delayed healing, focal erythema, honey-colored crusting, pustules, and pain. Although many would agree that prophylactic antibiotics are not necessary for non-ablative laser procedures, debate continues for
ablative resurfacing procedures. Some physicians do not recommend prophylactic use of antibiotics with ablative resurfacing citing the fact that the wounds created are typically classified as class I clean wounds. Others argue that the benefits of prophylaxis outweigh the risk of prophylaxis and thus they err on the side of prophylactic antibiotics. Factors such as underlying disorders that predispose to infection (e.g., diabetes, immunosuppression) may influence the decision-making process in favor of prophylaxis. The choice of prophylactic antibiotics for ablative laser resurfacing is based on the most likely causative organism, which is typically S. aureus and sometimes Streptococcus or Pseudomonas species. Thus, a good choice might include a first-generation cephalosporin, a penicillin such as cloxacillin or a fluoroquinolone such as ciprofloxacin. The goal of prophylaxis is to achieve adequate antibiotic levels at the wound site at the time of the laser procedure until the skin re-epithelializes. A typical regimen might start on the day prior to the procedure and continue until the skin has re-epithelialized, 5 to 10 days post-operatively. Use of prophylactic antivirals is recommended for ablative laser resurfacing as severe, significant scarring may result should infection with H. simplex develop. There is some degree of variability in timing, but dosing should generally begin 1 day pre-operatively and continue for 5 to 10 days post-operatively until re-epithelialization is complete. If infection is clinically apparent despite use of prophylactic antibiotics and antivirals, cultures must be done to identify the causative organism. Empiric oral antifungal as well as gram-positive and gram-negative coverage should be instituted pending culture results. Fungal infections of the skin may occur after ablative resurfacing procedures. They are generally easily treated with oral antifungal agents such as fluconazole. Perhaps the most severe complication after a laser procedure is scarring and textural change (Figs. 13.5 and 13.6). Scarring may occur with any laser device and is often the result of patient, physician, and device factors. It is more likely with over-aggressive treatment and post-operative infection, although other factors may also play a role. Prevention is the treatment of choice. Amongst other things, a careful history should ascertain delayed or abnormal healing (e.g., keloids), previous surgery in the areas to be treated that may interfere with laser treatment (e.g., face lift, blepharoplasty), conditions that
Figure 13.5 Four days after laser hair removal, an erosion is noted over the right upper lip of this 28 year old woman with skin phototype 5. Superficial eschars are noted over the remainder of the upper lip. The patient described a burning and stinging sensation during treatment that was worse than with her previous treatment. This was followed by blister formation, redness, and pain.
Figure 13.6 A prominent keloid over the right upper lip is noted 9 months after laser treatment for hair removal. The patient described an initial “burn” with blister formation followed by crust. The elevated scar first became evident 2 to 3 months after laser treatment. The type of laser used was unknown to the patient.
COMPLICATIONS A TO Z may affect healing (e.g., diabetes, H. simplex virus), and medications that may delay or alter healing (e.g., isotretinoin, immunosuppressive agents). Careful attention to the tissue response is critical during treatment. In general, it is preferable to undertreat and later perform a “touchup” procedure than to overtreat and cause scarring. Treatment parameters that increase the risk of scarring include too much stacking of pulses, excessive fluence, and too many passes. The presence of white or grayish discoloration of the skin during laser treatment may signify excessive thermal tissue damage and should prompt the physician to reassess treatment parameters or discontinue treatment altogether. Management of scarring includes early recognition and intervention with ultrapotent topical steroids and pulsed dye laser therapy. The latter may help with erythema and scar texture. Hypertrophic or keloidal scarring often benefits from intralesional steroid therapy. CONCLUSION
Cosmetic enhancement procedures such as botulinum toxin, injectable fillers, and lasers have matured immensely over the years and have the potential to greatly improve the quality of life of our patients. Optimal results are obtained when, amongst other things, the physician has a thorough understanding of potential complications. Careful attention to preventive measures, prompt recognition of complications, and rapid institution of treatment will minimize the risk of prolonged or permanent sequelae while maximizing desirable patient outcomes. REFERENCES
1. Flynn TC, Carruthers A, Carruthers J. Surgical pearl: the use of the ultra-fine II short needle 0.3 cc insulin syringe for botulinum toxin injections. J Am Acad Dermatol 2002; 46: 931–3. 2. Alam M, Arndt KA, Dover JS. Severe, intractable headache after injection with botulinum A exotoxin: report of 5 cases. J Am Acad Dermatol 2002; 46: 62–5. 3. Alam M, Dover JS, Klein AW, Arndt KA. Botulinum A exotoxin for hyperfunctional facial lines: where not to inject. Arch Dermatol 2002; 138: 1180–5. 4. Spiegel JH. Treatment of periorbital rhytids with botulinum toxin type A: maximizing safety and results. Arch Facial Plast Surg 2005; 7: 198–202. 5. Klein AW. Contraindications and complications with the use of botulinum toxin. Clin Dermatol 2004; 22: 66–75. 6. Levy PM. The ‘Nefertiti lift’: a new technique for specific re-contouring of the jalwine. J Cosmet Laser Ther 2007; 9: 249–52. 7. Carruthers J, Carruthers A. Botulinum toxin A in the mid and lower face and neck. Dermatol Clin 2004; 22: 151–8. 8. U.S. Food and Drug Administration website. Accessed July 26, 2009. [Available from http://www.fda.gov/Drugs/Drug Safety/PostmarketDrugSafetyInformationforPatientsand Providers/DrugSafetyInformationforHeathcareProfessionals/ ucm143819.htm] 9. Bashour M. History and current concepts in the analysis of facial attractiveness. Plast Reconstr Surg 2006; 118: 741–56.
105
10. Cohen JL. Understanding, avoiding and managing dermal fillers complications. Dermatol Surg 2008; 34: S92–S99. 11. Glogau RG, Kane MA. Effect of injection techniques on the rate of local adverse events in patients implanted with nonanimal hyaluronic acid get dermal fillers. Dermatol Surg, 2008; 34: S105–S109. 12. Andre P, Levy PM. Hyaluronidase offers an efficacious treatment for inaesthetic hyaluronic acid overcorrection. J Cosmet Dermatol 2007; 6: 159–62. 13. Fitzgerald R, Vleggaar D, Burgess C. Facial dermal fillers. Aesth Surg J 2008. 28(6): 699–701. 14. Douse-Dean T, Jacob CI. Fast and easy treatment for reduction of the tyndall effect secondary to cosmetic use of hyaluronic acid. J Drugs Dermatol 2009; 7(3): 281–3. 15. Hirsch RJ, Narurkar V, Carruthers J. Management of injected hyaluronic acid induced Tyndall effects. Lasers Surg Med 2006; 38:202–4. 16. Monheit GD, Rohrich RJ. The nature of long-term fillers and the risk of complications. Dermatol Surg 2009; 35: 1598–604. 17. Christensen L, Breiting V, Janssen M, et al. Adverse reactions to injectable soft tissue permanent fillers. Aesth Plast Surg 2005; 29: 34–48. 18. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284: 1318–22. 19. Narins RS, Coleman WP, Glogau RG. Recommendations and treatment options for nodules and other filler complications. Dermatol Surg 2009; 35: 1667–71. 20. Hirsch R, Stier M. Complications and their management in cosmetic dermatology. Dermatol Clin 2009; 27: 507–20. 21. Lemperle G, Rullan PP, Gauthier-Hazan N. Avoiding and treating dermal filler complications. Plast Reconstr Surg 2006; 118: 92S–107S. 22. Hirsch RJ, Cohen JL, Carruthers JD. Successful management of an unusual presentation of impending necrosis following a hyaluronic acid injection embolus and a proposed algorithm for management with hyaluronidase. Dermatol Surg 2007; 33: 357–60 23. Hirsch RJ, Lupo M, Cohen JL, Duffy D. Delayed presentation of impending necrosis following soft tissue augmentation with hyaluronic acid and successful management with hyaluronidase. J Drugs Dermatol 2007; 6: 325–8. 24. Glaich AS, Cohen JL, Goldberg LH. Injection necrosis of the glabella: protocol for prevention and treatment after use of dermal fillers. Dermatol Surg 2006; 32: 276–81. 25. Sclafani AP, Fagien S. Treatment of injectable soft tissue filler complications. Dermatol Surg 2009; 35: 1672–80. 26. Anderson, RR, Parrish, JA. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science 1983; 220: 524–7. 27. Alster TS, Wanitphakdeedecha R. Improvement of postfractional laser erythema with light-emitting diode photomodulation. Dermatol Surg 2009; 35(5): 813–5. 28. Moreno-Arias GA, Castelo-Cranco C, Ferrrando J. Side-effects after IPL photodepilation. Dermatol Surg 2002; 28: 1131–4.
14
Botulinum toxins type A: Advanced techniques Andreas Boker and Fredric S. Brandt
Since its discovery in 1895, botulinum toxin (BTX) has evolved from a poison to a versatile clinical tool with an expanding list of uses. The broad applicability of BTX results from its unique properties such as its transient duration and reversible effect, easy mode of application, and the fact that its effects can be localized to the target areas and their degree controlled with varying doses. Following its approval for cosmetic use by the Food and Drug Administration (FDA) in 2002, the use of BTX type A has revolutionized the facial rejuvenation market and has become the most popular cosmetic procedure performed in the United States every year since. In 2007 alone, the American Society for Aesthetic Plastic Surgery reported that out of the 11.7 million cosmetic surgical and nonsurgical procedures performed in the United States that year, 2.8 million (24%) procedures were BTX injections, making it the no. 1 non-surgical intervention by a large margin (1). With an ever-increasing demand for the procedure and the number of treated patients steadily growing, so is the experience and knowledge of the physicians that perform this procedure. PHARMACOLOGY
The cellular action of BTX eventually results in flaccid paralysis of the muscle by inhibiting the release of acetylcholine from nerve terminals. This process involves four steps (2): binding to receptor sites, internalization of the receptor complex, membrane translocation, and protease activity. The target of BTX type A (BTX-A) is the synaptosomeassociated protein of 25 kD molecular mass, commonly abbreviated SNAP-25 (3), while BTX types B and E cleave the vesicle-associated membrane protein (VAMP or synaptobrevin) (Fig. 14.1) (4). The action of BTXs on cholinergic synapses is reversed via the formation of an extensive network of accessory terminal sprouts from the damaged presynaptic axon. Moreover, vesicle turnover and restoration of cholinergic function is probably also mediated by synthesis of new, intact SNAP-25 (5). After approximately 90 days or more, a length of time that correlates well with that of the clinically observed duration of effect, recovery is essentially complete. Single-fiber EMG studies indicate abnormal neuromuscular transmission in muscles distant from the site of injection, despite the absence of clinical weakness, undermining the potential for spread of the toxin, particularly at higher doses (6).
factor ranging from three to six (7). This may be due to different concentrations of both botulinum neurotoxin and albumin. The higher albumin content of BOTOX® appears to prevent non-specific binding of neurotoxin to glass and plastic surfaces much more effectively than DYSPORT® whose protein content is much lower. Unless otherwise specified, material discussed in this review pertains to the use of BTX A under the trade name BOTOX® (Allergan, Inc., Irvine, California, USA) which the authors have most clinical experience with. DOSING, TOXICITY, AND IMMUNOLOGY
The toxicity of BTX-A is expressed in biologic mouse units, in which one unit (U) equals the median lethal dose (LD50) of a group of Swiss Webster mice that weigh 18 to 22 g each (8,9). The estimated lethal dose for a 70 kg person has been calculated to be approximately 40 U/kg (about 2500–3000 U), making poisoning by accidental overdosing with doses used for cosmetic procedures (typically less than 100 U per treatment session) highly unlikely. The concentration of BTX-A can be varied according to the physicians’ needs but in general the preferred dilution is 1 to 3 ml of normal saline without preservatives placed into a vial of 100 U of crystalline toxin. My personal preference is diluting with 2 ml of saline, which yields a solution containing 50 U/ml or 5 U of BTX-A per 0.1 ml. The clinical effect of BTX-A is dose related, which allows treatment to be modified according to the needs of the individual patient. The onset of muscle weakness occurs anywhere from 48 to 72 hours after injection of BTX-A and it can take up to 4 weeks for its maximum effect to develop. The development of immunoresistance seems to occur more often in patients treated with large doses and in which shorter intervals elapse between injections (10). It is important to avoid eliciting an immune response strong enough to induce the development of neutralizing immunoglobulin G (IgG) anti-BTX A antibodies to ensure future benefit from therapy. If they occur, the patient becomes unresponsive to future treatments with BTX-A. However, only a low number of patients actually develop this kind of antibodies and furthermore, the presence of antibody does not consistently correlate with absence of clinical effect. CONTRAINDICATIONS AND PRECAUTIONS
AVAILABLE PREPARATIONS OF BTX-A
There are two commercially available BTX-A toxins in the United States: BTX-A (BOTOX Cosmetic®, Allergan, Inc., Irvine, California, USA) which was developed in the United States and gained FDA approval for treatment of glabellar lines in 2002, and abobotulinumtoxin A (DYSPORT®, Medicis Aesthetics Inc., Scottsdale, Arizona, USA) which was approved by the FDA for cervical dystonia and moderate to severe glabellar lines in 2009. The latter, which was developed in the United Kingdom, has been used clinically in Europe and other parts for the world since 1990. One vial of DYSPORT® contains 300 U of toxin, 125 μg of albumin, and 2.5 mg of lactose, whereas one vial of BOTOX® contains 100 U of toxin, 500 μg of albumin, and 0.9 mg NaCl. Although the products differ in their composition with respect to contained units of neurotoxin they should be equal in potency. However, in the clinical setting, BOTOX® is alleged to vary from the potency of DYSPORT® by a
106
A detailed medical history should be obtained in every patient prior to treatment, including concomitant medication use and allergies. Individuals with pre-existing neuromuscular disease should be advised to be cautious when receiving BTX-A treatment for cosmetic purposes and remain a relative contraindication since there are reports of exacerbation of underlying conditions following treatment with BTX (11,12). Aminoglycoside antibiotics and calcium channel blockers interfere with neuromuscular transmission and may potentiate the effect of BTX-A, thus making their use a contraindication for BTX therapy. Similarly, BTX should not be administered to patients with known allergic reactions to any of its molecular component or to human albumin. Other relative contraindications for the use of BTX-A include patients that are psychologically unstable or who have unrealistic expectations from treatment. Special care should be taken when treating people who are dependent on facial animation and expression for their livelihood (e.g., actors, musicians, and politicians).
BOTULINUM TOXINS TYPE A: ADVANCED TECHNIQUES
107
Light chain cleaves Specific SNARE proteins Botulinum toxin endocytosed
Types B, D, F, G Types A, C, E
Light chain
SNARE complex does not form
Types C Heavy chain
Botulinum toxin
Membranes do not fuse
Neurotransmitter not released
Muscle cell Muscle fiber paralyzed Figure 14.1 Pharmacological action of botulinum toxin (BTX).
Although the safety of BTX-A on pregnancy has not been established, it remains classified as a category C drug by the U.S. FDA and its teratogenic effect needs to be studied further. CLINICAL USE OF BOTULINUM TOXIN A
The Upper Face The Fronto-glabellar Complex Even though the forehead “worry lines” and glabellar “frown lines” are frequently treated independently, these two regions must be approached as a distinct anatomical unit when attempting rejuvenation of the upper face using BTX. The justification for this lays in the intricate anatomical and inter-dependent functional relationship between these two regions of the face. Furthermore, the 3 cm radial spread of the toxin makes the involvement of adjacent structures of both areas practically inevitable and therefore obligates them to be considered conjunctly. Treating forehead wrinkles with BTX should be performed with due caution, and special attention needs to be directed at the degree of muscle paralysis achieved in the different regions. Excessive muscle weakness of the forehead musculature will leave the action of the brow depressors unopposed and lead to ptosis of the brow resulting in a “tired” look. This untoward outcome may even interfere with upward gaze. Moreover, there should be concern for the patient whose hyper functioning frontalis muscle actually supports a ptotic upper eyelid since relaxation of the forehead will result in eyelid ptosis (13). For that reason, it is exceedingly important to leave a proper degree of muscle function to avoid such complications. Accordingly, the important role of the glabellar or frown region in the facial expression of a variety of human emotions makes it another area where caution must be exercised when using botulinum toxin for facial rejuvenation purposes. Paralyzing the underlying musculature will hinder the overuse of these muscles during facial expression and even during everyday activities such as concentrating, reading or walking outside during bright daylight. Hence, the furrows will cease to be formed and the wrinkles disappear. Anatomy and Physiology Forehead. The main muscle of the forehead, the frontalis, originates in the tendinous galae aponeurotica near the coronal suture of the scull and inserts on the superciliary ridge of the frontal bone as well as onto
fibers of the procerus, corrugator and orbicularis oculi muscles (14) (Fig. 14.2). Typically, the frontalis muscle may have only one central tendinous sheath with little muscle fibers within the midline of the forehead. Therefore, less amount of BTX-A is required to induce paralysis in this region of the forehead. The frontalis muscle is responsible for the horizontal wrinkles of the forehead caused by elevation of the brows and forehead skin during various facial expressions (15). Its function is to oppose the effect of the depressor muscles of the glabella and brows. Glabella. Fibers from three muscle groups, the corrugator supercilii, the frontalis, and the procerus contribute to the motion in this area of the face. In addition fibers from the medial orbital portion of the orbicularis oculli contribute to the muscular bundle of the glabellar region. The corrugator muscle, which is the main target of BTX treatment lies deep in both the frontalis and procerus muscles and has its origin on the nasal process of the frontal bone just above the superomedial orbital rim. It extends laterally and upward and passes through the galeal fat pad to insert into the dermis superior to the middle third of the eyebrow (Fig. 14.2). Its function is brow adduction, moving the eyebrow and skin downward and medially giving rise to the glabellar crease (13,16). The direction of these creases and wrinkles appear usually perpendicular to the direction of the muscle fibers creating them. One beneficial effect of paralyzing the corrugator muscular group with BTX-A is the resulting unopposed action of the frontalis muscle, which will produce an upward pull of the eyebrows leading to an “opened-eyed” look (17). However, due to the complex intertwining of these muscle group fibers, targeting the corrugator muscle alone will somewhat affect the activity of both the frontalis and procerus muscles. Moreover, knowing that the medial fibers of the frontalis muscle aid in the lifting of the brows it is important to take caution not to paralyze these too when aiming at the corrugator muscle since this would conversely result in a brow droop and cancel out the desired result of the injection. Injection Technique The most important area of treatment on the forehead is the glabellar complex, for this not only alleviates frown lines but also elevates the brow. It is important to treat this area completely. The amount of BTX necessary to paralyze this complex varies depending upon the muscular
108
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
Frontalis
Corrugator supracilli
Procerus
Orbicularis oculi
Figure 14.2 Anatomy of the upper face.
(B)
(A)
Figure 14.3 Injection sites for glabellar frown lines: (A) arched female brow, (B) horizontal male brow.
mass of the individual, but generally speaking, 20 to 40 U are necessary. The variation in muscular mass is evident in the different approach when treating the female versus the male brow. The female brow is usually more arched compared to the more horizontal or flattering appearance in males (Fig. 14.3). Also, 5 to 10 U are injected in a single shot into the procerus muscle (Fig. 14.4). Each corrugator is then treated with 4 to 6 U placed at the inferior and superior belly of the muscle (Fig. 14.5) and lastly, 2 to 3 U are injected into the medial fibers of the orbital portion of the orbicularis oculi muscle as these also contribute to the frowning mechanism (Fig. 14.6). By performing this technique one should see complete paralysis of the glabellar complex as well as elevation of the medial brow (Fig. 14.7). With the diffusion properties of the toxin, one should also see partial or complete paralysis of the inferior portion of the frontalis muscle.
Nonetheless, some considerations need to be taken into account; if the patient has a very heavy brow, I would not further treat the forehead at the first treatment visit. The patient can return in two weeks time and be re-evaluated. At this point, if the frontalis muscle is minimally frozen, 2 to 3 U of toxin can be added at the upper portion of the muscle at 1.5 cm intervals for an additional total dose of 8 to 12 U (Fig. 14.8). In the case of the patient whose brow is not ptotic the entire frontoglabellar complex can be treated in one visit. In this case after treatment of the glabellar complex, 2 to 3 U can be added at 1.5 cm intervals on the mid-frontalis. Complications As mentioned earlier, the major cosmetic complication resulting from complete paralysis of the frontalis muscle is loss of expression of the
BOTULINUM TOXINS TYPE A: ADVANCED TECHNIQUES
109
Figure 14.6 Injection sites into orbital portion of orbicularis oculi muscle. Figure 14.4 Injection sites into the procerus muscle.
The wrinkles usually radiate outward and laterally from the lateral ocular canthus and are perpendicular to the direction of the fibers of the orbicularis oculi muscle. Weakening the muscles responsible for these dynamic lines will impede their further contraction during common activities like squinting of the eyes and as a result smooth out the overlaying skin. Flynn et al. demonstrated that subdermal injection of 2 U of BOTOX® into the lower eyelid together with treatment of the lateral ocular canthus resulted in a significant improvement of lower eyelid wrinkles and further prompted the opening of the palpebral aperture (23). It is important to remember that a snap test should always be performed before injecting the lower eyelids with BTX to test for the retraction of the skin, as patients with a delayed retraction of the lower eyelid may experience ectropion of the injected eye when the periocular muscles are rendered inactive by the toxin. Figure 14.5 Injection sites into the corrugator muscle.
upper face, marked by the inability to lift the brows and sometimes even the dropping of the eyelids. This should be avoided at all costs since patients will complain of a “mask-like” appearance and may even have trouble with upward vision. To circumvent this problem, it has been proposed to either inject the toxin subcutaneously instead of into the muscle itself or to inject multiple small doses of toxin at 1 to 2.0 cm intervals across the forehead (18). In the frown region, the main concern when injecting BTX-A into the corrugator muscle is upper eyelid ptosis and diplopia caused by diffusion of the toxin through the orbital septum to the levator palpebrae superioris and extraocular muscles from the injection site (19,20). This can be avoided to some extent by always staying superior to the medial orbital rim when injecting BTX-A around the eye (21). Other complications unrelated to the action of the toxin include headache and pain and/or bruising at the injection site. These are usually mild and last no longer than 24 hours post-injection (22). The Lateral Ocular Canthi Much of the wrinkling in the area around the eyes is the result of facial chronologic aging and superimposed extrinsic photodamage. But a significant component can also be attributed to the hyperactivity of the musculature underlying the skin around the eyes, making this the target for therapy with BTX.
Anatomy and Physiology The principal muscle in the area around the eye is the orbicularis oculi muscle. With its two components, the orbital and the palpebral, it encircles the periorbital region and inserts onto the medial and lateral canthal tendons as well as onto fibers of the frontalis, procerus, and corrugator supercilii muscles (Fig. 14.2) (13). Its combined functions are the forceful closure of the eyes and the depression of the brow and eyelids. Injection Technique Injection of BTX into this region should be directed at the lateral fibers of the orbital portion of the orbicularis oculi, which can be easily accessed by placing the injection 1 cm lateral to the orbital rim (19,21). Three to five units are injected at three points in a vertical line (Figs. 14.9 and 14.10). These injections can be made intramuscularly or intradermally if bruising is a concern. If the patient has a good snap test, 2 to 4 U can be placed 3 mm below the mid-papillary line for the correction infraorbital wrinkles (Fig. 14.11). Complications Complete paralysis of the orbicularis oculi not only is impossible but due to its important role in closing the eye, even unwanted. Inducing excessive weakness by either injecting too much toxin into the orbicularis oculi muscle or by it diffusing to neighboring muscles such as the frontalis muscle could result in improper eye closure or may cause the lateral brow to droop, respectively (13). Although very rare, paralysis of the lateral rectus muscle may cause diplopia (18,24) and accidentally
110
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
(A)
(B) Figure 14.7 Before and after photographs of fronto-glabellar complex (female).
Figure 14.8 Injection sites into the frontalis muscle.
weakening the levator labii superioris muscles when injection is aimed at the lower periorbital wrinkles can cause the upper lip to droop and as a consequence prevent a normal smile (25). Other reported adverse reactions include worsening of preexisting fat herniations of the lower eyelid (26) and skin redundancy beneath it. It is important to recognize patients with excessive lower eyelid skin or lower fat pads prior to treatment, since these will benefit the least from treatment with BTX alone and may need adjunctive cosmetic procedures like blepharoplasty, or laser resurfacing for optimal results. Similarly, patients who have swollen or puffy lower eyelids due to fluid accumulation prior to treatment may see their condition worsened if injected with BTX since the toxin’s paralytic effect may interfere with regional lymphatic drainage and accentuate fluid retention even more. Midface Nasolabial Fold Due to its multifactorial etiology and complex anatomical composition, the nasolabial fold poses a challenge for both the patient and the physician when attempting rejuvenation of the midface. The crucial physiologic and aesthetic activity of the various muscles that contribute to it makes the correction of the nasolabial furrow with BTX-A a difficult task. Inducing excessive paralysis in certain muscular components can easily lead to unwanted cosmetic and functional defects and is therefore critical to avoid. In general it is understood that BTX achieves limited improvement in this region of the face compared to high degree of complications.
Figure 14.9 Injection point into the lateral fibers of the orbital portion of the orbicularis oculi muscle.
Anatomy and Physiology A prominent nasolabial fold is the result of diverse factors that play a role in the development of the aging face, such as loss of subcutaneous fat, gravitational ptosis and laxity of the skin, and overuse of the muscles of facial expression. It is composed of subcutaneous fat and dense fibrous tissue, muscle fibers from the lip elevators and their fascia, and excess skin hanging over the cutaneous attachment of the zygomaticus major and minor, levator labii superioris and levator labii superioris alaeque nasi muscles (Fig. 14.12) (27). The combined activity of this muscular group is responsible for the wide range of motion associated with the movement of the mouth and lips. Since talking, smiling, and a broad array of facial expressions involve the use of the mouth and other structures of the midface, the nasolabial furrow is a common feature of the aging face, especially in very expressive people. The crease deepens with time as the effects of aging take their toll. This ultimately causes the breakup of the even biconvex contour of the face and an unwanted cosmetic appearance. Injection Technique One to two units of botulinum exotoxin are injected at the upper portion of the nasolabial fold 2 to 3 mm lateral to its intersection with the nose (Fig. 14.13). This will help flatten out the muscular prominence caused by the levator labii superioris alaeque nasi muscle pull.
BOTULINUM TOXINS TYPE A: ADVANCED TECHNIQUES
1 cm
Figure 14.10 Injection sites for crow’s feet: lateral view.
Figure 14.11 Injection point into inferior fibers of orbicularis oculi muscle.
Nonetheless, the cosmetic improvement is usually so subtle that it is not worth incurring in the risks associated with injection into this area. Complications As noted before, causing complete relaxation of the muscles of this area can result in cosmetically unacceptable results. The most commonly observed complication is ptosis of the upper lip, giving the patient a sad appearance (28). In addition, the compound bilateral muscular control of the lips makes it very easy to induce disproportionate kinesis of the lips if one side is paralyzed more than its counterpart. Furthermore, a resulting asymmetric smile or an incompetent mouth is an untoward effect that should be avoided at all cost. Thus, it is generally understood that the primary attempt at correction of the nasolabial fold should consider other means and leave the use of BTX-A as an adjuvant to, for example, soft tissue augmentation. It is known that weakening the fibers of the lip elevators before injecting the nasolabial folds with a filler material will enhance its effect and longevity by reducing supposed muscle atrophy and preventing immediate microextrusion from injection sites by repetitive muscular action (29). The Lower Face Perioral Region In the perioral region, fine vertical lines extending above and below the vermillion border on the upper and lower lips are an evident sign of aging, particularity in women, and are therefore a common reason for patients to seek medical advice for treating them. They result from a combination of long-term use of the underlying musculature and
111
actinic damage to the overlying skin. In addition, certain activities like smoking accentuates their depth and makes them even more apparent. Various treatment options including soft tissue augmentation with filling agents and abrasive resurfacing procedures yield satisfactory results in most of the cases. However, the injection of low doses of botulinum A exotoxin into the underlying muscular layer has also proven to effectively eliminate and smoothen out multiple fine rhytids (30). Anatomy and Physiology The muscular anatomy of the perioral region is complex and includes fibers from various muscle groups (Fig. 14.12). However, the principal muscle responsible for contracting the lips is the orbicularis oris muscle. It consists in part of fibers derived from other facial muscles (i.e., buccinator, caninus, and triangularis muscles) which are inserted into the lips, and partly of fibers proper to the lips. It originates from the alveolar border of the maxilla and the mandible and its fibers run circumferentially around mouth onto its cutaneous insertions. The main functions of this muscular group are opposition and protrusion of the lips. Another important muscle group involved in the kinesis of the mouth is the depressor anguli oris muscle, also called the triangularis. It arises from the oblique line of the mandible and its fibers then converge to be inserted by a narrow fasciculus into the angle of the mouth. At its origin it is continuous with the platysma muscle, and at its insertion with the orbicularis oris muscle. Its action is depression of the angles of the mouth. The mentalis muscle originates from the incisive fossa of the mandible and descends to be inserted into the integument of the chin. It raises and protrudes the lower lip, and at the same time wrinkles the skin of the chin (18). Injection Technique The upper lip is injected with 0.5 to 1 U at four points 2 to 3 mm above the vermillion border (Fig. 14.14). This can then be massaged gently after the injection. The same technique can be applied to the lower lip. The depressor anguli oris muscles are injected at the most inferior portion with 2 to 4 U placed on either side on an imaginary line drawn as a continuation of the nasolabial fold. This is usually done at about 1 cm above the intersection of this line and the angle of the jaw (Fig. 14.15). The injection of 5 to 10 U of BTX into the inferior portion of the midchin (mentalis muscle) will smoothen out the dimpling of the chin (Fig. 14.16) (31,32). Complications Due to the complex structure of the musculature in this area and its critical role in the proper function of the mouth and lips, the perioral region should be approached with care when attempting muscular paralysis with BTX for cosmetic purposes. Difficulties with certain facial expressions and even trouble with speech could ensue if the normal oral physiology is hindered. Cosmetic defects may include an asymmetric smile or the inability to properly close the mouth. As such, the lateral angles of the mouth should be spared entirely to avoid lip droop and all other injection sites should be injected with low doses and more superficially rather than deeply. When treating the chin, if done properly, complications are rare unless the toxin is injected too high into the chin where it could cause paralysis of the levator anguli oris and compromise the ability to elevate the corner of the mouth. The Neck The senescent neck is a common cosmetic concern to many patients as they age, especially in over expressive individuals that use this muscle
112
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT Zygomaticus major and minor Levator labii superioris Orbiculatis oris Depressor anguli oris Mentalis Platysma
Figure 14.12 Anatomy of the lower face and neck.
Figure 14.15 Injection sites into the depressor anguli oris muscle.
Figure 14.13 Injection points into zygomaticus major and minor muscles.
Figure 14.16 Injection sites into the mentalis muscle.
Figure 14.14 Injection sites into the orbicularis oris muscle.
frequently during facial animation. The platysma muscle has a direct influence on the looseness and tonicity of the skin of the neck. Its central bands actually thicken and contract with time, becoming visibly apparent with advancing age. This combined with actinic damage accumulated over the years makes the neck region a particularly apparent sign aging that needs to be addressed. Until recently, the only option available for correcting the resulting cosmetic traits was
BOTULINUM TOXINS TYPE A: ADVANCED TECHNIQUES
(A)
113
(B) Figure 14.17 Before and after photographs of the neck on treatment with BTX-A.
Complications It is generally understood that this is a safe and minimally invasive procedure. Complications are minimal and have included transient edema, ecchymoses, hematoma formation, muscle soreness, and neck discomfort. Some patients also developed headaches and some degree of neck weakness while lifting their head off a pillow (33). Most of these side effects lasted 1 to 2 weeks and resolved completely. More serious complications such as laryngeal muscle weakness, hoarseness, or dysphagia are rare and should be avoided.
REFERENCES
Figure 14.18 Injection sites into the platysma muscle complex.
undergoing rhytidectomy and other plastic surgery procedures. Nevertheless, the use of BTX-A for rejuvenating the aging neck has proven effective and well tolerated (Fig. 14.17) (33,34). Anatomy and Physiology The platysma muscle complex is a broad muscular sheet that comprises the anterolateral aspect of the neck. It has its origin on the fascia covering the upper parts of the pectoralis major and deltoid muscles including clavicular and acromial subcutaneous insertions. Its fibers cross the clavicle, and proceed obliquely upward and medially along the side of the neck. Some fibers are then inserted into the mandibular bone below the oblique line, others into the skin and subcutaneous tissue of the lower part of the face. Many of these fibers blend in with the perioral muscles about the angle and lower part of the mouth (Fig. 14.12). When the entire platysma complex is contracted, it produces a slight wrinkling of the skin of the neck in an oblique direction. Its anterior portion, the thickest part of the muscle, depresses the lower jaw and also serves in a small extent to depress the lower lip and angle of the mouth (35). Injection Technique The neck can be injected with as little as 20 U to as much as 100 U of BTX depending upon of the muscular mass present. First, the platysmal bands need to be identified having the patient clench their teeth. Each platysmal band is firmly held between the thumb and index finger and 2 to 5 U of toxin can then be injected from the superior to the inferior portion of each platysmal band at 1 to 1.5 cm intervals (Fig. 14.18). This usually comes out to four to five injection points per band.
1. http://www.surgery.org/download/2007stats.pdf 2. Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 2001; 8(Suppl 5): 21–9. 3. Graham ME, Washbourne P, Wilson MC, Burgoyne RD. Molecular analysis of SNAP-25 function in exocytosis. Ann N Y Acad Sci 2002; 971: 210–21. 4. Shiavo G, Benfenati F, Poulain B, et al. Tetanus and botulinum-B neurotoxins block transmitter release by proteolytic cleavage of synaptobrevin. Nature 1992; 359: 832–5. 5. dePaiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci 1999; 96: 3200–5. 6. Sanders DB, Massey W, Buckley EG. Botulinum toxin for blepharospasm: single-fiber EMG studies. Neurology 1986; 36: 545–7. 7. Klein AW, Carruthers A, Fagien S, Lowe NJ. Comparisons among botulinum toxins: an evidence-based review. Plast Reconstr Surg 2008; 121(6): 413e–22e. 8. Pearce LB, Borodic GE, First ER, et al. Measurement of botulinum toxin activity: evaluation of the lethality assay. Toxicol Appl Pharmacol 1994; 128: 69–77. 9. McLellan K, Das RE, Ekong TA, et al. Therapeutic botulinum type A toxin: factors affecting potency. Toxicon 1996; 34: 975–85. 10. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 1995; 45: 1743–46. 11. Erbguth F, Claus D, Engelhardt A, et al. Systemic effects of botulinum toxin injections unmasks subclinical Lambert–Eaton myasthenic syndrome [letter]. J Neurol Neurosurg Psychiatry 1993; 56: 1235–36. 12. Hara K, Matsuda A, Kitsukawa Y, Tanaka K, et al. Botulinum toxin treatment for blepharospasm associated with myasthenia gravis. Mov Disord 2007; 15: 22(9):1363–4.
114
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
13. Wieder JM, Moy RL. Understanding botulinum toxin: surgical anatomy of the frown, forehead and periocular region. Dermatol Surg 1998; 24: 1172–4. 14. Gray H. In: Warren HL, ed. Anatomy of the Human Body. Philadelphia, PA: Lea & Febiger, 1918. 15. Stennert E. Why does the frontalis muscle “never come back”? Functional organization of the mimic musculature. Eur Arch Otorhinolaryngol 1994; Suppl: S91–5. 16. Macdonald MR, Spiegel JH, Raven RB, Kabaker SS, Maas CS. An anatomical approach to glabellar rhytids. Arch Otolaryngol Head Neck Surg 1998; 124: 1315–20. 17. Huang W, Rogachefsky A, Foster J. Browlift with botulinum toxin. Dermatol Surg 2000; 26: 55–60. 18. Matrasso, SL. Complications of botulinum A exotoxin for hyperfunctional lines. Dermatol Surg 1998; 24: 1249–54. 19. Carruthers JDA, Carruthers A. Botulinum A exotoxin in clinical ophthalmology. Can J Ophtlamol 1996; 31: 389–400. 20. Knize DM. An anatomically based study of the mechanism of eyebrow ptosis. Plast Reconstr Surg 1996; 97: 1321–33. 21. Carruthers A, Carruthers J. Cosmetic uses of botulinum A exotoxin. In: Klein AW, ed. Tissue Augmentation in Clinical Practice: Procedures and Techniques. New York: Marcel Dekker, 1998. 22. Carruthers A, Carruthers J. Botulinum toxin in the treatment of glabellar frown lines and other facial wrinkles In: Jankovic J, Hallet M, eds. Therapy with Botulinum Toxin. New York: Marcel Dekker, 1994. 23. Flynn TC, Carruthers JA, Carruthers JA. Botulinum-A toxin treatment of the lower eyelid improves infraorbital rhytides and widens the eye. Dermatol Surg 2001; 27: 703–8. 24. Garcia, A, Fulton JE. Cosmetic denervation of muscles of facial expression with botulinum toxin: A dose–response study. Dermatol Surg 1996; 22: 39.
25. Matarasso SL, Matarasso A. Treatment guidelines for botulinum toxin type A for the periocular region and a report on partial upper lip ptosis following injections to the lateral canthal rhytids. Plast Reconstr Surg 2001; 108: 208–14. 26. Ascher B, Klap P, Marion MH, et al. La toxine boutulinique dans le treatment des rides fronto-glabellaires et de la region orbitaire. Ann Chir Plast Esthet 1995; 40: 67–76. 27. Carruthers A, Carruthers J. Cosmetic uses of botulinum A exotoxin. Adv Dermatol 1997; 12: 325–47. 28. Blitzer A, Binder WJ, Aviv JE, Keen MD, Brin MF. The management of hyperfunctional facial lines with botulinum toxin. A collaborative study of 210 injection sites in 162 patients. Arch Otolaryngol Head Neck Surg 1997; 123: 389–92. 29. Carruthers JD, Glogau RG, Blitzer A. Facial Aesthetics Consensus Group Faculty. Advances in facial rejuvenation: botulinum toxin type a, hyaluronic acid dermal fillers, and combination therapies— consensus recommendations. Plast Reconstr Surg. 2008; 121 (5 Suppl): 5S–30S. 30. Carruthers A, Carruthers J. Clinical indications and injection technique for the cosmetic use of botulinum A exotoxin. Dermatol Surg 1998; 24: 1189–94. 31. Papel ID, Capone RB. Botulinum toxin A for mentalis muscle dysfunction. Arch Facial Plast Surg 2001; 3: 268–9. 32. Le Louarn C. Botulinum toxin A and facial lines: the variable concentration. Aesthetic Plast Surg 2001; 25: 73–84. 33. Brandt FS, Bellman B. Cosmetic use of botulinum A exotoxin for the aging neck. Dermatol Surg 1998; 24: 1232–4. 34. Kane AC. Nonsurgical treatment of platysmal bands with injection of botulinum toxin A. Plast Reconstr Surg 1999; 103: 656–65. 35. Hoefflin SM. Anatomy of the platysma and lip depressor muscles. A simplified mnemonic approach. Dermatol Surg 1998; 24: 1225–31.
15
Botulinum toxin in the management of focal hyperhidrosis Dee Anna Glaser
Botulinum toxins can be used to treat secretory problems such as hyperhidrosis, chromhidrosis, sialorrhea, and Frey’s syndrome. This chapter will focus on the rationale for and the practical application of using botulinum toxins to treat patients with such problems.
Sweating is a normal physiological response to increased body temperature and is an important mechanism in releasing heat produced from endogenous as well as exogenous sources. The heat regulatory center is located within the hypothalamus, particularly involving the preoptic and anterior nuclei. Sweating is controlled by the sympathetic nervous system (1). Nerve fibers exit the preoptic or anterior nuclei and descend ipsilaterally through the spinal cord until they reach the intermediolateral column, where they exit the cord and enter the sympathetic chain. Although the neurotransmitter for the sympathetic nervous system is generally norepinephrine, acetylcholine is the neurotransmitter mainly involved in the sweating response. Other chemical mediators found in periglandular nerves include vasoactive intestinal peptide (VIP), atrial natriuretic peptide (ANP), galanin, and calcitonin gene peptide (CGP) (2). The eccrine glands, responsible for producing sweat, are distributed around the body, with high concentrations in areas such as the palms, soles, and forehead (Table 15.1). They are located at the junction of the dermis and subcutaneous fat and their function is to secrete water while conserving sodium chloride for electrolyte maintenance. Although they continually produce secretions, they are stimulated by heat, exercise, anxiety, and stress (3,4). Under severe heat stress, up to 10 l of sweat can be produced in a day; however, the normal rate is 0.5 to 1.0 ml/min. While rates vary among individuals, men generally sweat more than women (5). The apocrine gland opens into the hair follicle and is located mostly in the axillae and perineum. They become functional around puberty and are not important for thermoregulation. The scant viscous secretions are thought to function as chemical attractants or signals, as an odor is produced when the secretions reach the skin surface and interact with bacteria (1,3). The apocrine glands respond to adrenergic stimuli, epinephrine more than norepinephrine.
secondary process including lesions or tumors of the central or peripheral nervous system (9,10). More commonly however, it is idiopathic (primary) focal and is usually referred to simply as “hyperhidrosis.” It is characterized by excessive sweating of small areas of the skin, usually the axilla, palms, soles, face, or groin (Fig. 15.1) (11). The onset is usually in adolescence to early adulthood but can begin in early childhood, especially the palmar-plantar variants (7) (Table 15.3). The differential diagnosis for excessive sweating is extensive, and an underlying cause must be considered, especially when the hyperhidrosis is generalized, asymmetrically distributed, or has a late onset (6,12). A detailed history with comprehensive review of symptoms and thorough physical examination is the first step to identifying the type and cause of hyperhidrosis of a patient presenting with excessive sweating. The types or extent of further testing is based on the findings from the history and physical exam. This chapter will focus on primary focal hyperhidrosis henceforth identified simply as hyperhidrosis (HH). The prevalence of HH is reported to be 2.8% although it may be higher. It most commonly presents in the second or third decade of life and a family history has been reported in 30 to 50% of patients (13). The prevalence is similar for men and women, although interestingly, women are more likely to seek evaluation and treatment (11). Patients may sweat on a continuous basis throughout the day, but more commonly, there are episodes of profuse sweating with a sudden onset. Trigger factors include emotional stress, stress at work or in the public, higher environmental temperatures, and stimulants such as caffeine and exercise. However, patients also often have episodes of HH without a known initiating factor or trigger when they are cool, comfortable, and calm. Hyperhidrosis has a negative impact on many aspects of patients’ daily living: physically, psychologically, and occupationally (14–16). There is limited and mixed information on any real increase in cutaneous infections or other problems such as skin maceration with idiopathic hyperhidrosis (17,18). The greatest impact of HH is the significant reduction in the quality of life and the alterations it has on daily functioning (19). Patients report a lack of confidence, feeling depressed, refraining from meeting new people, and avoiding intimate activities. Work limitations are reported because of excessive sweating and patients describe having to change clothes during the day.
HYPERHIDROSIS
MEASURING HYPERHIDROSIS
Hyperhidrosis simply describes excess sweating beyond that necessary for physiological thermoregulation and homeostasis (6). Problems can occur within any portion of the system: from the hypothalamus to the sweat gland or duct (2). The amount of sweat necessary to be considered “excessive” is not well-defined and is variable between individuals. Patients with hyperhidrosis do not demonstrate any histopathologic changes in their sweat glands, nor are there any changes in the numbers of sweat glands (7). Hyperhidrosis may be generalized or focal, bilateral or unilateral, symmetric or asymmetric, primary or secondary in origin. Generalized hyperhidrosis affects the entire body whereas focal hyperhidrosis occurs in discrete sections of the body (8). Generalized hyperhidrosis is usually secondary in nature, and the differential diagnosis is extensive ( Table 15.2). Focal or localized hyperhidrosis may result from a
The Minor’s iodine-starch test is a simple way to detect the presence of sweat (Fig. 15.2). The hyperhidrotic area to be treated is dried thoroughly, an iodine solution is painted over the area and when thoroughly dried, a starch powder such as corn starch is sprinkled on the surface. With the interaction of sweat, a purple to black color develops. Decolorized iodine solutions do not perform the colorimetric change properly and should not be used for this test. Many physicians today use surgical preparations such as Betadine™ solution or swabs to perform the iodine-starch test. A plain corn starch that is used for cooking is readily available and inexpensive. The starch may be applied with a brush, cottonball, sifter or loose gauze. The iodine-starch test is useful in localizing the areas of sweat production but is not a quantitative test. For iodine-sensitive patients, Alizarin or Ponceau red dye and starch can be used. The pink powder turns to a bright red color when wet.
SWEATING
This chapter adapted from Botulinum Toxins in Clinical Aesthetic Practice, Second Edition, (Benedetto A, ed.), Informa Healthcare, New York, London, 2011.
115
116
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
Table 15.1 Eccrine Sweat Glands: Area and Quantity
Table 15.3 Criteria for Establishing the Diagnosis of Primary Focal Hyperhidrosis (6)
2
Area
Quantity (cm )
Sole of foot Forehead Palms Axillae Thigh Scrotum Back Lips Nail bed Nipple Inner preputial surface Labia majora Glans penis Glans clitoridis
620 360 300 300 120 80 65 None None None None None None None
Focal, visible excessive sweating of at least 6 months No apparent secondary cause At least two of the following characteristics • • • • • •
Source: From Ref. 68, p. 263.
Table 15.2 Forms of Hyperhidrosis Generalized
Focal/Localized
Fever Infections Malignancy Tumors Thyrotoxicosis Pheochromocytoma Diabetes mellitus Diabetes insipidus Hypoglycemia Hypopituitiarism Endocarditis Gout Medications Menopause Anxiety Drug withdrawal
Primary focal hyperhidrosis Intrathoracic tumors Rheumatoid arthritis Spinal cord disease or injury Stroke Syringomelia Ross syndrome Atrioventricular fistula Gustatory sweating Frey’s syndrome Localized unilateral hyperhidrosisa Cold-induced hyperhidrosis Eccrine nevus Social anxiety disorder Granulosis Rubra Nasi
Bilateral and relatively symmetric Age on onset <25 years Positive family history of primary focal hyperhidrosis Cessation of focal sweating during sleep Frequency of at least one episode per week Impairs daily activities
validated quantity that separates hyperhidrosis from euhidrosis, although it can exceed 30 times that of normal nonhyperhidrotic individuals. Hund suggests a minimum of 100 mg/5 min for men and 50 mg/5 min for women will identify axillary hyperhidrosis (5). A study of 60 patients demonstrated that the mean axillary sweat production was 346 mg/5 min for men and 186 mg/5 min for women with HH (healthy control subjects had values of 72 and 46, respectively). Likewise, the mean palmar gravimetric measurement was 300 mg/5 min (23). Gravimetric evaluation is typically reserved for research purposes and is not routinely used in clinical practices. A third method used to measure disease severity is with questionnaires and quality of life scales. Several such tools are available, including the Dermatology Life Quality Index (DLQI), the Hyperhidrosis Impact Questionnaire (HHIQ), and the Hyperhidrosis Disease Severity Scale (HDSS). The DLQI has 10 items that form six domains such that a total score of zero is best and 30 demonstrates the worst quality of life. The HHIQ has items for a baseline evaluation and ten items used to assess treatment follow-up. It too is most commonly used in clinical trials (24). The HDSS is based on one question that the patient can answer in the office (Table 15.4). The HDSS is a simple tool to use in the clinical setting and is responsive to treatment with a one-point HDSS improvement corresponding with approximately a 50% reduction in sweat. This validated scale can aid in selecting patients appropriate for therapy and for assessing effectiveness of treatment (25).
a
Also referred to as unilateral circumscribed idiopathic hyperhidrosis.
THERAPY
r
oin
he Ot
/sc Fa
ce
Gr
alp
tar an Pl
lm Pa
Ax
illa
ry
ar
80 70 60 50 40 30 20 10 0
Figure 15.1 Sites of hyperhidrosis in patients seeking medical evaluation. Source : From Ref. 11, p. 263.
Ninhydrin is another variant, but regardless of which variant is used, they all achieve a colorimetric outline of the sweating area (20–22). Gravimetric testing measures the amount of sweat produced during a given time. It can be performed using a preweighed filter paper that is placed on the affected area (typically for 5 minutes) and then reweighing the paper. Evaporation must be prevented. There is no standard or
Many treatments are available for HH, and therapy should be tailored to the needs of the individual based on factors such as age and health status, location, and severity of the disease, occupation, and lifestyle (Table 15.5). Antiperspirants are used as first-line therapy and function by decreasing sweat secretion through blockage of the distal eccrine ducts. Over-the-counter (OTC) products very rarely control patients with severe disease (HDSS 3 or 4) (see above) (7,11,26,27). Prescription strength products containing high concentrations of metal salts, most commonly aluminum chloride, are more effective than OTC preparations (28). Efficacy is still limited, and side effects are frequent with skin irritation, erythema, dryness, and pruritus. Systemic anticholinergic drugs such as glycopyrrolate, atropine, or oxbutynin provide a generalized acetylcholine blockade (Table 15.6) (26,29,30,31). Adverse effects such as dry eyes, dry mouth, and urinary retention are frequently encountered at the doses required to achieve symptom relief. Additionally, the generalized reduction in sweat production can be dangerous in individuals who engage in exercise, sports, or work in hot environments. Iontophoresis is an electrical device that uses direct current and tap water. The mechanism of action is unknown but may change the ability of the pores to secrete sweat, or physically block the release of sweat via ions that enter the ducts. It is most suited for treatment of the hands and feet. Anticholinergic agents can also be added to the tap water (32).
BOTULINUM TOXIN IN THE MANAGEMENT OF FOCAL HYPERHIDROSIS
(A)
(B)
(C)
(D)
117
(E) Figure 15.2 Performance of the Minor’s iodine-starch test. The hyperhidrotic area is doused with iodine solution (A) and after drying covered with starch powder (B). The hyperhidrotic area becomes clearly demarcated as a purple surface. Then the hyperhidrotic area is outlined (C). After removing the excess purple color from the center of the outline each injection site can be marked with gentian violet (D) to achieve the best results; (E) shows how the injections are placed. Source: From Ref. 68, p. 276.
Table 15.4 Hyperhidrosis Disease Severity Scale “Which best describes the impact of sweating on your daily activity?” 1 2 3 4
My (underarm) sweating is never noticeable and never interferes with my daily activity My (underarm) sweating is tolerable but sometimes interferes with my daily activity My (underarm) sweating is barely tolerable and frequently interferes with my daily activity My (underarm) sweating is intolerable and always interferes with my daily activity
Source: From Ref. 25.
Side effects are relatively minimal but is relatively time-consuming, limiting its use for many patients (Fig. 15.3) (33). Local surgical excision and liposuction or curettage techniques can be used to remove eccrine units (34). The outcome is technique dependant and is typically limited to the axilla. Endoscopic thoracic sympathectomy (ETS) offers long-term improvement but is not universally accepted. The sympathetic chain is interrupted at the T2, T3, and sometimes the T4 ganglion (35,36). Success rates for palmar disease approximate 95% but is less for axillary HH. Surgical and anesthetic-related adverse events are relatively rare, but the major issue with ETS surgery for HH is the potential for patients to develop compensatory sweating (Fig. 15.4) (37).
118
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
Table 15.5 Therapies Most Commonly Used for Hyperhidrosis Antiperspirants, over the counter Antiperspirants, prescription strength Iontophoresis Oral medications BoNTA or BoNTB Local excision of eccrine glands Liposuction and/or curettage Endoscopic transthoracic sympathectomy
Table 15.6 Anticholinergics Commonly Used to Suppress Hyperhidrosis Medication
Dosage
Glycopyrrolate 1% cream Glycopyrrolate (1 mg tablet) Oxybutnin Propantheline bromide
Apply 1% solution to affected area once daily 1–2 mg PO bid/tid, titrate to effect 5 mg PO bid/tid; not to exceed 5 mg qid 15 mg PO bid/tid 30 min ac initially; gradually titrate to effect 1–2 mg/day PO; not to exceed 6 mg/day
Benzotropine
Figure 15.4 Increased sweating of the entire trunk after mild exercise or even after mental stress as a result of severe compensatory hyperhidrosis occurring after endoscopic thoracic sympathectomy for hyperhidrosis of the head. Source : From Ref. 68, p. 271.
Source: From Ref. 68, p. 268.
neurotoxin type A (BoNTA) has been most extensively studied and used clinically to treat HH, but botulinum neurotoxin type B (BoNTB) has also been reported to work. The basic principle for using BoNTs to treat excessive sweating is to treat any underlying etiology as already discussed. Then the area of sweating should be identified using a colorimetric test such as the Minor’s iodine-starch test (Fig. 15.2). Since the sweat glands are typically located at the junction of the dermis and subcutaneous fat, BoNT is usually placed as a deep intradermal injection. It is important to avoid injecting deeper structures such as muscle to prevent unwanted affects on the underlying muscles and for optimal BoNT interaction at the neuron–eccrine interface. Injections are generally placed 1 to 2 cm apart to allow for diffusion to the entire area. Although this basic technique is used to treat all areas of the body, the more commonly treated sites will be covered in more detail. Due to the differences using the different BoNTA products, the newly assigned nonproprietary names will be listed when necessary. AXILLARY HYPERHIDROSIS
Figure 15.3 Iontophoresis procedure for palmar hyperhidrosis. To achieve satisfactory anhidrosis on both hands, it is important that both hands are treated in the anodal bath (red current). Therefore, after 10 minutes the red current plug has to be switched from one hand to the other and the treatment has to be repeated in the same manner. For palmoplantar therapy the treatment principles remain the same, but both hands are bathed in one and the feet in the other pan. Source : From Ref. 68, p. 270.
The incidence varies, but approximately 60 to 70% of patients seem to develop it, with its occurrence and severity being unpredictable (35,38,39). BOTULINUM TOXIN THERAPY
Since sweating is mediated by acetylcholine the use of botulinum neurotoxin (BoNT) to treat focal HH is a logical choice. The chemodenervation is localized, reversible, and yet long-lasting. Botulinum
No area has been as extensively studied as the axilla (14,40–45) with numerous studies showing the benefit of BoNTA, including large multicenter randomized, placebo-controlled trials in Europe and the United States. Naumann et al. reported on 320 patients with axillary HH that received 50 U of BoNTA (BOTOX® or onabotulinumtoxinA) per axilla or placebo (44). At 4 weeks, 94% of the onabotulinumtoxinA group had responded compared with 36% of the placebo group as measured by ≥50% reduction of sweat production from baseline. By 16 weeks, the response rates were 82% and 21%, respectively. Repeated injections with onabotulinumtoxinA over 16 months continued to produce similar results (40). The mean duration between onabotulinumtoxinA treatments was approximately 7 months and patient satisfaction was high. Similar results were published in a large phase III double-blind trial in North America (45). Subjects with axillary HH were randomized to receive placebo, 50 U, or 75 U onabotulinumtoxinA into each axilla. The HDSS was the primary efficacy in this study with gravimetric measurements being secondary. Successful response was seen in 75% of patients in both treatment groups compared with 25% in the placebo group (defined as ≥2 point reduction in HDSS) while 80 to 85% of the treated subjects had >75% reduction in sweat production. No significant differences were noted between the two
BOTULINUM TOXIN IN THE MANAGEMENT OF FOCAL HYPERHIDROSIS doses of onabotulinumtoxinA and the durability of therapy was approximately 7 months for both. A 3-year open label extension study revealed continued effectiveness and with similar duration of results (46). Specifically, the researchers were able to show a significant sustained improvement in the quality of life of subjects. The DLQI revealed significant improvement in overall quality of life and occupation and work-specific improvements were noted as well. The efficacy of Dysport® (abobotulinumtoxinA) has been shown in several studies. A multicenter trial of 145 subjects was performed with 200 U abobotulinumtoxinA in one axilla while the contralateral axilla was injected with placebo (41). After 2 weeks, the placebo-treated axilla was injected with 100 U abobotulinumtoxinA. Axillary sweating decreased within 2 weeks in both treatment sides and results were maintained for 6 months. There were no significant differences gravimetrically between the two doses used. Therapy was well-tolerated and 98% of subjects said they would recommend the therapy to others. Although studies have consistently shown that 50 U onabotulinumtoxinA per axilla provides safe and durable results (averaging ∼7 months), there is some debate whether higher doses of onabotulinumtoxinA can provide prolonged efficacy (47,48). One small open label study of 200 U onabotulinumtoxinA per axilla in 47 patients found prolonged results (over 19 months) in half of the patients, although the methodology was very different from other studies; starch iodine and telephone calls were used to assess patients (47). Likewise, 250 U of abobotulinumtoxinA (42) in each axilla resulted in prolonged benefit in a small study of 12 patients. Half remained symptom-free for 12 months and 9 months was achieved for 25% of the subjects (42). Currently the standard dose in the United States, and that listed in the package insert for onabotulinumtoxinA is 50 U per axilla. This achieves excellent results, high patient satisfaction, and helps to keep costs down. There is no such dosing consensus on other brands of BoNTA products. To optimize treatment, the area of axillary involvement should be identified before treatment by a Minor’s iodine-starch test (as previously reviewed) so that the BoNTA can be concentrated into the affected area. The key to performing a high-quality iodine-starch test is to thoroughly dry the region before beginning the test (Fig. 15.2). The axilla does not need to be shaved prior to performing an iodinestarch test or to injecting BoNTA. The BoNTA is injected into the deep dermis at the dermal subcutaneous level and placed 1.5 to 2 cm apart. Because the axillary skin is thin, a wheal should be seen with each injection. An average of 10 to 15 injections per axilla are required, but will depend on the size of the axilla and hyperhidrodic area (49). In the event that an iodine-starch test cannot be performed prior to treatment or is equivocal, the physician should treat the hair-bearing areas as descried above. Should symptoms fail to be alleviated within 2 weeks, the patient can return to the office and an iodine-starch test performed to identify any “active” eccrine glands. The skin should be injected with 3 to 5 u of onabotulinumtoxinA for each 1 cm surface area identified. Pain is minimal and the procedure is well tolerated. Although the package insert describes the use of unpreserved saline to reconstitute BoNTA, many physicians have found that the use of preserved saline reduces pain without altering efficacy (50,51). The use of 2% lidocaine to reconstitute BoNTA has been reported in one small study to be less painful than the use of unpreserved saline when injecting axillary HH and with equal efficacy (52). Side effects noted in studies include pain, hematoma, bruising, headache, muscle soreness, increased facial sweating, perceived compensatory sweating, and axillary pruritus. Treatment intervals are mandated by the longevity of an individual’s treatment response but will average every 6 to 7 months. Some clinicians have advocated that patients use a topical therapy twice a week when the sweating starts to return to try and extend the time interval between injections and help to keep costs to a minimum (53).
119
PALMAR HYPERHIDROSIS
BoNT injections are useful in the treatment of palmar HH. No largescale studies have been published but multiple small studies have demonstrated the ability of BoNT to establish clinical improvement in patients’ symptoms (23,54,55). Several challenges exist when treating hands such as choosing optimal doses, control of pain during injection, and side effects which include muscle weakness (23,56–60). The optimum dose of BoNTA to control palmar HH is unknown and the issue is complicated by large variations in hand size (Fig. 15.5). Published data report doses as low as 50 U per hand and as high as 200 U onabotulinumtoxinA per hand (55,61). Doses of abobotulinumtoxinA have ranged from 120 U per hand to 500 U per hand (22,54,62). Some authors have suggested using a defined dose per injection, with Swartling’s group using 0.8 U/cm2, and Naumann’s group using 2 U onabotulinumtoxinA injected every 1.5 cm on the palm but 3 injections per fingertip and two injections into each of the middle and proximal phalanx using 1 to 2 U per injection (55,63). The Canadian advisory committee recommends 1.5 to 2 u/cm2 with a mean dose of 100 U onabotulinumtoxinA per palm (7). It is unclear whether or not larger doses add to the duration of symptom relief or increase the risk of developing muscle weakness. When Wollina used 200 U of onabotulinumtoxinA per hand in 10 patients, his relapse time varied from 3 to 22 months (61). Saadia studied 24 patients: 11 received 50 U onabotulinumtoxinA per hand and 13 received 100 U/ hand. There was higher patient satisfaction reported in the high-dose group, but no difference in terms of duration (measured as a percentage of the palm area sweating) for the two doses. There were more patients with hand and finger weakness in the high-dose treatment group (55). Until larger studies
Figure 15.5 Variations in hand size. The larger hand is that of a 17-year-old male while the smaller hand is that of a 16-year-old girl. Hand size variations need to be taken into consideration when dosing BoNTA for palmar hyperhidrosis.
120
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
are available to address this issue, 75 to 100 U onabotulinumtoxinA per hand is a good starting point with adjustments being made as needed based on the size of the hand and past responses (27). Another challenge with palmar BoNT therapy is an apparent shorter duration of response when compared with axillary injections (56). Responses range from 3 to 12 months (64). Aghaei found that anhidrosis lasted up to 5 months for his patients treated with 500 U abobotulinumtoxinA per hand (62), although he observed hypohidrosis lasting an average of 10 months (62). The reason for this shorter duration is unknown but may be (64) related to a smaller diffusion radius in the thicker palm skin and compartmentalized areas of the phalanges, a higher number of cholinergic nerve endings or a differential recovery rate of the nerves in the hands compared with the axilla. Backflow of the BoNT solution upon injection can be an issue with palmar injections and perhaps this plays a role as well (65). Injection of the hand can be quite painful due to the density of nerve receptors and the large numbers of injections that are required. Pain during injection of the palm has been rated an average 68.1 ± 31.8 compared to 29.9 ± 24.5 for axillary treatment (using a visual analogue scale 1–100) (15). Several methods of pain control have been tried (Table 15.7), although a rare patient will not require anesthesia. Topical anesthetic containing lidocaine and cold packs tend not to provide adequate pain control. More intensive cold exposure can be helpful: the use of dichlorotetrafluoroethane or liquid nitrogen, submersion of the hand in an ice bath, direct exposure of an ice cube or ice pack (66,67). Machines that emit chilled air or utilize a chilled tip can be beneficial but more expensive. Kreyden describes a technique of iontophoresis with 2% lidocaine for 30 minutes, followed by a light spray of liquid nitrogen just prior to inserting the needle to inject BoNTA (68). The use of a dermojet to inject BoNTA was found to be less painful than standard needle injections, but was much less effective in controlling the sweating and thus not recommended as a useful tool to treat the palms (69). Benohanian has described the used of a pressure unit to inject lidocaine into the palms and soles without the use of needles, before injecting BoNTA (70). The Med-JetMBX II (MIT Canada) (71) device system consists of a CO2-powered variable dose injector to which a 12 cc disposable syringe is attached containing lidocaine. When the trigger is pulled, a volume of 0.02 to 0.3 cc anesthesia is injected to the targeted depth within the skin. The starting pressure is typically around 130 psi (with a range of 1 to 350 psi) depending on the epidermal thickness. The device is approved by Health Canada and the European Union. After the anesthetic wheals appear, BoNT can be administered with a standard needle system. Nerve blocks are effective and can be performed in the office (63,72–74). The palm is innervated by three nerves, median, ulnar and radial nerves. All can be anesthetized at the level of the wrist using 1% or 2% lidocaine (Fig. 15.6). Risks of a nerve block include infiltration of the nerve with subsequent nerve injury and vascular puncture. In addition, temporary hand weakness after the nerve blocks may limit the patients’ activities and ability to have both hands treated at one session.
A 30G 0.5-inch needle should be used to minimize any nerve trauma. Approximately 2 cc of 1% or 2% lidocaine is injected around each of the nerves. If the patient feels any unusual tingling or sensation during the injection, the needle should be withdrawn slightly. Twenty minutes or more may be necessary for the full effect to develop. Intravenous regional anesthesia (IVRA), also known as a Bier’s block is effective (75,76). An anesthetic such as prilocaine is injected intravenously following the application of a tourniquet cuff on the forearm. Exsanguination of the extremity is performed and an electronic double cuff is applied. Complete anesthesia is obtained in 20 minutes using 40 to 60 ml of 0.5% prilocaine. The total tourniquet time for IVRA ranges from 50 to 80 minutes and is well-tolerated. Due to the risk of toxic cardiovascular and central nervous system reactions, blood pressure and electrocardiogram are monitored during the IVRA and for about 30 minutes after the procedure. Vibratory anesthesia is gaining popularity (77). The theory is that the nervous system is unable to perceive fully two different types of sensory inputs simultaneously. A handheld vibrator is applied to the volar and dorsal surface of the hand near the site of BoNTA injection. This requires an assistant and there is some movement of the patient’s hand, which can make injections challenging. The use of one vibrator to the volar aspect does not diminish pain as much as the use of two vibrators (personal experience). Neither technique results in a painfree injection, but rather a diminishment of perceived pain. A study by Sherer found that pain threshold is significantly higher during vibration compare to pre- or postvibration, and that vibration applied distal to the site of pain provided better analgesia than vibration applied proximal to the site of pain (78). The author most commonly uses ice with pressure at this time for palmar injections. An ice cube is applied firmly to the planned injection site for 7 to 10 seconds (Fig. 15.7). If the patient requires additional pain control, a combination of ice and vibration is used. Ice is applied firmly to the area for 7 to 10 seconds and then the vibrator is firmly applied immediately adjacent to the injection site simultaneous to the injection (no more than 2–3 seconds). This technique does require an assistant and coordinated timing to optimize pain control. A 30G 0.5-inch needle with a leur lock syringe or insulin type syringe is especially helpful because of the thicker skin and higher pressures needed to inject the palm. Injections should be placed every 1 to 1.5 cm but the digits will usually need two to three injection sites per phalangeal unit (Fig. 15.8). Bruising is common with injections into the palm, but it is temporary. Weakness of the hand or fingers is possible but is usually minor
Radial nerve distribution
Radial injection site
Median nerve distribution
Table 15.7 Anesthesia Techniques Used for Palmar Injections Topical anesthesia Nerve blocks Cryoanalgesia
Dichloretetrafluoroethane Liquid nitrogen spray Ice cubes, ice pack, or ice bath Cold packs Machine-assisted cold air
Vibration Intravenous regional anesthesia (Bier’s block) General anesthesia or sedation anesthesia
Median injection site
Ulnar nerve distribution Ulnar injection site
Figure 15.6 The palm is innervated by the ulnar, median, and radial nerves. Nerve blocks are usually performed at the wrist.
BOTULINUM TOXIN IN THE MANAGEMENT OF FOCAL HYPERHIDROSIS
121
Children with palmar hyperhidrosis can be treated with BoNTs but pain control remains the biggest challenge. Less is known about the dosing, duration, and adverse events associated with pediatric use. Coutinho dos Santos published a series of nine children aged 6.5 to 15 years with palmar HH successfully treated with onabotulinumtoxinA. Nerve blocks were used for pain control and doses of 75 to 150 units were given per palm (83). PLANTAR HYPERHIDROSIS
Figure 15.7 Ice is firmly applied to the palm for 7–10 seconds before injection of botulinum toxin.
Figure 15.8 Typical injection pattern of palm and digits.
and of limited duration. The incidence varies in published series, but ranges from 0 to 77% (23,55–57,79). The most commonly affected area of weakness is the thenar eminence and can be measured in the thumbindex finger pinch, whereas gross strength or grip strength of the hand is not usually affected (55,58). Rarely, patients report numbness, tingling, or decreased dexterity. Injections of BoNTA should be in the dermal layer, especially over the thenar eminence to limit the chance that the drug will come in contact with the muscle layer. Subepidermal injections may increase the incidence of hematoma (57). There is one report of atrophy of the intrinsic musculature of the hands with “debilitating” weakness associated with BoNTA injections for palmar HH, after five treatment sessions using 500 U abobotulinumtoxinA per palmar basin every nine months (80). Patients should be adequately counseled on the risks of weakness, which is usually mild and transient. In an attempt to prevent muscle weakness, Zaiac advocates the use of the ADG® needle, a device designed for the injection of collagen (81). He found the average depth of the eccrine glands in 10 consecutive palmar biopsies to be 2.6 mm. By adjusting the needle to a length of 2.6 mm and using a total of 60 to 70 U onabotulinumtoxinA per palm, he had no weakness in a series of 10 patients. Likewise, Almeida uses an adapter to shorten her 7 mm 30G needle to measure 2.5 to 3.0 mm for palmar injections (60,82).
Very little has been published on BoNT therapy for plantar HH. Like the palms, there is no consensus on the optimal dose, the duration is variable and the injections are painful. Naumann used 42 and 48 units of onabotulinumtoxinA to treat two soles by injecting 3 U onabotulinumtoxinA (0.15 ml) into each 2 × 2 cm squares (84). Blaheta’s group used 100 U onabotulinumtoxinA per sole (100 U/5 ml saline) in a study of eight patients with severe plantar hyperhidrosis (85). Campanati studied 10 patients with plantar hyperhidrosis using 100 U onabotulinumtoxinA per foot. All patients had an improvement in symptoms and a “significant decrease of Minor’s test” for 12 weeks without significant side effects (86). An iodine-starch test will delineate the hyperhidrotic area, which can extend up the sides and onto the dorsum of the foot. BoNTA should be evenly distributed every 1 to 2 cm using small gauge needles and injecting into the deep dermis. Injections of the plantar surface can be technically more challenging due to the thickness of the stratum corneum in some areas, especially if calloused. The physician has to adjust for the variation in depth to accurately place BoNTA into the appropriate cutaneous level. The need for pain control has to be addressed like with palmar injections. IVRA can provide sufficient anesthesia for the sole and has been reported to be effective when administering BoNTA. In a small series of eight patients, IVRA was found to be more effective than nerve blocks in reducing the pain of BoNTA injections (87). However, nerve blocks can also be used and are generally performed at the level of the ankle (Fig. 15.9). The tibial and sural nerves need to be blocked, and if the dorsum of the foot must be injected, the superficial peroneal nerve can be anesthetized (82). Vadoud-Seyedi reported on using the Dermojet to inject BoNTA for plantar HH. Ten patients were treated with 50 U onabotulinumtoxinA/5 ml saline per foot. Fifteen to twenty points were injected per foot and no analgesia was used. The injections were tolerated well by all patients, although one developed a localized hematoma. The duration of benefit lasted 3 to 6 months, however, 20% of patients reported the treatment had no effect on their condition (88). At this time, the author’s preferred method of pain control is ice combined with vibration as described earlier (Fig. 15.10). Doses of 100 to 200 U onabotulinumtoxinA per foot are typically required. Bruising and pain with injection are the most common side effects. In the published literature, one patient reported weakness of plantar flexor muscles in both feet following BoNTA injections, with resolution in 10 days (89). FACIAL HYPERHIDROSIS
Primary facial HH has several patterns, but most commonly involves the forehead plus or minus the scalp. Patients with craniofacial HH may present with involvement of the forehead, scalp perimeter, entire scalp, cheeks, nose, upper lip, chin, or a combination of the areas (Fig. 15.11). Gustatory sweating is a relatively common complication after surgery or injury in the region of the parotid gland and will be discussed later in the chapter. All forms of facial HH can respond to BoNTA, with gustatory sweating responding for very long periods of time. There is a paucity of literature published on craniofacial hyperhidrosis. Kinkelin’s group injected a mean of 86 U onabotulinumtoxinA
122
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
(A)
(C)
(B) Figure 15.9 The injection point of tibialis. (A) Saphenous block, 1 = medial malleolus, 2 = posterior tibialis artery, 3 = injection points for tibialis block, 4 = area of subcutaneous infiltration for saphenous block; (B) Fibularis block, 1 = lateralis malleolus, 2 = area of subcutaneous infiltration for saphenous block; (C) Profundus block, 1 = dorsalis pedis artery, 2= injection points for fibularis profundus block. Source : From Ref. 68, p. 282.
Figure 15.10 When ice and vibration is combined, ice is applied with firm pressure for 7–10 seconds before applying vibration to the immediate treatment area.
(3 U BoNTA per injection site) over the forehead at equidistant locations (1–1.5 cm) in 10 men with frontal hyperhidrosis (90). The injections were kept 1 cm superior to the eyebrow to help prevent drooping of the eyelid; injections were intracutaneous. Five of 10 patients had partial disability in frowning of the forehead, but was limited to a maximum of 8 weeks. There was no ptosis noted and satisfaction was good or
excellent in 90% of the subjects. The benefits were maintained for 5 months in 90% of patients. Similarly, Tan and Solish report that symptoms return on average 4 1 2 months after treatment of the forehead (15). Böger treated 12 men suffering from bilateral craniofacial hyperhidrosis with abobotulinumtoxinA 0.1 ng per injection (91). Half of the forehead was treated using a total of 2.5 to 4 ng injected equidistantly with a total of 25 to 40 injections given. Decreased sweating was seen within 1 to 7 days after injection and lasted a minimum of 3 months, but one patient experienced anhidrosis for 27 months. Side effects were limited to temporary weakness of the frontalis muscle (100%), and brow asymmetry that lasted 1 to 12 months in 17% of subjects. It is the observation of the author that patients typically present with forehead sweating that may be combined with scalp sweating in a diffuse pattern or in an ophiasis pattern. OnabotulinumtoxinA injections are performed with 2 to 3 U every 1 to 2 cm avoiding the inferior 1 to 2 cm of the forehead to reduce the risk of brow ptosis (92) (Figs. 15.12 and 15.13) The forehead can be treated more inferiorly if the response is not sufficient and the patient is willing to accept brow ptosis. Doses range from 50 U (forehead) to 250 to 300 U for the forehead and entire scalp (92). GUSTATORY SWEATING (FREY’S SYNDROME)
Gustatory sweating occurs on the cheek in response to salivation or anticipation of food. It may result from misdirection of autonomic nerve fibers after surgery and is frequently observed in diseases of the parotid gland and in diabetes.
BOTULINUM TOXIN IN THE MANAGEMENT OF FOCAL HYPERHIDROSIS
(A)
123
(C)
(B) Figure 15.11 Cranio-facial hyperhidrosis. Right side of face Minor’s iodine-starch test prior to treatment. (A) Right side of face, (B) forehead, and (C) left side of face. Source : Photographs courtesy of Anthony V. Benedetto, DO, FACP.
Figure 15.12 Injection pattern for craniofacial hyperhidrosis. Injections should be intradermal to avoid muscular affect.
BoNT is a highly effective treatment option for gustatory sweating as shown by several uncontrolled studies (93–97) (Table 15.8). In a large open study of 45 patients, there was a significant reduction of local facial sweating after injection of onabotulinumtoxinA using a mean dose of 21 U (range 5–72 U) and no recurrence of sweating was observed during the follow-up period of 6 months. A marked long-lasting benefit of 11 to 36 months was also observed in three other open studies (95–97). Thus, BoNT appears to have a particularly long-lasting effect on gustatory sweating. The reason for this is unclear. In clinical practice, the Minor’s iodine-starch test should be performed before injection to visualize the affected area that has to be injected (Fig. 15.14). After the iodine and starch have been applied to the area, the patient should chew on a piece of candy or food to stimulate the facial sweating. Injections with 2 to 3 U onabotulinumtoxinA or 8 U abobotulinumtoxinA are given intradermally at sites 2.0 to 2.5 cm apart and evenly distributed over the affected area. Specific side-effects of the injection of BoNT include pain on injection, local hematomas, and local
124
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
Figure 15.13 Injection into the hairline for therapy of forehead hyperhidrosis.
Table 15.8 Selected Studies on BoNTA Treatment of Gustatory Sweating Author
Year
Design
n
Dose (mean)
Naumann et al. (94)
1997
Open
45
Bjerkhoel and Trobbe (95)
1997
Open
15
Laskawi et al. (96)
1998
Open
19
Laccourreye et al. (97)
1999
Open
33
21 mu onabotulinumtoxinA 37 mu onabotulinumtoxinA 31 mu onabotulinumtoxinA 86 mu abobotulinumtoxinA
Figure 15.14 Patient with Frey syndrome. Distinct hyperhidrosis of a confined area of the cheek during or after eating due to misdirected re-sprouting of postsynaptic salivomotor parasympathetic fibers after parotid gland surgery or infection. Source : From Ref. 68, p. 288.
Duration (mo) 6
13
11–27
12–36
muscle weakness due to diffusion of the toxin to adjacent muscles (particularly, the zygomatic muscle). OTHER SWEATING DISORDERS
Inguinal HH affects 2 to 10% of individuals with primary HH (14). It usually develops in adolescence and can be associated with excessive sweating at other body sites. Intradermal injections of BoNTA can control symptoms for 6 months or more. Identifying the surface areas that needs injection by the iodine-starch test can be technically challenging due to the body location, but is valuable (Fig. 15.15). Two to three units onabotulinumtoxinA are injected every 1 to 2 cm within the affected area; typical doses range from 60 to 100 U per side (98). Compensatory sweating is the most common complication of endoscopic transthoracic sympathectomy (ETS), ranging from 44% to 91% (99) (Figs. 15.4 and 15.16) Treatment has been particularly difficult but a couple of reports noted success using BoNTA. Huh used 300 U abobotulinumtoxinA to treat the chest and abdomen after identifying the area with an iodine-starch test (99). He diluted each 100 U of onabotulinumtoxinA with 10 ml saline and injected 0.1 ml into each square centimeter. The effects gradually reduced but were reported to remain for 8 months. Belin and Polo reported good results treating the upper abdomen with onabotulinumtoxinA, but unfortunately their patient’s compensatory sweating was from the nipple line down to his knees and the entire area was not treated (37). Kim and colleagues
Figure 15.15 Hyperhidrosis of the left groin area after a Minor’s iodine-starch test. As shown the affected area can be extensive, which has to be considered before treatment. Source : From Ref. 68, p. 290.
reported on 17 patients with severe compensatory hyperhidrosis being treated with BoNTA (100). One hundred to 500 units of onabotulinumtoxinA were used, administering 2 units every 1.5 cm. The injections were well-tolerated, but the authors noted incomplete resolution of the sweating due to insufficient dosing, and the duration lasted only 4 months. Chromhidrosis is a rare disorder characterized by the excretion of colored or pigmented sweat. It is most commonly confined to the face or axilla but has been noted elsewhere on the body. Matarasso used 15 U onabotulinumtoxinA into the affected area of each cheek which measured 3 cm in diameter. Within 48 hours, the patient had a marked reduction in the amount of discharged black sweat (101).
BOTULINUM TOXIN IN THE MANAGEMENT OF FOCAL HYPERHIDROSIS
125
Figure 15.16 Typical Minor’s iodine-starch test of a patient with compensatory hyperhidrosis after endoscopic thoracic sympathectomy for hyperhidrosis of the forehead. Note the anhidrotic area of the upper trunk (no coloration) and the (compensatory) hyperhidrotic purple area of the chest. Source: From Ref. 68, p. 290.
Figure 15.18 Patient with localized unilateral hyperhidrosis on his right wrist, showing the dripping hyperhidrosis after the Minor’s iodine-starch test. Source: From Ref. 68, p. 291.
colon (103). The pathogenesis of Ross syndrome is unknown. Multiple neuropathies of the autonomic nervous system or a failure in the synthesis or release of neurotransmitters have been suggested as possible causes (102). There is no histologic evidence of nerve fiber destruction. Therefore Ross postulated a defect in acetylcholine cholinesterase activity, rather than the degeneration of sweat glands. The progression of Ross syndrome is very slow. There is no therapy for the segmental progressive anhidrosis. The bothersome compensatory hyperhidrosis can be improved, however, with systemic antimuscarinic drugs or with injections of BoNTA into the affected areas, usually the face. In 1992 Itin et al. (104) presented a case study of a patient suffering from Ross syndrome with a defined area of anhidrosis in the right hand, the right axilla, and the right side of the face. In follow-up, after 11 years, the patient presented with additional anhidrotic areas in the right hemithorax and the underside of the left arm (Fig. 15.17). Unfortunately the patient refused treatment with onabotulinumtoxinA, even though the hyperhidrosis was so severe that electrolyte replacement was necessary (unpublished data). Figure 15.17 Patient with Ross syndrome characterized by progressive segmental anhidrosis with a compensatory band of excessive perspiration leading the patient to the physician. This is the very same patient 11 years after Itin et al. (46) first published their case study, showing extensive progression of the disease (unpublished data). Source: From Ref. 68, p. 289.
ROSS SYNDROME
Ross syndrome was first described by the neurologist Alexander T. Ross in 1958 (102). It is characterized by the triad of unilateral tonic pupils, generalized areflexia (Holmes–Adie syndrome), and progressive segmental anhidrosis with a compensatory band of excessive perspiration. Patients suffering from Ross syndrome usually do not perceive the hypohidrosis; instead, it is the compensatory segmental hyperhidrosis that is bothersome. In addition, many patients suffer from several symptoms of vegetative dysfunction, such as palpitation, stenocardia, orthostatic hypotonia, and irritable
Localized Unilateral Hyperhidrosis Localized unilateral hyperhidrosis (LUH) is a rare form of idiopathic localized hyperhidrosis and is defined as a confined area of hyperhidrosis of less than 10 × 10 cm, mainly found on the forehead or the forearm, whose pathogenesis is unknown (Fig. 15.18). Beside the unusual localization, the major difference from essential hyperhidrosis is that LUH has no typical triggering factor and occurs even while patients are asleep. The etiology of LUH is unknown but may be due to a misdirected reconnection of the sympathetic nerve fiber network after injury, similar to the Frey syndrome (105). Before onabotulinumtoxinA, no treatment was available for this distinctive but enigmatic skin disorder. However, excellent results have been experienced following injection of 30 U onabotulinumtoxinA in a patient suffering from LUH (105). USE OF BOTULINUM TOXIN TYPE B FOR HYPERHIDROSIS
Botulinum neurotoxin type B (BoNTB) use has been primarily limited to treatment of cervical dystonia, but there are a few reports of its use
126
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
for treating HH. Injection of BoNTB can induce focal anhidrosis in a dose-dependant fashion. Birklein found that a threshold dose of 8 U Neurobloc®/Myobloc® (rimabotulinumtoxinB) led to anhidrotic skin areas greater than 4 cm after 3 weeks. The duration was prolonged for 3 months when 15 U BoNT-B were injected, and for 6 months when 125 U were injected (106). Despite its ability to induce anhidrosis, the use of BoNTB is limited by the occurrence of systemic adverse events (107). Dressler reported that 100 U onabotulinumtoxinA, 2000 U rimabotulinumtoxinB, and 4000 U rimabotulinumtoxinB were equally effective in blocking axillary sweating when studying 19 HH patients (108). The extent of improvement was similar (16 weeks) in all groups, but the onset of action was earlier with the rimabotulinumtoxinB and there was greater discomfort with the rimabotulinumtoxinB compared with onabotulinumtoxinA. One patient developed severe dryness of the mouth starting 1 week after injection, lasting 5 weeks as well as accommodation difficulties and conjunctival irritation that lasted 3 weeks. Likewise, patients treated with 5000 U rimabotulinumtoxinB in each axilla achieved excellent reduction in sweating, but the incidence of side effects was high and included dry mouth, headache, and sensory motor symptoms of the hand (109). A patient treated with 2500 U BoNTB to each palm for HH developed bilateral blurred vision, indigestion, dry sore throat, and dysphagia (110). The largest published study to date on BoNTB to treat palmar HH included 20 subjects used 5000 U per palm (111). Adverse events were common: dry mouth or throat (90%), indigestion (60%), excessively dry hands (60%), muscle weakness (60%), and decreased grip strength (50%). Lower dosing may be the key to reducing the high incidence of side effects (112). However, because of the incidence of systemic side effects using BoNTB and the high safety profile using BoNTA to treat focal hyperhidrosis, to date, BoNTA is the neurotoxin of choice. FUTURE DIRECTIONS
The use of botulinum toxins has revolutionized the treatment of HH and other secretory disorders. Compared with other treatments, it is unmatched in its efficacy, ease of administration, and patient satisfaction. Development of quick, safe, and effective pain control is needed for the treatment of more tender areas such as the palms and soles. New delivery devices are already being researched to help provide the most comfortable and efficient therapy. Kavanagh and colleagues have successfully used a small iontophoresis machine to deliver BoNTA to two patients with severe palmar hyperhidrosis, sparing them the injections (113). Glogau demonstrated that onabotulinumtoxinA can be successfully delivered into the axillary skin when combined with a proprietary transport peptide molecule (114). Research is ongoing looking at the clinical applications of different BoNT serotypes. Another area of potential research is with combination therapy. For the present, BoNT therapy is a valuable, well-tolerated therapy and can provide meaningful improvement in the quality of life of patients with HH and other secretory disorders. REFERENCES
1. Goldsmith L. Biology of eccrine and apocrine sweat glands. In: Freedberg I, Eisen A, Wolff K, Goldsmith L, Katz S, Fitzpatrick T, eds. Fitzpatrick’s Dermatology in General Medicine. New York: McGraw-Hill, 1999: 157–164. 2. Goldsmith L. Goldsmith disorders of the eccrine sweat gland. In: Freedberg I, Eisen A, Wolff K, Goldsmith L, Katz SI, Fitzpatrick T, eds. Fitzpatrick’s Dermatology in General Medicine. New York: McGraw-Hill, 1999: 800–809. 3. Stenn K, Bhawan J. The normal histology of the skin. In: Farmer E, Hood A, eds. Pathology of the Skin. New York: McGraw-Hill, 2000.
4. Glogau R. Botulinum A neurotoxin for axillary hyperhidrosis: no sweat Botox. Dermatol Surg 1998; 24: 817–19. 5. Hund M, Kinkelin I, Naumann M, Hamm H. Definition of axillary hyperhidrosis by gravimetric assessment. Arch Dermatol 2002; 138: 539–41. 6. Hornberger J, Grimes K, Naumann M, et al. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. J Am Acad Dermatol 2004; 51: 274–86. 7. Solish N, Bertucci V, Dansereau A, et al. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: Recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol Surg 2007; 33: 908–23. 8. Kreyden O, Scheidegger E. Anatomy of the sweat glands, pharmacology of botulinum toxin, and distinctive syndromes associated with hyperhidrosis. Clin Dermatol 2004; 22: 40–4. 9. Cheshire W, Freeman R. Disorders of sweating. Semin Neurol 2003; 23(4): 399–406. 10. Grazziotin T, Buffon R, Manzoni A, Libis A, Weber M. Treatment of granulosis rubra nasi with botulinum toxin type A. Dermatol Surg 2009; 35: 1298–9. 11. Lear W, Kessler E, Solish N, Glaser D. An epidermiological study of hyperhidrosis. Dermatol Surg 2007; 33: S69–75. 12. Seline P, Jaskierny D. Cutaneous metastases from a chondroblastoma initially presenting as unilateral palmar hyperhidrosis. J Am Acad Dermatol 1999; 40: 325–7. 13. Strutton D, Kowalski J, Glaser D, Stang P. US Prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: Results from a national survey. J Am Acad Dermatol 2004; 51: 241–8. 14. Naumann M, Hamm H, Lowe NJ. Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial. Br J Dermatol 2002; 147: 1218–26. 15. Tan S, Solish N. Long-term efficacy and quality of life in the treatment of focal hyperhidrosis with botulinum toxin A. Dermatol Surg 2002; 28: 495–9. 16. Kowalski J, Ravelo A, Glaser D, Lowe NJ. Quality-of-life effect of botulinum toxin type A on patients with primary axillary hyperhidrosis: Results from a North American clinical study population. P196. 2-7-2003. American Academy of Dermatology Annual Meeting. 17. Walling H. Primary hyperhidrosis increases the risk of cutaneous infection: a case–control study of 387 patients. J Am Acad Dermatol 2009; 61(2): 242–6. 18. Ingordo V, Naldi L, Fracchiolla S, Colecchia B. Prevalence and risk factors for superficial fungal infections among Italian Navy Cadets. Dermatology 2004; 209(3): 190–6. 19. Hamm H, Naumann M, Kowalski J, et al. Primary focal hyperhidrosis: Disease characteristics and functional impairment. Dermatology 2006; 212: 343–53. 20. Bushara K, Park D. Botulinum toxin and sweating. J Neurol Neuros Psy 1994; 57(11): 1437–8. 21. Tugnoli A, Ragona R, Eleopra R, De Grandis D, Montecucco C. Treatment of Frey syndrome with botulinum toxin type F. Arch Otolaryngol Head Neck Surg 2001; 127: 339–40. 22. Schnider P, Binder M, Auff E, et al. Double-blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms. Br J Dermatol 1997; 136: 548–52. 23. Lowe N, Yamauchi P, Lask G, Patnaik R, Iyer S. Efficacy and safety of botulinum toxin type a in the treatment of palmar hyperhidrosis: A double-blind, randomized, placebo-controlled study. Dermatol Surg 2002; 28: 822–7.
BOTULINUM TOXIN IN THE MANAGEMENT OF FOCAL HYPERHIDROSIS 24. Swartling C, Naver H, Lindberg M. Botulinum A toxin improves life quality in severe primary focal hyperhidrosis. Eur J Neurol 2001; 8(3): 247–52. 25. Glaser DA, Kowalski J, Eadie N, et al. Hyperhidrosis disease severity scale (HDSS): Validity and reliability results from three studies. Presented at the annual meeting of the American Academy of Dermatology, Washington, DC, 2004. 26. Stolman L. Treatment of hyperhidrosis. Dermatol Clin 1998; 16(4): 863–9. 27. Glaser D, Hebert A, Parlser D, Solish N. Palmar and plantar hyperhidrosis: Best practice recommendations and special considerations. Cutis 2007; 79 (sup 5): 18–28. 28. Benohanian A, Dansereau A, Bolduc C, Bloom E. Localized hyperhidrosis treated with aluminum chloride in a salicylic acid gel base. Int J Dermatol 1998; 37: 701–3. 29. Praharaj SK, Arora M. Paroxetine useful for palmar-plantar hyperhidrosis. Ann Pharmacother 2006; 40: 1884–6. 30. Bajaj V, Langtry JAA. Use of oral glycopyrronium bromide in hyperhidrosis. Br J Dermatol 2007; 157: 118–21. 31. Klaber M, Catterall M. Treating hyperhidrosis: anticholinergic drugs were not mentioned. BMJ 2000; 321(7262): 703. 32. Naumann M, Davidson J, Glaser D. Hyperhidrosis: current understanding, current therapy CME. Medscape 2002. 33. Stolman L. Treatment of excess sweating of the palms by iontophoresis. Arch Dermatol 1987; 123: 893–6. 34. Swinehart J. Treatment of axillary hyperhidrosis: combination of the starch-iodine test with the tumescent liposuction technique. Dermatol Surg 2000; 26: 392–6. 35. Gossot D, Galetta D, Pascal A, et al. Long-term results of endoscopic thoracic sympathectomy for upper limb hyperhidrosis. Ann Thoracic Surg 2003; 75: 1075–9. 36. Kim B, Oh B, Park Y, et al. Microinvasive video-assisted thoracoscopic sympathicotomy for primary palmar hyperhidrosis. Am J Surg 2001; 181(6): 540–2. 37. Belin E, Polo J. Treatment of compensatory hyperhidrosis with botulinum toxin type A. Cutis 2003; 71: 68–70. 38. Andrews B, Rennie J. Predicting changes in the distribution of sweating following thoracoscopic sympathectomy. Br J Surg 1997; 84(12): 1702–4. 39. Kao M, Chen Y, Lin J, Hsieh C, Tsai J. Endoscopic sympathectomy treatment for craniofacial hyperhidrosis. Arch Surg 1996; 131(10): 1091–4. 40. Naumann M, Lowe N, Kumar C, Hamm H. Botulinum toxin type A is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study. Arch Dermatol 2003; 139(6): 731–6. 41. Heckmann M, Ceballos-Baumann A, Plewig G. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Eng J Med 2001; 344(7): 488–93. 42. Heckmann M, Breit S, Ceballos-Baumann A, Schaller M, Plewig G. Side-controlled intradermal injection of botulinum toxin A in recalcitrant axillary hyperhidrosis. J Am Acad Dermatol 1999; 41: 987–90. 43. Schnider P, Binder M, Kittler P, et al. A randomized, double-blind, placebo-controlled trial of botulinum A toxin for severe axillary hyperhidrosis. Br J Dermatol 1999; 140: 677–80. 44. Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. Br Med J 2001; 323: 596–9. 45. Lowe N, Glaser D, Eadie N, et al. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety. J Am Acad Dermatol 2007; 56: 604–11.
127
46. Glaser D, Kowalski J, Ravelo A, Weng EY, Beddingfield F. Functional and dermatology-specific quality of life benefits with repeated botulinum toxin type A treatment of primary axillary hyperhidrosis. Presented at the annual meeting of the American Academy of Dermatology, San Francisco, 2006. 47. Wollina U, Karamfilov T, Konrad H. High-dose botulinum toxin type A therapy for axillary hyperhidrosis markedly prolongs the relapse-free interval. J Am Acad Dermatol 2002; 46: 536–40. 48. Karamfilov T, Konrad H, Karte K, Wollina U. Lower relapse rate of botulinum toxin A therapy for axillary hyperhidrosis by dose increase. Arch Dermatol 2000; 136(4): 487–90. 49. Glaser D. Treatment of axillary hyperhidrosis by chemodenervation of sweat glands using botulinum toxin type A. J Drugs Dermatol 2004; 3: 627–31. 50. Alam M, Dover J, Arndt K. Pain associated with injection of botulinum A exotoxin reconstituted using isotonic sodium chloride with and without preservative: a double-blind, randomized controlled trial. Arch Dermatol 2002; 138: 510–4. 51. Sarifakioglu N, Sarifakioglu E. Evaluating effects of preservativecontaining saline solution on pain perception during botulinum toxin type-A injections at different locations: a prospective, single-blinded, randomized controlled trial. Aesth Plast Surg 2005; 29: 113–5. 52. Vadoud-Seyedi J, Simonart T. Treatment of axillary hyperhidrosis with botulinum toxin type A reconstituted in lidocaine or in normal saline: a randomized, side-by-side, double-blind study. Br J Dermatol 2007; 156: 986–9. 53. Lowe N, Campanati A, Bodokh I, et al. The place of botulinum toxin type A in the treatment of focal hyperhidrosis. Br J Dermatol 2004; 151: 1115–22. 54. Moreau M, Cauhepe C, Magues J, Senard J. Therapeutics: A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis. Br J Dermatol 2002; 149: 1041–5. 55. Saadia D, Voustianiouk A, Wang A, Kaufmann H. Botulinum toxin type A in primary palmar hyperhidrosis: randomized, single-blind, two-dose study. Neurology 2001; 57: 2095–9. 56. Naver H, Swartling C, Aquilonius S. Treatment of focal hyperhidrosis with botulinum toxin type A. Brief overview of methodology and 2 years’ experience. Eur J Neurol 1999; 6(4): S117–120. 57. Vadoud-Seyedi J, Heenen M, Simonart T. Treatment of idiopathic palmar hyperhidrosis with botulinum toxin. Dermatology 2001; 203: 318–21. 58. Glaser D, Kokoska M, Kardesch C. Botulinum toxin type A in the treatment of palmar hyperhidrosis: the effect of dilution and number of injection sites. American Academy of Dermatology Annual Meeting , Poster. 2001. 59. Baumann L, Frankel S, Esperanza W, Halem M. Cryoanalgesia with dichlorotetrafluoroethane lessens the pain of botulinum toxin injections for the treatment of palmar hyperhidrosis. Dermatol Surg 2003; 29(10): 1057–62. 60. Trindade de Almeida A, Kadunc B, Martins de Oliveira E. Improving botulinum toxin therapy for palmar hyperhidrosis: wrist block and technical considerations. Dermatol Surg 2001; 27: 34–6. 61. Wollina U, Karamfilov T. Botulinum toxin A for palmar hyperhidrosis. J Eur Acad Dermatol Venereol 2001; 15: 555–8. 62. Aghaei S. Botulinum toxin therapy for palmar hyperhidrosis: experience in an Iranian population. Int J Dermatol 2007; 46: 212–4. 63. Hund M, Rickert S, Kinkelin I, Naumann M, Hamm H. Does wrist nerve block influence the result of botulinum toxin A
128
64.
65. 66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77. 78.
79. 80.
81. 82.
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT treatment in palmar hyperhidrosis. J Am Acad Dermatol 2004; 50: 61–2. Perez BA, Avalos-Peralta P, Moreno-Ramirez D, Camacho F. Treatment of palmar hyperhidrosis with botulinum toxin type A: 44 months of experience. J Cosmetic Dermatol 2005; 4: 163–6. Glogau R. Treatment of hyperhidrosis with botulinum toxin. Dermatologic Clinics 2004; 22: 177–85. Kontochristopoulos G, Gregoriou S, Zakopoulou N, Rigopoulos D. Cryoanalgesia with dichlorotetrafluoroethane spray versus ice packs in patients treated with botulinum toxin a for palmar hyperhidrosis: self-controlled study. Dermatol Surg 2006; 32(6): 873–4. Smith K, Comite SL, Storwick GS. Ice minimizes discomfort associated with injection of botulinum toxin type A for the treatment of palmar and plantar hyperhidrosis. Dermatol Surg 2007; 33: S88–91. Kreyden OP. Botulinum Toxin in the Management of Focal Hyperhidrosis. In: Benedetto, AV, ed. Botulinum Toxin in Clinical Dermatology. Taylor & Francis, 2006; Chapter 10: pp. 281–285. Naumann M, Bergmann I, Hofmann U, Hamm H, Reiners K. Botulinum toxin for focal hyperhidrosis: technical considerations and improvements in application. Br J Dermatol 1998; 139: 1123–4. Benohanian A. Needle-free anaesthesia prior to botulinum toxin type A injection treatment of palmar and plantar hyperhidrosis. Br J Dermatol 2007; 156(3): 593–6. Benohanian A. What stands in the way of treating palmar hyperhidrosis as effectively as axillary hyperhidrosis with botulinum toxin type A. Dermatol Online J 2009; 15(4): 12. Trindade de Almeida AR, Kandunc BV, Martins de Oliveira. Improving botulinum toxin therapy for palmar hyperhidrosis. Derm Surg 2001; 27: 34–36. Hayton MJ, Stanley JK, Lowe, NJ. A review of peripheral nerve blockade as local anaesthesia in the treatment of palmar hyperhidrosis. Br J Dermatol. 2003; 149: 447–451. Campanati A, Lagalla G, Penna L, Gesuita R, Offidani A. Local neural block at the wrist for treatment of palmar hyperhidrosis with botulinum toxin: technical improvements. JAAD 2004; 51(3): 345–348. Vollert B, Blaheta H, Moehrle E, Juenger M, Rassner G. Intravenous regional anaesthesia for treatment of palmar hyperhidrosis with botulinum toxin type A. Br J Dermatol 2001; 144: 632–3. Ponce-Olivera RM, Tirado-Sanchez A, Arellano-Mendoza MI, Leon-Dorantes G, Kassian-Rank S. Palmar hyperhidrosis. Safety efficacy of two anaesthetic techniques for botulinum toxin therapy. Dermatology Online J 2006; 12(2): 9. Reed M. Surgical pearl: mechanoanesthesia to reduce the pain of local injections. J Am Acad Dermatol 2001; 44: 671–2. Scherer C, Clelland J, O’Sullivan P, Doleys D, Canan B. The effect of two sites of high frequency vibration on cutaneous pain threshold. Pain 1986; 25(1): 133–8. Solomon B, Hayman R. Botulinum toxin type A therapy for palmar and digital hyperhidrosis. J Am Acad Dermatol 2000; 42: 1026–9. Glass GE, Hussain M, Fleming AN, Powell BW. Atrophy of the intrinsic musculature of the hands associated with the use of botulinum toxin-A injections for hyperhidrosis: a case report and review of the literature. J Plastic Reconstr Aesthetic Surg 2009; 62(8): 274–6. Zaiac M, Weiss E, Elgart G. Botulinum toxin therapy for palmar hyperhidrosis with ADG needle. Dermatol Surg 2000; 26: 230. Trindade de Almeida A, Boraso R. Palmar hyperhidrosis. In: Trindade de Almeida A, Hexsel D, eds. Hyperhidrosis and Botulinum Toxin. Sao Paulo: Know-how Editorial Ltd, 2004: 155–62.
83. Coutinho dos Santos C, Gomes A, Giraldi S, Abagge K, Marinoni L. Palmar hyperhidrosis: long-term follow-up of nine children and adolescents treated with botulinum toxin type A. Pediatr Dermatol 2009; 26(4): 439–44. 84. Naumann M, Hofmann U, Bergmann I, et al. Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin. Arch Dermatol 1998; 134(3): 301–4. 85. Blaheta H, Deusch H, Rasner G, Vollert B. Intravenous regional anesthesia (Bier’s block) is superior to a peripheral nerve block for painless treatment of plantar hyperhidrosis with botulinum toxin. J Am Acad Dermatol 2003; 48(2): 302–4. 86. Campanati A, Bernardini M, Gesuita R, Offidani A. Plantar focal idiopathic hyperhidrosis and botulinum toxin: a pilot study. Eur J Dermatol 2007; 17(1): 52–4. 87. Blaheta H, Deusch H, Rassner G, Vollert B. Intravenous regional anesthesia (Bier’s block) is superior to a peripheral nerve block for painless treatment of plantar hyperhidrosis. J Am Acad Dermatol 2003; 48(2): 301–3. 88. Vadoud-Seyedi J. Treatment of plantar hyperhidrosis with botulinum toxin type A. Int J Dermatol 2004; 43: 969–71. 89. Sevim S, Dogu O, Kaleagasi H. Botulinum toxin-A therapy for palmar and plantar hyperhidrosis. Acta Neurol Belg 2002; 102: 167–70. 90. Kinkelin I, Hund M, Naumann M, Hamm H. Effective treatment of frontal hyperhidrosis with botulinum toxin A. Br J Dermatol 2000; 143: 824–7. 91. Boger A, Herath H, Rompel R, Ferbert A. Botulinum toxin for treatment of craniofacial hyperhidrosis. J Neurol 2000; 247(11): 857–61. 92. Glaser DA, Herbert AA, Pariser DM, Solish N. Facial hyperhidrosis: best practice recommendations and special considerations. Cutis 2007; 79(5 Suppl): 29–32. 93. Drobik C, Laskawi R. Frey’s syndrome: treatment with botulinum toxin. Acta Otolaryngol (Stockh) 1995; 115: 459–61. 94. Naumann M, Zellner M, Toyka K, Reiners K. Treatment of gustatory sweating with botulinum toxin. Ann Neurol 1997; 42(6): 973–75. 95. Bjerkhoel A, Trobbe O. Frey’s syndrome: treatment with botulinum toxin. J Laryngol Otol 1997; 111(9): 839–44. 96. Laskawi R, Drobik C, Schonebeck C. Up-to-date report of botulinum toxin type A treatment in patients with gustatory sweating (Frey’s syndrome). Laryngoscope 1998; 108: 381–4. 97. Laccourreye O, Akl E, Gutierrez-Fonseca R, et al. Recurrent gustatory sweating (Frey syndrome) after intracutaneous injection of botulinum toxin type A: incidence, management, and outcome. Arch Otolaryngol Head Neck Surg 1999; 125: 283–6. 98. Hexsel D, Dal’forno T, Hexsel C. Inguinal, or Hexsel’s hyperhidrosis. Clin Dermatol 2004; 22(1): 53–9. 99. Huh C, Han K, Deo K, Eun H. Botulinum toxin treatment fore compensatory hyperhidrosis subsequent to an upper thoracic sympathectomy. J Dermatol Treat 2002; 13: 91–3. 100. Kim W, Kil H, Yoon K, Noh K. Botulinum toxin: a treatment for compensatory hyperhidrosis in the trunk. Dermatol Surg 2009; 35(5): 833–8. 101. Matarasso S. Treatment of facial chromhidrosis with botulinum toxin type A. J Am Acad Dermatol 2005; 52(1): 89–91. 102. Ross AT. Progressive selective sudomotordenervation. Neurology 1958; 8: 808–17. 103. Kreyden OP. Rare forms of hyperhidrosis. In: Kreyden OP, et al., eds. Hyperhidrosis and Botulinum Toxin in Dermatology. Basel: Karger, 2002; 30: 178–87. 104. Itin P, Hirsbrunner P, Rufli T, et al. Das Ross Syndrom. Hautarzt 1992; 43: 359–60. 105. Kreyden OP, Schmid-Grendelmeier P, Burg G. Idiopathic localized unilateral hyperhidrosis. Case report of successful treatment
BOTULINUM TOXIN IN THE MANAGEMENT OF FOCAL HYPERHIDROSIS
106.
107.
108.
109.
with botulinum toxin type A and review of the literature. Arch Dermatology 2001; 137: 1622–5. Birklein F, Eisenbarth G, Erbguth F, Winterholler M. Botulinum toxin type B blocks sudomotor function effectively: a 6 month follow up. J Invest Dermatol 2003; 121(6): 1312–6. Schlereth T, Mouka I, Eisenbarth G, Winterholler M, Birklein F. Botulinum toxin A (Botox) and sweating-dose efficacy and comparison to other BoNT preparations. Autonom Neurosci 2005; 117: 120–6. Dressler D, Abid Saberi F, Benecke R. Botulinum toxin type B for treatment of axillary hyperhidrosis. J Neurol 2002; 249: 1729–32. Nelson L, Bachoo P, Holmes J. Botulinum toxin type B: a new therapy for axillary hyperhidrosis. Br J Plastic Surg 2005; 58: 228–32.
129
110. Baumann L, Halem M. Systemic adverse effects after botulinum toxin type B (myobloc) injections for the treatment of palmar hyperhidrosis. Arch Dermatol 2003; 139: 226–7. 111. Baumann L, Slezinger A, Halem M, et al. Double-blind, randomized placebo-controlled pilot study of the safety and efficacy of myobloc (botulinum toxin type B) for the treatment of palmar hyperhidrosis. Dermatol Surg 2005; 31: 263–70. 112. Hecht M, Birklein F, Winterholler M. Successful treatment of axillary hyperhidrosis with very low doses of botulinum toxin B: a pilot study. Arch Dermatol 2003; 295: 318–9. 113. Kavanagh G, Oh C, Shams K. BOTOX delivery by iontophoresis. Br J Dermatol 2004; 151: 1093–5. 114. Glogau R. Topically applied botulinum toxin type a for the treatment of primary axillary hyperhidrosis: results of a randomized, blinded, vehicle-controlled study. Dermatol Surg 2007; 33: S76–80.
16
One syringe wonder Mary P. Lupo
The art and science of injectable dermal fillers are continuing to evolve as techniques improve and safer, more durable, and more versatile fillers are brought to market. The science of dermal filler results has been documented in numerous double-blinded, controlled studies (1–3). Many articles have outlined off-label uses found to be safe and effective (4–7). Complications have been documented to help practicing physicians prevent and effectively treat the untoward result and prevent significant sequelae (8–14). The artistry of fillers is visible in the natural enhancement and augmentation that is possible by using good clinical judgment and meticulous injection technique. Economics for doctor and patients is an important, yet often neglected aspect of a filler practice in educational books, journals, and at meetings. This chapter will discuss the importance of optimal use of small amounts of filler in order to give patients who are either on a budget or simply apprehensive the ability to try one syringe and still get results. The emphasis will be on clinical judgment and the strategy needed during patient consultation, how to stretch one syringe, product choices, and injection tips. This premise was the result of my hearing so many complaints at live demonstrations that attendees could not relate to patient results that were based on four or more syringes being injected. They expressed dismay that they were not learning techniques they could reasonably use in their practices. Practicing in a somewhat economically depressed city, yet having a thriving filler practice I felt uniquely qualified to discuss this issue. I presented this lecture at several meetings, including American Society for Dermatologic Surgery (ASDS) and the Cosmetic Boot Camp and now in this textbook. WHEN TO SAY “NO,” HOW TO SAY “THAT IS ALL I CAN DO,” WHY TO SAY “YOU NEED IT HERE INSTEAD”
There are patients to whom one syringe will be a waste of money. To those patients, it is best to do nothing rather than have a patient waste their money. The truth is that this is very rare however, if you can make the patient understand exactly what only one syringe can realistically do. The 80-year old may want to look 50, but when they understand that it would take thousands of dollars of filler (and likely several laser sessions and a facelift), they may just settle for a syringe of filler around the lips to reduce lipstick bleeding (Figs. 16.1 and 16.2). The point is that communication is the key to success with fillers whether the patient is 30 or 80, and it is the one thing that will determine if you succeed in pleasing the patient. Remember, this is an elective procedure and your success will depend on whether the patient elects to do the procedure, and then you must deliver on their understood expectation for them to return a second time. I often show patients while he/she may need nasolabial, marionette, and cheeks done, with just one syringe, I can really only do the marionette well. So the first rule for a one syringe wonder is “Do a very good job with one syringe, and the patient will return for more.” Of course the corollary of this rule is if you do a poor job, you will never see them again. Never, therefore, take one syringe and spread it over multiple areas of need. That will result in a dilution of effect and no real visible improvement. The second rule therefore is “Use one syringe effectively in one area to maximize its impact.” Another very important tip is to complement the filler with botulinum toxin to enhance the effect. For example, I almost always throw
130
in, at no charge on the first filler visit to treat the marionette area, 9 U to 15 U of botulinum toxin type A into the mentalis and depressor angularis oris to modulate the pull of these muscles that accentuate the marionette fold and pre-jowl sulcus (Figs. 16.3 and 16.4). Using a little toxin (4–10 U) into the obicularis oris makes one syringe of filler placed into lipstick lines work much better. Rule three: “Complement the benefit of one syringe with neurotoxin for greater effect.” PRODUCT SELECTION
There are several Food and Drug Administration (FDA) approved fillers available for injection. Hyaluronic acid (HA) fillers are the most popular. This is likely because of the documented safety of this filler, as well as the fact that it is reversible with hyaluronidase. In my practice, however, it is not the reason that it is my workhorse dermal filler. I have found great safety and effectiveness in all currently available fillers. The major advantage of HA is that it can go into the lips and others cannot. When I have a younger patient in need of a little softening of the nasolabial fold, they inevitably want “just a little in the lips” (Figs. 16.5 and 16.6). This means I cannot safely inject calcium hydroxy apatite, poly-L-lactic acid, or the current formulation of porcine collagen. These products have well-known problems with nodules when injected into the lips. For this reason, the fourth rule of one syringe wonder is “Hyaluronic acid fillers are the most versatile and can be stretched the easiest.” The large volume of material in and the stiffness of the product within the syringe actually make calcium hydroxy apetite one of the best options for a one syringe wonder, if the patient requires or desires no lip augmentation (Figs. 16.7 and 16.8). Finally, it is often very important to understand that the area of concern may not be where you actually should inject. The nasolabial fold should not be injected if there is mid-cheek lipoatrophy. This will result in a “monkey” look to the face by building up the fold when the patient would look more natural with cheek augmentation instead (Figs. 16.9 and 16.10). STRETCH THE ONE SYRINGE
There are some definite tricks to stretch the effectiveness of one syringe of dermal filler. The results of HA filler have the longest duration in the nasolabial fold when injected into the dermis. Non-HA fillers can, however, get a “woody,” indurated texture when injected into the dermis, so they should be injected just beneath the dermis for best results (Fig. 16.11). When injected beneath the muscle, long duration is also achieved. When the filler is injected into the subcutaneous tissue, much so the fifth rule is “When injecting dermal fillers, the least dramatic effect will be achieved if you are in the subcutaneous plane.” The angle of placing the needle for injection is also very important. When injecting cheeks, I recommend going in at 90° and placing the needle tip under the muscle above the periosteum, then pivoting the needle up toward the skin for injection in order to give the most dramatic lift of the cheeks. Deep bolus injections above the bone and beneath the muscle give very effective long-lasting correction with less material (Fig. 16.12). When injecting into the dermis, use the needle to scrape along the dermis and “subsize” the tissue. This will result in greater long-term
ONE SYRINGE WONDER
131
Figure 16.1 Eighty-year old before 1 cc hyaluronic acid (HA) filler.
Figure 16.2 Eighty-year old after 1 cc hyaluronic acid (HA) filler.
Figure 16.3 Before 1.3 cc calcium hydroxyapatite and 15 U botulinum toxin.
Figure 16.4 After 1.3 cc calcium hydroxyapatite and 15 U botulinum toxin.
Figure 16.5 Seven months before 0.8 cc hyaluronic acid (HA) filler into scar, nasolabial fold, and lips of 32-year-old female.
Figure 16.6 Seven months after 0.8 cc hyaluronic acid (HA) filler into scar, nasolabial fold, and lips of 32-year-old female.
132
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
Figure 16.7 Before 1.3 cc CaHA into nasolabial and marionette of 52-year-old
Figure 16.8 After 1.3 cc CaHA into nasolabial and marionette of 52-year-old female.
female.
Figure 16.9 Before 0.8 cc hyaluronic acid (HA) filler into cheeks of 38-year-old
Figure 16.10 After 0.8 cc hyaluronic acid (HA) filler into cheeks of 38-year-old
female.
female.
Figure 16.12 Cheek augmentation. The dots represent the needle’s point of entry at
Figure 16.11 Fifty-eight-year-old female treated with CaHA too superficially.
90° to a depth under the muscle above the bone (i.e., it goes straight in and down). The arrow represents where the needle is then pivoted up; the bolus is injected at the tip of needle and there is then retrograde threading of filler as the needle is slowly withdrawn.
ONE SYRINGE WONDER
Figure 16.13 Result 4 years before regular one syringe of 1.0 cc hyaluronic acid (HA)
133
filler using the “subsizing” technique.
Figure 16.14 Result 4 years after regular one syringe of 1.0 cc hyaluronic acid (HA) filler using the “subsizing” technique.
Figure 16.15 Before treating top third of defects 0.8 cc hyaluronic acid (HA) filler in
Figure 16.16 After treating top third of defects 0.8 cc hyaluronic acid (HA) filler in
43-year-old female.
43-year-old female.
collagen stimulation (Figs. 16.13 and 16.14). Another trick to improve the nasolabial and marionette folds with one syringe is to correct the top one-third of these folds only (Figs. 16.15 and 16.16). Using the “bridging” (crosshatching) technique of perpendicular dermal
injections helps build this area up rather than just filling along the line (Fig. 16.17). When injecting only the lips, add little boluses into the lip tubercles for a natural enhancement that allows just one syringe to go further (Figs. 16.18 and 16.19).
134
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
Figure 16.17 “Bridging” or linear crosshatching of perpendicular threads: the arrows show the direction of injections (both antegrade and retrograde threading).
Figure 16.18 Before 1.0 cc hyaluronic acid (HA) filler into tubercles of lips.
SUMMARY
One syringe can do wonders if a good product is placed correctly into a well-informed patient. When patients understand the limitations of one syringe, but see measurable benefit, it will translate into a happy patient who returns for more. REFERENCES
1. Narins RS, Brandt F, Leyden J, et al. A randomized, double-blinded, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for the correction of nasolabial folds. Dermatol Surg 2003; 29: 588–95. 2. Baumann LS, Shamban AT, Lupo MP, et al. Comparison of smoothgel hyaluronic acid fillers with cross-linked bovine collagen: a multi-center, double-masked, randomized, within-subject study. Dermatol Surg 2007; 33: S128–S135. 3. Monstrey SJ, Pitaru S, Hamdi M, et al. A two-stage phase I trial of Evolence30 collagen for soft-tissue contour correction. Plast Reconstr Surg. 2007; 120: 303–11. 4. Lupo MP. Hyaluronic acid fillers in facial rejuvenation. Semin Cutan Med Surg. 2006; 25: 122–6. 5. Vleggaar D. Soft-tissue augmentation and the role of poly-L-lactic acid. Plast Reconstr Surg 2006; 118(Suppl 3): 46S–54S. 6. Jacovella PF, Peiretti CB, Cunille D, et al. Long-lasting results with hydroxylapatite (Radiesse) facial filler. Plast Reconstr Surg 2006; 118(Suppl 3): 15S–21S.
Figure 16.19 After 1.0 cc hyaluronic acid (HA) filler into tubercles of lips.
7. Lupo MP, Thomas JA, Murphy DK, Walker PS. Effectiveness of next generation hyaluronic acid dermal fillers in the treatment of severe nasolabial folds [abstract]. J Am Acad Dermatol. 2007; 56: AB199. Abstract P 2909. 8. Lowe NJ, Maxwell CA, Patnaik R. Adverse reactions to dermal fillers: review. Dermatol Surg. 2005; 31: 1616–25. 9. Hirsch RJ, Lupo M, Cohen JL, Duffy D. Delayed presentation of impending necrosis following soft tissue augmentation with hyaluronic acid and successful management with hyaluronidase. J Drugs Dermatol 2007; 6: 325–8. 10. Alam M, Dover JS. Management of complications and sequelae with temporary injectable fillers. Plast Reconstr Surg 2007; 120: 98S–105S. 11. Glogau RG, Kane MC. Effect of injection techniques on the rate of local adverse events in patients implanted with nonanimal hyaluronic acid gel dermal fillers. Dermatol Surg 2008; 34: S105–S109. 12. Hirsch RJ, Brody HJ, Carruthers JDA. Hyaluronidase in the office: a necessity for every dermasurgeon that injects hyaluronic acid. J Cosmet Laser Ther 2007; 9: 182–5. 13. Hirsch RJ, Narurkar V, Carruthers J. Management of injected hyaluronic acid induced Tyndall effects. Lasers Surg Med. 2006; 38: 202–4. 14. Brody HJ. Use of hyaluronidase in the treatment of granulomatous hyaluronic acid reactions or unwanted hyaluronic acid misplacement. Dermatol Surg 2005; 31: 893–7.
17
Hyaluronic acid fillers Mary P. Lupo
INTRODUCTION
Nonsurgical rejuvenation has become the cornerstone of cosmetic dermatology practices. The art of combining lasers, botulinum toxins, and dermal fillers is replacing cold steel surgery. Since dermatologists first pioneered the concept of office-based dermabrasion in the 1960s and lunchtime fillers and peel procedures in the 1980s, there has been a continued growth of innovations to improve aging skin without the need for radical plastic surgery. Softer, more natural corrections are replacing pulled and plastic alterations. Dermal fillers are critical to this style of patient care. Bovine collagen was first approved by FDA in 1981. For over 20 years, it was the only filler option in the United States to efface lines and wrinkles of the face. But there were barriers to success. Poor duration, allergenicity, and inability to deliver volumetric correction of the aging face made bovine collagen an important, but inadequate “first step.” Finally in 2003, the United States saw its first new dermal filler: non-animal stabilized hyaluronic acid (HA). This delayed, but important, second step was quickly followed by other dermal filler innovations. Although there are newer and different fillers now available, HA remains the workhorse filler in most practices. The reasons for this are the effectiveness, versatility, and safety of HA products. SCIENCE OF HYALURONIC ACID FILLERS
HA is a glycosaminoglycan found in connective tissue of cartilage, bone, synovial fluid, and skin. It is identical in all mammals. Its viscoelastic properties, lack of immune variances between species, and prevalence in the dermis make it an ideal substance for cosmetic skin augmentation. HA decreases with intrinsic, chronological aging and is impacted by photoaging, or extrinsic aging. This senescence and loss of tissue causes reduction in dermal hydration and volume and is a factor in formation of lines, folds, and wrinkles. HA is a polysaccharide of repeating units of D-glucuronic acid and N-acetyl-glucosamine. Uncrosslinked HA has a very short dwell time in the dermis before it is completely eliminated by the lymphatics and metabolized in the liver into carbon dioxide and water. Chemical crosslinking is necessary to improve duration and utility as a dermal filler. HA is highly hydrophilic and binds water in proportion to its concentration, and these factors make it an ideal material to lift and fill the aging face. Other parameters that affect the final performance and utility of an HA filler are molecular weight, particle size, and the degree of crosslinking percentage of the HA. All these factors combine to give a final product which will have very specific physical properties that impact the usefulness of the HA in varying situations, the ease or difficulty of injection, and the likelihood of various complications such as swelling. There are currently several proprietary versions of HA fillers available in the United States. HYALURONIC ACID FILLERS: OPTIONS
HA fillers are approved as devices, not drugs. Safety and efficacy have been established for improvement of facial lines and folds such as the nasolabial fold. Many other HA dermal fillers are available outside the United States and likely several will eventually appear in the U.S. marketplace. For purposes of this discussion, only those FDA approved in the United States as of this writing will be included. Restylane (Medicis Aesthetics Inc., Scottsdale, Arizona, USA) was the first to be approved in December 2003. In the original pivotal trial, it
was found to have significant duration of correction when compared to Zyplast (1). Restylane is 20 mg/ml concentration, approximately 330 to 430 μm particle-size, of medium viscosity and designed for mid-todeep dermal injection. The source of the HA is non-animal, from streptococcal fermentation. Like all HA products to follow, no skin testing was required before administration. Hylaform was approved in April 2004 and Hylaform Plus (both from Inamed) in October 2004. These are derived from avian rooster combs and are particles sized. These HA products are of higher molecular weight than Restylane, but much lower concentration (5.5 mg/ml). The particle size of Hylaform is 500 μm, and Hylaform Plus is 750 μm. In a comparative trial, Restylane Perlane had better duration of effect (2). Perlane, released by Medicis in May 2007, has a concentration of 20 mg/ml and is a larger particlesized HA (750– 1000 μm) but its duration has not been found to be greater than Restylane (3). After Allergan’s acquisition of Inamed, the Hylaform line was phased out. Captique (also from Inamed) was the second HA approved derived from a bacterial source. Its approval came in December 2004. This product was similar to Hylaform in concentration (5.5 mg/ml) and particle size (500 μm) but lower in molecular weight like Restylane. When Inamed was acquired by Allergan, it too was phased out, but re-emerged in 2008 to be the first dermal filler available with lidocaine. Renamed Prevelle, it is available from Mentor Corporation (Santa Barbara, California, USA). Although Elevess from Anika Therapeutics, Bedford, Massachusetts, USA,. was the first HA–lidocaine combination product to get an FDA approval in 2007, it has only recently become available again since Artes, its distributing company went bankrupt. Re-emerging in July 2009, as Hydrelle from Coapt Systems Inc., Palo Alto, California, USA, it is the highest concentration of HA (28 mg/ml) on the market to date in the United States (4). Like Juvederm, it is not particle sized. Juvederm Ultra and Ultra Plus became available in June 2006. The manufacturer (Allergan Inc., Irvine, California, USA) uses a proprietary process that results in a “smooth cohesive gel” rather than being a uniformly particle-sized suspension. Both products are 24 mg/ml, but the higher degree of crosslinking of the Ultra Plus version results in a more robust and longer lasting dermal filler (5). PRACTICAL APPLICATIONS
The most important variable in patient outcome from HA fillers is the injecting physician. The level of training and experience, innate artistry, and the level of familiarity with the product all impact the final result of dermal filler injections. I have given lectures entitled: “It’s not the filler, it’s the Filler” reviewing the fact that experienced dermatologists and other core aesthetic physicians can get great results when using any filler and inexperience can result in disastrous results even with safe dermal fillers (Fig.17.1). HA fillers are very versatile in that many areas can be injected and various depths can be injected (6). Exciting new research suggests that the mechanical stretching of aging skin with HA filler can result in activation of fibroblasts and subsequent de-novo collagen production in vivo (7). Layering HA filler into the subcutaneous or sub-muscular planes as well as deep and middermal levels can result in more natural correction of greater durability (Figs. 17.2 and 17.3). HA fillers can be used in any area on the face with excellent results. The nasolabial fold is the primary area for correction, but experienced aesthetic physicians understand the importance of cheek enhancement
135
136
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
to lift a deflated cheek and reposition it to give a lift to the nasolabial fold (Figs. 17.4 and 17.5). By injecting both areas, less material is needed in the nasolabial fold and this helps prevent over-filing of this area and a resulting “muzzle” look to the face. HA fillers are particularly good for cheek and nasolabial correction because of the molding capabilities of the product (8). Deeper injections beneath the obicularis oculi in the upper cheek often improve atrophy along the arcus marginalis (Figs. 17.6 and 17.7) as well as the extended orbital-malar groves that are the result of volume loss in the cheek area and add to the redundancy of the nasolabial fold (Figs. 17.8 and 17.9). The marionette fold can result in a droopy, sad, or angry look and can accentuate the jowls when the marionette and pre-jowl sulcus converge. The use of filler deep into these areas can re-sculpt the chin, lift the mouth corner, and reshape an aging jaw line. The complementing
action of botulinum toxin into the mentalis and depressor angularis oris muscles can improve the overall result (Figs. 17.10 and 17.11) (9). HA fillers, especially the less viscous and less crosslinked types, can be used in fine lines around the eyes and mouth and to complement the action of botulinum toxin in the glabellar lines when these lines are deeply etched into photoaged skin. The glabellar area must be injected into the upper dermis to prevent inadvertent vascular injection and catastrophic complications from occlusion and skin necrosis. The earlobes are the popular new area for HA filling as well, to improve the position of earring studs. Loss of volume from age results in thin, elongated earlobes. The replacement of volume plumps the lobe and shortens it, allowing the earring to point forward rather than down. By far the most popular use of HA filler is for lip augmentation (Figs. 17.12 and 17.13). As we age, the loss of lip volume from intrinsic aging and photoaging as well as the dynamic wrinkles and lines that develop as a result of talking, lip pursing, and smoking result in an aged, “pinched” appearance. The distance between the nose and the upper lip increases as the distance from the lower lip to the chin decreases. Ptosis of the mouth corners adds to the sad and aged look of the mouth. While no filler is FDA approved for lip augmentation, HA has been used safely “off-label” for years (10). In contrast, calcium hydroxylapatite and poly-L-lactic acid are not recommended in the lips because of the high incidence of nodule formation (Fig. 17.14). COMPLICATIONS
Figure 17.1 Fifty-three-year-old female 1 year after injection of 1 cc Hylaform Plus by nurse practitioner.
Figure 17.2 Sixty-three-year old female prior to injection.
No medical procedure is without risks. Dermal filling with HA, however, has a long track record of safety when used by experienced, board certified core aesthetic physicians. The fact that HA fillers are temporary usually translates into temporary side effects. Transient and selflimiting complications of redness and swelling are not uncommon with any filler. Because of the hydrophilic nature of HA, higher concentration products will naturally be associated with greater incidence of swelling (11). Over-correction should, therefore, be avoided. Granuloma formation can occur with any filler as well, but is less common
Figure 17.3 3.5 years after repeated injection with 1 cc hyaluronic acid (HA) filler into deep submuscular plane and dermis, showing good long-term effect.
HYALURONIC ACID FILLERS
Figure 17.4 Before treatment with 0.8 cc hyaluronic acid (HA) filler into the cheek.
137
Figure 17.5 After treatment with 0.8 cc hyaluronic acid (HA) filler into the cheek.
Figure 17.6 Before treatment with 0.2 cc hyaluronic acid (HA) filler.
Figure 17.7 After treatment with 0.2 cc hyaluronic acid (HA) filler.
Figure 17.8 Before treatment under the obicularis oculi muscle for correction of the malar groove.
Figure 17.9 After treatment under the obicularis oculi muscle for correction of the malar groove.
138
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
Figure 17.10 Fifty-six-year-old female before treatment.
Figure 17.11 After treatment of hyaluronic acid (HA) and botulinum toxin type A.
Figure 17.12 Thirty-year-old female before treatment with 0.8 cc hyaluronic acid
Figure 17.13 Nine months post-treatment.
(HA) filler.
with HA than semi-permanent fillers such as poly-L-lactic acid and calcium hydroxy apetite and permanent fillers such as polymethylmethacrylate (12). Complaints of asymmetry or lumpiness can be very long lasting with other dermal fillers, but because of the availability of hyaluronidase, these problems are quickly reversed with HA fillers. Other fillers must be allowed to gradually diminish over time. Nodules or “lumps” are best managed as quickly as possible. Gentle massage between the thumb and forefinger immediately after injection can usually smooth out minor irregularities. Any nodule or lump present for more than 1 week should be addressed. Sometimes a slight nick into the skin can result in the ability to milk the excess material out of the skin (Figs. 17.15 and 17.16). If not, hyaluronidase should be considered. I use FDA-approved Vitrase, diluted to 75 mg/ml. About 10 to 30 mg is injected per lump. The patient is seen back in 24 to 72 hours for possible re-treatment as needed (Figs. 17.17 and 17.18). Bruising is a common but very disturbing complication of HA filler injections. While other common side effects like redness and swelling typically last less than 24 hours, bruising often worsens over 24 hours and can last one week. This has significant impact on social “downtime” and may give the patient hesitation to repeat the procedure in the future. HA has structural similarities to heparin. The after-production addition of lidocaine with or without epinephrine into the HA syringe by the treating physician may decrease bruising because of the vasoconstrictive action of the epinephrine. Plain lidocaine is not
Figure 17.14 Two years after injection of CaHA into lips.
vasoconstrictive, but studies with HA and added lidocaine without epinephrine has not demonstrated increased bruising (13). Bruising may also be reduced by decreasing the number of needle sticks, by avoiding the fanning technique of injection and by slowing the rate of the injection to reduce tissue trauma (14). Various reports of the
HYALURONIC ACID FILLERS
139
Figure 17.15 Patient with hyaluronic acid (HA) filler injected too superficially,
Figure 17.16 After extrusion of hyaluronic acid (HA) through a lancet nick into
resulting in blue hue from the Tindle effect.
the skin.
Figure 17.17 Patient one year after hyaluronic acid (HA) filler caused nodules.
Figure 17.18 One week after injection with hyaluronidase.
Figure 17.19 Forty-eight hours after injection with 0.4 cc hyaluronic acid (HA) filler into nasolabial fold, showing reticulated pattern characteristic of vascular compromise.
Figure 17.20 One week after use of hyaluronidase to dissolve hyaluronic acid (HA) compressing vasculature.
140
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
benefits of Arnica and a proprietary lotion derived from a witch hazel extract used for two weeks prior to injection may reduce bruising (15). Finally, a high concentration glycerin product was found to decrease bruising by 65% when applied immediately post injection (16). Pain management during the injection session will result in happier patients, more likely to return for future injections. Topical anesthetics, ice, vibration therapy, nerve blocks, superficial gingival blocks, post-production addition of lidocaine, and “talkasthesia” have all been reported to help improve the patient experience (17). The addition of lidocaine by physicians at the time of injection has been found to decrease pain, improve patient tolerability without affecting the correction (18). The most disastrous and potentially permanent complication of HA filler injection is necrosis or blindness from inadvertent injection into the arterial circulation. The occlusion of the arteriole from the particulate material, or the compression of the arterial vasculature from the filler, can significantly compromise circulation to the skin and result in loss of tissue and permanent scarring. For this reason, the injecting physician should inject slowly and watch for any sign of vascular compromise such as a skin color change (blue or blanched) and immediately stop injection if this occurs. It would be advised to also massage the area, use topical nitroglycerin paste, and give the patient a full dose of aspirin. With HA, the use of hyaluronidase to dissolve the filler has been found to help prevent continued sequelae from vascular compression (Figs. 17.19 and 17.20) (19). The patient should be closely monitored if tissue breakdown occurs and meticulous wound care implemented. Any scars can later be addressed with laser or dermabrasion. SUMMARY
Hyaluronic acid fillers are the most popular fillers in the United States because of efficacy, safety, duration of result, versatility, and reversibility. These factors can give the treating physician confidence and the patient peace of mind. As with all medical procedures, the best results are achieved when an experienced physician chooses a safe dermal filler for an informed, prepared, and appropriate patient. REFERENCES
1. Narins R, Brandt F, Leyden J, et al. A randomized, double-blind, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for the correction of nasolabial fold. Dermatol Surg 2003; 29: 588–95. 2. Carruthers A, Wayne C, de Lorenzi C, et al. Randomized, doubleblind comparison of the efficacy of two hyaluronic acid derivatives, Restylane Perlane and Hylaform in the treatment of nasolabial folds. Dermatol Surg 2005; 31: 1591–600. 3. Perlane package insert, Medicis Aesthetics, Inc. Scottsdale, Az. 4. http://news.prnewswire.com/DisplayReleaseContent.aspx? ACCT=ind_focus.story&STORY=/www/story/07-06-2009/ 0005054929&EDATE=(july 25,2009.
5. Lupo MP, Smith SR, Thomas JA, et al. Effectiveness of Juvederm Ultra Plus dermal filler in the treatment of severe nasolabial folds. Plast Reconstruc Surg 2008; 121: 289–97. 6. Lupo MP. Hyaluronic acid fillers in facial Rejuvenation. Semin Cutan Med Surg 2006; 25: 122–6. 7. In vivo stimulation of de novo collagen production caused by cross-linked hyaluronic acid dermal filler injections in photodamaged human skin. Arch Dermatol 2007; 143: 155–63. 8. Carruthers J, Carruthers A. Hyaluronic acid gel in skin rejuvenation. J Drugs Dermatol 2006; 5(10): 959–64. 9. Carruthers J, Glogau R, Blitzer A, et al. Advances in facial rejuvenation: botulinum toxin type A, hyaluronic acid dermal fillers, and combination therapies—consensus recommendations. Plast Reconstruct Surg 2008; 121(Suppl): 5S–30S. 10. Bosniak S, Cantisano-Zilkha M, Glavas IP. Nonanimal stabilized hyaluronic acid for lip augmentation and facial rhytids ablation. Arch Facial Plast Surg 2004; 6: 379–83. 11. Clark CP. Animal-based hyaluronic acid fillers: scientific and technical considerations. Plast Reconstr Surg 2007; 120(Suppl): 27S–31S. 12. Lowe NJ, Maxwell CA, Patnaik R. Adverse reactions to dermal fillers: review. Dermatol Surg. 2005; 31: 1616–25. 13. Weinkle SH, Bank DE, Boyd CM, et al. Safety and Effectiveness of a 24 mg/mL hyaluronic acid injectable gel with and without lidocaine. In: Poster Exhibit. 5th Annual Cosmetic Boot Camp. Aspen Co., June, 2009. 14. Glogau RG, Kane MC. Effect of injection techniques on the rate of local adverse events in patients implanted with nonanimal hyaluronic acid gel dermal fillers. Dermatol Surg 2008; 34: S105–9. 15. Hagège JC. Prevention of edemas and bruises after facelift and rhinoplasty. Presented at 23rd International Congress of the French Society of Aesthetic Surgery, Paris, 2006. 16. Lupo MP. A double-blinded, randomized, placebo-controlled split faced within subject evaluation of a bruise reduction serum. Poster Exhibit, 5th Annual Cosmetic Boot Camp, Aspen Co., June 2009. 17. Smith K, Niamtu J, Carruthers J. Pain control in cosmetic facial surgery. In: Carruthers J and Carruthers A, eds. Soft Tissue Augmentation Philadelphia, PA: Saunders Elsevier, 2008: 127–41. 18. Svetman G, Lupo MP, Waller W. Comparison of the efficacy and tolerability of non-animal stabilized hyaluronic acid filler with and without lidocaine hydrochloride 2% for the correction of nasolabial folds. Poster Exhibit, 5th Annual Cosmetic Boot Camp. Aspen Co., June 2009. 19. Hirsch RJ, Lupo M, Cohen JL, Duffy D. Delayed presentation of impending necrosis following soft tissue augmentation with hyaluronic acid and successful management with hyaluronidase. J Drugs Dermatol 2007; 6: 325–8.
18
Calcium hydroxylapatite dermal filler for aesthetic correction of face and hands Roberta D. Sengelmann
INTRODUCTION
As the boomer population ages, the quest for a more youthful appearance has generated safe, painless, efficacious, and long-lasting solutions to the loss of elasticity, gradual subcutaneous atrophy, and muscular weakening that are most obviously but not exclusively perceived in the face. The injection of soft tissue filler has met this need, with an array of available permanent and semi-permanent dermal fillers. A relative newcomer to semi-permanent soft tissue filler solutions, Radiesse® Dermal Filler (Merz Aesthetics, San Mateo, California, USA) has received increased attention from practitioners worldwide since its clinical introduction early in this decade. Easily administered during one office visit in well under an hour, Radiesse, a longer-lasting, semi-permanent, non-allergenic soft tissue filler, involves little to no patient downtime and produces immediate results with minimal injection dosage without significant adverse events (1). The biocompatibility of Radiesse renders the filler a durable, safe restorative for moderate to severe facial wrinkles and folds, including nasolabial folds (NLFs), and for HIV-associated facial lipoatrophy. Both of these applications received FDA approval in 2006. Radiesse has also been approved as a corrective for vocal cord insufficiency due to neurological impairment, oral/maxillofacial defects, and as a radiographic tissue marker. In addition to its approved uses, Radiesse has performed effectively in a number of documented off-label clinical applications. These include marionette line and oral commissure correction, chin and lip support, acne scar fill, brow elevation, midface volume restoration, pre-jowl sulcus correction, ear lobe repair, nasal sculpting, and dorsal hand augmentation (1–4). In its current formulation, Radiesse is not appropriate for injection into the lips. COMPOSITION AND MECHANISM OF ACTION
Radiesse is composed of 30% synthetic CaHA microspheres (25–45 µm in diameter) suspended in a 70% aqueous carrier gel of sodium, carboxymethylcellulose, glycerin, and water. Formulated in 1.5, 1.3, 0.8, and 0.3 ml syringes, the tiny CaHA particles and gel can be injected with a fine-gauge needle as small as 28 gauge. On the other hand, the viscosity of Radiesse is substantial enough that oftentimes one syringe during one treatment session suffices—depending upon the degree of volume loss. Upon subdermal injection, the material instantly adds volume to the targeted soft tissue of the skin and requires no overcorrection (5). Within 8 to 12 weeks, the gel carrier is absorbed by the body (6). The biodegradable CaHA microspheres left behind serve as a matrix for new collagen development. These subdermally scattered microspheres are progressively enveloped by collagen, preventing particle migration while enabling longer lasting corrective durability and a smooth, natural appearance and feel (7). The CaHA spherules are eventually metabolized into calcium and phosphate ions and excreted by the body’s urinary system. Multiple safety and efficacy studies have shown the inherent biocompatibility of CaHA. In a pilot study conducted to evaluate the clinical, histologic, and in vivo ultrastructural behavior of Radiesse in human skin, injected CaHA microspherules exhibited minimal cellular inflammation or fibrosis under electron or light microscopy (7). While post-injection soreness and some edema have been reported, Radiesse has caused no allergic, toxic, or irritating response among tested
subjects. Furthermore, the compound’s biocompatibility precludes testing for patient sensitivity prior to injection (1,8). In addition, Radiesse presents no threat of calcification because CaHA contains neither osteo-progenitor cells nor bone morphogenic proteins. CaHA will not interfere with the interpretation of X-rays or CT scans. While not always apparent on X-rays, CaHA is clearly distinguishable from surrounding bone on CT scans, permitting unobstructed scrutiny of adjacent structures. In a study of 58 patients treated for either HIV-related facial lipoatrophy or nasolabial fold correction, images taken from 1 to 426 days following Radiesse injection showed that CaHA was unlikely to be confused with serious radiographic anomalies (9). DURABILITY, EFFICACY, AND COMPARABILITY
When used for augmenting moderate-to-severe nasolabial folds, a relatively small amount of Radiesse (1.0–2.0 ml) is required to induce optimal results visible from 10 to 36 months (10,11). Depending upon the application and the patient, cosmetic enhancement generated by Radiesse persists for approximately 1 year. While comparable to other semi-permanent soft tissue fillers as an alternative to corrective surgical intervention, Radiesse has distinguished itself in a number of studies aimed at evaluating the performance of CaHA, collagen, and hyaluronic acid derivatives. Collagen In a pivotal, multi-centered, prospective, split-face 6-month study to evaluate the long-term efficacy and safety of Radiesse, 117 randomly selected subjects with moderate-to-severe NLFs were injected with Radiesse and the human collagen (HC) filler Cosmoplast (Inamed, Santa Barbara, California, USA). During the time of initial treatment, subjects were injected with a total mean volume of 1.2 ml of Radiesse and 2.4 ml of HC. Graded on the Lemperle Rating Scale, folds treated with Radiesse were rated superior (84.6% at 3 months, 78.6% at 6 months) to those treated with HC (12.8% at 3 months, 16.2% at 6 months) (12). On the Global Aesthetic Improvement Scale (GAIS), 94.6% of Radiessetreated folds garnered at minimum an “improved” grade in comparison with 2.7% for HC. No significant adverse effects were reported. A 39-month post-marketing, follow-up study involving 90% of the original subjects showed that nearly half the CaHA-treated folds were deemed at least “improved” (Figs. 18.13) (13,14). Hyaluronic Acids In two randomized, blinded, multi-center trials designed to assess the efficacy, durability and safety of CaHA versus hyaluronic acids (Juvederm, Allergan, Irvine, California, USA; Perlane, Medicis, Scottsdale, Arizona, USA; Restylane, Medicis, Scottsdale, Arizona, USA) for the correction of NLFs, the fillers compared favorably in safety results. Noteworthy was the considerably smaller volume of CaHA necessary to achieve full correction, representing a cost-effective choice for physicians. CaHA was rated highest in patient satisfaction and likelihood to return for treatment in the future. In both trials, NLFs treated with CaHA received higher ratings on the GAIS in duration of effect (15,16). Radiesse and Persons of Color To determine the efficacy of Radiesse when subdermally injected into the NLFs of people with dark skin, investigators treated NLFs of
141
142
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
100 patients (African–American, Hispanic, Asian and other) in a randomized, open-label, prospective, five-center trial. Study results provided investigators with evidence that Radiesse does not incite scarring, keloidal formation, or altered pigmentation (17). INDICATIONS
While currently FDA-approved for injection in moderate-to-severe wrinkles and folds (including NLFs) and for HIV-related lipoatrophy, Radiesse has proved an effective corrective option in a number of applications for which general guidelines regarding injection technique, amount of filler, patient indications, and expected longevity of results may be modified. PATIENT COUNSELING AND EVALUATION
Although skin pre-testing is deemed unnecessary for Radiesse, a physician should examine the chart for evidence of past hypersensitivity. Given the potential risk of adverse reaction, physicians will want to be cautious about injecting any filler into persons with a history of bleeding disorder, keloidal formation, hypertrophic scarring, collagen disease, or acute or chronic infections. For 5 to 10 days prior to treatment candidates should be instructed to refrain from taking anticoagulants, anti-inflammatories, vitamin E or other medicines, or nutritional supplements that may inhibit clotting or otherwise interfere with the healing process. Antiviral prophylaxis is rarely needed, except in patients who suffer from frequent herpes simplex virus outbreaks on their face. Some patients may be taking blood thinners such as warfarin, clopidogrel, aspirin, herbal medications, or supplements; discontinuation of these medications may help prevent bruising. However, medications should not be discontinued without permission of the prescribing physician. Informed consent is recommended for all procedures and off-label usage needs to be discussed. Given the potentially overwhelming choice of approved fillers and their applications, the physician should ensure that patients are aware of corrective options available to them for specific aesthetic purposes. A candid discussion to calibrate patient and physician expectations may reduce patient anxiety regarding safety and discomfort while providing insight regarding post-treatment care, down time, and treatment durability. Pre- and post-treatment photographs of the affected area(s) should be taken on the day of treatment and then ideally at a one-month posttreatment visit. PRETREATMENT ANESTHESIA AND RADIESSE-LIDOCAINE MIXING
A number of protocols may be utilized for administering anesthesia depending upon the individual patient and the area being treated. Traditionally, anesthetizing the area with ice, vibration, topical anesthetic, local or regional anesthesia (infraorbital and mini-nerve blocks) has been known to facilitate a nearly pain-free experience for the patient (1). The author prefers infraorbital and mental nerve blocks using 0.5% lidocaine with epinephrine 1:200,000 for perioral treatment, e.g., nasolabial folds, marionette lines, tear-trough, and, for filling elsewhere, e.g., hands, temples, cheek bones, prejowl sulcus, angle of mouth, Radiesse mixed with lidocaine. A 2008 investigation confirmed the viability of administering a mixture of Radiesse and lidocaine in treating the sensitive dorsum of the hand (18). The study bore out the investigators’ hypothesis that such an admixture might minimize the need for nerve blocks and, given the reduced viscosity of the newly constituted filler, mitigate the shortterm swelling commonly witnessed. Approved in July 2009 by the FDA, the lidocaine/Radiesse filler mixture requires the connection of one 1.3 ml/1.5 ml syringe of Radiesse to a 3.0 ml syringe containing <0.5 ml of lidocaine via a Rapid Fill™ Luer-Lok-to-Luer-Lok adapter (Baxa; Engelwood, Colorado, USA).
Figure 18.1 Creating an admixture of Radiesse and lidocaine, using female-to female connector.
The process begins with the introduction of filler into the syringe filled with anesthetic. The materials are pushed back and forth approximately 20 times between syringes or until the substance is fully mixed. Slowly injected into the skin, the filler combined with lidocaine has proved subdermally pliant (18,19). Appropriate for both face and hands, the Radiesse/lidocaine regimen has been clinically assessed as a more comfortable alternative for anesthesia administration, in addition to abbreviating the time spent in treatment (Fig.18.1) (20). GENERAL GUIDELINES FOR RADIESSE INJECTION TECHNIQUES
Injection techniques vary according to the area targeted for treatment, motility of the tissue, and amount of filler required for correction. Radiesse is classically injected in a retrograde manner via linear, threading, and/or crosshatching technique. A 1.25-inch, 25- to 28-gauge needle should be inserted at the dermal/subcutaneous junction while the physician advances and withdraws approximately 0.5 ml per pass of filler into the fold (1). A 0.5-inch needle is indicated for areas requiring less volume, e.g., marionette lines, radial lip lines, acne scars, glabella, nose, and ear lobules. As a nuance in technique, the author prefers to inject both on advance and withdrawal of the needle in much smaller volumes, closer to 0.05 to 0.1 ml per pass, for a smooth, natural outcome. Importantly, Radiesse must be injected slowly, so that small amounts are deposited at this level in the tissue; to avoid, palpability and irregularity. The depot or deep threading techniques are recommended for deep supraperiostal injections. This involves 0.1 to 0.15 ml of filler per pass. The material is subsequently molded for maximum dispersal. Areas that this technique is used include over the maxillary bone (cheek, tear trough), frontal bone (eyebrows), mandibular bone (jawline and prejowl sulcus), and in the dorsal hand. Again, Radiesse is injected quite slowly and methodically (Fig. 18.2). TIPS FOR SUCCESSFUL TREATMENT
Physicians may want to keep in mind certain “rules of thumb” regarding the administration of Radiesse.
• •
Filler should be injected for 1:1 correction. Touch-ups can be made at subsequent visits. A 25- to 28-gauge needle is recommended with a 1.25-inch length for NLFs, cheeks, chin, pre-jowl sulcus, labiomental crease, tail of brow, jawline, temples or with a ½-inch length for the marionette lines, radial lip lines, acne scars, glabella, nose, ear lobules, and dorsal hands.
CALCIUM HYDROXYLAPATITE DERMAL FILLER FOR AESTHETIC CORRECTION OF FACE AND HANDS
143
Epidermis
Dermis
Subcutis Muscle Supraperiosteal injection Periosteum
Deep dermis
Bone
Dermal/SQ junction Figure 18.2 Radiesse is placed at or below the dermal/subcutaneous junction.
Figure 18.3 Threading and fanning for nasolabial folds.
NASOLABIAL FOLDS
Appropriate candidates for nasolabial fold correction are generally men and women over 40 years of age with some degree of facial ptosis and malar fat pad descent. Radiesse works best for convexities in the area of the upper nasolabial fold and isthmus of the upper lip. It also nicely treats deep creasing. An infraorbital nerve block may be used to anesthetize the area from lower lids to the upper lip and as far lateral as the oral commissure. The physician should guide a 27-gauge, 28-bore, 1¼ -inch Radiesse needle deep into the dermal plane of the crease, staying medial to the fold, to provide volume fill and structural support to the line or fold.
Some injectors prefer a ½-inch needle for more control. In this case, it is important to overlap threaded areas for a smooth contour (see Fig. 18.1). Tiny aliquots (0.05–0.1 ml) of product are injected on advance and withdrawal for a smooth, natural look. Filling occurs so slowly that it should not be evident to the injector. With any given pass, mid-dermal threads address coarse rhytids whilst deeper threads into deep dermis and superficial subcutis serve to elevate tissue and correct the folds. Full correction in this area does not mean obliterating the shadows; obliteration would give an unnatural appearance and a convexity to the upper cutaneous lip that is ape-like. This approach should be explained to the patient at the outset. While some degree of molding can occur immediately following injection, this cannot compensate for poor technique (usually too much volume deposited in one place, injection too high in skin, or lateral to the nasolabial fold causing added fullness). Additionally, fine superficial creasing cannot be completely corrected with Radiesse but can be improved. This also must be explained to the patient with this indication. To reduce post-treatment redness and swelling, the physician may wish to avoid over-massaging the skin during the procedure and limit the molding process as needed for post-injection correction (1). In the perialar area, filler should be deposited using a fanning technique with retrograde threading to lift and fill the concavity. Following injection, the physician should use both hands to palpate the area to achieve symmetrical contouring. Of note, the angular artery parallels the nasolabial fold as it courses upward from the oral commissures toward the nasal ala in the subcutaneous plane. To avoid cannulating this vessel, injections should be done high in the subcutis and slowly enough so that, if a vessel is injected, the volume of product is small enough so as to be ineffectual. Compromise of the angular artery, especially at the superior aspect of the fold, has been described with various fillers and can lead to tissue ischemia and subsequent scarring (Figs. 18.3 and 18.4).
144
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
(A)
(B)
S/P 1.5 cc Radiesse per side (Mixed with 0.2 cc 2% lido)
(C) Figure 18.4 (A–C) Treatment of nasolabial folds and cheeks.
MIDFACE/CHEEKS
Changes in cheek ptosis arise from resorption and descent of cheek fat pad, remodeling and resorption of cartilaginous and bony structures, laxity in the zygomatic ligament, loss of skin elasticity, simple gravity, and an individual’s genetic makeup. The midface and cheeks have been good applications for Radiesse due to its volumizing properties. Pretreatment counseling with the patient includes the medical history already mentioned here, management of realistic expectations, and cautions to the patient against inadvertently manipulating the injected product through use of goggles, facials, microdermabrasion, and even large-framed and heavy glasses. Post-counseling, the patient is ready for midface/cheek augmentation. Prior to injection, the physician should properly mark the patient's face to determine structures of interest. First, palpate and mark the infraorbital rim on each side of the face. Should one infraorbital rim be lower than the other, the physician should follow the level of the lower rim to enhance symmetry. Product should never be placed above the orbital rim. The superior and inferior cheek borders are also marked, as is the zygomatic arch, to provide guidance in the correct placement of the cheek. In addition, a medial canthal line should be drawn parallel to the nasolabial folds. Product should stay lateral of this line to avoid injection into the angular artery. The medial canthal line, the infraorbital rim, and the infraorbital foramen form a medial lower lid triangle where injection should be approached only by injectors extremely comfortable with the anatomy of the area and their injection techniques. Anesthetic applications may include entry site anesthesia, ice, skin chilling, topical products, and vibration. Recently, Radiesse has been approved to be mixed with lidocaine prior to injection as an added anesthetic option. The infraorbital nerve should not be blocked when injecting the cheeks as this might mask compromise of the infraorbital nerve at the foramen during injection. Instead, entry site anesthesia
and mixing product with a small amount of lidocaine before injecting can comfort the patient without taking away this precaution. As a rule of thumb, injection should be supraperiosteal whenever possible (onlay implantation), especially when addressing the zygoma, the maxilla, and area below the infraorbital rim. This supraperiosteal placement is necessary to avoid lymphatic irritation and/or obstruction in this delicate area of the face. Subdermal injections should only be used for lateral zygoma enhancement when blending into the surrounding area. Subdermal injections should never be done in the medial aspect of the midface. Physicians will want to stay below the infraorbital rim, avoid injection of product on the infraorbital foramen and nerve, and inject lateral to the medial canthus. Onlay implantation will help avoid contact with the malar septum and therefore may aid in preventing some adverse events in this area. For zygoma and malar enhancement, the first insertion point is likely to be from the mid-zygomatic arch, parallel and inferior to the infraorbital rim. The needle should be slowly advanced to the periosteum, then lifted slighty above the periosteum, and repositioned in the supraperiosteal plane. Retrograde linear threads of 0.1 ml of Radiesse can be placed in the supraperiosteal plane, starting just below the infraorbital rim, and then progressing inferiorly in a fanning pattern. Care should be taken to stay superior and lateral to the infraorbital foramen when laying threads of product in this area. The index finger of the non-dominant hand can be placed right at the infraorbital rim to serve as a barrier to inadvertent product injection or migration above the orbital rim. If depot aliquots are to be used in addition to the deep threading technique described above, 0.2 ml aliquots can be used. Some physicians have found that serial puncture depots, with the needle held at a 90° angle to the malar eminence, are useful for injecting aliquots just over the bony prominence. Again, care should be taken to see that aliquots remain small and, when molded, do not encroach on the foramen.
CALCIUM HYDROXYLAPATITE DERMAL FILLER FOR AESTHETIC CORRECTION OF FACE AND HANDS Should a “shelf ” appear in the malar area as the result of aliquot injections, additional augmentation in the zygomatic-temporal zone may be needed for softening. For further refinement and blending, Radiesse injections of 0.05 ml may be placed in the subdermal plane, layered above the supraperiosteal injections. These injections should be lateral to the lateral canthus and deep in the subdermal plane to avoid vasculature and the orbital septum. To recap, when treating the midface, Radiesse is to be placed over the periosteum, especially in the lower lid and medial cheek areas. Small aliquots of product are recommended in the medial midface area to allow for exact placement of product and prevent placement of product near or on the infraorbital foramen/nerve. Aliquots should not exceed 0.2 ml anywhere in the cheeks. No more than 0.2 ml should be placed in the medial lower triangle described earlier (medial canthal line, infraorbital rim, and infraorbital foramen). Post-treatment, the patient should receive post-care instructions, including the admonition to avoid massaging the treated area. Photos should be taken two to four weeks post-injection. SUBMALAR CHEEK HOLLOWS
Caused by the loss or redistribution of subcutaneous fat, submalar cheek hollows may assume the form of concavities and lines lateral to nasolabial folds. Treatment is expected to provide volume replacement and stimulate fibroblasts to produce innate collagen. Once again, patients should be advised that etched lines will not be fully corrected, but contours will be greatly improved. If the malar area needs filling, this area should be addressed before the submalar area, to avoid adding undue weight to the area and facial imbalance. After pretreatment with regional or local anesthesia (the author prefers entry site anesthesia and mixing Radiesse with lidocaine), ice, cooling agent, topical anesthetic or vibration, the needle should be inserted into the subdermal subcutaneous plane with special care to avoid the orbicularis oris muscle inferiorly, and the parotid gland laterally. A higher risk of nodularity will occur if the needle injects the orbicularis oris due to perpetual movement in this area. The parotid gland extends irregularly from just below the zygomatic arch to the angle of the mandible. Passing through the parotid gland are the facial nerve and its branches. Above this, in the subcutaneous plane coursing over parrotid gland and running upward toward the temporal region is the superficial temporal artery. Trauma to it would cause significant ecchymoses. Preferably a 1¼-inch needle is used to administer Radiesse in this area. Once inserted, an easy glide is detected in the subdermal/subcutaneous plane. At this point, the needle is advanced and fine threads (0.05–0.10 ml each) are injected on advance and withdrawal although the bulk of the strand is likely laid down in a retrograde fashion as the needle is withdrawn. Linear threading, fanning, and crosshatching techniques at oblique angles are employed until full correction is obtained. Optimal correction requires 0.5 to 1.5 ml per side (more in the case of HIV lipoatrophy patients). Immediately following full correction, the area should be molded with thumb and forefinger as needed. Patients may benefit from a touch-up 1 to 3 months after initial treatment (Figs. 18.5). NASAL SCULPTING
The nose offers both opportunities and challenges for aesthetic correction. Defects that warrant correction include dorsal hump, “skier’s nose,” concavity (from trauma, chronic drug use, piercing), post-rhinoplasty or post-trauma deformity, nasal tip ptosis, or deep horizontal furrow over the nasal root. Especially indicated for patients interested in nasal contour correction with a desire to avoid surgical rhinoplasty, this application requires discussion of realistic expectations and follow-up care. Nasal sculpting may require more than one injection per session,
145
Figure 18.5 Radiesse injection points in malar cheek and submalar region.
depending upon the correction. However, the physician must take care not to over-treat. Small, subtle changes go a long way due to the strong structural integrity of the nasal bone and cartilages. A maximum of 0.3 ml of Radiesse is advised per injection sitting. Before treatment, the patient should be apprised of nasal asymmetries and the estimated amount of product necessary to achieve correction. In addition to customary medical history, physicians should assess the effect upon the procedure of previous rhinoplasty or nose trauma. A surgically repaired tip can be corrected but may be less receptive to volume filling due to tissue scarification. Prior to anesthetizing, the area to be injected should be marked. Infraorbital nerve blocks are a nice way to achieve nasal sidewall anesthesia without distortion of nasal contours. An ethnoid block may also be helpful but may not provide sufficient anesthesia when lifting the nasal tip. If not adequate, a small amount of local anesthesia can be injected. This tends to be necessary to boost anesthesia of the nasal tip and columella, where small amounts are adequate. An intraoral approach is helpful when numbing the base of the columella. When treating the nose, small strands (approximately 0.1 ml each) are injected supraperiosteally/supraperichondrially. Because of the highly vascular nature of the nose, injections should be done carefully and slowly. For dorsal hump treatment, Radiesse is injected above and below the deformity and should be injected over the midline and bilaterally, to bridge and support the nose. It may be helpful to visualize administration in the form of a small “w”: one strand midline; one strand right of midline; one strand left of midline. Product may be corrected to a visual endpoint and molded lightly. To treat nasal tip ptosis, the needle should be inserted at a 90° angle at the base of columella in the supraperiosteal plane. Small boluses may be injected into the area to bolster the columella and lift the tip. If a small bolus is insufficient to lift the tip, an additional bolus can be placed immediately superior to the first injection in order to correct the problem. The bridge and tip of the nose present certain challenges that accompany treatment of any area with little to no potential space. Over-injection can cause compression of vasculature and possible occlusion and necrosis. While rare, minimizing total injection volume to 0.3 ml per session and 0.1 ml at injection site may be useful (Figs. 18.6 and 18.7). MARIONETTE LINES, ORAL COMMISSURE
Characterized by a mouth frown, marionette lines can be difficult to correct. Small volumes of locally administered anesthesia or mental nerve blocks are advised. Using a 0.5 to 2.75-inch needle, Radiesse is injected along the dermal/subcutaneous junction, starting at the most inferior aspect of the fold and working toward the oral commissures.
146
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
(A)
(B) Figure 18.6 (A,B) Injection points for Radiesse treatment of nasal defects.
(A)
(B) Figure 18.7 (A) Before and after 0.3 ml Radiesse treatment in bridge and columella for dorsal hump camouflage. Photo: Hilton Becker, MD, Boca Raton, Florida, USA, courtesy of Merz Aesthetics. (B) Before and after 0.3 ml Radiesse to left dorsum and nasal tip. Photo: Brock Ridenour, MD, Creve Coeur, Missouri, USA.
CALCIUM HYDROXYLAPATITE DERMAL FILLER FOR AESTHETIC CORRECTION OF FACE AND HANDS Fanning and cross-hatching is used at the corner of the mouth to suspend the angle of the mouth. The entire area, which may include the lateral chin zone, should be treated and progressively brought to full correction. The physician may mold intermittently with forefinger and thumb to assess symmetry. Bimanual (one finger on the skin and one intraorally pushing out on the buccal mucosa) palpation is very helpful in this regard. Because this area bruises readily, a slow, methodical technique is optimal. If injections are placed too high in the skin, irregularities in contour will be evident for quite some time following treatment. It is important to stop injecting several millimeters prior to needle exit, lest product extrudes from the needle entry/exit site and collects there. These small
147
collections of Radiesse look very much like milia but are not as easily evacuated and often require a small incision and extraction. If unavoidable, they can be treated on the day of injection (Figs. 18.8 and 18.9). PRE-JOWL SULCUS
With age, a perceptible hollowing of the area lateral to the chin develops due to bone resorption and soft tissue loss. This causes volume loss, deepening labiomental creases, and chin pad sagging. Amplifying this area with filler sculpts the chin while offering support for the sagging jaw line. Radiesse works famously here to restore contour in a durable fashion. While volumizing this area is not a substitute for face lifting in patients with significant jowling and facial descent, it may be all that is needed in middle-aged patients with early aging changes or in older patients who need the support despite a lift. The facial artery courses through the subcutaneous plane in this area. As such, a deep plane of injection overlying periosteum is used from a lateral or medial approach. Many physicians prefer a depot technique in this area, laying down 0.1 to 0.2 ml aliquots over bone and molding. Others prefer a slow, deep threading technique. The key is to place the product just along the edge of the mandibular border, in order to strengthen and provide a two-dimensional change in facial shape. Placement above the mandibular border will result in a threedimensional improvement in shadows. Bruising can be impressive in this area and the patients should be prepared for this (Fig. 18.10). CHIN RECESSION
Figure 18.8 Crosshatching for marionette lines and oral commissures.
(A)
Before Radiesse
Most of the time, when we treat the chin, treatment arises from a need for more projection and is related to heredity. While chin aging with
(B)
(C)
6 months after 2 cc Radiesse
12 months post Radiesse
Figure 18.9 (A,B) Treatment of marionette lines with 2 ml Radiesse.
148
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
(A)
Before Radiesse to chin and lower face lift
(B)
2 months after 1.3 cc Radiesse to chin and lower face lift
Figure 18.10 (A,B) Treatment of chin before and after injection of 1.3 cc Radiesse.
bone and muscle resorption occurs to some degree, more commonly, facial aging, and ptosis are accentuated by lack of adequate chin volume. Improving chin projection can strengthen the jaw and neckline for a more balanced appearance. The area to be treated is marked prior to anesthesia. Pretreatment with ice, skin-cooling agent, topical anesthetic, or vibration is necessary if a mental nerve block is not going to be used (19). With the patient seated upright, head positioned at 90° to the body, the physician should palpate the mandibular rim at the midpoint of the chin before inserting the needle from below the chin. The injection plane is under mentalis muscle and over periosteum, using a depot or short-threading technique. This technique mitigates risk of injury to the mental nerve as it exits the cranium in the midpupillary line and courses toward the lip depressors. Injections can occur from one prejowl sulcus all the way across to the other or just in the midline, depending on need. Volumes range from 1.0 to 3.0 ml to attain maximal correction. In general, volume is placed both anteriorly and inferiorly. Pressure and molding along the boney ridge allows for proper product placement and contouring (Fig.18.11). CUTANEOUS LIP LINES
Fine rhytids appearing above the upper lip are bothersome to those wearing lipstick, as the color begins to bleed into the tiny lines. Nicknamed “smokers’ lines,” the cutaneous lip lines appear as innate hyaluronic acid collagen and subcutis and are depleted as the skin loses elasticity. Due to the delicacy of the area and superficial etching of the lines, patients should be prepared for more than one treatment approach for full correction. While Radiesse can nicely provide support to the soft tissues in the upper lip, it does not replace the need for skin resurfacing, fine line fillers, and/or botulinum toxin for prominent radiating lip rhytids caused by aging and sun damage. Nerve blocks at the infraorbital foramen are the best way to manage patient discomfort in this area. Injections here are performed at the subdermal but supramuscular level. There is a high risk of bruising in this location. As soon as any bruising is noticed, ice and compression must be used. Thinning Radiesse via reconstitution with lidocaine can be helpful to provide for the smooth outcome that is so critical here. Staying superior of the vermilion border and administering 0.05 ml Radiesse per thread using a 28-gauge needle, the physician should
Figure 18.11 Before and after 0.8 cc Radiesse for pre-Jowl sulcus.
insert the needle just above each oral commissure for retrograde thread placement into the immediate subdermal plane, in a long, transverse “v” or “w” pattern. This is a conservative technique that consumes an average volume of 0.2 ml on each side. The area should then be gently molded in a slight up and down, vertical manner (Fig. 18.12). HANDS
With the baby boomer population increasingly comfortable with facial nonsurgical aesthetic restoration, attention has turned to the hands, where the aging process is evidenced by a skeletonized appearance with visible bony architecture, tendons, and veins.
CALCIUM HYDROXYLAPATITE DERMAL FILLER FOR AESTHETIC CORRECTION OF FACE AND HANDS People with exceptionally thin skin may not be appropriate candidates for this procedure. In addition to the customary concerns, special attention should be paid to candidates with a history of breast cancer, lymphedema, or carpal tunnel syndrome. In addition, since treating the hands may provoke delayed swelling, patients engaged in occupations requiring fine motor skills where swelling would prohibit function need to be warned prior to treatment. Anesthesia generally includes local anesthesia at three to five injection sites and some form of comfort measure(s) for the rest of the hand—ice, chilling, topical anesthetic, or vibration. Radiesse is mixed with 1% or 2% plain lidocaine via a female-to-female adapter on a 3 ml syringe. Epinephrine is discouraged because it may cause vasoconstriction and increase the small risk of tissue ischemia.
149
The physician may inject at one to five sites scattered over the hand dorsum and use vigorous massage to spread product. Injection points are generally spaced 2 to 4 cm apart and tend to occur in between the distal halves of the metacarpal heads. Using the noninjection hand to lift the skin away from the dorsal aspect of the hand being treated, the skin is tented up away from vessels, tendons, and fascia prior to injection. A bolus technique is used to deliver 0.3 to 0.5 ml of Radiesse (21). If a single injection site is selected, a retrograde injection bolus of the lidocaine–Radiesse mixture (0.5–1.3 ml) may be introduced in the areolar plane between the subcutaneous layer and superficial fascia (22). No more than 1.3 ml should be used per injection session for each hand.
Temple Eyebrow
Prejowl Chin
Figure 18.12 Radiesse injection points for cutaneous lip lines and other facial sites.
(A)
Before Radiesse
(B)
After 1.3 cc Radiesse
Figure 18.13 (A,B) Hand augmentation with Radiesse. Originally appeared in J Dermatol Ther; used by permission of physician, Mariano Busso, MD, and the J Dermatol Ther.
150
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
Once injected, the Radiesse needs to be contoured. To do so, the patient makes a fist of the injected hand as the provider manipulates and massages the injected area, firmly massaging the dorsum until the filler has been evenly spread. Ice packs should be applied to prevent bruising. If the patient requires additional volume, refinement may be provided at a 6- to 8-week touch-up appointment. In addition to bruising, exquisite tenderness can occur post-treatment if fascia is accidentally injected or traumatized. This generally occurs 1 to 2 weeks later and manifests as an area of redness and swelling. The patient should be assessed to rule out infection and managed with NSAIDs and empiric antibiotics. Resolution of the affected area may take several weeks (Fig. 18.13). POST-OPERATIVE TREATMENT
Post-operative treatment includes gentle molding by the practitioner to assess symmetry. Ice packs applied to the treated area will mitigate swelling and bruising. However, patients may experience transitory redness, soreness, swelling, itching and bruising. While a few hours of rest are recommended, it is rare for patients injected with Radiesse to experience down time. The advantage of nonsurgical aesthetic intervention is its optimal impact on the patient’s self-confidence and its minimal impact on the quality of the patient’s daily life. OTHER APPLICATIONS
The versatility of Radiesse has paved the way for a number of applications in other areas of the face and head, including mental creases, glabella, lateral brow, temple, earlobes, and tear trough. Radiesse has been used in these off-label areas—alone and, in some cases, in combination with other soft tissue fillers. The applications are beyond the scope of this chapter but are options for physicians highly experienced in injection of dermal fillers. CONCLUSION
Gone are the days when cosmetic correction involved a considerable outlay of money, pain, significant bruising, and long recovery time. Radiesse is a contemporary product that provides real-time results with little pain and almost no post-treatment recovery periods. Peerreviewed studies cited here have clearly supported the safety, efficacy, and durability of Radiesse in midfacial and lower facial applications. Physicians can use Radiesse in their clinical settings, confident that the result of their injections will result in high satisfaction levels in their patients and relatively long-lasting improvements in appearance. ACKNOWLEDGMENTS
The author appreciates the editorial assistance provided by David J Howell, PhD, San Francisco, California, and Sally Sherwood, MA, New York, New York. REFERENCES
1. Graivier MH, Bass LS, Busso M, Jasin ME, Narins, RS, Tzikas TL. Calcium hydroxylapatite (Radiesse®) for correction of the mid- and lower face: consensus recommendations. Plast Recon Surg 2007; November (Suppl): 55S–66S. 2. Becker, H. Nasal augmentation with calcium hydroxylapatite in a carrier-based gel. Plast Recon Surg June 2008; 121(6): 2142–7. 3. Busso M, Karlsberg PL. Cheek augmentation and rejuvenation using injectable calclium hydroxylapatite (Radiesse®). Cosmetic Dermatol 2006; 19(6): 583–8.
4. Goldberg DJ, Amin S, Hussain M. Acne scar correction using calcium hydroxylapatite in a carrier-based gel. J Cosmet Laser Ther 2006; 8: 134–6. 5. Sadick NS, Katz BE, Roy D. A multicenter, 47-month study of safety and efficacy of calcium hydroxylapatite for soft tissue augmentation of nasolabial folds and other areas of the face. Dermatol Surg 2007; 33: S1222–127. 6. Tzikas TL. Evaluation of Radiance™ FN soft tissue filler for facial soft tissue augmentation. Arch Facial Plast Surg 2004; 6: 234–9. 7. Marmur ES, Phelps R, Goldberg DJ. Clinical, histologic, and electron microscopic findings after injection of a calcium hydroxylapatite filler. J Cosmet Laser Ther 2004; 6: 223–6. 8. Hubbard W. Bioform Implants: Biocompatibility. Franksville (WI): Bioform Inc., 2003. 9. Carruthers A, Liebeskind M, Carruthers J, Forster B. Radiographic and computed tomographic studies of calcium hydroxylapatite for treatment of HIV-associated facial lipoatrophy and correction of nasolabial folds. Dermatol Surg 2008; 34: S78–S84. 10. Alam M, Yoo SS. Technique for calcium hydroxylapatite injection for correction of nasolabial fold depression. J Am Acad Dermatol 2007; 56: 285–9. 11. Jones D. Semi-permanent and permanent injectable fillers. Dermatologic Clinics 2009; 27(4): 433–44. 12. Lemperle G, Holmes RE, Cohen S, Lemperle SM. A classification of facial wrinkles. Plast and Reconst Surg 2001; 108(6): 1735–50. 13. Smith S, Busso M, McClaren M, Bass LS. A randomized, bilateral, prospective comparison of calcium hydroxylapatite microspheres versus human-based collagen for the correction of nasolabial folds. Dermatol Surg 2007; 33: S112–S121. 14. Bass LS, Smith S, Busso M, McClaren M. Calcium hydroxylapatite for treatment of nasolabial folds: long-term safety and efficacy results. Aesthetic Surg J 2010; 30(2): 235–8. 15. Moers-Carpi M, Vogt S, Santos BM, Planas J, Vallve SR, Howell DJ. A multi-center, randomized trial comparing calcium hydroxylapatite to two hyaluronic acids for treatment of nasolabial folds. Dermatol Surg 2007; 33: S144–S151. 16. Moers-Carpi M, Tufet JO. Calcium hydroxylapatite versus nonanimal stabilized hyaluronic acid for the correction of nasolabial folds: a 12-month, multicenter, prospective, randomized, controlled, split-face trial. Dermatol Surg 2008; 43: 210–15. 17. Marmur ES, Taylor SC, Grimes PE, Boyd, CM, Porter JP. Six-month safety results of calcium hydroxylapatite (Radiesse) for treatment of nasolabial folds in Fitzpatrick skin types of IV–VI. Dermatol Surg 2009; 35(s2): 1641–5. 18. Busso M, Voigts R. An investigation of changed in physical properties of injectable calcium hydroxylapatite in a carrier gel when mixed with lidocaine and with lidocaine epinephrine. Dermatol Surg 2008:34:S16-S24. 19. Busso M. Calcium hydroxylapatite (Radiesse®): safety, techniques and pain reduction. J Drugs Dermatol 2009; 8(10): 21–3. 20. Marmur ES, Green L, Busso M. Controlled, randomized study of pain levels in subjects treated with calcium hydroxylapatite premixed with lidocaine for correction of nasolabial folds. Dermatol Surg 2010; 36(3): 309–15. 21. Marmur ES, Al Quaran H, Earp A. A multi-patient, pilot study of calcium hydroxylapatite injection for treatment of the aging hand. Dermatol Surg 2009; 35(12): 1978–84. 22. Werschler, WP. Treating the aging hand with soft tissue filler: off-label application promises few visits and long-term results. MedEsthetics 2009; 5(5): 10–11.
19
PLLA (Sculptra) Cheryl M. Burgess
PLLA OVERVIEW
Introduction Poly-L-lactic acid (PLLA; Sculptra® Aesthetic; Dermik, Bridgewater, New Jersey, USA) is an injectable medical device with approval by the U.S. Food and Drug Administration (FDA) for the treatment indicated to correct shallow to deep nasolabial fold (smile lines) contour deficiencies and other facial wrinkles which are treated with the appropriate injection technique in healthy people; it is also approved for the treatment of facial lipoatrophy in patients with human immunodeficiency virus (HIV). It is a biodegradable bioabsorbable synthetic polymer, which has been used for several decades in resorbable medical devices, such as sutures, surgical sealant meshes, screws, plates, and membranes for guided tissue regeneration (1,2). Facial lipoatrophy can develop due to (i) the natural course of aging in healthy adults, (ii) surgical procedures to cause extensive weight loss, (iii) specific disease states, either inherited or acquired, in which lipodystrophy syndrome causes metabolic disturbances that lead to abnormalities in adipose tissue, and (iv) treatment of HIV patients with certain antiviral cocktails (3). The etiology remains unclear, but studies suggest a strong link between lipodystrophy syndrome and treatment with protease inhibitors and nucleoside reverse transcriptase inhibitors. Researchers remain uncertain as to whether the effect results from individual or synergistic drug activity 3–6. Lipodystrophy syndrome has proven difficult to define, leading to widely varying estimates of prevalence among patients with HIV that range from 15% to greater than 80% (7). The highest estimate of lipodystrophy incidence was 83% and occurred in patients within 8 to 10 months of initiating protease inhibitor therapy (3). Several scales for grading lipoatrophy severity have been developed. However, the Facial Lipoatrophy Grading Scale ( Table 19.1) that was introduced in 2006 by the Facial Lipoatrophy Panel is the current standard for grading lipoatrophy severity in all patients. In soft tissue augmentation, PLLA is used exclusively to produce volume in areas of “sinking and sagging” skin. It is not intended for the focused treatment of specific wrinkles. Rather, PLLA is intended for the treatment of areas requiring contouring or sculpting. PLLA can be used with other soft tissue fillers for a variety of applications in soft tissue augmentation. It can be used to build up the maxillary fat pads, but should not be injected into the lips (2). PLLA is also appropriate for rejuvenation of hands, correction of foot problems, and the correction of localized lipoatrophy from medical conditions. The effects of volume restoration can persist for as long as 18 to 24 months, but are not permanent (2,8). After this period, only one booster treatment is needed to maintain the cosmetic effect (9). Mechanism of Action PLLA differs in mechanism from other fillers because in point of fact it is not a dermal filler. To the contrary, PLLA is a biocompatible, biodegradable synthetic polymer that serves as a catalyst that stimulates the process of neocollagenesis (10–14). PLLA causes an immediate effect by physically occupying space. However, this initial response is temporary, lasting only one week or less (8). Once the carrier solution is absorbed, a delayed but progressive volumizing effect begins. PLLA causes a foreign body giant cell reaction that leads to the gradual production of collagen. This occurs through a process of hydration, loss of cohesion and molecular weight, and
solubilization and phagocytosis of PLLA by the host’s macrophages. PLLA is slowly degraded into lactic acid microspheres and CO2 through non-enzymatic hydrolysis. Respiratory excretion eliminates CO2, leaving behind crystals, which stimulate collagen and a granulomatous reaction. This inflammatory reaction elicits (i) resorption, (ii) formation of fibrous connective tissue about the foreign body, and (iii) dermal fibroplasia that leads to the desired cosmetic effect (2). Over the course of several months, the process of dermal thickening is gradually achieved (10–14). Safety History Special training is required for the authorized use of PLLA. Without proper training, the potential for certain adverse events increases. However, PLLA use is especially safe. Since 1999, over 150,000 people in more than 30 countries have been treated with PLLA for a variety of facial volume and contour deficiencies (1,15). In our own clinic— the Center for Dermatology and Dermatologic Surgery (Washington, D.C., USA)—PLLA has been successfully used to treat lipoatrophy of the hands, feet, face, and buttocks in both immunocompetent and immunocompromised patients. In fact, of 61 HIV-infected patients treated with PLLA, excellent responses to treatment was observed in 100% of patients at 6 months follow-up. After treatment was complete, the patients were followed every 6 months from 2001 to 2005, with no reports of allergic reactions, infections, or severe adverse events (2). Several other studies have shown safety and efficacy in both immunocompetent and HIV-infected patients 16–18. For example, a study in 102 HIV-positive patients receiving highly active antiretroviral therapy (HAART) and 620 cosmetic (presumed immunocompetent) patients, treatment with PLLA resulted in optimal volume enhancement in all the patients, even at two years post-final injection. In addition, adverse events were minimal, and included five cases of palpable, non-visible papules, and one possible foreign body reaction found one-year post-injection, resulting in a mild visible nodule. No allergic reactions were observed (19). Clinicians have begun to identify other conditions for the use of PLLA. For example, a recent publication has reported that the use of PLLA to treat acne and varicella scars yielded excellent safety and efficacy results (20). Also in development, is the novel use of PLLA as an injectable craniofacial implant in a supraperiosteal location to address both soft tissue volume loss and loss of craniofacial support (21). In the United States, the safety record of PLLA has continued to be excellent—only a small number of adverse events have been reported in connection with PLLA treatment. In Europe, the earlier experience with PLLA was marked by a much greater propensity for adverse events. When adverse events have occurred with the use of PLLA, insufficient reconstitution and incorrect injection technique has typically been implicated. Physicians must remember that PLLA is not a filler, and requires a different approach to treatment and injecting. Thorough knowledge and training is absolutely required. Additionally, because of the gradual mechanism of dermal thickening, physicians must employ patience, as well as an artistic approach to restoring volume. Duration of Effect Soft tissue augmentation with PLLA is not permanent. Since the effect of augmentation is limited to approximately 24 to 30 months, there is less concern for errors in technique to become permanent. There is also less concern for problems that result as facial contours continue to
151
152
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
change with age. For example, permanent fillers that initially provide satisfactory results may become more visible with age or create an unnatural appearance as patients grow older (22). INDICATION: TREATMENT OF LIPOATROPHY IN PATIENTS WITH HIV
Treatment of Lipoatrophy in Patients with HIV New advances in antiretroviral therapy have enabled patients with HIV and acquired immune deficiency syndrome (AIDS) to live longer, healthier lives (23). This therapy, however, is not without adverse effects. Patients receiving HAART often develop lipodystrophy syndrome, a condition characterized by insulin resistance, hyperlipidemia, and fat loss/redistribution. Lipodystrophy-associated fat redistribution consists of fat loss from the limbs, buttocks, and face; fat accumulation in the abdomen and the dorso-cervical fat pad (the so-called “buffalo hump”), and sometimes breast hypertrophy (4). The most visible component of fat redistribution—the component that causes the patient the most distress—is facial lipoatrophy (5). Facial lipoatrophy begins in the nasolabial region, progresses outward to the temples, and finally affects the eye sockets. As fat loss progresses, the facial skin comes to rest directly on the underlying muscles, resulting in a gaunt, anorexic appearance (3). For the patient, the psychosocial effects of facial lipoatrophy are significant. Collins surveyed HIV-infected patients regarding their feelings about their body fat changes (5). The study found that patients often felt their doctors expressed much less concern about the effects of lipoatrophy than the amount of concern felt by the patient (3,5). Poor body image, low self-esteem, and depression were frequently described. Patients reported being socially withdrawn and that sexual relationships were adversely affected. Some patients were forced by their appearance into disclosing their HIV status. Perhaps most significant, some patients stopped taking their antiretroviral regimen in order to avoid the adverse psychosocial affects of fat wasting (5). Patient Selection PLLA can be used to treat HIV patients with any level of severity (Table 19.1). Prior to beginning treatment, the physician should carefully discuss details of (i) patient satisfaction and expectations, (ii) potential discomfort during or after injection, (iii) risk for adverse events, (iv) the results that should be expected immediately after the initial treatment and throughout subsequent sessions, and (v) typical durability expected after all sessions have been completed. The patient’s medical history should be reviewed, with attention to the use of prescription and nonprescription medications, allergies, autoimmune disorders, history of cold sores, and prior facial operations or soft tissue augmentation, including facial implants. Patients should be counseled to avoid medications, herbs, or supplements that might increase bleeding. Informed consent should be obtained. Table 19.1 Facial Lipoatrophy Grading Scale to Assess the Degree of Lipoatrophy in all Patients Grade 0 Grade 1
Grade 2 Grade 3
Grade 4 Grade 5
No facial lipoatrophy. Mild flattening or shadowing of one or more facial regions. No prominent pony landmarks. No visibility of underlying musculature. Intermediate point between grade 1 and grade 3. Moderate concavity of one or more facial regions. Prominence of bony landmarks. May have visibility of underlying musculature. Intermediate point between grade 3 and grade 5. Severe indentation of one or more facial regions. Severe prominence of bony landmarks. Clear visibility of underlying musculature.
Source : Adapted from Ref. 29.
PLLA-Injection Preparation Unlike many other products for soft tissue augmentation, PLLA does not come ready to use. It must be reconstituted prior to use. Experts recommend reconstituting in a minimum of 5 ml of sterile water to allow for light-to-moderate plunger pressure, and to help distribute the product evenly (1). In highly mobile areas, such as around the eye and around the lip, it is recommended to reconstitute PLLA in 6 to 8 ml. However, it is not recommended to use large dilutions in large areas or in non-mobile areas (24). Treatment Plan Physicians must fully comprehend the differences in technique between this product and dermal fillers before attempting to use PLLA. Therefore, physicians must adjust their approach from treating a “specific line” to a strategy of “returning volume to a facial area” (1). PLLA is not injected in the typical place where fillers such as collagen or hyaluronic acid (HA) are injected. PLLA should be placed in the deep dermis or subcutaneously for creating supportive structure and foundation. Correct placement in the deep dermal and/or deep dermal subcutaneous plane is crucial; too shallow and visible nodules and/or blanching of the skin occurs (2). PLLA, due to the thickness of the hydrogel or insufficient reconstitution and preparation, tends to clump in the syringe and is somewhat difficult to inject. In addition, the gradual mechanism of dermal filling means that overcorrection is not required and must be avoided (1). Several treatments, administered 4 weeks apart or more, are required to achieve maximum benefit; the exact number depends on the severity of the lipoatrophy. Mild cases may require two to three treatment sessions; moderate cases, approximately three to four treatment sessions; and severe lipoatrophy could require four to six treatment sessions. In our treatment of HIV patients with lipoatrophy, we found that the required amount of PLLA varied from one to four vials, depending on the degree of lipoatrophy severity and areas of involvement. The number of treatment sessions also varied. Mild cases required two to three treatment sessions; moderate cases, approximately four treatment sessions; and severe lipoatrophy required four or more treatment sessions. The amount of PLLA was gradually decreased over subsequent sessions (2). Injection Technique Several treatments, administered four or more weeks apart, are required to achieve maximum benefit; the exact number depends on the severity of the lipoatrophy. Mild cases may require three treatment sessions; moderate cases, approximately four treatment sessions; and severe lipoatrophy could require five to seven treatment sessions (9). Injection Steps Obtain pre-operative photographs. Prior to injection, the areas of correction are prepped with isopropyl alcohol. The treatment areas are anesthetized with topical lidocaine, nerve blocks, or 1% lidocaine with or without with 1:100,000 epinephrine infused into the reconstituted vial of PLLA. Areas of concavity are outlined with a wax marking pencil or eyeliner pencil (Fig. 19.1A). Before and after results of contouring the outlined areas (Fig. 19.1B and C). For the enhancement of the under-eye area, prevent the development of subcutaneous nodules in the thin skin of the orbital rim, by injecting under the orbicularis oculi musculature. If at the time of injection, the PLLA suspension is not fully reconstituted, vigorously Shake the suspension and then warm it to a temperature of 92°C to 96°C (197.6–204.8°F) by submerging the suspension in hot water or by using a Bed Buddy (microwave for 2–3 minutes). These steps cause the covalent bonding to occur
• • • • • •
PLLA (SCULPTRA)
•
•
more rapidly. In more sophisticated laboratories, use a laboratory vortex mixer to shake vigorously prior to the procedure and during the procedure to prevent settling of the suspension. The PLLA suspension is injected into the dermal subcutaneous juncture with a 25-gauge 0.5-, 1-, or 1.5-inch needle. For bolus injections, use a 25-gauge 0.5- or 1-inch needle. Move the needle in a fan-like sweep through the horizontal plane, in approximately 15° increments from each other, while injecting the PLLA with a retrograde technique (Fig. 19.2A). Place the needle adjacent to the first location in the same horizontal plane and repeat the injection using a fanning motion so that the fans overlap and cross to create a lattice of PLLA deposits (Fig. 19.2B). For injections into the temples, give a bolus injection using 0.5-inch 25-gauge needle (no fanning) (Fig. 19.1B).
• •
153
Minimize bruising by using arnica montana, bromelain, or Bruise Relief ®. Vigorous massage and manual sculpting was performed by the physician and/or nurse on patients with and without HIV for 5 minutes to treatment areas to distribute the material evenly. To minimize bruising and swelling, patients were given instructions to apply ice packs to the injected areas for 15 minutes of every hour over the next 12 to 24 hours.
Operative Steps Because dermal thickening is a gradual process, the full effects of PLLA may take three months to six months to develop (15). This is a gradual process, which differs significantly from traditional methods of augmentation, and requires a radically different approach and
(B)
(A)
(C) Figure 19.1 (A–C) Areas of concavity are outlined with a wax marking pencil or eyeliner pencil.
(A)
(B)
Figure 19.2 (A) Place the PLLA using a fan-like technique and disperse during retrograde withdrawal of the needle. (B) Place the needle adjacent to the first location in the same horizontal plane and repeat the injection using a fanning motion so that the fans overlap and cross to create a lattice of PLLA.
154
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
treatment plan. Rather than immediately looking for an optimal correction, physicians should treat, wait, assess, and only then, decide how much more correction is needed (24). Moreover, dermal thickening is not achieved in equal amounts with each injection. More
(A)
(C)
correction takes place after the final injection, compared with the initial injection (15). Results
(B)
(D) Figure 19.3 Facial lipoatrophy (three sessions at 6 months): (A,C) before; (B,D) after.
(A)
(B) Figure 19.4 Facial lipoatrophy (three sessions at 1 year): (A) before; (B) after.
PLLA (SCULPTRA)
(A)
155
(B) Figure 19.5 Facial lipoatrophy facial contouring: (three sessions at 6 months): (A) before; (B) after.
TREATMENT OF LIPOATROPHY CAUSED BY THE AGING PROCESS IN HEALTHY INDIVIDUALS
Safety and Efficacy History A recent study by Hanke and Redbord found PLLA to be safe and efficacious for the satisfactory treatment of lipoatrophy in HIV and lipoatrophy of aging. In their study, 65 patients (27 HIV positive; 38 HIV negative) were treated with PLLA for facial lipoatrophy from August 2004 to August 2006. Nearly all patients reported that they were very satisfied with the PLLA treatments (93% of HIV-positive patients; 89.5% HIV-negative patients). Patient Selection PLLA can be used to treat cosmetic patients with a lipoatrophy severity of grade 2 to grade 5 (severe) (Table 19.1). PLLA Injection Preparation Experts recommend reconstituting in a minimum of 5 ml of sterile water to allow for light-to-moderate plunger pressure, and to help distribute the product evenly (1). In highly mobile areas, such as around the eye and around the lip, it is recommended to reconstitute PLLA in 6 to 8 ml. However, it is not recommended to use large dilutions in large areas or in non-mobile areas (24). Treatment Strategy: The Atrophy/Hypertrophy Model for Aging The atrophy/hypertrophy model for aging represents a shift from focusing on wrinkles and gravitational sagging to a more comprehensive approach that treats the aging face from “the inside out.” To address the correct use of PLLA in soft tissue augmentation, it is vital that physicians understand the natural progression of changes in the aging face, the microstructural changes, and especially the macrostructural changes. In the young face, superficial and deep fat is distributed evenly, creating a homogenous topographical appearance with smooth primary arcs and convexities. With age, the distribution of fat becomes altered by fat atrophy and hypertrophy, producing hills and valleys with demarcations between the cosmetic units. Fat atrophy becomes clinically apparent in the temple and cheek and is followed by fat loss around the chin and mandibular areas. Features become concave, characterized by flat lips, sunken temple and cheek, scalloped mandible, and increased shadowing from hills and valleys. With aging, the most significant change in appearance is the sagging of excess skin, which develops as primary arcs become straight lines. Skin tends to drape inferiorly and diagonally from the temporal area toward the
perioral region, creating a central focus on the perioral and mandibular regions. Fat atrophy is observed in the periorbital, forehead, buccal, temporal, and perioral areas. Fat atrophy is the result of decreased fat cell size, diminished fat cell function, impaired fat cell differentiation, and redistribution of fat cells. Fat hypertrophy occurs submentally, in the jowl, lateral nasolabial fold, lateral labiomental crease, and lateral malar areas. The accumulation of fat pulls the encumbered skin downward under the force of gravity. The loss of fat leaves skin excessive in proportion to the diminished volume, causing the excess skin to sag (25,26). Volume must be restored in regions experiencing fat atrophy and excess fat must be removed from regions where fat has accumulated. Correcting the distribution of volume throughout the face can help restore homogenous topography, eliminate demarcations between cosmetic units, and restore the primary arcs (25). Injection Technique Several treatments, administered four or more weeks apart, are required to achieve maximum benefit; the exact number depends on the severity of the lipoatrophy. Mild cases may require two to three treatment sessions; moderate cases, approximately three to four treatment sessions; and severe lipoatrophy could require four to six treatment sessions. Injection Steps Obtain pre-operative photographs. Prior to injection, the areas of correction are prepped with isopropyl alcohol. The treatment areas are anesthetized with topical lidocaine, nerve blocks, or 1% lidocaine with or without with 1:100,000 epinephrine infused into the reconstituted vial of PLLA. Areas of concavity are outlined with a wax marking pencil or eyeliner pencil (Fig. 19.1A). For the enhancement of the under-eye area, prevent the development of subcutaneous nodules in the thin skin of the orbital rim, by injecting under the orbicularis oculi musculature. If at the time of injection, the PLLA suspension is not fully reconstituted, vigorously Shake the suspension and then warm it to a temperature of 92°C to 96°C (197.6–204.8°F) by submerging the suspension in hot water or by using a Bed Buddy (microwave for 2–3 minutes). These steps cause the covalent bonding to occur more rapidly. In more sophisticated laboratories, use a laboratory vortex mixer prior to the procedure and during the procedure to prevent settling of the suspension.
• • • • • •
156
•
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT The PLLA suspension is injected into the dermal subcutaneous juncture with a 25-gauge 0.5-, 1-, or 1.5-inch needle. For bolus injections, use a 25-gauge 0.5- or 1-inch needle. Move the needle in a fan-like sweep through the horizontal plane, in approximately 15° increments from each other, while injecting the PLLA with a retrograde technique (Fig. 19.2A). Place the needle adjacent to the first location in the same horizontal plane and repeat the injection using a fanning motion so that the fans overlap and cross to create a lattice of PLLA deposits (Fig. 19.2B).
(A)
• •
Minimize bruising by using arnica montana, bromelain, or Bruise Relief®. Vigorous massage and manual sculpting was performed by the physician and/or nurse on patients with and without HIV for 5 minutes to treatment areas to distribute the material evenly. To minimize bruising and swelling, patients were given instructions to apply ice packs to the injected areas for 15 minutes of every hour over the next 12 to 24 hours.
Results
(B)
(C)
Figure 19.6 Cosmetic treatment of lipoatrophy (two sessions at 12 months). The patient is a 71-year-old black female patient with facial sinking and sagging; she is not a candidate for a face-lift. (A) Before; (B) after one session at 9 months; (C) after sessions at 1 year.
TREATMENT OF LOCALIZED FACIAL LIPOATROPHY FOR OTHERWISE HEALTHY YOUNG INDIVIDUALS
Patient Selection PLLA can be used to treat cosmetic patients with a lipoatrophy severity of grade 2 (mild–moderate) to grade 5 (severe) (Table 19.1). Treatment Strategy Physicians must fully comprehend the differences in technique between this product and dermal fillers before attempting to use PLLA. Therefore, physicians must adjust their approach from treating a “specific line” to a strategy of “returning volume to a facial area” (1). PLLA is not injected in the typical place where fillers such as collagen or HA are injected. PLLA should be placed in the deep dermis or subcutaneously for creating supportive structure and foundation. It can be used to build up the maxillary fat pads, but should not be injected into the lips (2). In addition, the gradual mechanism of dermal filling means that overcorrection is not required, as it is with some of the dermal fillers, and must be avoided (1). In our treatment of HIV patients with lipoatrophy, we found that the required amount of PLLA varied from one to four vials, depending on the degree of lipoatrophy severity and areas of involvement. The number of treatment sessions also varied. Mild cases required one to two treatment sessions; moderate cases, approximately three to four treatment sessions; and severe lipoatrophy required three to four or more treatment sessions. The amount of PLLA was gradually decreased over subsequent sessions(2).
Injection Technique Several treatments, administered four or more weeks apart, are required to achieve maximum benefit; the exact number depends on the severity of the lipoatrophy. Mild cases may require two to three treatment sessions; moderate cases, approximately three to four treatment sessions; and severe lipoatrophy could require four to six treatment sessions (9). Injection Steps Obtain pre-operative photographs. Prior to injection, the areas of correction are prepped with isopropyl alcohol. The treatment areas are anesthetized with topical lidocaine, nerve blocks, or 1% lidocaine with or without with 1:100,000 epinephrine infused into the reconstituted vial of PLLA. Areas of concavity are outlined with a wax marking pencil or eyeliner pencil. For the enhancement of the under-eye area, prevent the development of subcutaneous nodules in the thin skin of the orbital rim, by injecting under the orbicularis oculi musculature. If at the time of injection, the PLLA suspension is not fully reconstituted, vigorously Shake the suspension and then warm it to a temperature of 92°C to 96°C (197.6–204.8°F) by submerging the suspension in hot water or by using a Bed Buddy (microwave for 2–3 minutes). These steps cause the covalent bonding
• • • • • •
PLLA (SCULPTRA)
•
to occur more rapidly. In more sophisticated laboratories, use a laboratory vortex mixer prior to the procedure and during the procedure to prevent settling of the suspension. The PLLA suspension is injected into the dermal subcutaneous juncture with a 25-gauge 0.5-, 1-, or 1.5-inch needle. For bolus injections, use a 25-gauge 0.5- or 1-inch needle. Move the needle in a fan-like sweep through the horizontal plane, in approximately 15° increments from each other, while injecting the PLLA with a retrograde technique (Fig. 19.2A). Place the needle adjacent to the first location in the same horizontal plane and repeat the injection using a fanning motion so that the fans overlap and cross to create a lattice of PLLA deposits (Fig. 19.2B).
• •
157
Minimize bruising by using arnica montana, bromelain, or Bruise Relief ®. Vigorous massage and manual sculpting was performed by the physician and/or nurse on patients with and without HIV for 5 minutes to treatment areas to distribute the material evenly. To minimize bruising and swelling, patients were given instructions to apply ice packs to the injected areas for 15 minutes of every hour over the next 12 to 24 hours.
Results
(A)
(B)
(C)
(D)
Figure 19.7 Medical indication for localized lipoatrophy two sessions, two vials. The patient had two sessions that were 8 weeks apart with two vials of PLLA per session. (A,B) Before; (C,D) after.
158
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
OFF-LABEL USE: REJUVENATION OF THE HANDS
Legal and Ethical Considerations for Using PLLA Off-Label The legal and ethical considerations for the off-label use of any drug or medical device can appear complex. However, FDA regulations allow physicians to use medications or devices in an off-label manner when doing so is recognized as a common practice of physicians. In fact, for many diseases, the best treatment or only treatment available may be the off-label use of a medication. In such cases, this is not only acceptable, it might be considered unethical to do otherwise. According to Goldberg, “there is no question as to the legality
(A)
of off-label use for dermal fillers.” The off-label use of an FDA-approved dermal filler is legal when “off-label” is defined as using the filler in a manner consistent with how it is used by other physicians—once dermal fillers are used in such a way, there is no basis for liability (27,28). Patient Selection Hands with a significantly “bony prominence” (Fig. 19.8A) respond better to soft tissue augmentation compared to hands with significantly visible veins.
(B)
(C) Figure 19.8 Off-label use of PLLA for rejuvenation of hands: (A) before; (B) example of pinching and lifting the skin of the dorsal aspect of the hand before; (C) after.
(A)
(B)
Figure 19.9 Off-label use of PLLA for lipoatrophy of the metatarsal foot pads. (A) before; (B) after (note fullness in the metatarsal head regions).
PLLA (SCULPTRA) Injection Technique Most filler substances can be injected in the subdermal plane of the skin of the dorsum of the hands.
• • • •
Collagen HA Calcium hydroxylapatite PLLA
Filler substances are injected into the interosseous spaces with a 0.5- to 1-inch 25- to 27-gauge needle depending on the filler substance. Entry is through the web spaces. Dilution is accomplished with 8 ml sterile water and 2 ml of lidocaine/with epinephrine. The augmentation requires multiple sessions to obtain the full enhancement. Injection Steps The dorsal skin of the hand is pinched and lifted (Fig. 19.8B) or tented for easy access to the subdermal plane. The needle is advanced avoiding prominent dorsal veins. Injection is in a retrograde manner as the needle is being pulled out of the skin. Massage is particularly important in the enhancement of the hands, due to the elevated risk of papule or nodule formation.
• • •
OFF-LABEL USE: CORRECTION OF FOOT PROBLEMS
Patient Selection Metatarsal fat pad lipoatrophy
•
Injection Technique Place plantar surface of the foot on an ice compress (ice anesthesia). Use one vial at 3 cm3 dilution with sterile water plus 1 cm3 lidocaine/with epinephrine and a 21-gauge needle with a 1 cm3 syringe. Patient may require two to three treatment sessions at one month apart (Fig. 19.9).
• • •
Injection Steps Inject 1 cm3 at each metatarsal fat pad area. PLLA is injected between the first, second, third, and fourth metatarsal heads. Massage for 2 to 3 minutes.
• • •
SUMMARY
Poly-L-lactic acid (PLLA) has been shown safe and effective for the treatment of facial lipoatrophy through numerous studies in both immunocompromised and immunocompetent patients. PLLA works by a mechanism of action that it is completely different from other products for soft tissue augmentation. Significant differences in mechanism, treatment strategy, injection preparation, and injection technique require an approach, completely different from other products for soft tissue augmentation. In addition, a successful treatment strategy depends on the full understanding that aging of the face develops from the collective effects of fat atrophy and hypertrophy. Although PLLA is FDA approved to treat facial lipoatrophy, it is also used for offlabel treatment of the foot and hands in the United States. There are no legal risks when using PLLA off-label, as long as the off-label use is consistent with the common practices of other dermatologists and plastic surgeons. The formation of granulomas and nodules is avoided by using correct techniques that include (i) complete reconstitution with adequate dilution of PLLA, (ii) proper injection technique, and (iii) a strategy of treating facial units and not wrinkles. Today, new clinical applications for PLLA are gaining interest and studies have demonstrated excellent safety and efficacy in these new
159
uses. For the dermatologist and plastic surgeon, this represents an exciting, but challenging era. As the marketplace of soft tissue fillers continues to grow, clinicians must develop expertise in a variety of divergent techniques. Therefore, the necessity for appropriate medical education and continued training on specific products becomes increasingly crucial. REFERENCES
1. Vleggaar D, Bauer U. Facial enhancement and the European experience with Sculptra (poly-L-lactic acid). J Drugs Dermatol 2004; 3(5): 542–7. 2. Burgess CM, Quiroga RM. Assessment of the safety and efficacy of poly- L-lactic acid for the treatment of HIV-associated facial lipoatrophy. J Am Acad Dermatol 2005; 52(2): 233–9. 3. James J, Carruthers A, Carruthers J. HIV-associated facial lipoatrophy. Dermatol Surg 2002; 28: 979–86. 4. Dieterich DT. Long-term complications of nucleoside reverse transcriptase inhibitor therapy. AIDS Read 2003; 13: 176–84, 87. 5. Collins E, Wagner C, Walmsley S. Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Read 2000; 10: 546–50. 6. Jones SP, Qazi N, Morelese J, et al. Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens. J Acquir Immune Defic Syndr 2005 15; 40(5): 565–72. 7. Moyle G. Lipodystrophy: lack of agreement on definition and etiology presents a challenge to research and therapy. AIDS Read 2002; 12: 438, 440–2. 8. Mest D. Experience with injectable poly-L-lactic acid in clinical practice. Cosmetic Dermatol 2005; 18(2 S2): 5–8. 9. Resources DAAI. Legal and Regulatory Issues Regarding New-Fill. Resources DAAI, Inc., 2001. 10. Cutright DE, Hunsuck EE. Tissue reaction to the biodegradable polylactic acid suture. Oral Surg Oral Med Oral Pathol 1971; 31(1): 134–9. 11. Li S, Vert M. Aliphatic polyester. In: Scott G, Gilead D, eds. Degradable Polymers. London: Chapman and Hall; 1995. 12. Hartman M. Biopolymers from Renewable Resources. Berlin, Heidelberg: Springer-Verlag; 1998. 13. Gruber P, Hall E, Kolstad J, Iwen M, et al., inventors. US Patent 5142023, 1992. 14. Micard V, Guilbert S. Thermal behavior of native and hydrophobized wheat gluten, gliadin and glutenin-rich fractions by modulated DSC. Int J Biol Macromol 2000; 27: 216–29. 15. Werschler W, Bondar G, Esch P. Six simple steps to Sculptra success: expert advice for incorporating this new filler agent into your practice. Skin and Aging 2005; 13(1): 56–64. 16. Onesti MG, Renzi LF, Paoletti F, Scuderi N. Use of polylactic acid in face lipodystrophy in HIV positive patients undergoing treatment with antiretroviral drugs (HAART). Acta Chir Plast 2004; 46(1): 12–5. 17. Valantin MA, Aubron-Olivier C, Ghosn J, et al. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. Aids 2003; 17(17): 2471–7. 18. Moyle GJ, Lysakova L, Brown S, et al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med 2004; 5(2): 82–7. 19. Bauer U. Improvement of facial aesthetics at 40 months with injectable Poly-L-lactic acid (PLLA). Paper presented at: The Aesthetic Meeting 2005, 2005; New Orleans, LA. 20. Beer K. A single-center, open-label study on the use of injectable poly-L-lactic acid for the treatment of moderate to severe scarring
160
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
from acne or varicella. Dermatol Surg 2007 Dec; 33(Suppl 2): S159–S167. 21. Vleggaar D, Fitzgerald R. Dermatological implications of skeletal aging: a focus on supraperiosteal volumization for perioral rejuvenation. J Drugs Dermatol 2008; 7(3): 209–20. 22. Saylan Z. Facial fillers and their complications. Aesthet Surg J 2003; 23: 221–4. 23. Isada CM. New developments in long-term treatment of HIV: the honeymoon is over. Cleve Clin J Med 2001; 68: 804–7. 24. Anonymous. Questions and answers: ASCDAS 3rd Annual Meeting. New options in the recognition and treatment of lipoatrophy with volume restoration. Cosmetic Dermatol 2005; 18(3): 235–9.
25. Donofrio LM. Fat distribution: a morphologic study of the aging face. Dermatol Surg 2000; 26(12): 1107–12. 26. Alster T, Jorizzo J, Hanke W, et al. The aging face: more than skin deep CME. [Available from: http://www.medscape.com/viewprogram/340; 2004] 27. Goldberg DJ. Legal ramifications of off-label filler use. Clin Plast Surg 2006; 33(4): 597–601. 28. Goldberg DJ. Legal ramifications of off-label filler use. Dermatol Ther 2006; 19(3): 189–93. 29. Ascher B, Coleman S, Alster T, et al. Full scope of effect of facial lipoatrophy: a framework of disease understanding. Dermatol Surg 2006; 32(8): 1058–69.
20 Permanent fillers Derek Jones
Currently the only injectable permanent filler with specific U.S.– Food and Drug Administration (FDA) device approval is Artefill. Liquid injectable silicone is available legally for off-label use only. Other permanent fillers such as Aquamid are currently undergoing FDA study. Permanent fillers should be reserved for select indications where temporary fillers may not perform as well or have suitable longevity, such as in HIV lipoatrophy or certain cases of acne scarring. As errors or adverse events with permanent fillers may be unforgiving, they should be avoided in patients who are naïve to injectable soft tissue augmentation, or are unclear of their treatment goals. LIQUID SILICONE
Liquid silicone (LIS), an inert and biocompatible synthetic polymer, was first used as an injectable filler in the 1950s. Before collagen injectable fillers became available in the early 1980s, LIS was the injectable filler of choice. However, there was no standardized FDA-approved LIS and different products of varying purity were often injected in large bolus form, which led to frequent product migration. Many products were intended for industrial rather than in vivo use, and impurities lead to frequent foreign body reactions. Subsequently, in the early 1990s, all forms of silicone for cosmetic implantation were banned by the FDA, citing possible toxicity and systemic reactions related to LIS and silicone breast implants. After a lengthy review, the FDA resolved safety issues regarding implantable and LIS, and in the 1990s, two new forms of highly purified LIS were approved (Silikon-1000 in 1997 and Adatosil-5000 in 1994) for use as an injectable intraocular implant to treat retinal detachment. While this is the only FDA-approved indication for LIS, the FDA Modernization Act of 1997 makes off-label uses legal, provided that the physician or drug manufacturer does not advertise for such use. Therefore, LIS may now legally be used off-label for softtissue augmentation (see “Indications” below). Compared to Adatosil, Silikon-1000 has a lower viscosity and is the most suitable for injectable soft tissue augmentation, as it is easier to inject through smaller gauge needles. Current opinion on liquid injectable silicone is polarized between opponents and advocates. Opponents argue that despite use of proper technique and products, serious adverse events are common and that LIS is inherently unpredictable. Proponents rely on a wealth of anecdotal data to argue that liquid injectable silicone is safe and effective as long as three rules are employed: (i) Use highly purified FDA-approved LIS; (ii) employ microdroplet serial puncture technique (defined as 0.01 cc per injection site injected into the subdermal plane), and (iii) use small volumes (0.5 ml for smaller defects and up to 2 ml for larger areas of atrophy) at each session with multiple sessions staged at monthly intervals or longer. Mechanism of Action After LIS is injected, a capsule of new collagen develops to encircle each microdroplet of silicone. This process continues for about 3 months, during which time the collagen capsule adds volume around the LIS microdroplet. The collagen also holds the droplets in place to prevent migration (1). Indications Although LIS is used off-label for many indications, it is the author’s opinion that LIS should not be routinely employed for the average
cosmetic patient until longer term studies with current products resolve some of the controversy regarding longer term safety and efficacy. However, for the unique and disfiguring defects associated with HIV facial lipoatrophy (FLA) and serious acne scarring, LIS produces cosmetically superior and more durable results than currently available less permanent options (see “Efficacy and Safety” below). Efficacy and Safety LIS has been demonstrated to be an excellent choice for HIV-associated FLA. In one trial, highly purified 1000-cSt silicone oil was studied among 77 patients with HIV-FLA who received 2 ml of Silikon 1000 at monthly intervals with microdroplet technique until optimal correction was achieved. The researchers reported that the number of treatments, amount of silicone, and time required to reach optimal correction were directly related to the initial severity of lipoatrophy and that highly purified 1000-cSt silicone oil is a safe and effective treatment option for HIV-associated lipoatrophy (Fig. 20.1) (2). Fiveyear data are now available on this cohort and no serious adverse events have been found (D Jones, data on file). Using the microdroplet, multiple-injection technique, Barnett and Barnett also have had success with injections of LIS for acne scars lasting over a 10-, 15-, and 30-year follow-up period (3). Technique Clinicians should inject only highly purified FDA-approved LIS, such as Silikon-1000, using the microdroplet serial puncture technique (0.01 ml or less injected through a 27-gauge needle into the immediate subdermal plane at 2–4 mm intervals). Intradermal injections should be avoided, as these may create intradermal papules (4). However, intradermal injections may be used for atrophic dermal acne scars, using 0.001 ml microdroplets. Very small amounts of LIS should be injected at monthly intervals, or longer. The immediate goal is undercorrection. Optimal correction occurs slowly as fibroplasia develops around the microdroplets, creating further tissue augmentation and anchoring each microdroplet into place. POLYMETHYLMETHACRYLATE
Injectable polymethylmethacrylate (PMMA, Artefill, Artes Medical, San Diego, California, USA) is a suspension of 20% PMMA smooth microspheres and 80% bovine collagen. Artefill is the product of third-generation PMMA microsphere technology. Previous generations include Arteplast (used in Germany from 1989 to 1994) and Artecoll (used worldwide, except in the United States and Japan, from 1994 to 2006). Artefill represents a third-generation product containing fewer nanoparticles (less than 20 µm), which were thought to be associated with granulomatous reactions observed with previous generations. Artefill was approved by the FDA in 2006 for the correction of nasolabial folds. Artes filed for Chapter 7 bankruptcy in December 2008, and was subsequently acquired by Suneva, Inc. (San Diego, California, USA) who now distributes the product in the United States. Mechanism of Action After PMMA is injected, the collagen vehicle is absorbed within 1 to 3 months. Afterward, foreign body neocollagenesis ensues which engulfs and encapsulates the remaining estimated six million PMMA
161
162
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
(A)
(B)
Figure 20.1 (A,B) Pretreatment and post-treatment liquid injectable silicone for HIV-associated facial lipoatrophy. Source : Courtesy of Derek Jones, MD.
Before treatment
(A)
After 6 months
(B)
After 1 year
(C)
After 5 years
(D)
Figure 20.2 (A–D) Results of Artefill for the treatment of nasolabial folds at pretreatment, one year post treatment, and beyond one year post treatment. Source : From Ref. 5.
particles in 1 ml of Artefill. This process of fibroplasia also contributes to tissue augmentation. Although the collagen is absorbed, the PMMA is permanent and not re-absorbed (5). Indications Injectable PMMA is indicated for nasolabial folds. It is also been used off-label for glabellar frown lines, radial lip lines, and mouth corners. Injectable PMMA is contraindicated for use in patients with a positive result to the required Artefill skin test, patients with severe allergies (as indicated by a history of anaphylaxis or multiple severe allergies), patients with known lidocaine hypersensitivity, patients with a history of allergies to bovine collagen products, and patients with known susceptibility to keloid or hypertrophic scarring.
The product should not be used for lip augmentation. Efficacy and Safety The U.S. pivotal clinical trial for Artefill was a controlled, randomized, prospective, double-masked trial of 251 patients at eight centers across the United States. Patients received either Artefill or bovine collagen dermal filler (control). Efficacy was rated by masked observers using a photographic Facial Fold Assessment Scale. The study demonstrated a significant improvement with Artefill compared with the control group at 6 months ( p < 0.001) in nasolabial folds. A subset of patients was observed at 12 months and all showed persistent wrinkle correction (Fig. 20.2) (5). A subgroup of 69 patients returned for follow-up 4 to 5 years later. Investigator Facial Fold Assessment ratings at 4 or 5 years were improved from baseline by 1.67 points (p < 0.001). Nearly all subjects
PERMANENT FILLERS
(A)
163
(B)
(C) Figure 20.3 Bio-Alcamid abscess pre- (A) and post- (B) incision and drainage; gram stain of drained material reveals streptococcal bacteria (C). Source : From Ref. 9.
(95.5%) reported that they were at least somewhat satisfied and 81.8% reported that they were either satisfied or very satisfied (6). Five patients reported six late adverse events that occurred from 2 to 5 years after the initial injection. Of these, four were mild cases of lumpiness, and two were severe. The total number of late, adverse events was 6 (2.2%) of 272 of wrinkles injected (6). Granulomatous reactions (manifested by inflamed red nodules), which were more common with previous generations of Artefill, may be treated with intralesional cortisone combined with antibiotic therapy. Technique Injectable PMMA is placed into the dermal–subcutaneous junction using the tunneling or linear threading technique with a 26-gauge, 5/8inch needle. Overcorrection is not recommended. It is preferable to inject more deeply as superficial injection can cause permanent skin surface texture or color impairment. Patients should be evaluated 4 to 6 weeks after the injection to assess the need for further treatments. Optimal correction usually requires two to three treatments, and touch-up implantations should be at intervals of at least 2 weeks or longer depending upon the amount of implant used, the site of placement, and the dynamics of the corrected sites. INVESTIGATIONAL PERMANENT AGENTS: HYDROGEL POLYMERS
Hydrogel polymers are a novel class of fillers, comprised mostly of water with a small amount of synthetic polymer. The so-called injectable “endoprosthesis” agents include Bio-Alcamid (Polymekon, Milan, Italy) and Aquamid (Aquamid, Ferrosan, Copenhagen, Denmark), both of which are used in Europe but are not yet FDA approved. These
nonbiodegradable fillers are composed of 96% water and 4% synthetic polymer: polyalkylimide, in the case of Bio-Alcamid, and polyacrylamide for Aquamid. Both agents are used for large-volume augmentation such as hemi-FLA (Romberg’s disease) or HIV-associated lipoatrophy. Mechanism of Action Once injected, the gel particles become covered by a thin collagen capsule (0.02 mm) which completely surrounds the particles and isolates them from the host tissues, creating an injectable prosthesis. According to the manufacturer, Bio-Alcamid has much stability, integration among living tissues, and more simple removal, if required, than other dermal fillers. The results are considered permanent, but removal can potentially be performed through incision and drainage. Indications While both agents are used for replacement of facial volume due to lipoatrophy, they also used for the treatment of nasolabial folds, lip augmentation, depressed scars, and enhancement of cheekbones and jawline. They are not indicated for the treatment of fine wrinkles. Efficacy and Safety Recent reports in the literature document the success of Bio-Alcamid for the treatment of HIV-associated FLA (7,8). According to the manufacturer, risk of infection or allergy is very low (0.6%) and only 0.2% of patients have had an immune response to the implant, which created localized swelling that required drainage over a 1- to 6-month period. Late-appearing bacterial abscesses are common with Bio-Alcamid. A paper by the author and colleagues reports five patients who received
164
COSMETIC BOOTCAMP PRIMER: COMPREHENSIVE AESTHETIC MANAGEMENT
Bio-Alcamid for HIV-associated lipoatrophy and developed lateappearing streptococcal bacterial abscesses (Fig. 20.3) (9). In each case, an acute abscess developed several months and up to years after the initial injection of Bio-Alcamid. All five cases responded quickly to incision and drainage combined with antibiotic therapy, although in two cases the abscesses became recurrent. In one case, the patient also developed methicillin-resistant Staphylococcus aureus infection and required extensive intravenous antibiotic therapy. Based on the cases, it appears that local oral streptococcal bacteria may be capable of directly invading the interior of the implant material, which may evade host defenses. It also seems possible that the bacteria may reach the implant through a needle puncture during a dental or surgical procedure, possibly warranting prophylactic antibiotic therapy before dental and surgical procedures in patients who have received Bio-Alcamid. A recent study by Narins studied 315 subjects using Aquamid with a linear threading technique in the nasolabial folds against a parallel group who received Restylane. The correction achieved with Aquamid was considered non-inferior to Restylane at 6 months and continued to be effective at 12 months. One serious adverse event (infection) occurred in the Aquamid group and resolved. A 12-month extension study is currently underway to determine the longer term safety and efficacy of Aquamid (10). Bio-Alcamid and other hydrogel polymers carry the risk of foreign body reaction, infection, migration, or granuloma formation. Technique These agents are injected subcutaneously, usually under local anesthesia, and massaged smooth by the clinician. A thin layer of collagen gradually forms around the injected gel over a period of 4 to 8 weeks when the gel becomes completely surrounded and isolated from host tissues—in effect making it an endogenous prosthesis.
REFERENCES
1. Alam M, Gladstone H, Kramer E, et al. ASDS guidelines of care: injectable fillers. Dermatol Surg 2008; 34: S115–S148. 2. Jones D, Carruthers A, Orentreich D, et al. Highly Purified 1000-cST silicone oil for treatment of human immunodeficiency virus-associated facial lipoatrophy: an open pilot trial. Dermatol Surg 2004; 30: 1279–86. 3. Barnett JG, Barnett GR. Treatment of acne scars with liquid silicone injections: 30-year perspective. Dermatol Sug 2005; 31: 1542–9. 4. Jones D. HIV facial lipoatrophy: causes and treatment options. Dermatol Surg 2005; 31: 1519–29. 5. Cohen SR, Holmes RE. Artecoll: a long-lasting injectable wrinkle filler material: report of a controlled, randomized, multicenter clinical trial of 251 subjects. Plast Reconstr Surg 2004; 114: 964–76. 6. Cohen SR, Berner CF, Busso M, et al. Artefill: a long-lasting injectable wrinkle filler material—summary of the U.S. Food and Drug Administration trials and a progress report on 4- to 5-year outcomes. Plast Reconstr Surg 2006; 118(35): 64S–76S. 7. Protopapa C, Giuseppe S, Caporale D, et al. Bio-Alcamid in druginduced lipodystrophy. J Cosmet Laser Ther 2003; 5: 226–30. 8. Treacy P, Goldberg D. Use of a biopolymer polyalkylimide filler for facial lipodystrophy in HIV-positive patients undergoing treatment with antiretroviral drugs. J Dermatol Surg 2006; 32: 804–8. 9. Jones DH, Carruthers A, Fitzgerald R, et al. Late-appearing abscesses after injections of nonabsorbable hydrogel polymer for HIVassociated facial lipoatrophy. Dermatol Surg 2007; 33: S193–8. 10. Narins R. A 12-month controlled study in the United States of the safety and efficacy of hydrogel, a permanent soft-tissue filler. Abstract Presentation, American Society of Dermatologic Surgery Annual Meeting, Phoenix Arizona, October 2009.
21
Liposuction my way Patricia Wexler
The past 20 plus years of tumescent liposuction performed in my practice have seen remarkably few dramatic changes. Despite the introduction of power technology and the addition of various laser and light sources to assist liposuction, the basic premise of tumescent liposuction has remained constant. This has afforded my patients a high degrees of safety and satisfaction with the outcomes I achieve. Before discussing the technique of liposuction, we need to discuss the art of liposuction. Some of my best cases were performed in my first two years of practice when I had no power technology at all, and all of my cases were done using a 60 cc syringe and luer-lock cannulas. This procedure required huge amounts of time, effort and perspiration and performing a two or three liter case using tumescent anesthesia could take hours. However, my patients were awake and I had the opportunity to bond with them and explain the procedure as we proceeded. Performing the procedure slowly also enabled me to learn a great deal about contouring the body. I learned patience in sculpting the waist and lower back. I learned to proceed slowly and cautiously in shaping inner thighs and knees. I also learned to use the cannula in my right hand and to use my left as a tactile aid to guide the procedure. The addition of vacuum assisted aspiration, followed by powerassisted liposuction, and now laser-assisted liposuction, has done more to add longevity to the joints of the surgeon than to the contour of the patient. Laser-assisted liposuction has a role in my practice in a limited number of cases which I will go on to explain; and I am anxious to see what role external ultrasound and radiofrequency will have in the future. But in general, tumescent liposuction is the same today as it was when I started over 20 years ago. Liposuction remains as much an art form as a medical technique and its evolution in my practice has followed that form. Part of liposuction can be taught from physician to physician but some of it (the art portion) needs to be learned as an individual artist. Each procedure begins with a thorough patient evaluation. The most successful liposuction starts not with the actual insertion of the cannula but with choosing your patient carefully. Liposuction is not a method of weight reduction, it is not a quick diet, and it is not a solution to an unhappy marriage. It is however, a perfect procedure for someone with a body disproportion whose weight is virtually stable, and who is highly motivated to maintain their weight with good eating habits and exercise. Each of these points needs to be explained to the patient and should be included in the consent form. THE CONSULTATION
When a patient comes for a liposuction consultation they are first seen in my consultation room where we discuss their goals and expectations. A history is taken of their prior cosmetic procedures, any weight fluctuations within the past several years, and any history of bariatric surgery, along with any intentions of pregnancy in the near future. This is all done to ascertain whether they are initially good candidates and whether they will be able to maintain good results. I conclude with a general medical history to see if they are medically capable to undergo the procedure or require further evaluation. Then we proceed to the exam room where they are provided a gown and examined undressed and photographs of the appropriate areas are taken. I evaluate at that point for proportion, volume, skin tone, skin laxity, and prior surgical defects which could make success less than perfect.
The patient is weighed, and if I deem the patient a good candidate for the procedure I then review the photographs that were taken, along with before and after photographs I feel are relevant to their case so we can discuss expectations. I point out both the positive and negative outcomes they should expect. We then discuss which type of liposuction I plan to use. Further along we will discuss when I veer from my tumescent liposuction with power assistance and use laser-assisted liposuction. At this point I will say if the patient is a good candidate we would do pre-operative testing. Patients under the age of 50 are screened as medically indicated, i.e. autoimmune disease, history of cancer, history of radiation, etc. Over the age of 50, patients require medical clearance consisting of blood work including CBC with different platelets; Chemistry 18, PT, PTT, EKG, and a letter of medical clearance from the primary care physician or internist; additional medical clearance is requested if the history requires it. All testing is done within one month of the procedure. If the procedure is delayed the patient is reevaluated and the screening and testing are repeated. These are our specific guidelines due to our Joint Commission certification. At the time of the consultation, both my surgical coordinator and I review with the patient the pre- and post-operative instructions thoroughly which includes what to expect in preparation of the procedure, the morning of surgery, the procedure, and post-operative care. They are then given literature to take home, along with any prescriptions they made need to take before and after the procedure. In my office, this would in